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Scientific Abstract 
Tuberculosis caused by the Mycobacterium (M.) tuberculosis-complex (MTBC) of organisms 
remains one of the most prevalent and deadly infectious diseases of man and other animals. 
The mycobacteria responsible are a highly conserved group of pleomorphic acid-fast bacilli 
which cause chronic granulomatous infections. Tuberculous infections in humans and cattle 
often remain latent for prolonged periods of time before progressing to disease that has 
severe, negative consequences for the health and welfare of the infected host. Some of the 
organisms within the MTBC are highly specialised and limited to just a single or small number 
of host species whereas others, such as M. bovis, can infect a broad range of mammals 
including humans. Companion animals are susceptible to MTBC infections and understanding 
of the significance and frequency of these infections has grown in recent years. Cats and dogs 
share unrivalled proximity to their owners and therefore pose a small but real risk for the 
zoonotic transmission of tuberculous infections. Despite the high frequency of mycobacterial 
infections observed in companion animals, diagnostic tests to identify the commonly 
encountered mycobacterial species are lacking.  
The first aim of this work was therefore to improve on the currently available diagnostic test 
methodologies for companion animals. A diagnostic PCR assay was developed and applied 
to 380 histologically confirmed feline and eight canine mycobacteriosis samples. This novel 
assay specifically targeted the mycobacterial species most frequently identified by 
mycobacterial culture (M. bovis and M. microti) and was optimised for use with formalin-fixed 
tissue; a prerequisite for the safe handling of tuberculous tissue from companion animals by 
UK laboratories. The assay was suitable for both feline and canine tissue with a significantly 
quicker turnaround time, higher rate of test positive results and a significant increase in the 
proportion of M. microti diagnoses compared to culture results.  
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Since evaluation of cytokines has shown diagnostic potential in other species, this project 
explored the potential of cytokine profiling in cats for the rapid and sensitive detection of 
mycobacteriosis. By evaluating serum/plasma from 116 naturally infected cats, this study 
demonstrated a consistent elevation in the cytokines associated with macrophage activation 
and antigenic stimulation compared to control cats. Sub-group analysis showed that elevations 
in PDGF-BB were specifically associated with M. microti infections whereas elevated TNF-α 
sensitively identified cats infected with M. bovis. 
Investigation of an unprecedented outbreak of M. bovis associated with the ingestion of a 
putatively contaminated raw food product led to the use of the interferon-γ release assay 
(IGRA) as a screening test for clinically healthy cats, a purpose for which it had not previously 
been evaluated. Nearly a third of clinically normal IGRA test-positive cats were subsequently 
found to have structural disease detected by diagnostic imaging. Though this raises questions 
regarding the specificity of the IGRA in clinically normal cats, it was an invaluable diagnostic 
tool to evaluate individual cats involved in the outbreak.  
The work on feline TB was complemented by similar investigations of canine TB. When an 
outbreak of M. bovis tuberculosis occurred in a kennel of 164 working Foxhounds, a testing 
strategy to successfully bring the outbreak under control and investigate the cause was 
developed. Collaborative work undertaken to screen at risk humans exposed to the hounds 
identified a latently infected person, highlighting the zoonotic risk posed by M. bovis infections 
in companion animals. Eight novel and existing diagnostic testing methodologies were 
evaluated for use in dogs of which a cell-based IGRA, and three serological tests comprising 
a novel comparative peptide ELISA, the Chembio DPP VetTB assay and the Idexx M. bovis 
Ab ELISA showed diagnostic potential for canine TB. Additional analysis employing a 
Bayesian latent class modelling approach revealed that the IGRA developed herein was as 
sensitive and specific as comparable tests in other species. The serological assays were 
shown to have markedly lower sensitivity than the IGRA but had higher specificities. All four 
tests had positive and negative predictive value estimates which indicate that these tests can 
be informative to clinicians who suspect cases of canine TB.   
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A review of 1012 cases of canine TB highlighted an apparently lower incidence of infections 
in dogs compared to cats, but an increased severity of clinical signs when disease occurred. 
To investigate this discrepancy a protocol to derive macrophages from canine and feline bone 
marrow was developed. These cells acquired cell surface molecules indicative of a 
macrophage phenotype during ten days of culture with recombinant CSF-1. The response of 
primary macrophages and the DH82 canine histiocytic cell line was assessed following 
stimulation with LPS, infection with M. bovis Bacille Calmette Guerin, M. bovis AF2122/97 (the 
reference strain) or a clinical isolate of M. bovis. These investigations consistently revealed 
that DH82 cells do not accurately represent primary canine macrophage biology which was 
associated with altered morphology, lack of nitrite production and significantly reduced 
secretion of the pro-inflammatory cytokines IL-6 and TNF-α. Overall, the work presented in 
this thesis demonstrates novel advancement of the diagnostic methodologies for identifying 
cases of companion animal mycobacteriosis and in particular cases of TB. It further begins to 
explore the immunological basis for the clinical differences seen between species that may 




















Lay Summary  
Tuberculosis (TB) caused by the Mycobacterium tuberculosis-complex (MTBC) of organisms 
remains one of the most prevalent and deadly infectious diseases of man and other animals. 
TB infections in humans and cattle often remain latent for prolonged periods of time before 
progressing to disease. Some of the organisms within the MTBC are highly specialised and 
limited to just a single or small number of host species whereas others, such as 
Mycobacterium bovis, can infect a broad range of mammals including humans and pets. 
Our understanding of the significance and frequency of these infections in pet cats, and to 
some extent in dogs, has grown in recent years. Cats and dogs share unrivalled proximity 
to their owners and therefore pose a small but real risk for the zoonotic transmission of 
tuberculous infections. Despite the high frequency of mycobacterial infections observed in 
companion animals, diagnostic tests to identify the commonly encountered mycobacterial 
species are lacking.  
The aim of this project was to improve on the currently available diagnostic tests for 
companion animals and in doing so also developed a greater understanding of the immune 
response of cats and dogs to these infections which will allow future research to explore 
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Chapter 1: Introduction to Companion Animal 
Mycobacterial Disease. 
The genus Mycobacterium sits within the family Mycobacteriaceae, order Actinomycetales. 
Mycobacteria are aerobic (or in some cases, microaerophilic), non-spore-forming, non-motile, 
pleomorphic bacterial rods1-4. They are more resistant to heat, extremes of pH, and routine 
disinfection than almost all other bacteria, properties conferred by their notably thick, 
hydrophobic cell wall, which contains high concentrations of mycolic acids and lipids1-4. The 
cell wall also provides resistance to decolourisation with acid-alcohol1-4. This acid-fast staining 
property, combined with their morphology, make species of the genus recognisable 
microscopically, including in histopathological and cytological specimens1-4.  
The genus contains an increasingly recognised number of species that have been 
documented to cause widely divergent clinical syndromes1,2. At one extreme, these species 
have among them some of the most ancient, notorious, and arguably successful obligate 
pathogens of both people and animals. The most widely known and best characterised 
mycobacterial diseases of people are tuberculosis (most commonly caused by Mycobacterium 
(M.) tuberculosis) and leprosy (caused by M. lepromatosis and M. leprae)2,5. Nine thousand-
year-old human remains in the Eastern Mediterranean contain evidence of the DNA of 
mycobacteria belonging to the M. tuberculosis-complex (MTBC)6, and MTBC DNA has been 
recovered from the diseased bones of a bison trapped in permafrost circa 17,000 years ago7; 
Using the most recent methods to exclude environmental contamination has identified MTBC 
DNA in samples that date from up to circa 5000 years ago8. The MTBC are of significant global 
health concern; one third of the current global human population is estimated to be infected 
with a MTBC organism, of which 5-10% will likely develop active clinical disease9,10, and it is 
estimated that up to 85% of all African bovids reside in areas with a high prevalence of poorly 
controlled bovine tuberculosis11.  
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At the other end of the spectrum are numerous potentially pathogenic environmental non-
tuberculous mycobacteria (NTM). Being opportunistic pathogens in certain circumstances, 
they are now recognized as an increasing global public health problem, particularly in 
immunocompromised patient groups such as cystic fibrosis sufferers12. Of these 
environmental mycobacteria, members of the M. avium-intracellulare-complex (MAC) in 
particular are an emerging threat to human health, with a growing body of evidence that 
hospital admissions due to NTM-associated pulmonary disease are increasing, particularly in 
countries with a low incidence of tuberculosis, typically ascribed to increasing numbers of 
these patients surviving for longer, the use of advanced diagnostic tools, and a larger clinical 
awareness of the role of NTM in disease12.  
The taxonomy of the genus is notoriously complex, and a major overhaul of current taxonomic 
nomenclature may soon become necessary. Two primary systems exist for the taxonomic 
division of the genus. The Runyon scheme was developed in the latter half of the 20th century 
and has dominated the scientific literature until very recently13. It is based on an isolate’s 
laboratory growth characteristics including; substrate usage, growth time until colonies are 
visible, and subsequent colony phenotype. As it is not possible to grow all species under 
artificial (i.e. laboratory) conditions, and with the advent of advancing molecular techniques 
(such as next generation whole genome sequencing), there is an increasing departure from 
the Runyon system towards using molecular phylogeny as the taxonomic basis for speciating 
the genus14.  
Conceptually, mycobacteria can most easily be divided into two main groups:  
1. The members of the MTBC (M. tuberculosis, M. bovis, M. bovis bacille Calmette–
Guérin [M. bovis-BCG] M. africanum, M. pinnipedii, M. caprae, M. canettii, M. orygis, 
M. suricattae, M. mungi and M. microti), which are considered obligate intracellular 
pathogens15,16.  
2. Opportunistic saprophytes which are variably distributed in the environment, 
especially in soil and water systems (both natural and man-made)17. These are 
generally known as the NTM but are alternatively referred to as ‘mycobacteria other 
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than tuberculosis’ (MOTT) or ‘atypical’ mycobacteria18. Of the more than 170 uniquely 
characterised NTM species, approximately 25 have been shown to be potentially 
pathogenic in humans and animals14. This group can be further subdivided in to (i) 
slow-growing (e.g. M. avium). (ii) rapid-growing (e.g. M. chelonae) or (iii) fastidious 
mycobacteria (e.g. M. lepraemurium). The latter group of organisms cannot be 
cultured by routine laboratory methods and have an enigmatic ecological niche (the 
so called “fastidious mycobacteria”). Genetic studies of these organisms typically 
group some of them amongst the slow growers, while others form a separate group 
containing M. leprae (and related bacteria, M. lepromatosis, Candidatus ‘M. 
lepraefelis’19, as well as possibly M. tarwinense, M. visibile and the causative agent of 
bovine mycobacterial thelitis20). 
Although much is known regarding tuberculous mycobacterial infections in humans and cattle, 
fewer studies have reported tuberculosis in companion animals. The importance of 
mycobacterial infections in companion animals has become ever increasingly apparent in the 
last two decades19,21-26. Approximately 1% of all feline biopsy samples submitted for 
histopathological analysis in the UK have been shown to display changes consistent with 
mycobacteriosis, and a third of these have demonstrable acid-fast bacilli (AFB) when stained 
with carbol-fushin using the Ziehl-Neelsen (ZN) method, with a thin rod-like appearance 
indicative of the presence of mycobacteria21. Currently, comparable data do not exist for dogs, 
but the recognition of canine mycobacteriosis is increasing.  
1.1 Feline Mycobacteriosis 
1.1.1 Feline Tuberculosis 
The MTBC consists of phylogenetically highly related species of mycobacteria capable of 
causing tuberculosis in man and/or other animals. Of these species, only M. bovis and M. 
microti have frequently been detected in cats22-26. Successfully cultured samples from cats 
with suspected mycobacterial infections in the only UK study published to date confirmed that 
19% of feline mycobacterial infections were caused by M. microti and a further 15% by M. 
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bovis (data reproduced in Table 1.1)24. Therefore, any given cat with a mycobacterial infection 
in the UK has a greater than a third probability of having tuberculosis. Similar data have not 
been published for other tuberculosis-endemic locations such as the United States (USA).  
Table 1.1: Mycobacterial culture results from UK cats. Samples had histological findings 
indicative of mycobacteriosis and were submitted to the Animal Health and Veterinary 
Laboratories Agency (now Animal and Plant Health Agency [APHA]) for mycobacterial culture 




Number Percentage of total 
submissions 
Percentage of culture positive 
submissions 
M. microti  63 19 40 
M. bovis 52 15 33 
M. avium 24 7 15 
M. malmoense 4 1 3 
M. fortuitum 4 1 3 
M. celatum 1 <1 <1 
M. intracellulare 1 <1 <1 
Unclassified 10 2 6 
No growth 180 53 - 
Culture positive total 159 47 - 
Grand total 339 100 - 
 
M. tuberculosis infection, the leading cause of human tuberculosis, is reported as being ‘very 
rare’ in the cat and it is possible that some (if not all) of the small number of cases of feline M. 
tuberculosis infections reported in the literature could, in fact, have been due to other MTBC 
mycobacteria as historic typing methods are now widely accepted to have been inaccurate for 
sub-classification of the MTBC27. Furthermore, it has been demonstrated that cats have a 
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natural resistance to disease caused by this pathogen based on experimental challenge 
studies28, though the underlying mechanism for this remains unclear.  
Consistent strong geographical predispositions exist wthin feline infections with mycobacteria 
in general. In the UK, M. bovis infections are strongly co-incident with where there are high 
levels of endemic infection in local bovine and wildlife populations such as the south-west of 
England24,29. In comparison, M. microti infections are much more common in areas with high 
prevalence of this infection in the wild rodent population, typically south-east of London, the 
north of England and throughout Scotland24,29.  
Tuberculosis is most frequently diagnosed in adult male cats with a history of frequent hunting 
behaviour24. The median age at which clinical disease presents is three years for M. bovis and 
eight years for M. microti. Unlike human tuberculosis, there is no link between feline MTBC 
infections and classical immunosuppression caused by exogenous retroviral infections i.e. 
feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection, with 
diagnoses of these infections being made as frequently in mycobacteria-infected cats as the 
general UK cat population.   
When the anatomical distribution of lesions is considered in the context that the highest 
incidence of infections occurs in young hunting cats (particularly those catching small rodents), 
that data show mice and voles are permissive hosts for M. microti26 and that mice, rats, stoats, 
mink and ferrets (as well as a wide range of larger mammals) can harbour M. bovis29,30, this 
cumulatively provides good evidence that cats are infected through injuries sustained while 
hunting and fighting. Interestingly, however, this does not fully explain the male predilection 
for clinical disease caused by these infections as female cats are frequently more avid hunters 
than their male counters which should logically increase their exposure to infection. Whether 
or not this difference therefore represents sex-linked differences in innate immune function 
has not been examined to date.  
Spoligotyping and/or genotyping of isolates of both M. microti and M. bovis shows almost 
perfectly matching geographic distributions of feline, bovine and wildlife strains of these 
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mycobacteria in the UK24,29,30. In the case of M. bovis, prey species most probably act as 
intermediate hosts, picking up infections from environmental sources such as areas around 
infected badger setts or other contaminated areas where M. bovis can persist for extended 
periods within the environment30.  
Cases of feline tuberculosis appear to have a lower incidence outwith the UK. This may reflect 
differences in the epidemiology of these organisms – for example, M. bovis has been 
eliminated from much of central Europe, Australia and some states in the USA31-34. However, 
there does appear to be an increase in the incidence of M. microti (in companion animals as 
well as wildlife such as wild boar) in some countries, including France, Switzerland and 
Germany, where M. bovis is no longer considered to be a major concern31-34.   
Cases of tuberculosis have occurred where cats within the same household or in close 
geographical proximity have presented with clinical signs of active disease within a short time 
of each other35,36. It is difficult to interpret the epidemiological significance of such cases as 
these cats will share a single source of prey that may harbour infection (e.g. local woodland); 
it is therefore possible that such infections are independently acquired rather than being 
representative of cat-to-cat transmission. However, multiple within-household cases have 
occurred where at least one cat has had no history of outdoor access (Professor Gunn-Moore; 
unpublished observation). In these cases, cat-to-cat transmission is the putative route of 
infection, probably by close contact such as grooming. Indeed, direct cat-to-cat transmission 
was documented in an outbreak of M. bovis infection in a group of research cats37. It should 
be noted that the number of these cases remains small and the risk to healthy, 
immunocompetent cats in contact with an infected cat is generally considered low. 
Nosocomial transmission of M. bovis has been reported38. In one outbreak, the index case, 
with a purulent ulcerated submandibular lesion, was euthanased and two cats that underwent 
elective surgery in the same practice soon after developed confirmed tuberculous disease. It 
is significant to note that the subsequent cases developed severe systemic disease in a much 
shorter timescale than is typical of disease acquired through sylvatic infection38. While only 
this single well documented instance exists in published literature, this likely reflects under-
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recognition in clinical practice. Similarly, although it has not been definitively demonstrated, 
there is strong circumstantial evidence for humans with active tuberculosis infecting their pet 
cats39,40. This is unsurprising given the small infectious dose of as few as ten mycobacteria 
such as M. bovis required to cause disease in most mammals, including cattle and 
presumptively also cats41,42.  
Clinical Signs 
Most tuberculosis cases present with localised nodular cutaneous disease (Figure 1.1), 
frequently with a degree of ulceration, and occasionally with a draining sinus tract23-25. The 
lesions are typically distributed around the face, extremities and tail base – the so-called “fight 
and bite sites” (Figure 1.2). Skin lesions may be accompanied by a localised or occasionally 
a generalised lymphadenopathy. Lymphadenopathy, usually of the submandibular or popliteal 
nodes, may alternatively be the only presenting sign (termed an incomplete primary 
complex)23. 
 
Figure 1.1: A typical alopecic cutaneous nodule (granuloma) above the right eye of a four-
year-old, male, neutered, retrovirus negative (i.e. negative for FIV and FeLV infections) 
domestic short hair (DSH) cat caused by M. bovis infection. Image courtesy for Rory Lyndon 





Figure 1.2: A facial granuloma (a “fight and bite site”) over the rostro-lateral aspect of the 
temporomandibular joint of a four-year-old, female, neutered, retrovirus negative, DSH cat due 
to M. microti infection. 
A predominately gastrointestinal (GI) form of the disease exists, where granulomas form in the 
intestines24. There is thickening of the intestine, accompanied by multicentric abdominal lymph 
node involvement, almost always including the mesenteric nodes. The subsequent intestinal 
malabsorption causes weight loss, diarrhoea, vomiting and anaemia24. This form of the 
disease was traditionally associated with cats drinking tuberculous cows’ milk and therefore, 
since the introduction of statutory pasteurisation, this presentation has declined in incidence. 
Pulmonary lesions can occur when bacteria are inhaled, resulting in classical tubercle 
formation in the lungs and associated lymph nodes (e.g. sternal, bronchial and hilar). Much 
more common, however, is pulmonary disease secondary to the putative haematogenous 
spread of bacteria from the site of inoculation in the skin. This generates a diffuse interstitial 
pattern of disease43 (Figure 1.3) which eventually becomes bronchial and is clinically 
observable as progressive dyspnoea followed by the development of a soft productive cough. 





Figure 1.3: A right latero-lateral thoracic radiograph of a five-year-old, male, entire, retrovirus 
negative, Egyptian Mau cat infected with M. microti. The radiograph shows diffuse interstitial 
pathology with soft tissue opacity (outlined in yellow) plus peribronchial and sternal 
lymphadenopathy (outlined in orange); these are typical findings associated with secondary 
pulmonary dissemination of tuberculosis in the cat. Radiograph courtesy of Emma Campbell 
(Registered Vterinary Nurse [RVN]). 
Disseminated disease can cause a range of clinical signs, including hepato-splenomegaly, 
pleural and pericardial effusions, generalised lymphadenopathy, weight loss and pyrexia24.  
Ocular involvement (chorioretinitis44, conjunctivitis45) and tuberculous arthritis/osteomyelitis 
have been occasionally reported46,47. 
1.1.2 Non-Tuberculous Mycobacteriosis 
Slow-growing NTM 
These organisms include those whose reference isolates take longer than seven days to 
culture in laboratory conditions48. The MAC organisms are significant within this group as they 
are the most frequently confirmed NTM infection in companion animals, and are also potential 
zoonoses24. Slow-growing mycobacteria that are known to cause disease in cats include: 
MAC49-68 (specifically, M. avium subsp. avium69,70, M. avium subsp. hominissuis71-73 and M. 
intracellulare 74,75), M. genavense76, M. malmoense23,77, M. celatum, M. terrae complex78, M. 






These organisms are defined as those whose reference isolates can be grown in laboratory 
culture conditions within seven days at temperatures of between 24oC and 45oC. Documented 
feline infections include members of the M. fortuitum group23,86-93 (specifically, M. fortuitum,73,94 
M. porcinum,95 and M. alvei95), M. smegmatis group75,87,96,97 (M. smegmatis sensu stricto,73,95 
M. goodii,73,88,95 M. wolinskyi73), M. chelonae/abscessus group86,88,91,98 (including M. 
abscessus subsp. bolletti [formerly M. massiliense99 ]), M. mageritense group,95 M. 
mucogenicum group,75 M. falvenscens,86 M. phlei,100 and M. thermoresistible.73,101-103. Cases 
have been reported from tropical (Brazil94), subtropical (south eastern and south western 
USA88,91,100), and temperate regions, including Australia,95,97,102 New Zealand,75 Canada,75 
Finland,104 Germany,103 UK23 and the Netherlands98,101. Geographical differences exist with 
respect to species incidence; most infections in cats in eastern Australia are caused by M. 
smegmatis group (followed by M. fortuitum),87,105-107 whereas, in southwestern USA, cats are 
most commonly infected with M. fortuitum group, followed by M chelonae/abscessus 
group86,88,90.  
Fastidious NTM 
To date; M. lepraemurium (closely related to M. avium), Candidatus “M. tarwinense” (related 
to the M. simiae group), M. visibile, and Candidatus “M. lepraefelis” (both related to M. leprae 
and M. lepromatosis) have been confirmed as capable of causing “feline leprosy syndrome” 
(FLS) in cats. These infections are reported from New Zealand,108,109  eastern Australia,110,111 
western Canada,112,113 the UK,114,115 south-western USA,116 the Netherlands117. France,118,119 
New Caledonia, Italy,120 the Greek island of Kythira,121 and Japan122.  
Similar to the MTBC (as described in Section 1.1.1), the NTM bacteria most often infect cats 
via presumed cutaneous inoculation, which is reflected in the typical distribution of lesions23. 
Inoculation of the organism directly into subcutaneous adipose tissue appears to increase the 
severity of rapid-growing NTM disease in cats, to which overweight cats are unsurprisingly 
predisposed.   
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Risk factors that have been identified for NTM disease in cats include, the administration of 
immunosuppressive drugs such as exogenous corticosteroid administration69, multidrug 
chemotherapy protocols for lymphoma treatment,20 cyclosporine treatment in the context of 
renal transplantation53, exogenous retroviral infection76,123 (plus lymphoma in one case85), 
idiopathic αβ-T cell lymphopenia (particularly CD4+ αβ-T-cells)83, or concurrent comorbidities 
such as advanced chronic kidney disease and cryptococcosis50. Studies of human 
tuberculosis and NTM infected patients have revealed low body mass index (BMI), specifically 
a low body fat percentage124,125, as well decreased interleukin (IL)-10 and interferon gamma 
(IFN-γ) production capacity by peripheral circulating leukocytes as risk factors for disease 
following infection126,127. Equivalent studies have not been conducted in companion animals, 
so it is unclear how relevant these factors are to veterinary patients. The MAC infections are 
seen more frequently in Somali, Abyssinian51 and Siamese59 breeds of cat, but there is no 
recognised breed predisposition for the other NTM.  
The MAC organisms have been the most frequently successfully cultured of the NTM from UK 
cats23 (Table 1.1); however, the culture data for NTM infections, in general, is inevitably 
skewed by the fact that fastidious organisms cannot be cultured, and by the routine use of 
media most sensitive for MTBC culture (e.g. Middlebrook 7H11 OADC) by many reference 
laboratories in the UK. Therefore, more data need to be collected with regards to the molecular 
epidemiology of mycobacterial infections in cats on a worldwide basis. 
Clinical Signs 
Disease caused by NTM is more variable in clinical presentation than tuberculosis, but 
generally results in (i) (sub)cutaneous nodules, (ii) granulomatous panniculitis, or (iii) 
disseminated disease. The nodular and disseminated forms can have a very similar 
presentation and distribution to tuberculous lesions (i.e. the head, limbs and trunk, Figure 1.4). 






Figure 1.4: An alopecic, erythematous granuloma on the lower lip of a six-year-old, male, 
neutered, retrovirus negative, DSH cat caused by M. avium infection. The lesion is notable for 
its similarity in gross appearance to tuberculous lesions such as those shown in Figures 1.1 
and 1.2. Image courtesy of Laura de los Santos (RVN). 
 
Granulomatous panniculitis is the most common manifestation of disease caused by the rapid-
growing NTM. 75,86,88-91,96-97,104,107,107-111 It is characterised by multiple punctate drainage tracts 
and subcutaneous nodules which can coalesce to form large areas of (mostly) non-painful, 
non-healing ulcerated skin overlaying inflamed fat pads (Figure 1.5). Initially, cats tend to 





Figure 1.5: Extensive subcutaneous panniculitis affecting the (shaved) ventral skin of an eight-
year-old, male, neutered, retrovirus negative, DSH cat caused by M. smegmatis infection. 
Image courtesy of Faye Swinborne (MRCVS, Willows Referral Centre). 
Later in the clinical course, the subcutaneous tissue becomes thickened, the overlying skin 
becomes ulcerated, alopecic and punctuated with fistulae discharging a watery to oily exudate. 
Infection often tends to start in the inguinal region, although it can begin in the axillae, flanks 
or dorsum. The disease may subsequently spread to contiguous areas of the lateral and 
ventral abdominal wall, perineum and tail-base. Severely affected cats may become pyrexic, 
anorexic and reluctant to move, particularly if lesions are secondarily infected with skin 
commensals such as Staphylococcus and/or Streptococcus spp. 
Occasionally, pyogranulomatous pneumonia caused by rapid-growing NTM has been reported 
in cats. These cases usually present with coughing, dyspnoea, fever, malaise, and weight loss. 
These infections have been caused by M. fortuitum in two cats (after aspiration of orally 
administered lactulose in one case)93,133 and M. thermoresistibile, following a bath in 
another102,134.  
Uncommonly reported clinical presentations include peripheral vestibular disease, generalised 
involvement of lymphoid tissue, pulmonary disease, GI disease and intracranial infection 
causing subsequent neurological signs.  
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Infections caused by the fastidious NTM typically manifest as single or multiple cutaneous 
and/or subcutaneous nodules often located on the head, limbs or trunk, and regional lymph 
nodes may be involved135,136. As with the slow-growing NTM, nodules are typically non-painful 
and non-adherent to underlying tissues. The skin over the lesions may be intact, alopecic or 
ulcerated. Lesions caused by M. lepraemurium and Candidatus ‘M. lepraefelis’ tend to be 
found on the head, limbs and trunk (although anywhere on the integument can theoretically 
be involved), or may be widespread, involving many cutaneous sites135. Lesions caused by 
Candidatus ‘M. tarwinense’ are also mostly found on the head (particularly the eyes, lips or 
mouth and front limbs), and it has not been shown to cause widespread cutaneous disease136. 
Cases of M. visibile infection,137 and at least one case of Candidatus ‘M. lepraefelis’,8 have 












1.2 Canine Mycobacteriosis 
1.2.1 Tuberculosis 
There is little published data regarding the incidence of tuberculous mycobacterial infections 
in dogs, and most of the information about this disease’s clinical presentation comes from 
sporadic case reports, mostly of M. tuberculosis138-143 and M. bovis infections144-150. There are 
only very rare individual cases of M. microti infection151. Anecdotally, the incidence of 
tuberculosis in the UK appears to be much lower in dogs than cats, but the clinical severity 
much greater. Dogs typically present with extensive GI disease (weight loss, vomiting, and 
diarrhoea) and pulmonary pathology (Figure 1.6). In the UK, dogs also seem more likely to 
become infected with MTBC pathogens than the other mycobacterial species, though this may 
be an artefact of which infections can definitely speciated with the limited availability of 
diagnostic tests for dogs, rather than a reflection of true incidence. As with cats, the range of 
clinical signs is wide and has been known to include reticulo-endothelial, musculoskeletal, 
cutaneous and/or neurological signs146,147.  
 
Figure 1.6: A latero-lateral thoracic radiograph of a six-year-old, male, neutered, Jack Russell 
terrier dog infected with M. bovis. The radiograph shows multifocal to coalescing areas of soft 
tissue opacity (granulomas; outlined in yellow) distributed throughout the lung fields with 
associated marked peri-bronchial lymphadenopathy. 
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The greatest risk factor reported for a dog acquiring an MTBC infection is for it to be cohabitant 
or in close contact with a human suffering from active tuberculous disease; most cases of M. 
tuberculosis infections in dogs have occurred because of reverse zoonotic transmission from 
an infected human i.e. anthropozoonosis152,153.  
1.2.2 Non-Tuberculous Mycobacteriosis 
Slow-growing NTM 
Typically, MAC organisms are the most frequent slow-growing NTM mycobacteria recovered 
from dogs154-166. Miniature Schnauzers and Basset Hounds are reportedly predisposed154-166. 
M. avium subspecies avium, M. avium subspecies paratuberculosis (MAP) and M. avium 
subspecies hominisuis have all been identified from canine samples154-166.  
Clinical presentations of canine MAC infection include multi-systemic disease, including any 
combination of generalised lymphadenopathy, anaemia, weight loss, hepatopathy and/or 
splenomegaly154-166. As with feline infections, many of these presentations are clinically 
indistinguishable from tuberculosis. 
M. kansasii has been isolated from a three-year-old Whippet with chronic pleural effusion167 
and also from a mammary mass of a  two-year-old Chihuahua168. The latter case also had 
chronic generalised demodicosis implying an underlying immune deficit was present, and it 
subsequently succumbed to the mycobacterial infection after prednisolone treatment for 
cutaneous lymphoma. Disseminated M. genavense infection was diagnosed in a two-year-old 
pug presenting with generalised lymphadenopathy, abdominal organomegaly, pyrexia and 
limb pain169.  
Localised dermal infections in dogs due to M. ulcerans, the causative agent of Buruli Ulcer, 
have been reported in endemic areas of Victoria, Australia170. This organism produced a 
cytotoxin, mycolactone, which is responsible for the deep skin ulcerations that are a hallmark 
of this disease. Although the exact ecology of M. ulcerans has not been determined, it has a 
worldwide but highly focal endemicity, with most human infections occurring in West Africa 
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and the coastal regions of South-eastern Australia. It is suspected that the organism gains 
entry via breaches in the epidermis, possibly in some cases involving mechanical insect 
vectors171. Animal cases have only been reported from Australia, and also include 
possums,172,173 koalas,174 a long-footed potoroo172, alpacas175, horses176 and a cat84.  
Rapid-growing NTM 
Sporadic canine infections have been reported. M. goodii was isolated from a dog with 
uncontrolled hyperadrenocorticism177. Systemic M. smegmatis group infection was diagnosed 
in a young Bassett Hound178 (perhaps due to the same immunological defect that renders this 
breed susceptible to MAC infections). M. fortuitum group skin and pulmonary infections have 
also been reported. 179-183  
Fastidious NTM 
Canine leproid granuloma (CLG) is caused by an, as-yet uncharacterised, fastidious 
mycobacterium related to Candidatus ‘M. tarwinense’ and M. simiae. It has greatest 
prevalence in Australia,184 New Zealand,185,186 Brazil187-189 and the USA190. Zimbabwe (where 
the first case dates back to 1973191), and Colombia have also reported cases. In 2014, a case 
was diagnosed in Europe (Italy) for the first time192 and cases have since been suspected in 
the UK (O’Halloran, manuscript in preparation).  
Over-represented breeds include the Boxer dog and its crosses, Staffordshire bull terriers, 
Foxhounds and Doberman Pinchers. Short-coated hunting dogs, especially Spaniel breeds, 
have also been found to be predisposed and active hunting work has been shown to be a risk 
factor for the disease.186,190  
The route of infection is proposed to be an arthropod vector due to the location of lesions which 
inoculates the mycobacteria into the skin and gives rise to the sites of disease and case 
predilection.  
Clinically, the disease is characterized by cutaneous nodules on the head, especially involving 
the dorsal fold of the pinnae (Figure 1.7), but may also be located on the lateral trunk, rump 
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and/or limbs. Lesions may be singular or coalesce to cover large areas in some animals. As 
lesions get larger, they may ulcerate and can become pruritic if secondarily infected.193 
Affected dogs are typically systemically well and spread of the disease to draining lymph 
nodes, contiguous structures, as well as internal organs does not occur. 
 
Figure 1.7: The first suspected case from the UK of ‘canine leproid granuloma’ lesions on the 
dorsal pinna of a three-year-old male neutered Labrador retriever dog. Image courtesy of 
Fiona Fahy (MRCVS).   
1.3 Diagnosing Mycobacterial Disease in Companion Animals 
A correct diagnosis of mycobacteriosis can be challenging to achieve, in companion animals 
as well as other species including humans and cattle. This is the case for a variety of reasons; 
importantly, several infectious agents can produce overlapping clinical signs whilst diagnostic 
tests can lack sensitivity. 
Importantly, different mycobacterial species carry differing prognoses, optimal treatment 
choice, and zoonotic potential. 
Feline cases that would warrant a high index of suspicion for mycobacterial infection include 
skin nodules or abscesses that do not heal and/or are only partially responsive to first-line 
antibiotic treatment such as amoxicillin. This is particularly true for geographical locations 
where there is traditionally a high prevalence of MTBC (e.g. UK) or feline leprosy infections 
(e.g. south eastern Australia, New Zealand). 
Differential diagnoses of nodular lesions of the skin and subcutaneous tissues include 
infections due to other saprophytic bacterial species (such as Nocardia spp.), fungi and algae, 
eosinophilic granuloma complex, or primary or metastatic neoplasia. 
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1.3.1 Laboratory Abnormalities 
During the clinical examination of any case of suspected mycobacterial infection, it is essential 
to fully establish the extent of any local disease and detect any cases with disseminated 
disease or systemic involvement. 
Serum biochemistry and haematology 
If abnormal, these typically reveal non-specific changes e.g. a stress leukogram. More 
significant abnormalities are usually reflective of more severe or systemic disease and include 
anaemia and an elevated serum calcium concentration.194  
Hypercalcemia and hypovitaminosis D 
Hypercalcemia has been described in human adults with most granulomatous disorders, 
including mycobacterial disease, although the majority of hypercalcemic patients are 
asymptomatic for their hypercalcemia. Reported rates of hypercalcemia in M. tuberculosis-
infected (human) adults vary widely from 6% to 48%195. However, symptomatic hypercalcemia 
in human tuberculosis cases is uncommon, with rates of ∼3% in adults196. The equivalent rate 
of hypercalcemia in companion animals in response to mycobacteria is unknown, but some 
cases have been reported,24,39,194 whether this was causing or contributing to any of their 
clinical signs e.g. anorexia, is unclear.  
Intimately linked with calcium metabolism is that of vitamin D. Briefly, vitamin D is hydroxylated 
in the liver to 25-hydroxyvitamin D (25(OH)D), the form most widely measured to assess 
vitamin D status, and is further metabolized by 1α-hydroxylase in the kidney to 1,25 
dihydroxyvitamin D3 (1,25(OH)2D3; (calcitriol) which is the hormonally active form of vitamin 
D.194-197 Calcitriol increases the concentration of calcium in the blood through increasing 
intestinal absorption, reducing renal excretion and inducing osteoclast-mediated reabsorption 
from bone.194-197 
There is a long-standing association between vitamin D concentrations and mycobacterial 
immunity, and it has recently been shown that calcitriol has a directly anti-mycobacterial 
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activity in vitro, as macrophages are capable of producing calcitriol upon Toll-like receptor 
(TLR)-2 stimulation, when they phagocytose mycobacteria198-200. The result is that circulating 
25(OH)D concentration decreases, and intracellular ionised calcium concentration increases. 
If the extent of infection is large, then these effects become detectable as systemic 
hypovitaminosis D and hypercalcemia.198-200 This phenomenon has been long established in 
human medicine and more recently in feline patients with tuberculosis.194,197 Similarly, in both 
species, the presence of either factor at diagnosis is a poor prognostic indicator. What remains 
unclear, however, is whether these findings are merely a marker of disease which has already 
disseminated (and so will inevitably be harder to treat), or whether they inherently influence 
disease outcome. Some clinical trials in humans have attempted to establish the benefit, if 
any, of supplementing tuberculosis patients with vitamin D during therapy as an alternative or 
in combination with reducing sub-clinical hypercalcemia201-205, but the results to date have 
been discordant, and its use is not currently included in any treatment guidelines.   
The exogenous retroviral status of cats should be established as these infections may be a 
poor prognostic indicator. That being said, FIV and/or FeLV-positivity has not been established 
as a predisposing factor for feline tuberculosis, unlike in humans where disseminated 
mycobacteriosis can be an “Acquired immunodeficiency syndrome-defining” infection,206 and 
where Human Immunodieficiency virus (HIV) infection is a potent risk factor for tuberculosis 
and confers a particularly poor prognosis.207  
1.3.2 Diagnostic Imaging 
Radiography  
Radiography is useful for detecting systemic involvement, especially pulmonary 
dissemination, and for monitoring disease progression and/or treatment response.208 While 
radiographic changes of mycobacterial infection are variable, pathology is most frequently 
seen in the thorax, consisting typically of a diffuse interstitial, alveolar or bronchial pattern with 
peri-bronchial and sternal lymph node involvement observed with increasing disease 
severity.208 It is important to note that no pattern is pathognomonic for mycobacteriosis (e.g. it 
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may also be consistent with a diagnosis of neoplasia or other infection e.g. toxoplasmosis) 
and that observed lung pathology can be mixed.  
Computed tomography 
Similar findings are seen with the use of computed tomography (CT) imaging, though the 
sensitivity of detection is increased with this modality, and a diffuse structured interstitial lung 
pattern is most common, being either nodular or reticulonodular in nature209,210 (Figure 1.8). 
Both imaging modalities also play a key role in monitoring a patient’s response to therapy (see 
Prognosis). 
 
Figure 1.8: A transverse CT scanned section through the thorax of a three-year-old, male, 
neutered, retrovirus negative, Oriental cat caused by M. microti infection. The scan reveals a 
diffuse structured interstitial pattern (black arrow) comprising mixed nodular (orange arrow) 
and linear structures (red arrow), characteristic of a reticulonodular pattern which is typical of 
feline tuberculous pulmonary pathology. Image courtesy of Alison Major (MRCVS). 
 
Abdominal imaging 
This can be achieved using radiography, CT and/or ultrasonography, and can reveal 
hepatosplenomegaly, abdominal masses, mineralised or granulomatous mesenteric lymph 
nodes, and/or ascites.23,24  
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1.3.3 Specific Investigations 
Cytology 
Cytology can be very useful in the diagnosis of mycobacterial disease. Fine needle aspiration 
(FNA) of lesions can be used to prepare glass slides of sampled tissue. Subsequent 
Romanowski-type (e.g. Diff QuikTM) staining may reveal granulomatous to pyogranulomatous 
inflammation with “negatively staining rods” or “ghost bacilli” either within the cytoplasm of 
reactive macrophages and giant cells, or within the extracellular space (Figure 1.9a). 
Subsequent slides are then frequently re-examined following acid fast-staining (e.g. using ZN 
or Fite’s method) to confirm the presence of mycobacteria. A modified ZN-staining procedure 
is occasionally needed for rapid-growing mycobacteria, as they are not as acid-fast as other 
species (Figure 1.9b). An FNA has the advantage of being less invasive than an incisional or 
excisional biopsy, but is likely to have lower sensitivity; particularly in tuberculosis lesions 
which frequently have few (if any) visible mycobacteria.  
 
Figure 1.9a: Left: Cytological appearance of a FNA from a dermal granuloma in the skin of a 
three-year-old male neutered DSH cat due to M. bovis infection, stained with DiffQuick. Fields 
of view (x40 magnification) have been put together to display reactive epithelioid macrophages, 
which contain intracytoplasmic non-staining (“ghost”) bacilli consistent with the presence of 
mycobacteria (black arrows). Right: A Ziehl-Neelsen (ZN)-stained slide made from the same 





Figure 1.9b: A ZN-stained section (x100 magnification) of a granulomatous lesion biopsied 
from the nose of a one-year-old, male neutered, retrovirus negative, DSH cat caused by 
infection with M. microti. Staining reveals numerous positively stained (pink), slender, curved 
bacilli both intracellularly and within the extracellular space suggestive of mycobacteriosis.  
 
Histopathology 
Histopathology is frequently the first line of diagnostic investigation in these cases. The most 
typical approach taken is to surgically remove or biopsy a non-healing skin lesion, 
subcutaneous mass or chronically enlarged lymph node. In some cases, if there is only a 
single cutaneous lesion, this may prove curative.211  
Histopathology alone cannot speciate mycobacteria, and this is needed to establish the risk to 
owners and other animals in the household, potential treatment options, and prognosis. 
However, typical histopathologic findings in most cats with mycobacteriosis include 
granulomatous inflammation with foamy, epithelioid and/or palisading macrophages, 
occasionally with significant infiltration of lymphocytes distributed at the periphery of the 
granuloma and/or neutrophils (i.e. pyogranulomatous inflammation; Figure 1.10).211 ZN-
staining may reveal highly variable numbers of AFB which is idiosyncratically influenced by 
the immune response of the host, the location of the granuloma, and the species of infecting 
organism (MTBC and rapid-growing NTM infections are generally considered have fewer 
visible AFB compared to slow-growing and fastidious NTM infections, though this is not always 
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the case, and is not diagnostic). The use of modified Fite’s or fluorescent Auramine-O stain 
may increase the sensitivity of detection of mycobacteria in histological samples.212  
 
Figure 1.10: Histological appearance of granulomatous inflammation in a two-yeaar-old male 
neutered DSH cat caused by M. bovis infection demonstrating a typical focal, sub-dermal 
organising granuloma with a large area (outlined in black) of central necrosis. This section is 
stained with haematoxylin and eosin and imaged at x10 magnification. Higher magnification 
revealed extensive effacement of the normal tissue architecture with numerous palisading 
macrophages with large nuclei and foamy cytoplasm infiltrating the tissue surrounding the 
necrotic area. ZN-staining of the same biopsy (not shown) revealed moderate numbers of AFB 
within the area of necrosis. Image courtesy of Shannon Street (MRCVS).  
Historically, the pathological picture seen with feline leprosy was divided into a tuberculoid 
form of disease which classically affected young cats with few mycobacteria being seen within 
the lesions, and a separate, leproid form which affected older cats, with numerous 
mycobacteria being seen within the lesions.213,214 Greater insights have been gained from 
recent studies, and the pathology now appears to vary more with infective species of 
mycobacteria than patient demographics, with most infections caused by Candidatus ‘M. 
tarwinense’ and Candidatus ‘M. lepraefelis’ being lepromatous in nature (91-95%), whereas 







Specialist Mycobacterial Culture 
 Isolation of mycobacteria following laboratory culture is currently the gold standard diagnostic 
test for confirmation of mycobacterial infection in UK companion animals24. However, in some 
laboratories it has a low sensitivity and may fail, even when AFB have been demonstrated in 
the lesion24. Ideally, samples should be sent to a recognised reference laboratory e.g. the 
Animal and Plant Health Agency (APHA) laboratory Weybridge in the UK. When culture is 
successful it can take a protracted period for some species to grow visible colonies, e.g. M. 
microti generally requires a minimum of 12 weeks to culture, during which time treatment 
needs to be instigated based on a presumptive diagnosis, especially if this is supported by 
previous histological evidence24,211.  
Drug susceptibility testing of rapid-growing NTM is not only useful for clinical purposes, but 
historically has also been used to provide phenotypic data for typing of isolates (for example, 
susceptibility to trimethoprim, polymyxin B, and tobramycin). The National Committee for 
Clinical Laboratory Standards Mycobacterial Subcommittee has nominated broth dilution as 
the gold standard,5 although this can be technically demanding and is not offered routinely by 
many diagnostic laboratories. 
Molecular Diagnostics 
Polymerase chain reaction (PCR) testing provides a rapid and typically accurate diagnosis 
(excluding contamination) and can be performed on fresh, frozen or formalin-fixed-paraffin-
embedded tissue and Romanowsky-stained (but not ZN stained) cytology slides.215 There are 
currently no commercially available animal specific molecular-based diagnostic tests for the 
detection of mycobacterial species of veterinary importance. Available methodologies in the 
UK are those used for the diagnosis of active mycobacterial diseases in human patients. 
These tests have a high sensitivity for MTBC organisms i.e. those that are significant human 
pathogens, but are not validated for others that are uniquely of veterinary importance e.g. M. 
lepraemurium. The relative probability of successfully achieving a diagnosis from veterinary 
submissions is likely to be related to the number of AFB present in any given biopsy sample. 
Though exceptions have been documented216, as a general rule, it is thought that samples 
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with moderate to large numbers of AFB are reasonably likely to yield a diagnostic quantity and 
quality of mycobacterial DNA; whereas those with few or no AFB are unlikely to provide useful 
results and other diagnostic methodologies are usually considered preferable in these 
instances.  
There is not yet a consensus on a single gene that should be used for the genetic speciation 
of all mycobacteria. Even within the MTBC, the reductive evolution of these organisms 
complicates the picture. The most frequently utilized genes for mycobacterial identification are 
those which encode for; 16S rRNA,215 the 65kDA heat shock protein (hsp65),217 the β-subunit 
of bacterial RNA polymerase (rpoB),218 16-23S rRNA internal transcribed spacer ITS 
region219,220 and, less frequently, the DNA gyrases (gyr). Assays targeting the insertion 
sequence (IS)6110 element for MTB complex,221 IS2404 for M. ulcerans,222  and multiplex 
IS901 and IS1245 for differentiation of M. avium subsp. avium and M. avium subsp. 
hominissuis223 have also been utilised in the diagnosis of small animal infections.53,66  
The MTBC mycobacteria have identical sequences at the 16S rRNA gene, and 16-23S internal 
transcribed spacer (ITS) region and all contain IS6110, therefore other genetic methods, 
including genomic deletion analysis,224 spoligotyping225 and mycobacterium interspersed 
repetitive unit and variable number of tandem repeats (MIRU-VNTR) analysis226 must be used 
to differentiate the members of this group. 
Although its popularity has reduced with the accessibility of genetic sequencing, PCR 
restriction fragment analysis or restriction fragment length polymorphism [RFLP] analysis is a 
commonly used DNA profiling technique for identification of NTMs. This technique involves 
amplification of a particular gene (e.g. ITS227, hsp65228,229, IS1245 for M. avium230), and 






Matrix-assisted laser desorption ionization–time of flight mass spectrometry 
Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF-MS) 
can identify bacterial organisms quickly and cheaply. Although primarily used for cultured 
samples, it is now being used directly on clinical samples. Since the equipment used is 
relatively new, most veterinary laboratories have limited access to this technology; however, 
its use is likely to grow as the technology becomes cheaper and more available. The sample 
is mixed with an energy absorbing organic compound (known as ‘matrix’). The resultant 
crystalized sample and matrix is then ionized by a laser beam. This results in the addition of 
protons to the liberated ions of the sample, after which they are then accelerated at a set 
potential towards a detector. The ions become separated according to the mass to charge 
ratio and the time it takes to reach the detector is known as the ‘time of flight’. The resultant 
mass spectrometry produces a characteristic spectrum known as a peptide mass fingerprint. 
It is this fingerprint that is then compared to known results in a database, and the resultant 
organism can be identified. The available spectral database for mycobacteria is steadily 
improving. Mycobacteria require prior inactivation and disruption of the mycolic acid-rich cell 
wall, both for biosafety reasons (in the case of the MTBC) and to liberate proteins within the 
cells. Success rates vary but the differentiation between MBTC and NTM is usually very 
reliable.231 MALDI-TOF MS requires more biomass compared to molecular techniques, which 
means substantially longer turnaround times for slow-growing mycobacteria.  
Interferon Gamma Release Assay 
The IFN-γ release assays (IGRA) were developed on the principle of quantitatively evaluating 
IFN-γ production by peripherally circulating antigen-specific effector T-memory cells upon in 
vitro stimulation with mycobacterial antigens, to aid the diagnosis of both active and latent 
tuberculosis in bovines, and subsequently adapted for human patients.22 These assays have 
been widely adopted for the diagnosis of tuberculosis in cattle and humans in the form of the 
BOVIGAMTM and QuantiFERON-TB Gold testTM 203 respectively. In humans, the QuantiFERON 
test has been shown to have far greater sensitivity (80%) than the previously used tuberculin 
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skin test (also known as the Mantoux test; see later section) which has a reported sensitivity 
of just 28%232.  
The basis of IGRA tests is that either whole blood or peripherally-circulating blood 
mononuclear cells (PBMC) are incubated in-vitro in the presence of mycobacterial antigens 
restricted to specific subsets of mycobacterial species. The amount of IFN-γ produced is then 
quantified by enzyme linked immunosorbent assay (ELISA).232-235 This value is then 
interpreted to support a diagnosis, in the context of clinical signs and other diagnostic 
investigations.232-235 
The IGRA tests have several advantages over other diagnostic techniques for tuberculosis; 
they are significantly quicker at generating results than culture or even PCR methods, they are 
relatively non-invasive requiring only a single peripheral blood sample, and they can be 
repeated if necessary as conducting the assay does not alter the systemic immune response, 
unlike the tuberculin skin test232-235.  
Since 2008, an adapted IGRA has been validated for use in cats, and the QuantiFERON –TB 
GoldTM assay has been useful in assessing M. tuberculosis infections in dogs.236-238 For the 
feline assay, PBMC are isolated from heparinised peripheral blood samples obtained from 
domestic cats with a high index of suspicion of mycobacterial disease e.g. they have clinical 
signs and/or histological findings indicative of mycobacterial disease236,237. These cells are 
then incubated for four days in vitro across several conditions; 
a) complete cell culture media i.e. negative control,  
b) a mitogen - a potent stimulator of IFN-γ production by all capable cells (i.e. a positive 
control), 
c) purified protein derived from M. avium-complex (PPDA), 
d) purified protein derived from M. bovis (PPDB) and 
e) a combination of recombinant peptides 6kDa early-secreted antigenic target (ESAT-
6) and 10kDa culture filtrate protein (CFP-10).  
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After four days, the amount of IFN-γ which has been released into the cell culture supernatant 
is measured by ELISA. A response to PPDB antigen which is greater than that to PPDA is 
indicative of MTBC infection with a sensitivity of up to 100% in cats.236,237  The response to 
ESAT-6 and CFP-10 can be used to subdivide the MTBC as M. microti does not produce these 
molecules. Both ESAT-6 and CFP-10 are the major secreted antigens coded for at the esx-1 
locus on the region of difference (RD)-1 of the genome239,240. M. microti and M. bovis-BCG are 
RD-1 gene deletion strains as they do not possess the esx-1 locus, but all other members of 
the MTBC do and so encode for these two proteins.236-240 Therefore, in dogs the IFN-γ 
secretion levels that follow a pattern “PPDB > PPDA, and ESAT-6/CFP-10 positive”, would be 
observed in response to either M. tuberculosis or M. bovis infection238. However, in cats this 
pattern is considered diagnostic of M. bovis, as this species is so rarely, if ever, infected with 
M. tuberculosis236,237. Unfortunately, some animals (bovine and feline) infected with M. bovis 
do not respond to the ESAT-6 and CFP-10 peptides by production of antigen-specific IFN-γ; 
a small study showed that this occurred in 20% of cats and a similar proportion (~18%) of 
cattle, so this test does not always reliably discriminate between M. bovis and M. 
microti.236,237,240 
If the response to PPDA peptide is greater than PPDB (and ESAT-6/CFP-10 is negative), this 
is indicative of a MAC infection, while no response to any non-control peptides but where 
mycobacteria have been identified e.g. histologically, indicates an infection with another NTM 
organism240.  
Orthologues of the MTBC molecules ESAT-6 and CFP-10 are encoded by a small number of 
NTM (M. kansasii, M. szulgai, M. marinum, M. riyadhense, M. genavense, M. bohemicum, M. 
interjectum, M. flavescens, M. xenopi, and M. malmoense)242 and so it is possible for patients 
to show a significant response to this protein combination only or in combination with PPDA 
as a result of infections with these organisms. Though no such results have been published, 
they have anecdotally been observed. Given that reports of domestic animals being infected 
with these species are limited to individual case reports243,244, the likelihood of the IGRA false-
diagnosing MTBC or MAC would seem to be low. 
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Screening in-contact animals 
Where animals are known to be in epidemiologically significant contact with a patient that has 
clinically active disease but remains asymptomatic it is possible, unlike with all other testing 
strategies, to submit blood samples for IGRA testing. However, results obtained from such 
testing must be interpreted with caution. Large prospective cohort studies of human patients 
have shown that those with a positive tuberculin skin test (TST: see below) have a 1.4 to 1.7-
fold higher rate of developing active tuberculosis within one year compared to those with a 
negative TST result.245 Three studies provided incidence rate ratios of tuberculosis stratified 
by IGRA as well as TST status at baseline.245 The association with subsequent incident 
tuberculosis in test-positive individuals compared to test-negatives was higher but not 
statistically significant  leading to the conclusion by the World Health Organisation (WHO) that 
both IGRA and TST methods appear to have only modest predictive value, suboptimal 
sensitivity, and do not help identify those who were at highest risk of progression to disease.245 
Therefore, the decision of whether to test in-contact animals and then to instigate therapy or 
not based singularly on IGRA results is currently made at the discretion of individual clinicians 
and animal owners. 
Tuberculin Skin Testing 
The TST (also known as the Mantoux test, Mendel–Mantoux test, Mantoux screening test, 
tuberculin sensitivity test, Pirquet test, or PPD test) is a tool for screening human patients for 
tuberculosis.245-250 The Mantoux method of the TST is the major tuberculin skin test used 
around the world, largely replacing multiple-puncture tests such as the Tine test. 245-250 The 
Heaf test, a form of Tine test, was used until 2005 in the UK, when it was replaced by the 
Mantoux method.251 The TST is endorsed by the American Thoracic Society and Center for 
Disease Control and Prevention (CDC).252,253 Purified protein derivative (PPD) tuberculin is a 
precipitate of species-non-specific molecules obtained from filtrates of sterilised, concentrated 
mycobacterial cultures.248 The tuberculin reaction was first described in humans by Robert 
Koch in 1890 and the test was first developed and described by the German physician Felix 
Mendel in 1908.245 A standard dose of five tuberculin units in 0.1 ml, according to the CDC,253 
31 
 
or two tuberculin units of Statens Serum Institute tuberculin in 0.1 ml solution, according to the 
National Health Service,251 is injected intra-dermally and the test is ‘read’ 48 to 72 hours 
later251-253. A person who has been infected with mycobacteria will undergo a type IV (delayed) 
hypersensitivity reaction leading to a quantifiable swelling at the site of inoculation.254 The 
reaction is read by measuring the diameter of induration (palpably raised, hardened area) 
across the forearm in millimeters.251-254 The test is considered positive if it is greater than a 
pre-defined threshold which is altered depending on; the background risk or the patient, the 
clinical index of suspicion, the endemic prevalence of the country/region and any underlying 
immunological disorders.251-254.  
In cattle; official M. bovis eradication campaigns also use intradermal tuberculin testing as 
statutory diagnostic assays for the detection of M. bovis specific cell-mediated immune 
responses developed during the infection.255-257 Single intradermal skin testing (SIT) detects a 
delayed-type hypersensitivity reaction to the intradermal injection of PPDB, administered at 
the cervical site in Europe or at the caudal fold of the tail in USA and New Zealand.255-257 Three 
days (72 +/- 4 hours) after inoculation, the skin fold thickness at the site of injection is examined 
and measured.255-257  
The single intradermal comparative cervical tuberculin test (SICCT), i.e. comparison between 
PPDA and PPDB, is used in high prevalence areas of bovine M. bovis infections and allows 
better discrimination between animals infected with M. bovis and those infected with MAC or 
environmental mycobacteria which leads to improved test specificity.257 
The use of tuberculin skin testing has been evaluated in both cats and dogs with mycobacterial 
infections and led to unreliable results which did not correlate with the findings of other 
established diagnostic tests and so is not used clinically.238,259 Recent work in cattle has shown 
that performing the SIT/SICCT in ruminants can go on to boost both the cell-mediated and 
humoral immune responses of the individual animals leading to an increase in sensitivity for 
subsequently performed IGRA or antibody assays.258 This effect has not been explored in 
companion animals to date.  
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1.4 Treatment of Mycobacterial Disease in Companion Animals 
Once a diagnosis has been achieved (or while pending culture results but based on clinical 
signs and histopathological findings) the next challenge for clinicians and owners is managing 
a mycobacterial infection in a companion animal. If treatment is to be attempted, obtaining a 
successful outcome requires a prolonged course of multi-antibiotic therapy, and success is 
dramatically influenced both by owner and patient compliance. Drug toxicity, particularly in 
feline cases, and the costs associated with medications and disease monitoring can make 
optimal regimes difficult to maintain.  
Drug-resistant tuberculosis with the detection of multi-drug, extensive-drug or total-drug 
resistant isolates, as well as the continuing human HIV pandemic, has dominated the focus of 
many of the recent changes to anti-mycobacterial drug therapies, including anti-tuberculosis 
therapy.260-262 This is of even greater importance for drugs used in human protocols.  
1.4.1 Treatment of Feline Tuberculosis  
Surgery 
As discussed, by far the most frequent clinical sign of feline tuberculosis is a single or small 
number of skin nodules.23,24 In most cases, these are removed by excisional biopsy facilitating 
a diagnosis to be made. In these cases, complete surgical resection may be curative.211 
However, this cannot always be guaranteed, and adjunctive medical therapy is almost always 
indicated.211 Surgery may be considered for any lesions remaining at the time of diagnosis or 
that may have subsequently arisen. However, there is a significant risk of wound dehiscence 
in many cases. There is no evidence that revision surgery confers a benefit to rigorous medical 
management,211 so is not widely advocated. 
In cases of intra-articular tuberculosis or significant osteomyelitis, medical management alone 
has consistently been found to be inadequate for successful management.47,263,264 This is 
thought to be due to the lack of penetration of anti-tuberculosis medications into the synovial 
space, as well as the aggressive osteolysis caused by these pathogens, often before the time 
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of diagnosis (Figure 1.11). In such instances amputation of all or part (at least one joint above 
the lesion) of the limb with adjunctive medical therapy is often required for a successful 
outcome.47 
 
Figure 1.11: A cranio-caudal radiograph of the right distal forelimb of a four-year-old, male, 
neutered, retrovirus negative Maine Coon cat with an intra-articular infection with M. microti. 
The radiograph demonstrates severe osteolysis of the carpal bones as well as the distal radius 
and ulna (outlined in yellow) surrounded by extensive soft tissue swelling (white arrows). 
Image courtesy of Professor Noel Fitzpatrick MRCVS.   
Medical therapy 
The current CDC and WHO guidance on the appropriate drug combination for human 
treatment has changed and treatment with rifampicin, isoniazid, pyrazinamide and ethambutol 
(combined) for six months is now advocated.265 This regime cannot be readily translated 
directly into veterinary medicine. Isoniazid and ethambutol have been associated with severe 
nephrotoxicity, hepatotoxicity, and neurotoxicity in companion animals, and isoniazid carries 
the further risk of inducing optic neuritis, as such these drugs should not be used as first-line 
therapies for companion animals.266-270 Pyrazinamide is ineffective against M. bovis271 and has 
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also been associated with hepatotoxicity in cats.272 Given the lack of diagnostic capacity to 
rapidly and definitively diagnose the causative agent in companion animal mycobacterial 
disease, the use of pyrazinamide is currently considered contraindicated as a first line agent. 
As an alternative regime, standard first line therapy for feline tuberculosis should comprise a 
fluoroquinolone, a macrolide/azalide and rifampicin.  
The fluoroquinolone of choice is pradofloxacin (where available) due to its excellent safety 
profile in the cat and its known in vitro activity against mycobacteria when compared to older 
fluoroquinolones.95 Where this is not available the use of moxifloxacin is advocated as it has 
a very similar pharmacological profile to pradofloxacin.105 Alternative fluoroquinolones that 
could be considered would be the older drug marbofloxacin or the human drug ciprofloxacin 
(the active metabolite of enrofloxacin273). Enrofloxacin itself is an unacceptable choice in the 
cat due to its association with acute irreversible retinopathy.274 The macrolide/azalide of choice 
is azithromycin due to a dosage pattern of once every 24 hours which eases adherence to 
treatment, plus its concentration within pulmonary macrophages.275,276  
Rifampicin has long been a cornerstone of anti-tuberculosis, and more general anti-
mycobacterial medical therapy. It belongs to the rifamycin class of antibiotics and acts to inhibit 
DNA-dependent RNA-polymerase activity in susceptible bacteria.277 Importantly, it has good 
efficacy against both extracellular mycobacteria as well as those slowly and persistently 
replicating within macrophages following phagocytosis.227 However, it should never be used 
as a monotherapy for mycobacterial disease as resistance develops rapidly.278,279 Rifampicin 
is known to be a potent inducer of the hepatic cytochrome P450 system and so has the 
potential to be significantly hepatotoxic when used chronically.280,281 Before starting treatment, 
it is advised that clinicians assess a patient’s liver function by evaluation of serum biochemistry 
and haematology as well as considering bile acid stimulation testing if there are concerns. 
Treatment with rifampicin should be stopped if circulating levels of liver enzymes significantly 
exceed the upper reference interval, hyperbilirubinemia develops, or patients develop clinical 
signs attributable to hepatic dysfunction. Liver support drugs e.g. S-adenyl methionine (SAMe) 
have been used in a small number of cases both to prevent and reverse increases in liver 
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enzyme activity of feline patients on long term anti-mycobacterial therapy. Once recovered, 
the rifampicin can be re-introduced at half of the previous dose, while continuing with SAMe, 
plus close monitoring to ensure the hepatopathy does not recur. Rifampicin is excreted in all 
bodily fluids and may cause urine, tears, and saliva to discolour to red-orange in color.282 This 
is not clinically significant, but it can be distressing for clients who are unprepared, especially 
as there is the potential for the discoloration to be mistaken for haemorrhage. Deposition of 
the drug within the skin can cause skin discoloration, irritation and, occasionally, hyperesthesia 
in cats; the complete converse of humans where it is used as a therapy for cholestatic 
pruritus.283,284 Rifampicin is unevaluated a potential teratogen and so should only be handled 














Table 1.2: First-line anti-tuberculous medications for use in cats; a triple combination 
comprising one of the fluoroquinolones, a macrolide/azalide and rifampicin is frequently 
used.285  
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Not in dogs <12 
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Hepatotoxicity; induction of 
liver enzymes, anorexia, 
generalized erythema and 
pruritus. 
CNSa signs.  
Discoloration of body fluids. 
PO; per os a Central nervous system b NSAIDs; non-steroidal anti-inflammatory drugs. 
The duration of treatment is dependent on the clinical signs present at the time of diagnosis. 
Three months of triple therapy as outlined should be considered a minimum in all cases.285 
Treatment should be extended for two months beyond the resolution of all clinical signs which 
here also includes any pulmonary dissemination detectable on standard radiography (Figures 
1.13a and 1.13b).211,285 Treatment for cutaneous plus pulmonary disease is typically for six 
months. Monitoring for the resolution of pulmonary changes using CT studies is more difficult; 
due to the increased sensitivity of this modality, subtle changes such as minor scars remain 




Figure 1.12a: A latero-lateral thoracic radiograph of a three-year-old, female, entire, retrovirus 
negative, DSH cat infected with M. bovis. The radiograph, taken at the time of diagnosis shows 
multifocal to coalescing areas of soft tissue opacity (granulomas) distributed throughout the 
lung fields (yellow arrows) with associated peri-bronchial lymph node enlargement (outlined in 
orange). 
 
Figure 1.12b: A lateral thoracic radiograph taken from the same cat following three month of 
triple antibiosis consisting of rifampicin (10mg/kg), azithromycin (10mg/kg) and pradofloxacin 
(5mg/kg) given orally every 24 hours. The radiograph shows complete resolution of the 
previously identified pathology.  
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Therapy for refractory cases is more difficult as it requires the use of drugs which have 
increased frequency and severity of side effects. Rifampicin therapy should be maintained 
whenever possible and can be further combined with isoniazid and ethambutol.211,285 
Treatment should still last for a minimum of three months and two months beyond the 
resolution of clinical signs. 211,285 
Human patients who are believed to have latent infection (as they are IGRA positive for 
tuberculosis, but do not show any clinical signs), may be offered a six-month course of 
isoniazid monotherapy.286 Currently there is no strong evidence to suggest that this reduces 
the incidence of those who go on to develop active disease in cats. However, such prophylactic 
therapy could be considered by individual clinicians on a case by case basis.  
Table 1.3: Second line anti-tuberculous medications for use in cats; a triple combination 
should be used comprising both isoniazid, ethambutol and rifampicin (see Table 1.2).285 
Drug Dosing  Contraindications Side Effects 
Isoniazid 10-20 mg/kg PO q 24hours  Poorly evaluated in 
cats. 
Hepatic dysfunction. 




Acute kidney injury. 









If dosing is maintained, then the prognosis is considered to be fair, with one review stating that 
40% of cases reached and maintained complete clinical remission, though it remains unclear 
as to whether this constitutes bacteriological cure.211 The remaining 60% of cases showed 
variable responses from temporary or partial remission to no response to treatment.211 
However, these data relate to a retrospective cohort, many of which were treated with what 
would be considered sub-optimal therapies, such as short courses of fluoroquinolone as 
monotherapy. With the approach outlined above, clinical experience suggests a positive 
prognosis of 70-80% of feline tuberculosis cases, particularly those with cutaneous and/or 
pulmonary involvement.285 
1.4.2 Treating Feline NTM Infections 
Surgical intervention is often a pre-requisite to obtaining a diagnosis in these cases. However, 
many feline NTM infections are progressive and are likely to recur following the excision of 
lesions, even when clear surgical margins have been achieved. It is, therefore, advisable to 
follow up surgical intervention with adjunctive medical treatment.  
Slow-growing NTM 
The treatment of some NTM infections (particularly M. avium) may be more difficult and less 
rewarding than for tuberculous infections. This is because many of these organisms do not 
readily grow in laboratory conditions, so it has not been possible to generate good sensitivity 
data across many clinical isolates from companion animals. Additionally, the drug resistance 
patterns of these organisms vary widely, not just between species but also between isolates 
of the same species.287 Furthermore, in vitro drug susceptibility testing results do not always 
correlate with in vitro drug activity, as some of the genes which confer resistance (e.g. to 
macrolides) are inducible, so their presence does not necessarily correlate with observed 
susceptibility profiles, especially for MAC organisms.287 The Clinical and Laboratory Standards 
Institute criteria for the antimicrobial susceptibility testing of NTM recommends broth 
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microdilution as the gold standard, preferably performed by a reference laboratory, or similarly 
experienced facility.288  
Most published susceptibility data apply to members of the MAC complex, M. kansasii and 
rapid-growing mycobacterial species.288 Recommendations for susceptibility testing of 
uncommonly isolated species, which have been assessed to be clinically significant in people, 
may include testing against rifampicin, clarithromycin, amikacin, ciprofloxacin, ethambutol, 
linezolid, moxifloxacin, and trimethoprim-sulfamethoxazole.288  
The optimal drug regime is hard to readily determine. It is also important to note that MAC 
isolates are typically resistant to most commonly used second generation fluoroquinolones 
(e.g. enrofloxacin, marbofloxacin, orbifloxacin). Significant pharmacokinetic interactions have 
also been reported in human patients with NTM infections; e.g. rifampicin can reduce the 
bioavailability of both isoniazid and moxifloxacin, resulting in lower serum concentrations but 
extended half-life.289,290 How far this contributes to the emergence of drug-resistant isolates 
and/or worse clinical outcomes is not clear and its implications for feline and canine patient 
treatment are currently unknown.  
Anecdotally, the most successful protocols appear to consist of three drugs from; a macrolide 
(clarithroymycin or azithromycin), a fluoroquinolone (pradofloxacin, moxifloxacin or possibly 
marbofloxacin [in the case of isolates other than M. avium]), plus rifampicin or clofazimine. As 
with tuberculous infections, drug therapy should be continued for two to three months from the 
time of clinical remission to reduce the risk of recurrence. Some cats require extended (up to 
a year) or indefinite therapy to remain asymptomatic. Relapses have also been reported.23 
Rapid-growing NTM 
The management of mycobacterial panniculitis in cats is well described, particularly those 
caused by strains of M. fortuitum in the USA.291-293 The use of lipophilic antimicrobial agents 
directed by susceptibility data and, where appropriate, surgical resection and reconstructive 
techniques has made this an eminently treatable disease in many instances.291-293 All 
infections caused by rapid-growing NTM should undergo culture and drug susceptibility testing 
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but generally; members of the M. smegmatis-complex are usually susceptible to doxycycline 
and fluroquinolones but are often resistant to clarithromycin.294,295 M. fortuitum tends to show 
higher levels of resistance to antimicrobials in general, although also tends to be susceptible 
to fluroquinolones and clarithromycin,296,297 while M. chelonae tends to be resistant to all 
commonly used drugs except clarithromycin, gatifloxacin, and linezolid.296-299 Minimum 
inhibitory concentrations for ciprofloxacin, enrofloxacin, moxifloxacin and pradofloxacin using 
the broth microdilution method have been reported for feline M. fortuitum, M. goodii and M. 
smegmatis sensu stricto isolates.77,88 
In areas such as Australia, where M. smegmatis and M. fortuitum-complex infections 
predominate, treatment should commence empirically with one of the newer generation 
fluoroquinolones (pradofloxacin or moxifloxacin) 19,213,214, whereas in the USA where M. 
chelonae infections are more commonly diagnosed, the best first line choice is clarithromycin 
or azithromycin.296 Multi-drug therapy is ideal to reduce to induction of resistant clones297. 
Thus, the addition of additional drugs (e.g. doxycycline) based on in vitro susceptibility data is 
recommended. In refractory cases, clofazimine, cefoxitin, linezolid or amikacin may be used if 
indicated by drug susceptibility data.19,213,214 
Cases are reassessed every few weeks for evidence of adequate clinical response. In some 
cases, a cure may be achieved with medical therapy alone; however, some may eventually 
become refractory to treatment, requiring wide, sometimes radical, surgical en bloc resection 
of residual infection, and then continuation of appropriate antibiotics for a further few 
months.130 The total duration of therapy for mycobacterial panniculitis caused by rapid-growing 
mycobacteria is usually three to 12 months (ideally, one to two months past clinical resolution 
of signs, as with other mycobacterial classes).130 
Pneumonia caused by rapid-growing mycobacteria, depending on geographical location 
empirical treatment with pradofloxacin and/or clarithromycin should be started immediately 
upon the finding of mycobacteria within diagnostic specimens and then adjusted upon receipt 
of drug susceptibility data.92,103 Treatment should always consist of using two or three suitable 
agents and should be continued for one to two months past resolution of signs.285 Pulmonary 
43 
 
lesions that are refractory to appropriate medical therapy may need to be surgically resected, 
and antibiotic therapy should then be continued post-operatively for several months. 
Fastidious NTM 
There have been rare instances of spontaneous resolution of feline leprosy infections, 
especially those caused by M. lepraemurium,300,301  although most cases require interventional 
treatment to achieve a cure. Definitive treatment guidelines for each of the fastidious species 
are yet to be established because the antibiotic susceptibility of these organisms is largely 
unknown due to the difficulty in culturing these organisms on cell-free media, and a lack of 
data from prospective treatment trials.   
M. lepraemurium grown in cell-culture viability assays suggests that it is highly susceptible to 
rifampicin and clofazamine.302 Although M. lepraemurium appears to be somewhat susceptible 
to dapsone,302 the potential side effects of hepato- and neurotoxicity and blood dyscrasias 
limits the use of this drug use in cats. 
Wide surgical resection of nodular skin lesions, plus clarithromycin combined with rifampicin 
or a newer generation fluoroquinolone, such as pradofloxacin or moxifloxacin (with or without 
clofazamine) appears to be the most efficacious treatment regimen (Table 1.4).19,213,214 As with 
other mycobacterial infections, it is recommended that medical therapy be continued for at 
least two to three months past the resolution of clinical signs or following the resection of all 








Table 1.4: Additional medications for the treatment of NTM infections of cats, in addition to 
those in Table 1.2.19,213,214 
Drug Dosing Contraindications Side Effects 
Clofazimine 4-10mg/kg PO q 24 h 
OR 25-50mg/cat PO q 24 h  












Gastrointestinal signs; most 
frequently vomiting. 
Oesophagitis with the 
doxycycline hyclate salt of 
the drug 
Amikacin 10-15mg/kg q 24 h by 
intravenous, intramuscular 
or subcutaneous injection 




*Due to the potential for photosensitization, cats should be kept indoors for the duration of 
treatment. 
Prognosis 
Data regarding the prognosis of feline NTM infections suggest variable success rates but 
resolution occurs in approximately 60% though the outcome of each case is likely multifactorial 
depending on several factors including the causative agent and the extent of the infection, with 
systemic disease carrying the worst prognosis.19,213,214 Generally, localised infections caused 
by any species have a relatively favourable prognosis if treated with an appropriate 
combination of drugs and surgery, if necessary. Given the nature of the often expensive and 
time-consuming schedule of multidrug therapy for many months many treatment failures result 
from lack of compliance.  
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1.4.3 Treating Canine Tuberculosis 
The basis of therapy for canine MTBC infections is almost identical to that developed for feline 
infections. It consists predominately of medical therapy comprised of triple combination 
antibiosis. As for cats, the preferred combination of rifampicin, a macrolide/azalide and a 
fluoroquinolone (ideally pradofloxacin) should be administered for a minimum of three months 
and for at least two months beyond clinical resolution. In the dog, in addition to the 
fluroquinolones described for use in cats, enrofloxacin is a possible treatment option (Table 
1.5). Because dogs are generally more compliant with the oral administration of medications 
clarithromycin is the preferred choice of macrolide due to its proven in vitro anti-mycobacterial 
efficacy.296 It is also less expensive than azithromycin (because it is available as a generic 
product in the UK) which may be an important consideration when treating large breed dogs.  
Zoonotic transmission of MTBC agents from dogs to their owners has historically been thought 
most likely when the dog has cavitating lung granulomas (tubercles) and a productive cough 
resulting in the expectoration of organisms which can aerosolise and then be inhaled by 
humans in close contact with the patient.41,146,259,304 There has been recent advocacy towards 
the inclusion of antitussive agents such as codeine phosphate into the treatment of dogs that 










Table 1.5: Data for the use of enrofloxacin in the dog.216 
Drug Product Dosing Contraindications Side Effects 
Enrofloxacin Baytril™ 5-20 mg/kg 
PO q 24 h 
Not in dogs <12 
months of age (18 
months in giant 
breeds) due to 
potential adverse 
effects on cartilage. 




The prognosis for canine tuberculosis is considered guarded to poor. This is likely a reflection 
of the advanced degree of systemic disease and consequent multiple organ dysfunction that 
is typically present at the time of diagnosis. It may also reflect an increase in virulence 
associated with M. tuberculosis infection which is relatively common among MTBC infected 
dogs. It is possible, however, that if M. bovis or M. microti infections were recognised early 
and appropriate therapy instigated, then similar outcomes as those seen for feline tuberculosis 
could be achieved.  
1.4.4 Treating Canine NTM Infections 
There is a paucity of canine-specific data due to the rarity of infections, but successful 
outcomes have been achieved following the same therapeutic protocols as those used for 
feline NTM infections. One dog was successfully treated for disseminated M. genavense with 
clarithromycin, ethambutol, and enrofloxacin.169  
Cases of CLG typically resolve spontaneously within one to three months of diagnosis.184,189,303 
The efficacy of reported treatments is difficult to establish; however, occasionally persistent 
infections of greater than three to six months are observed, and in these instances treatment 
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with anti-mycobacterial agents is probably warranted. Where lesions are localised, minimal 
surgical resection and then adjunctive medical therapy is frequently curative. Combination 
antibiotics, known to have efficacy against the slow-growing mycobacteria are appropriate 
choices, for example, pradofloxacin/moxifloxacin, rifampicin, clofazimine and/or 
clarithromycin. Some authors have reported successful use of topical clofazimine in silver 
sulphasalazine, with or without dimethyl sulfoxide.303 
Treatment of M. ulcerans infection in dogs typically involves eight to ten weeks of a third-
generation fluoroquinolone (e.g. enrofloxacin) plus either clarithromycin or rifampicin.170 














1.5 Public Health Risks of Companion Animal Mycobacteriosis  
Before beginning treatment, it is important to ensure that owners and persons in close contact 
with the patient are fully informed of, and clearly understand the potential zoonotic risks 
associated with being in contact with an infected animal. The greatest risk is posed by 
members of the MTBC of mycobacteria: 
 M. tuberculosis: Though rare, infection of any companion animal with M. tuberculosis 
would be considered a significant zoonotic risk.39,41,138,139-143 Finding an infected 
companion animal should trigger a search for a possible infecting human. Infected 
companion animals should be euthanased and their bodies cremated (not buried). 
 M. bovis: Currently, only ~1% of human tuberculosis cases in the UK are caused by M. 
bovis infection.11 Globally, in the last 150 years, only six cases of human M. bovis-
tuberculosis have been published that resulted from exposure to cats, and where 
infections have occurred the cats have had skin lesions discharging purulent material 
containing many AFB.285 Since 2014, Public Health England, Public Health Wales and 
Health Protection Scotland have all considered the risk to humans from M. bovis infected 
pets to be “very low”.305 That said, the risk is still present and should be considered 
seriously in the context of humans with specific risk factors for transmission (see below) 
and the clinical signs present. Extensive and/or purulent lesions pose the greatest risk to 
human health and are generally less responsive to treatment. By comparison, single non-
ulcerated skin lesions and/or regional lymphadenopathy carry very low zoonotic risk and 
may be very amenable to treatment.285 
 M. microti: The risk to humans of M. microti is significantly lower than that of M. bovis.306 
Fewer than 30 human cases of M. microti infection have been documented in published 
literature and 11 (~40%) of these had specific risk factors (see below) – none have been 
shown to have resulted from exposure to an infected cat or dog.306 
 MAC: Whilst not members of the MTBC, this group of organisms can infect humans in the 
presence of specific risk factors (see below) – again, none have been shown to have 
resulted from exposure to an infected companion animal.307 
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1.5.1 Specific Risk Factors for Zoonotic Transmission  
This list has been compiled from advice published by public health organisations from across 
public health services across the UK304,305, the CDC252 as well as WHO guidelines245. Humans 
are considered at heightened risk if they: 
 are under five years old (some sources suggest 12 years) 
 are pregnant 
 are HIV-positive 
 suffer from substance misuse 
 have been diagnosed with diabetes mellitus 
 suffer (severe) kidney disease 
 have ever received a solid organ transplant  
 are a cancer patient receiving chemotherapy or radiation therapy 
 have any medical condition requiring treatment with systemic corticosteroids 
 require specialized treatment for rheumatoid arthritis or Crohn’s disease 
 are receiving tumour necrosis factor alpha (TNF-α) inhibitors 
 have undergone gastrectomy or jejunoileal bypass 
 suffer from silicosis 
In any of the above situations, owners and veterinarians are strongly discouraged away from 








1.6 The Immune Response to Mycobacterial Infection 
The innate immune system is a crucial component of the early response to mycobacterial 
infections.308-314 Myeloid cells of the innate system initiate antimicrobial pathways early and 
throughout infection which are key drivers that can act to limit clinical disease, but conversely 
these cells can also act as persistence niches for mycobacteria. 308-316 Established doctrine 
dictates that, ultimately, protective immunity against mycobacterial infection/disease lies within 
the development of an effective adaptive immune response, and a strong CD4+ αβ T-cell 
response in particular, forming classical adaptive cell-mediated immunity (CMI) within infected 
hosts. 313,314,317,318. 
Cellular immunity is frequently defined as the protective mechanisms of the immune response 
other than antibody production, usually mediated by T lymphocytes, which is readily induced 
in response to intracellular pathogens.313  Whilst the innate and adaptive responses are often 
examined in isolation it is far more probable that in vivo these systems act contemporaneously 
and synergistically.311-313.  
1.6.1 Cells of the Monocyte-Macrophage Lineage 
Many immune cell phenotypes are involved in the response to challenge, infection, control and 
potential elimination of mycobacteria once an individual has been exposed including 
macrophages, classical dendritic cells (cDC), both CD4+ and CD8+ CD3+αβ T-cells, γδ T-cells, 
B cells and natural killer (NK) cells.307-315 
Of all these cells, arguably one of the most critical is the macrophage, as their maturation and 
activation at the site of infection dominates the early stages of the innate immune response 
against mycobacteria.311-314 Cells of the monocyte-macrophage lineage (MML) originate from 
bone marrow and precursors enter peripheral circulation from where they egress into tissues 
and become mature phagocytes.315,319-322 Committed progenitor cells within the MML progress 
through a series of well-defined and morphologically distinct stages; a common myeloid 
progenitor shared with granulocytes gives rise to monoblasts, pro-monocytes and then 
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monocytes which migrate into the blood and extravasate into tissues where they are 
particularly associated with mucosal surfaces. 315,319-322 Similarly, cDC form a phagocytic 
network protecting mucosal and external body surfaces.323,324 
During this differentiation process, macrophages acquire the surface expression of proteins 
which aid the functionality and identification of cells from the lineage.323-326 Such 
immunophenotypic markers include, but are not limited to, cluster of differentiation (CD)14, 
CD172a (also referred to as SIRPα), CD16, CD163 and ADGRE1 (also referred to as 
F4/80).320, 323-326 
The production of mononuclear phagocytes from progenitor cells is directed by colony-
stimulating factors, which are to some extent lineage restricted and hierarchical in their 
actions.319-322  These include macrophage colony-stimulating factor (CSF-1, also known as M-
CSF), IL-34 (an alternative ligand of the CSF-1 receptor [CD115]), granulocyte-macrophage 
colony-stimulating factor (GM-CSF, also known as CSF-2) and fms-like tyrosine kinase 3 
ligand (Flt3L).315-326 These growth factors instruct the common myeloid progenitor to adopt a 
mononuclear phagocyte differentiation fate.319-322   
The biological roles of cells from the MML are complex compared to other mature phagocytic 
cell phenotypes; for example, compared to neutrophilic granulocytes they possess marked 
longevity, play a pivotal role in embryonic development and in post-natal life are critical to 
wound and tissue repair.315-326 However, the defining functional features of mononuclear 
phagoctyes include; the ability to sense and migrate towards gradients of microbial products 
and/or signalling molecules such as certain chemokines, phagocytose large particles such as 
whole microbes (e.g., bacteria, fungi) or dying cells, present antigens to the adaptive immune 
system, secrete chemokine and cytokine mediators resulting in the migration and activation of 
immune and non-immune cells and they exhibit cytotoxic activity against neoplastic or 
senescent cells. 315-326 
Whilst the majority of scientific literature regarding these cells focusses on murine and human 
models, previous work has shown that mature macrophages can be generated from both 
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circulating feline and canine monocytes (monocyte derived macrophages, MDM) cultured in 
vitro in the presence of the recombinant human (rh)-CSF-1 protein.321,325,327-329 These cells 
were defined as being macrophage-like based on their in vitro morphology and surface 
expression of molecules including CD14 and major histocompatibility complex clas II (MHC 
class II) for feline cells, and CD163 on canine cells. 327-329   
Similarly, bone marrow cells cultured in the presence of rh-CSF-1 or recombinant CSF-2 has 
been shown to reliably generate mature macrophages (bone marrow derived macrophages; 
BMDM) in a number of species including sheep,330 cattle,331,332 goats, buffalo, pigs320,334 and 
horses,333 although, to date, not companion animals or humans.334 These studies have all 
shown that these cells fulfil the earlier functional definition of mononuclear phagocytes.330-334  
The generation of cDC in vivo is complex but it is widely accepted that it is Flt3L-dependent.335-
337 In vitro, along with recombinant CSF-2, the terminal differentiation of dendritic cells in vitro 
from CD14+ monocytes also requires the presence of the cytokine IL-4.338,339 
Monocytes, macrophages, and cDC express a large number of cell surface proteins that 
mediate functional roles.315,340-343 Microbial pattern recognition receptors (PRRs) are an 
essential component of innate immunity, they detect and recognise conserved pathogen 
associated molecular patterns (PAMPS), resulting in the activation of stimulated MML cells 
(and neutrophils) as part of the host response to eradicate invading pathogens whilst 
maintaining immunological tolerance by recognition of self.311-316 An important class of PRRs 
is the TLR family which recognise a wide range of microbial pathogens and pathogen-related 
products.311-316 TLRs are expressed to a far higher degree by monocytes than 
neutrophils.315,316 Upon binding of specific ligands, TLRs signal via a pathway involving the 
adaptor protein MyD88, or via a MyD88-independent pathway involving TIR-domain-
containing adapter-inducing interferon-β (TRIF), to activate NF-κβ and stimulate pro-
inflammatory cytokine production from a range of cells including monocytes and 
macrophages.311-316 Other cell-membrane associated receptors cooperate with specific TLRs 
to enhance pathogen recognition, for example, CD14 and MD-2 bind lipopolysaccharide (LPS) 
53 
 
and interact with TLR-4 to facilitate recognition and enhance eradication of Gram-negative 
bacilli from circulation and infected tissue sites.344,345 
In response to mycobacteria, tissue resident macrophages become classically activated, in 
murine studies referred to as acquisition of the M1 phenotype, and produce a plethora of pro-
inflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-10.346-348 Although the mechanisms 
of activation and TLR agonism appear to be remarkably conserved across mammalian 
species, the results of this activation can lead to differing outcomes across the variety of 
species for which this has been studied.332-334 The TLR4 interaction with its co-receptor MD-2, 
CD14 and LPS is perhaps the best-characterised of these activation pathways.344,345 A large 
body of evidence suggests that TLR-4 agonism induces TNF-α expression by macrophages 
from a wide range of species.315,328,329,339,348 In contrast however, whereas mouse and chicken 
BMDM respond to LPS stimulation by upregulating arginine metabolism, inducible nitric oxide 
synthetase (iNOS) and nitric oxide synthase 2 (NOS2) to produce free radical ‘reactive 
nitrogen species’ (RNS);334,349 stimulated BMDM/MDM from rabbits, sheep, goats, monkeys, 
horses, and badgers do not349-356. Previous evaluation of bovine alveolar macrophages has 
conflictingly shown that these cells, unlike BMDM derived from this species, are able to induce 
NOS2 mRNA and produce nitric oxide (NO) in response to LPS.356-359 It is not currently known 
if this reflects differences in study protocols or functional and/or true metabolic differences 
between the cell types of possibly differing maturation states and disparate locations. Recently 
published comparative genome analysis has hypothesised that the species differences may 
be explained by variations in distant upstream gene promoters which are relatively poorly 
conserved.356  
There are also pathogen associated differences, for example M. tuberculosis does not induce 
NO production from human MDM in vitro whilst M. avium induces a significantly greater NO 
response than uninfected control cells.360 This may be part of the explanation for the host 
restriction of mycobacteria so that some species such as humans can be persistently infected 
with M. tuberculosis without always developing clinical disease.  
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Overall, however, the relative role that alternatively activated metabolic pathways may have in 
contributing to the comparative susceptibility or resistance of an individual or species to 
mycobacterial infection or disease remains untested. Whilst a theoretical contribution has been 
argued for in the literature,354 no link has yet been proven and to date there is no experimental 
evidence to definitively support the hypothesis that macrophages which do not produce NO 
are more permissive to mycobacterial replication or less competent at mycobacterial killing 
than those that do.  
1.6.2 The Initiation of Infection 
Infection with Mycobacteria spp. begins once the physical barriers to infection are 
breached.361-368 Primarily in humans, cattle and in occasional companion animal cases, 
tuberculous infections occur via the respiratory tract.285,361-368 Small aerosols consisting of 
droplet nuclei which contain an infectious dose of MTBC mycobacteria are expectorated by an 
individual animal (of the same or different species) with active pulmonary disease; this dose 
is considered to be as few as one to ten viable colony forming units (CFU) for most species.361-
368  Due to the small size of the droplets they can remain aerosolised for extended periods of 
time, and are subsequently inhaled by a susceptible individual. 361-368   
Also by virtue of their small size, these inhaled particles are able to avoid the physical bronchial 
defence mechanisms and penetrate into the terminal alveolar space whereupon the 
mycobacteria present are recognised and engulfed by phagocytes; predominantly alveolar 
macrophages and cDC. 361-368 Mycobacteria may also interact with non-phagocytic cells in the 
alveolar space including alveolar endothelial cells and both Type 1 and Type 2 
pneumocytes.361-368 The interaction between parenchymal cells and infectious organisms is 
thought to be enhanced by the presence of IFN-γ, which is itself produced in response to such 
an infectious challenge.369 
In cases where the respiratory tract is not the primary site of infection, as occurs in the majority 
of feline mycobacteriosis cases, the skin is breached e.g. by a bite from an infected rodent, 
leading to direct intradermal inoculation of the bacteria.23,24,285 This almost certainly then allows 
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them to be directly exposed to resident (i.e. mature) tissue macrophages and cDC, as occurs 
with intradermal vaccination in other species.370,371 This interaction is known to be extremely 
rapid; studies of intradermal vaccination of neonatal calves with M. bovis-BCG demonstrated 
trafficking of mycobacteria-laden antigen presenting cells to the local lymph node within half 
an hour of inoculation and MAP has been shown to translocate across the bovine gut with 
similarly rapid kinetics.372-376  
In gastrointestinal cases of mycobacterial disease (Section 1.1.1), the bacteria are understood 
to be phagocytosed by gut-associated macrophages.373-376 Macrophages and antigen 
presenting microfold cells of the gastrointestinal mucosa play a unique role in host immunity 
and tolerance.377,378 These cells reside predominately within the lamina propria (with fewer 
present deeper within the muscularis and sub-muscosal gut layers) and gut-associated 
lymphoid tissues such as the Peyer’s patches.375,376 Microfold cells exist within close proximity 
to vast numbers of commensal bacteria and under normal healthy state conditions murine 
cells are known to constitutively possess an anti-inflammatory gene expression profile and 
transcriptome, for example producing IL-10 and transforming growth factor (TGF)-β.379 Holding 
this state is believed to be essential for maintaining tolerance to commensal bacteria and food 
antigens and can become dysregulated in disease states such as inflammatory bowel disease 
(IBD).377-380  
The mechanism of invasion of the alimentary system by mycobacteria in companion animals 
has yet to be investigated; however, the example of the comparatively well studied bovine 
model of paratuberculosis (Johne’s disease) may provide some insights into the mechanisms 
involved in other species. Johne’s disease in ruminants is caused by MAP which breaches the 
host gastrointestinal defences to establish a chronic infection.375,376 The preferred route of 
entry for MAP is thought to be direct microfold cell invasion mediated by the formation of a 
fibronectin bridge between MAP organisms and microfold cell surface integrins.381 The 
mycobacteria then traffic rapidly to the mesenteric lymph nodes where they establish 
persistence niches, in part by preventing the formation/maturation of the phagolysosome.382 A 
supplementary cellular invasion mechanism for MAP is direct entry into epithelial cells via the 
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apical surface, whereupon an as yet ill-defined phenotypic change in the mycobacteria 
facilitate increased direct invasion of both other epithelial cells and gut-associated MML 
cells.375  
Studies of white-tailed deer (Odocoileus virginianus) naturally infected with M. bovis have 
identified a high frequency of lesions (over 76% of infected animals in one study) with lesions 
in the palatine tonsils.383,384 Similarly in cattle a lower but still significant proportion (40%) of 
skin test positive cattle naturally infected with M. bovis had lesions within the palatine 
tonsils.385,386 This suggests that the tonsils may play an important role in the pathogenesis of 
tuberculosis in ruminants and possibly in other species too.383-387 The tonsils are ideally located 
to sample bacteria entering through the oral or nasal cavities; mycobacteria may become 
trapped within tonsillar crypts, where follicle-associated epithelia actively take up 
microorganisms via microfold cells, a process which may have a significant impact on the 
efficacy of oral mycobacterial vaccines.386-390 
It is possible that the same or similar mechanisms to these may allow NTM and MTBC 
organisms to invade the alimentary system of companion animals and cause clinical disease.   
1.6.3 Phagocytosis and Antigen Presentation 
Phagocytosis of pathogens, apoptotic cells and debris is a key feature of MML cell function in 
host defence and tissue homeostasis.315,316,319,321,323 Phagocytosis is a process by which 
macrophages and other phagocytic cells take up relatively large, extracellular particulate 
material, such as bacteria and senescent cells, degrade them in a controlled manner and 
subsequently present antigen epitopes to T-cells. 313,315,316,319,321,323   
The agonism of PRR on MML cell surfaces induces a cascade of signalling events; the 
phosphorylation of multiple tyrosine kinases, cellular membrane extension, pseudopodia 
formation, actin polymerisation, reorganisation of the actin-based cytoskeleton, formation of a 
cell membrane bounded vesicle enclosing the phagocytosed particle and its engulfment into 
the cytoplasm to generate the structure of the early phagosome which continues to develop 
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and mature.391-400 Phagocytosis of mycobacteria can occur through a diverse range of 
mechanisms, such as opsonic phagocytosis whereby foreign material is coated in proteins 
present in serum, namely complement proteins and antibodies, which subsequently bind to 
specific receptors on the surface of phagocytic cells i.e. complement receptors or 
immunoglobulin-G constant region receptors (FcγR1 [CD64], FcγR2 [CD32] and FcγR3 
[CD16]).391-400 In addition, non-opsonic phagocytosis can occur when phagocytes recognise 
and directly bind PAMPs on the surface of pathogens via receptors such as CD14 and 
CD163.391-400 
Phagocytosis is a major target of mycobacterial immune evasion (Section 1.6.5), but in 
instances were phagosome maturation is completed, these organelles fuse with lysosomes 
which carry an arsenal of hydrolytic enzymes and anti-microbial peptides to form the 
phagolysosome.391-400 The acidic and highly oxidative environment of the phagolysosome is 
essential for the activation of cathepsins, oxidants and cationic peptides with the goal of 
eventually leading to pathogen lysis and clearance.391-400 
A further essential downstream function of phagocytosis is the presentation of antigen to 
CD3+αβ T-cells (Figure 1.13).401-416 This process requires pathogen components generated by 
phagolysosome-mediated lysis to be loaded onto major histocompatibility complex proteins, 
to be trafficked through the Golgi apparatus to the cell surface where the antigen epitope is 
presented to the T-cell receptor of naïve cells.401-416 Mature, tissue resident cells of the MML 
(i.e. macrophages and cDC) possess all three of the MHC subtypes; class I , class II and class 
III.401-416 The mononuclear phagocytes predominantly present antigen in association with MHC 
class II molecules.401-416 In addition B-lymphocytes (also referred to as B-cells) are also 
professional antigen presenting cells despite their absence from mucosal surfaces and their 
inability to phagocytose.401-416 Instead the uptake of antigen is via receptor-mediated 
endocytosis.401-416 The B-cell receptor has uniquely high affinity for a given antigen and the 
processing of antigen onto MHC class II is therefore extremely efficient, even when the 
quantity of antigen is low. 401-416 This interaction in shown in Figure 1.13 and the role of B-cells 
in mycobacterial infections is discussed in Section 1.6.4. 
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Classically, antigen derived from phagocytosis or endocytosis becomes surface-associated 
with MHC class II and is then presented singularly to naïve CD4+CD3+ T-cells whilst cytosol 
derived antigens are presented on MHC class I to CD8+CD3+ T-cells.401-416 However, cDC 
have enhanced antigen presentation capacity compared to macrophages and will readily 
“cross present” phagocytosed antigen epitopes to both CD3+ T-cell subsets.401-416 This is 
shown schematically in Figure 1.13. 
 
Figure 1.13: A schematic representation of antigen presentation pathways utilised by the 
professional antigen presenting cell phenotypes: macrophages, classical dendritic cells and 
B-lymphocytes to naïve CD4+ and CD8+ CD3+ αβ-T-cells subsets via MHC classes I and II. 
Reproduced from Lybaert et al. (2017) In view of personalized immune-therapy. Advanced 
Science, 4(6):1-8.     
1.6.4 The Role of B-cells in Mycobacterial Infection  
The intracellular nature of mycobacterial pathogenesis results in the development of a strong 
CMI response with the production of antibodies historically only thought to occur in the late 
stages of disease progression.417-421 Activated B-cells, defined (in mice) by surface CD19 
expression, and plasma cells, defined (in mice) by surface CD138 expression, are generally 
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considered to play a supportive role in the response to MTBC organisms as opposed to an 
essential or critical one.417-421 However, B-cell aggregates have been demonstrated in 
proximity to MTBC mycobacteria in infected mice, cattle, humans and non-human 
primates.422,423 The role of these co-localised B-cells may include enhancement of the CMI 
response by providing an alternative mechanism for antigen presentation, antibody dependent 
cytotoxicity and/or activation of the classical complement cascade which requires antibody-
antigen complex formation.417-423 For example, the opsonisation of M. tuberculosis with 
antibodies present in autologous heat-inactivated sera has been shown to enhance 
phagocytosis, intracellular mycobacterial killing and pro-inflammatory cytokine production by 
macrophages,424 suggesting that there may be an enhancement of the immune response 
against mycobacteria by the activation of B-cells, and possibly for the mycobacteria of the 
MTBC in particular. 
Though considered to be a proportionately minor part of the adaptive immune response to 
MTBC, the presence of specific antibodies in circulation provide an attractive option for the 
development of novel diagnostic tests.257,430 Serodiagnostic assays by their nature are 
comparatively cheaper and quicker than tests relying on the detection of delayed 
hypersensitivity (i.e. CMI) responses to inoculated mycobacterial antigens (tuberculin, or PPD) 
such as the human TST or bovine SICCT430 which are described in Section 1.1.3. Antibody-
based tests are additionally beneficial as they can be used to test an individual animal at a 
single time point,257 which is particularly useful for wildlife reservoirs of infection such as the 
Eurasian badger (Meles meles) in the UK425,426 and white tailed deer in the USA compared to 
tuberculin testing which require the test to be “read” after a set time interval.427-429  
Early investigations into the utility of serodiagnostics for the detection of bovine M. bovis 
infections initially utilised relatively crude mycobacterial lysates such as PPDB but found these 
assays to have poor specificities, presumably at least in part due to the large number of shared 
antigens between MTBC and environmental mycobacteria, to which many cattle are likely 
sensitised in the course of grazing pasture.430 The elucidation of (bovine) immunodominant 
antigens within PPDB which are specific to M. bovis (and other MTBC mycobacteria) such as 
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MPB70 (a soluble secreted protein), MPB83 (a glycosylated lipoprotein), ESAT-6 and CFP-10 
have greatly improved the specificity of these assays.431-433 A number of such testing protocols 
and products are now commercially available and these have reported specificities of up to 
98%.431-433  
The IDEXX M. bovis Ab assay (IDEXX Laboratories, USA) is a conventional antibody capture 
ELISA based system which detects circulating antibodies against MPB70 and MPB83.434,435 
This system can be automated, providing the capacity for whole herd screening programmes 
which are both rapid and economical.434 Waters et al. (2011) evaluated this assay using sera 
collected from naturally infected cattle from four countries; the USA (n=122), the UK (n=188), 
Eire (n=130) and New Zealand (n=42).434 The sensitivity varied greatly by country with as high 
as 77% reported for UK cattle but only 40% for New Zealand cattle.434 It is probable that the 
drop in sensitivity is a reflection of the lower prevalence of infection in New Zealand (and the 
USA) compared to the UK as this, by definition, has a profound impact on the sensitivity and 
positive predictive value of any diagnostic test. Alternatively, it may reflect differing stages of 
disease with more advanced disease (such as a lesioned phenotype) increasing the circulating 
antibody titres and therefore sensitivity of this and other serodiagnostic assays.   
Enfer Scientific (Eire) have developed a multiplex fluorescence immunoassay which utilises 
antigen arrays to detect antibodies specific against up to seven M. bovis antigen preparations 
in several species, including cattle, goats, banded mongooses (Mungos mungo) and alpacas 
(Vicugna pacos).435-440 The sensitivity and specificity obtained in cattle with this immunoassay 
has varied with the population under study.435-437 In goats confirmed as M. bovis infected by 
SICTT, histopathology and culture, the multiplex test detected 57/60 (95.0%) of positive 
animals in one herd and 120/120 (100%) in a second herd and gave positive signals in a 
further 4% of SICTT-negative animals.439,441 It has been reported as having a lower sensitivity 
in the UK for detecting M. bovis infections in cattle when compared to the BOVIGAMTM IGRA 
(by approximately 10%) but critically it has the capacity to differentiate between M. bovis 
infected and M. bovis-BCG vaccinated calves,436,437 making it potentially useful as a DIVA 
assay (discrimination between infected and vaccinated animals) which is an essential pre-
61 
 
requisite to the widespread introduction to cattle herds of M. bovis-BCG as a vaccine  against 
bovine tuberculosis in the UK.   
Chembio Diagnostic Systems (USA) have developed rapid animal-side testing platforms 
including two dual path platform (DPP) assays; the VetTB Assay for Cervids and the VetTB 
assay for Elephants which detect M. bovis and M. tuberculosis infections respectively.442-444 
The DPP technology involves two nitrocellulose strips which are connected in a “T” shape 
inside a cassette device (Figure 1.14). This allows independent delivery of the test sample and 
the antibody-detecting reagent, in contrast to the single-strip format used previously e.g. in the 
CervidTB STAT-PAK test.430 The DPP VetTB test requires as little as 5μL of serum sample 
and provides a cage side result that can be obtained within approximately 20 minutes.442 The 
presence and intensity of the visible line produced in response to either of the two separate 
antigens used, MPB83 and a CFP10/ESAT-6 fusion protein can be assessed.442 
 
Figure 1.14: The VetTB Assay for Cervids. The sample well (top left) and the buffer well 
(bottom centre) form a ‘T-shape’ nitrocellulose strip. A positive antibody response leads to the 
development of a visible line within the result window (top right) after approximately 20 minutes 





1.6.5 Mycobacterial Avoidance of Host Immunity 
Following phagocytosis, rather than initiating the mechanisms described above for pathogen 
degradation and subsequent antigen presentation, mycobacteria have evolved mechanisms 
to evade immune mediated destruction.446-449 This may lead to intracellular replication within 
MML cells, and for mycobacteria to be able to survive for an extended period prior to the 
development of an effective CMI response.446-449  Development of CMI has been shown to 
take approximately two to eight weeks to reach (diagnostically) detectable levels in humans 
following M. tuberculosis infection235 and approximately four weeks following experimental 
bovine infection with M. bovis.445 This delay in the induction of CMI may occur in part due to 
virulent mycobacteria possessing a multitude of evasion tactics which aim to subvert the early 
phases of the host innate immune response and thus allow mycobacterial replication and the 
establishment of infection. They inhibit host defence mechanisms such as phagosome 
maturation, phagolysosome fusion, antigen processing and presentation as well as IFN-γ 
signalling.446-449  These mycobacteria may also escape the phagosome into the cell cytoplasm 
whereupon they reinstate or maintain an environment conducive to their own survival and 
replication by scavenging toxic oxygen radicals and RNS produced by the host to kill them.446-
449 
The RNS, are toxic to mycobacteria and are produced by macrophages via calcium-insensitive 
iNOS upregulation.198,396 MTBC organisms can avoid host-mediated killing by preventing the 
fusion of RNI-containing lysosomes with phagosomes and by directly detoxifying RNIs.446 For 
example the PPE2 protein encoded by M. tuberculosis travels to the host nucleus and inhibits 
NO formation.4501,451 At least a further 30 genes are upregulated in MTBC mycobacteria when 
cultured in the presence of RNS including two haemoglobin-like molecules which may act as 
“nitrogen sinks”, demonstrating that these pathogens have evolved a significant number of 
mechanisms to avoid host mediated destruction by this mechanism.450,451 During this process 
mycobacteria become established within the protected niche of the innate immune cells, where 
they can persist, potentially indefinitely.  
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As discussed in Section 1.6.1, the recognition of highly conserved PAMPS by specific PRR is 
a pivotal early stage in the co-ordination of the host immune response against mycobacteria.346 
Cellular components of mycobacteria are recognised by host receptors including TLR-2 and 
TLR-4, nucleotide-binding oligomerisation domain (NOD)-like receptors, dendritic cell-specific 
intercellular adhesion molecule grabbing non-integrin (DC-SIGN), dectin-1 and C-type lectins 
including CD206 (the mannose receptor).344,345,452 These receptors may be expressed by both 
immune and non-immune cells e.g. fibroblasts and epithelial cells.452 An intracellular signalling 
cascade is initiated following PAMP recognition by TLR which leads to altered gene expression 
downstream through transcriptional regulation.452 Binding to other receptors such as DC-
SIGN, CD206 and complement receptors may provide alternative routes of MML cell entry for 
mycobacterial species; for example M. tuberculosis has been shown to specifically target DC-
SIGN on human pulmonary cDC (but not alveolar macrophages) as a mechanism of entry, 
following which, further cDC maturation is impaired reducing IL-12 secretion whilst they are 
induced to produce IL-10 and so act to supress the activation of other local immune cell 
phenotypes.453,454  
Stimulation of the TLR-2 and TLR-4 receptors as well as the TLR-1 and TLR-6 receptors by 
mycobacterial derived ligands results in downstream activation of the nuclear transcription 
factor NF-κβ which in turn leads to the up-regulation of genes encoding pro-inflammatory 
cytokines TNF-α, IL-1β and IL-6. 344,345 The expression and secretion of a range of 
chemokines, reactive oxygen and nitrogen species including NO is also induced. The pro-
inflammatory response is regulated by a negative feedback mechanism in order to prevent 
host tissue damage from a cytokine storm or systemic inflammatory response syndrome 
(SIRS).455-457 This feedback is mediated by a family of tyrosine kinases (Tyro3/Axl/Mer aka 
TAM) which restrict TLR mediated signalling.455-457 This endogenous negative feedback is 
exploited by the MTBC. Mycobacteria directly agonise TLR-2 for prolonged periods, resulting 
in endogenous downregulation of MHC class II in a subset of macrophages, reducing their 
ability to present antigens.455-457 It has been suggested that this subset of macrophages 
cannot, therefore, subsequently prime naïve T-cells and so provide a niche for mycobacteria 
to persist out with host recognition.455-457 
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The evasion of macrophage-mediated destruction allows mycobacteria to replicate within the 
phagosome and induce necrosis of the engulfing cell. The released bacilli can continue to 
replicate extracellularly and are subsequently taken up by surrounding phagocytes. Whilst 
macrophages continue to fail at halting mycobacterial replication, cDC migrate to the local 
lymph node and prime CD3+ T-cells (both CD4+and CD8+ subtypes) against mycobacterial 
antigens. As discussed above, the subversion mechanisms mycobacteria enact differ between 
cDC and macrophages, the persistence mechanisms which target cDC in particular may 
facilitate wider dissemination of infection via lymphatic drainage whereas intra-macrophage 
persistence would seem more likely to allow local infection to establish at the initial point of 
challenge. The delay in infected cells reaching lymphoid centres has the effect of delaying the 
instigation of the adaptive immune response and therefore allows mycobacterial persistence.  
Apoptosis, an alternate mechanism of cell death, can also be manipulated by mycobacteria. It 
has been shown that there is increased CD4+ and γδ T-cell apoptosis when cells from (human) 
tuberculosis patients are cultured with M. tuberculosis antigens compared to those from 
healthy controls.458-461 Similarly, pulmonary tuberculosis is associated with increased soluble 
FAS ligand concentrations, decreased lymphocyte proliferative responses, reduced IL-2 
secretion and IL-2 receptor expression whilst T-cell apoptosis also occurs in areas of caseous 
necrosis within tuberculous granulomas.458-461 
1.6.6 Granuloma Formation  
The hallmark lesion of mycobacterial infections, including tuberculosis, is the granuloma; a 
compact, organised aggregate of immune cells formed as part of the host immune response 
to the persistent stimuli of pathogens.462-464 The formation and structure of mycobacterial 
granulomas have been studied in significant detail in recent years with the development of a 
zebrafish (Danio rerio) model using infection with M. marinum.465 The most impressive feature 
of this model is the ability to perform non-invasive, high-resolution, long-term time-lapse and 
time-course experiments to visualise infection dynamics with fluorescent markers due to the 
transparent nature of the host.465 This, coupled with the ease of genetic manipulation since 
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the advent of CRISPR-Cas9 technology, has allowed studies to be performed which had 
previously been impossible in other model species. For example, one recent study compared 
the time taken to achieve granuloma formation, or lack of it, in zebrafish deficient in the RAG1 
gene which is essential for the development of an adaptive lymphocyte immune 
response.466,467 In-depth characterisation of bovine and human granulomas formed during M. 
bovis and M. tuberculosis infections respectively has shown a remarkable level of cross-
species conservation of the key features of granuloma formation.468-470   
Immune cell types present within a granuloma include macrophages, cDC, neutrophils, αβ T-
cell subtypes, γδ T-cells, NK cells and reactive stromal cells; all of these cells produce a 
complex array of cytokines and chemokines which act to drive granuloma development (Figure 
1.15).468-470 As discussed above, following phagocytosis, mycobacteria-induced inhibition of 
phagosome-lysosome fusion enables the intracellular survival and replication of pathogen 
within macrophages which rupture, releasing mycobacteria into the extracellular space leading 
to the local recruitment of macrophages and dendritic cells. 
 
Figure 1.15: Structure and cellular constituents of the tuberculous granuloma. Reproduced 




Within a granuloma, some macrophages undergo transformation to have tightly interdigitated 
cell membranes that link adjacent cells; these epithelioid cells can be highly phagocytic but in 
some cases do not contain bacteria at all. 468-470   Granuloma-associated macrophages can 
also fuse into multinucleated giant cells or differentiate further into foam cells, which are 
characterised by lipid accumulation that givens them their foamy appearence.468-470   Foam 
cells have been noted to be most frequently located at the rim of the necrotic centre of a mature 
tuberculous granuloma. The consequences of these changes are not well understood, but in 
general, foam cells and multinucleated giant cells have been reported to contain only a few 
mycobcateria, if any. Mycobacteria are most commonly present in the central necrotic areas 
in which dead and dying macrophages can be seen.468-470   
Mycobacteria laden cDC migrate via lymphatics to the local lymph nodes and present antigen 
via MHC class I and upregulated surface MHC class II to naïve T-cells resulting in priming of 
both CD4+ and CD8+ subsets.468-470 The primed antigen specific T-cells migrate back to the 
focus of infection under the influence of chemokines such as the CXCL11-CXCR3 axis.468-470 
Subsequently, an accumulation of activated, occasionally necrotic, macrophages and mature 
cDC exist in the centre of the granuloma surrounded by tightly adhered (palisading) 
macrophages which develop an epithelioid phenotype.468-470 Surrounding this are activated 
fibroblasts which being to lay down a fibrous capsule which is then, in turn, ringed by primed 
T-cells, giving rise to the formation of a “classical” granuloma at the site of infection as is 
frequently seen in human and bovine tuberculosis infections (Figure 1.15).468-470 
Within a granuloma, the secretion of cytokines is a key driver of continued control of infection 
and maintenance of latency.446,447 One the most important is the production of IFN-γ by CD4+ 
T-cells, NK and γδ T-cells.445,471,472 IFN-γ has been shown to activate macrophages, inducing 
increased synthesis and secretion of cytokines, particularly TNF-α, the production of both 
nitrogen and oxygen radicals and the enhancement of phagolysosome fusion.445 
The γδ T-cells are a unique population of lymphocytes, like other non-conventional T-cell 
subsets bearing invariant T-cell receptors (TCRs), such as CD1d-restricted NK cells, γδ T-
cells exhibit several characteristics that place them at the border between the innate immune 
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system.471,472 The γδ T-cells may be considered a component of adaptive immunity in that they 
rearrange T-cell receptor genes to produce functional diversity and will develop a memory 
phenotype. However, the various subsets may also be considered part of the innate immune 
response where a restricted T-cell receptor may be used as a PRR.471-475 For example, 
according to this paradigm, large numbers of (human) Vγ9/Vδ2 T cells respond within hours 
to mycobacteria, and highly restricted intraepithelial Vδ1 T cells will respond to stressed 
epithelial cells bearing sentinels of danger. Recent work has shown that human Vγ9/Vδ2 T 
cells are also capable of phagocytosis, a function previously thought to be exclusive to cells 
of the MML.481,482 In cattle, a broadly equivalent subset are the γδ T-cells bearing the workshop 
cluster (WC)1 which accumulate rapidly at the site of infection. A number of bovine studies 
have shown that recruitment of γδ T-cells leads to the rapid expansion of the local population 
at the site of infection within six hours of intradermal inoculation (for example with PPDB or M. 
bovis-BCG).471-475 The recruited cells infiltrate the granuloma and in vitro studies using bovine 
WC1+ γδ T-cells has demonstrated their significant capacity for the secretion of IFN-γ and 
other chemokines which may aid the development of an appropriately organised 
granuloma.471-475 Very little is known about γδ T-cells of companion animals, beyond rare case 
reports of lymphomas caused by their neoplastic replication.476-480  
The exact relationship between the granuloma and a host’s attempt at mycobacterial 
clearance is still not yet fully understood. The current paradigm asserts that the granuloma 
acts to physically wall off bacilli and limit further dissemination of infection into local tissues 
whilst simultaneously producing an ideal microenvironment for the interaction of different 
immune cells and the cytokines that they produce.313,364,369 At the same time, the hypoxic, 
acidic environment created at the centre of the granuloma induces the expression of a number 
of genes within the mycobacteria such as plcA, PlcB and PhoP which are associated with the 
induction of a state of dormancy and replication cycle arrest.483 This complex, ongoing process 
of interactions between the innate and adaptive immune system and mycobacteria is thought 
to be the means by which human hosts achieve latency.446  
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Studies have shown that only approximately 5-10% of individuals infected with M. tuberculosis 
will succumb to clinical disease within the first two years after infection (termed “primary 
tuberculosis”), a further 5-10% will develop disease later in life (termed “post-primary 
tuberculosis”), whilst the remainder develop life-long latent infection with no signs of disease 
at any time.245,265 In companion animals, the relative frequency of the different possible clinical 
outcomes of infection i.e. sterilising immunity, primary or post-primary disease, or latency, is 
unknown. It may also be significantly different when infection is caused by different members 
of the MTBC or NTM species.  
Recrudescence of infection into post-primary disease is most frequently believed to result 
following a local or systemic decline in the hosts immune response and therefore capacity to 
dynamically contain mycobacteria with granulomas, examples of which include the occurrence 
of an immunosuppressive/modulatory myeloid disorder e.g. lymphoma, prolonged periods of 
stress, the development of chronic kidney disease or diabetes mellitus, or old age.245,265,446 In 
companion animals, many of these conditions occur frequently within the aged population, and 
in cats in particular, so the possibility of recrudescence of any mycobacterial infections must 











1.7 Aims and Objectives  
The aim of this project is to improve our current understanding of mycobacterial infections in 
companion animal species, and tuberculosis in particular.  
 
In order to achieve this aim, this project will meet the following objectives: 
1. Improve on the diagnostic tests currently available for cats and dogs by developing a 
molecular assay for formalin-fixed paraffine embedded (FFPE) tissue, which can 
identify the presence of mycobacterial DNA in tissue samples and discriminate 
members of the TB complex.  
2. Use samples acquired clinical cases and from outbreak situations to identify the 
potential diagnostic methods for canine mycobacterial diseases given the paucity of 
currently available options 
3. Examine the feline and canine immune responses to mycobacteria in depth to 
increase our understanding and to identify future diagnostic candidates.  
4. Develop an in vitro model that can be used to futher study the early-host pathogen 
interaction between companion animals and mycobacteria in order to allow future 
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Chapter 2: Development of a PCR Assay for the 
Detection of Mycobacteria spp. in Companion Animal 
Formalin Fixed Paraffin Embedded Tissue Biopsies. 
Abstract  
Molecular methods are increasingly being used for the diagnosis of mycobacterial infections 
in human patients but no validated molecular testing methods are currently commercially 
available for the assessment of mycobacteria present in feline or canine tissue samples in the 
UK. This study is the first to develop a polymerase chain reaction assay for the speciation of 
mycobacterial infections that focusses on the UK companion animal population. In line with 
molecular techniques described to diagnose lepromatous diseases in both cats and dogs, this 
study extracted amplifiable DNA from the majority of formalin-fixed paraffin-embedded tissue 
samples despite most of them containing few acid-fast organisms when Ziehl–Neelsen stained 
sections were graded using a newly developed bacillary grading system. The six-gene 
mycobacterial panel targeting the hsp65, 16s rRNA, Ag85-B, Rv1506c, ESAT-6 and IS-1311 
genes was validated using cultured reference isolates of mycobacteria. Subsequently, the 
assay was used to examine 380 feline formalin-fixed paraffin-embedded tissues and eight 
canine samples where mycobacterial infection was suspected. Importantly, no cases of M. 
tuberculosis infection were identified. In the feline tissues the prevalence of M. bovis infections 
was found to be 11.3%, broadly similar to previous analysis of mycobacterial culture results 
whilst the prevalence of M. microti (30.6%) was significantly higher in this study population 
than has previously been reported. M. avium-intracellulare-complex infections were only rarely 
identified in this cohort of feline samples. Sequencing of the hsp65 gene fragment diagnosed 
nine feline infections caused by M. malmoense (n=3), M. smegmatis (n=3), M. kansasii (n=2) 
and M. fortuitum (n=1). All eight canine samples were found to be infected with M. bovis. Whilst 
the sensitivity of this assay for tuberculous infections was high (88.2%), future work is required 
to improve the sensitivity for diagnosis non-tuberculous mycobacterial infections.  
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2.1 Introduction  
The identification of mycobacterial infections in human medicine has been dramatically 
improved by the introduction of molecular methods aimed to reduce the time to diagnosis as 
compared with culture (Dorn-In, 2019; Wang, 2019). For companion animals in the UK, 
histopathological examination of clinical samples to detect acid-fast bacilli (AFB) is almost 
always the first microbiological test for the diagnosis of mycobacterial infection (O’Halloran 
and Gunn-Moore, 2017). However, this method has a limited sensitivity and specificity and 
does not provide any information on the mycobacterial species (O’Halloran et al. 2016). In 
particular, microscopy cannot distinguish mycobacteria of the Mycobacterium (M.) 
tuberculosis-complex (MTBC) from the non-tuberculous mycobacteria (NTM) which have 
different zoonotic risks and optimal treatment protocols (Gunn-Moore, 2014).  
Currently, specialist mycobacterial culture represents the gold standard and official reference 
method for the microbiological diagnosis of mycobacterial infections in companion animals 
(Middlemiss and Clark, 2018). Culture provides a pure isolate for subsequent genotypic 
identification and in some laboratories, antimicrobial susceptibility testing (Harvell et al. 2000). 
However, culture is affected by the growth rate of mycobacteria, especially for the slow-
growing species which includes all of the MTBC organisms, as they need more than seven 
days to form a colony as compared with ~48–72 hours for the more rapidly growing 
mycobacteria (when starting with a pure inoculum) (Harvell et al. 2000). The slow growing 
species such as M. bovis and M. microti can take two to four months to isolate from tissue 
samples (Gunn-Moore et al. 2011a). In addition, infections due to some mycobacteria may not 
be detected by conventional culture because of the requirement of specific nutrients such as 
Mycobactin J for M. avium subspecies paratuberculosis (MAP), specific temperature culture 
conditions e.g. 30 °C for M. marinum or 42 °C for M. xenopi, whilst some mycobacteria, such 
as M. lepraemurium, remain uncultivable on synthetic media in vitro (Malik et al. 2013; 
Nakanaga et al, 2013).  
Molecular methods have the potential to shorten the diagnosis from a minimum of several 
weeks to just days as well as offering the opportunity to widen the breadth of identifiable 
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species (Wang et al. 2019). The only molecular diagnostic test available to companion animals 
in the UK is available via the National Mycobacterial Reference Laboratories, e.g. Leeds 
University Mycobacterial Reference Laboratory (LUMRL), established and run to diagnose 
human cases of mycobacterial disease (O’Halloran et al. 2019). These laboratories have the 
advantage of using well-established methods for polymerase chain reaction (PCR) based 
diagnosis but lack validation for animal samples (O’Halloran et al. 2019). Due to the pathology 
of human tuberculosis as a predominantly pulmonary disease, human laboratory testing is 
optimised for testing small volumes of fresh sputum samples (e.g. GenoType MTBC; Hain 
Life-Sciences, Germany). The effect of formalin fixation and the use of whole tissue as the 
starting material on test performance (e.g. sensitivity and specificity) has not been assessed. 
A further drawback is the high financial cost of the test which has generally precluded its 
mainstream use for companion animals to date. 
Culture data for UK cats has identified M. microti as the most frequently diagnosed 
mycobacterial infection, with M. bovis the second most common; therefore one third (34%) of 
UK feline mycobacterial infections are defined as tuberculous i.e. caused by organisms within 
the MTBC (Gunn-Moore et al. 2011a).  
The consistent genetic differences between members of the MTBC are genomic regions of 
difference (RD) which can be used as markers to distinguish species within the complex (Teo 
et al. 2013). Though rare in companion animals, disease due to M. tuberculosis infection is 
extremely important to diagnose due to the inherent risk to human health. M. tuberculosis 
encodes eight RD, numbered 4-11, which have been lost from M. bovis through reductive 
evolution (Liébana et al. 1996; Huard et al. 2006). The MTBC organisms frequently isolated 
from feline tissue; M. bovis and M. microti, can be discriminated from one another by RD-1 
(which encodes a number of virulence factors) and its loss is the reason for the relative 
attenuation of M. microti in humans (Pym et al. 2002). 
Other than the MTBC, members of the M. avium-intracellulare-complex (MAC) represented 
the most frequently identified group of mycobacteria cultured from UK cats (Gunn-Moore et al. 
2011a). The molecular identification of these organisms is more challenging than speciation 
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of the MTBC as it typically depends on the presence or absence of a variety of insertion 
sequences (IS) (Collins et al. 1997). The ability of these IS to move position within the genome 
sometimes generates mutations and so brings into question the sensitivity of individual IS 
sequences to identify particular MAC species (Kim et al. 2018). There are similar concerns 
about the specificity of these targets; for example, there has been a considerable debate 
surrounding the specificity of IS-900 to MAP (Englund et al., 2002; Keller et al. 2002; Sohal et 
al. 2002; Johansen et al. 2005; Semret et al. 2006) 
The principal aim of this study was to evaluate the usefulness of a novel mycobacterial gene 
PCR panel for use on companion animal formalin-fixed paraffin-embedded (FFPE) tissue 
biopsies. The gene panel was designed to include pan-mycobacterial markers; the heat shock 
protein 65kDA (hsp65) and 16S rRNA encoding genes along with the additional PCR targets 
of; the antigen 85 complex protein B (Ag85-B), RD-4, RD-1 and a reportedly MAC-specific IS, 
IS-1311.  
2.2 Materials and Methods  
This study was conducted with prospective approval from the School of Veterinary Medicine 
Ethical Review Committee at the University of Edinburgh and all relevant guidelines and 
regulations were adhered to throughout.   
2.2.1 Tissue Acquisition 
A total of 380 FFPE tissue biopsies of mycobacteria-induced granulomas were obtained from 
two groups of domestic cats.  
The first group comprised 154 biopsies from cases diagnosed from across the UK that were 
treated for mycobacterial infections confirmed by at least one of; histological tissue 
examination, specialist mycobacterial culture, interferon gamma release assay (IGRA) and/or 
mycobacterial PCR performed by LUMRL. These cats were diagnosed and clinically managed 
under the supervision of the author and/or Professor Gunn-Moore with biopsy material 
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donated for the purposes of this research with informed owner consent once the material was 
no longer required for diagnostic and/or clinical purposes.  
The second group of 226 samples came from cats that had tissue biopsies evaluated 
histologically between 2009 and 2015 at a large private diagnostic veterinary laboratory; Finn 
Pathologists, Norfolk. These samples were diagnosed by routine haematoxylin and eosin 
staining as containing pyo/granulomatous inflammation. Where possible, the aetiology was 
confirmed as mycobacterial by the identification of intra-lesional AFB with typical 
mycobacterial morphology.   
Canine mycobacterial infections are diagnosed much less frequently in the UK compared to 
feline infections (Snider and Cohen, 1972). Therefore, canine biopsy material was collected 
on an ad hoc basis from different diagnostic laboratories and submitted by general practice 
veterinarians who could obtain owner consent for the use of the remnant tissue for this project. 
In total only eight canine tissue samples were analysed.  
2.2.2 Selection of Genes and Primer Design 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is frequently used to normalise 
quantitative gene expression in RNA analyses as a so-called “housekeeping gene” due to its 
ubiquitous expression in mammalian cells (Leutenegger et al. 1999; Kipar et al. 2001; 
Taglinger et al. 2008). In this study, oligonucleotide primers (Table 2.1) specific for a section 
of the feline (297bp) and canine (230bp) GAPDH genes were designed to act as a control for 
successful extraction of amplifiable DNA from the FFPE biopsy samples. Primers specific for 
GAPDH genes were designed using the annotated nucleotide sequences of the reference 
genomes for the domestic cat (Felis silvestris catus; Ensembl accession number 
NM_001009307.1) and dog (Canis lupus familiaris; Ensembl accession number AF327898.1) 
respectively. Primers were assessed using genomic DNA extracted from remnant whole blood 
samples using the Qiagen DNeasy Blood and Tissue kit (Qiagen, Germany) according to the 
manufacturer’s instructions and the PCR amplification protocol as outlined below.  
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Six genes were selected for inclusion in a panel of mycobacterial genes. Firstly; a frequently 
analysed gene that can be sequenced for the speciation of mycobacteria, a 439 base pair (bp) 
partial section of the hsp65, which is present in all mycobacteria. It was amplified using primers 
Tb11 and Tb12 as first described by Telenti et al. (1993), shown in Table 2.1. 
Table 2.1: The oligonucleotide primer sequences used in this study. hsp65: 65kDa heat shock 
protein as described by Telenti et al. (1993), Ag85-B: Antigen 85 complex protein B, ESAT-6: 
6kDA early-secreted antigenic target, GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 
bp: base pair.  







hsp65 ACCAACGATGGTGTGTCCAT CTTGTCGAACCGCATACCCT 439 
16s rRNA ACTGAGATACGGCCCAGACT TCACGAACAACGCGACAAAC 279 
Ag85-B TACCAGTCGGGACTGTCGAT ACATGTCTGCGGCCTTGTAA 355 
Rv1506c TCTTGGAGTACCTGCGCTTG ACTACGTTTCGAAGGTCGGG 290 
ESAT-6 CCAGGGAAATGTCACGTCCA ATGCGAACATCCCAGTGACG 233 
IS-1311 CCCCTCGAACGACTCAACAA AACGGATTGGTCGGCTGAAT 201 
Feline 
GAPDH 
CACCATCTTCCAGGAGCGAG CTCCATGGTGGTGAAGACCC 297 
Canine 
GAPDH 
GTGAACGGGAAGCTCACTGG TCCGATGCCTGCTTCACTAC 230 
 
The second mycobacterial gene targeted alongside hsp65 was the 16s rRNA gene, also 
common to all mycobacteria (Gürtler, et al. 2006). This was designed to amplify a smaller 
product than the hsp65 sequence in order to try to increase the sensitivity of the PCR assay. 
The proteins A, B and C of the antigen 85 complex (Ag85) are among of those most abundantly 
produced by MTBC organisms in culture. Each protein is encoded by a separate gene within 
the genome and each has almost perfect sequence homology across the MTBC group 
Karbalaei-Zadeh-Babaki et al. 2017).  
The Rv1506c gene encoded on the RD-4 genome segment is present in M. tuberculosis but 
has been lost from the other MTBC of importance in companion animals (M. bovis and M. 
microti), and so it was included as a screening marker to identify any potential M. tuberculosis 
cases (Ru et al. 2017). In order to discriminate M. tuberculosis and M. bovis from M. microti, 
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primers targeting the virulence factor 6kDa early-secreted antigenic target (ESAT-6) encoded 
on the RD-1 segment of the genome was included into the gene panel (Pym et al. 2002).  
Finally, IS-1311 which is reportedly common to all of the MAC organisms, since it is present 
at high copy numbers per mycobacteria it is a likely sensitive diagnostic marker for this group 
of mycobacteria (Keller et al. 2002).  
Apart from the hsp65 gene, all other oligonucleotide primers were designed specifically for 
inclusion in this study using Primer3 software. Primers to identify pan-mycobacterial genes 
and those common to the MTBC were designed using the National Center for Biotechnology 
Information (NCBI) type strain genomes; M. tuberculosis H37Rv or M. bovis AF2122/97 as the 
reference sequence, whilst the NCBI type strain M. avium subspecies paratuberculosis K10 
genome was used as the reference for IS-1311. As only short DNA fragments are usually 
recoverable from FFPE tissues all mycobacterial gene primers were designed to be 20bp long 
with a melting temperature of 59ºC±1ºC whilst generating a product of 300bp±150bp in size. 
2.2.3 DNA Extraction from FFPE Tissues  
Each FFPE tissue block to be tested was mounted onto a HM325 rotary microtome (Thermo 
Fisher Scientific, USA), and blocks were trimmed in to remove excess paraffin with a 
disposable Feather S35 microtome blade. Once the full tissue surface was exposed, three 
sequential 20µm sections (or all of the tissue if less than this was present) were cut and placed 
into a certified DNAse free 1.5mL screw-top Eppendorf tube. The paraffin was removed by 
incubating the cut sections in 1mL of xylene at 65ºC on a heat block for 15 minutes, the xylene 
was discarded and this step was then repeated. The tissue was rehydrated by resuspension 
through a sequential alcohol gradient comprising 100% ethanol, 99% ethanol, 95% ethanol 
and then 70% ethanol solutions. At each stage of the gradient, tissue was vortexed for 30 
seconds and then incubated at room temperature for at least one hour. Between each step, 
samples were briefly centrifuged (10 seconds) at 6,000 x g and the supernatant was removed 
and discarded.  
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Rehydrated tissue was re-suspended in 300µL of an enzymatic digestion buffer (50mM Tris-
HCl [pH7.5], 10mM EDTA, 0.5% sodium dodecyl sulphate [SDS] and 50nM NaCl) containing 
lysozyme (Sigma Aldrich, UK) to a final concentration of 20mg/mL which was incubated at 
37ºC for a minimum of 48 hours. Proteinase K (Thermo Fisher Scientific, USA) was added to 
each of the samples to a final concentration of 300mg/mL, which were then incubated at 56ºC 
for one hour. The proteinase K was inactivated by heating the samples to 95ºC for 10 minutes. 
Macerated tissue was transferred, with the digestion buffer, to a 2mL tube pre-filled with sterile 
(acid washed) 0.1mm silica beads (Scientific Laboratory Supplies, UK). The samples were 
homogenised using a FastPrep bead beater (MP Biomedical, UK) setting P60 for 40 seconds 
following the addition of 180µL of tissue lysis buffer (Buffer ATL, DNeasy Blood and Tissue 
Kit; Qiagen, Germany). 
Once samples had been returned to room temperature by incubation on ice, 200µL each of 
100% ethanol and buffer AL (DNeasy Blood and Tissue Kit; Qiagen, Germany) were added 
and samples were mixed by vortexing for 20 seconds.  
The tubes were centrifuged at 6,000 x g for one minute and the supernatant was transferred 
to a DNA isolation column (DNeasy Blood and Tissue Kit; Qiagen, Germany). The column was 
centrifuged at 6,000 x g for one minute and the collection tube containing flow through was 
discarded; 500µL of buffer AW1 (DNeasy Blood and Tissue Kit; Qiagen, Germany) was 
pipetted onto the column which was then centrifuged at 6,000 x g for one minute followed by 
the addition of 500µL of buffer AW2 (DNeasy Blood and Tissue Kit; Qiagen, Germany).  
Columns were centrifuged at 8,000 x g for two minutes and then transferred to a clean 1.5mL 
DNase free Eppendorf tube. DNA was eluted from the column by adding 50µL of elution buffer 
(Buffer AE, DNeasy Blood and Tissue Kit; Qiagen, Germany) directly to the membrane and 
incubating at room temperature for five minutes. Elution of the DNA was performed by 
centrifuging the columns at 8,000 x g for one minute. DNA was quantified using a Nanodrop 
spectrophotometer ND-1000 and stored at -20ºC until needed for further analysis.  
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In addition to the mycobacteria containing tissue samples, a non-mycobacteria infected (i.e. 
negative) control skin sample was included. This tissue was a FFPE skin biopsy from a cat 
with a known cowpox virus infection that was mycobacteria-free. 
2.2.4 PCR Amplification 
All PCR reactions were performed in 96 well PCR plates in a final volume of 20µL containing; 
10µL of GoldStar 2x PCR Mix (Eurogentec, Belgium), 0.15µL 25mM MgCl2, 0.25µL 25pmol/µL 
combined forward and reverse oligonucleotide primers, 6.25µL nuclease-free water and 2µL 
of template DNA. Each PCR plate contained a positive template control for the gene being 
assessed (DNA extracted from reference strain culture colonies, described in Section 2.2.5), 
a sample of the DNA extracted from the non-mycobacteria skin sample as well as a no 
template (water only) negative control. 
The PCR plates were sealed with adhesive plate sealant, centrifuged and transferred to a 
thermocycler. The same programme was used for all reactions comprising an initial step of 
heating the samples to 95°C for three minutes followed by 45 cycles of; 95°C for 30 seconds, 
60°C for 30 seconds and 72°C for 45 seconds, followed by a final elongation step of 72°C for 
five minutes.  
The final reaction samples were mixed with 2µL of 10x gel loading buffer (Thermo Fisher 
Scientific, USA) and analysed by 2% agarose gel electrophoresis containing SYBR Safe 
(Thermo Fisher Scientific, USA) at 120V for 45 minutes in order to visualise the products using 
GeneSNAP software and partner gel imager.  
2.2.5 Culture and DNA Extraction from Mycobacterial Reference Strains 
Reference strains of M. bovis (strain AF2122/97; ATCC BAA-935 obtained from Professor 
Jayne Hope, The Roslin Institute), M. bovis bacille Calmette–Guérin (M. bovis-BCG, strain 
1173P2 [Pasteur], obtained from Dr Kirsty Jensen, The Roslin Institute) MAP (strain K10; 
ATCC BAA-968; obtained from Dr Heather Baird; The Roslin Institute) were grown in the 
containment level two and three (for M. bovis) laboratory facilities of The Roslin Institute, 
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University of Edinburgh. Single aliquots containing 1mL of mycobacteria suspended in culture 
media were added to 9mL of Middlebrook 7H9 media (Sigma Aldrich, UK) supplemented with 
Middlebrook ADC growth supplement (Sigma Aldrich, UK) to 10% by volume and 0.5g/500mL 
Tween 80 (Sigma Aldrich, UK). The culture media for MAP was additionally supplemented 
with 2 mg/L of Mycobactin J (Allied Monitor, Inc., USA).  
Cultures were incubated at 37oC/5% CO2 with agitation in a shaking incubator for 14 days, 
after this time the optical density (OD) was measured daily using a spectrophotometer until an 
OD600 of 0.6 was reached, indicating that the mycobacteria had reached the exponential 
growth phase. At this time, the 10mL culture was added to a further 90mL of Middlebrook 7H9 
ADC media and returned to the incubator. Again, the cultures were grown 37oC/5% CO2 with 
agitation for 14 days before daily assessment of the OD value. Once an OD600 of 0.6 had been 
reached, the mycobacteria were aliquoted into sterile 1mL screw-topped Eppendorf tubes and 
stored at -80 oC until further use.  
A single inoculum of M. smegmatis type strain (NCTC 8159 [Cornell 3], ATCC 19420; obtained 
from Dr Jo Stevens, The Roslin Institute) was grown overnight (16 hours) in 250mL of 
Middlebrook 7H9 media (Sigma Aldrich, UK) supplemented with Middlebrook ADC growth 
supplement (Sigma Aldrich, UK) to 10% by volume and 0.5g/500mL Tween 80 (Sigma Aldrich, 
UK) at 37°C/5% CO2 with agitation. The following day it was confirmed that an OD600 of 0.6 
had been reached and the mycobacteria were aliquoted into sterile 1mL screw-topped 
Eppendorf tubes and stored at -80 oC until further use. 
Genomic DNA was extracted from each species of mycobacteria as needed by thawing single 
1mL aliquots and centrifuging the Eppendorf at 16,000 x g for 15 minutes to pellet the 
mycobacteria and the supernatants were discarded. The cells were resuspended in 180 μL of 
Enzymatic Lysis Buffer, comprising 20 mM Tris-Cl pH8.0, 2 mM sodium EDTA, 1.2% Triton X-
100 and 20mg/mL lysozyme, prepared immediately before use).  The solution was incubated 
at 37°C for at least 60 minutes before 25μL proteinase K and 200μL buffer AL (DNeasy Blood 
and Tissue kit; Qiagen, Germany) and mixed thoroughly by vortexing. Following an incubation 
at 56°C for 30 minutes; 200μL 100% ethanol was added and again mixed by vortexing. The 
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mycobacterial lysate was transferred to a Qiagen DNeasy column which was then centrifuged 
at 6,000 x  g for 60 seconds. The flow-through was discarded from the collection tube, 500μL 
of buffer AW1 (Qiagen DNeasy Blood and Tissue kit) was added to the column which was 
then centrifuged at 6,000 x g for 60 seconds. The flow-through was discarded and this wash 
process was repeated with 500μL of buffer AW2 with centrifugation at 16,000 x g for two 
minutes. The column was dried by further centrifugation at 16,000 x g for two minutes. To elute 
the DNA from the column 50μL of buffer AE (Qiagen DNeasy Blood and Tissue kit) directly 
onto the membrane and left to incubate at room temperature for five minutes. The column was 
then placed into a nuclease-free Eppendorf and centrifuged at 6,000 x g for 60 seconds. The 
resulting DNA was analysed using a Nanodrop spectrophotometer ND-1000 and stored at -
20°C when not in use.  
The Roslin Institute does not currently hold Health and Safety Executive approval to culture 
M. tuberculosis so extracted DNA (from strain H37Rv; ATCC 25618) was obtained directly 
from Dr Robin Skuce, Agri-food & Biosciences Institute.  
2.2.6 Sequencing and Molecular Speciation 
All of the PCR primers used in this study were validated by sequencing of the product 
produced, similarly, where a PCR product was obtained for the mycobacterial hsp65 gene 
from a sample, this was retrieved for sequencing. The agarose gel containing the sample was 
visualised by ultraviolet trans-illumination and the product band was removed using a sterile 
disposable scalpel blade. The DNA was removed from the agarose using a PureLink Quick 
Gel Extraction Kit (Invitrogen, USA) by weighing the gel extract and adding three times the 
volume of gel solubilisation buffer (Buffer L3, PureLink Quick Gel Extraction Kit) and heating 
to 50oC until fully dissolved.  
One volume of isopropanol was added to the agarose solution and the solution was mixed by 
vortexing. The entire volume was then transferred to a DNA mini-column. Columns were 
centrifuged at 6,000g for a minute, the flow-through was discarded and 500µL of wash buffer 
(Buffer W1, PureLink Quick Gel Extraction Kit) was added to the membrane. Columns were 
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centrifuged at 6,000 x g for two minutes and the flow-through was discarded. The DNA was 
eluted into 50µL of nuclease free water by centrifugation at 8,000 x g for two minutes after 
incubating the membrane for five minutes at room temperature.  
The quantity of DNA was estimated by comparing the original PCR band density to the known 
concentrations in the nucleotide ladder (1Kb DNA Ladder; Promega, USA) using ImageJ 
software. Purified DNA was also assessed using a Nanodrop spectrophotometer ND-1000 
and diluted to a final concentration of 20ng in 30µL prior to being sent to the University of 
Dundee for Sanger sequencing by independent reactions using 3.2pmole of the forward 
oligonucleotide primer sequence (University of Dundee, 2019).  
Generated sequence data was analysed using FinchTV software to obtain a consensus 
sequence. The mycobacterial species was determined by Basic Local Alignment Search Tool 
(BLAST) analysis.  
2.2.7 Bacillary Grading System 
The Ziehl–Neelsen (ZN) staining method was used to grade the number of AFB present in 
each biopsy. For the biopsy material examined by a private diagnostic pathology service, the 
pathologists’ assessment was converted into a score (Table 2.2). For the blocks included via 
the Edinburgh cohort, tissue slides were produced, stained and analysed. For these tissues, 
4µm thick sections were cut from the FFPE tissue samples using a HM325 Rotary Microtome 
with disposable Feather S35 blades (Thermo Fisher Scientific, USA). These were mounted 
onto Superfrost Plus slides (Thermo Fisher Scientific, USA) and incubated in an oven at 65°C 
for a minimum of 16 hours. The tissue sections were dewaxed and rehydrated, flooded with 
filtered dilute carbol-fuschin stain containing phenol (ProLab Diagnostics Inc., UK) and heated 
over a flame inside a vented fume-cabinet until visible fumes were produced. The slides were 
left to stain for ten minutes. Following thorough rinsing with water, decolourisation was carried 
out using an acid-alcohol solution of 5% sulphuric acid by volume diluted in methanol. The 
slides were counterstained by immersing in haematoxylin for seven seconds, followed by 
Scott’s Tap Water for seven seconds. The tissue sections were dehydrated and coverslips 
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were mounted using Pertex mounting medium (Pioneer Research Chemicals Ltd., UK). Slides 
were examined under oil emersion light microscopy and the number of AFB was graded 0-5 
using a modified scoring system, similar to those previously reported for bovine and 
companion animal samples (Malik et al. 2002; Garbaccio et al. 2019), detailed in Table 2.2. 
Table 2.2: Grade descriptors for the modified mycobacterial burden grading system used in 
this study. Grades were based on the evaluation of three HPF fields. HPF; high power field 
(oil emersion, light microscopy), AFB; acid fast bacilli. 
Score Finn Pathologist description of 
mycobacterial burden 
Approximate number of 
mycobacteria 
0 Negative None seen in section examined 
1 Rare/solitary Single AFB per HPF or fewer 
2 Few/scattered Up to ten AFB per HPF 
3 Moderate Ten to 50 AFB per HPF 
4 Large number 50-100 AFB per HPF 
5 Vast/Innumerable Too many AFB to count accurately 
6 Not counted Insufficient material after PCR to 



















2.3 Results  
2.3.1 PCR Assay  
A cohort of 380 feline and eight canine FFPE biopsy samples were examined using the novel 
mycobacterial PCR protocol developed in this study. Of the feline samples examined, 154 cats 
had been treated under the supervision of the author and/or Professor Gunn-Moore. All of 
these cases were referred due to the clinical suspicion of mycobacterial infection based on the 
presence of compatible clinical signs that included combinations of; single or multiple skin 
nodules/masses, sometimes with enlarged local lymph nodes, unexplained weight loss and/or 
respiratory disease with typical pathology visible on diagnostic imaging. Pulmonary interstitial 
disease was the most frequently reported abnormality diagnosed on thoracic imaging although 
bronchial changes were seen occasionally; only rarely were pulmonary tubercles visible. 
Mycobacterial infection was confirmed in the University of Edinburgh sub-set by identifying 
AFB with mycobacterial morphology on histological examination of diseased tissue alone in 
only 36 cats (of 154, 23%). The remaining cats had at least one diagnostic test performed 
(independent to this study), these included an interferon gamma release assay (IGRA; n=71, 
46%), mycobacterial culture (n=49, 32%) and/or PCR at LUMRL (n=8, 5%). Ten cats had both 
an IGRA and culture performed, but all were culture negative so the IGRA diagnosis was 
accepted. Four cats had an IGRA and PCR test performed which were in agreement, and no 
cats had both PCR and culture performed. Based on the results of these independent 
mycobacterial test results, 118 cats of these 154 were given a specific diagnosis comprising 
60 M. microti, 36 M. bovis, 14 MTBC infections (without further discrimination), four MAC and 
one each of M. fortuitum, M. kutatamoesnse, M. malmoense and M. chelonae infections. 
Tissue blocks collected from Finn Pathologists, Norfolk all had a histological finding of 
(pyo)granulomatous inflammation suggestive of mycobacterial infections. The overwhelming 
majority (219, 97%) of these lesions were associated with AFB that displayed typical 
mycobacterial morphology. No specific aetiological agent was observed in the remaining 
seven tissue samples when sections were stained with ZN, Periodic acid–Schiff and Giemsa 
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stains. However, the granulomatous inflammatory infiltrate in all seven was dominated by 
aggregates of reactive macrophages surrounded or interspersed with moderate numbers of 
neutrophils and surrounded by small numbers of lymphocytes, so any cause other than 
mycobacterial infection was deemed to be extremely unlikely and therefore all samples in this 
study were included as mycobacteria-infected.  
Histopathological examination identified AFB with mycobacterial morphology in all of the 
canine samples. All eight of the dogs were infected with M. bovis, as indicated by IGRA and 
confirmed by specialist mycobacterial culture in two cases. 
Primers targeting the feline and canine GAPDH gene were tested using feline and canine 
genomic DNA respectively, extracted from remnant whole blood samples. Both of the primer 
sets selected produced only a single amplicon of the predicted product size and resulted in no 
non-specific amplification under no template control conditions, Figure 2.1.  
 
Figure 2.1: The GAPDH gene product was successfully amplified from feline (297 base pairs 
[bp], left) and canine (230bp, right) genomic DNA (fg-DNA and cg-DNA respectively) templates 
and not from a no template control (NTC).  PCR products (black arrows) were loaded into a 
2% agarose gel, alongside a 1Kb DNA ladder (200bp and 300bp markers are indicated by 
white arrows). 
Once DNA had been extracted from all 380 feline and eight canine tissue biopsies, all samples 
were shown to contain DNA by Nanodrop spectrophotometer ND-1000 analysis. To establish 
that the DNA was amplifiable by PCR, amplification of GAPDH from host genomic DNA was 
attempted. This was successful from 346 (91%) of the feline samples and all eight (100%) 
canine tissues.  
The set of six mycobacterial genes were chosen for inclusion in the diagnostic mycobacterial 
panel; hsp65, 16s rRNA, Ag85-B, Rv1506c, ESAT-6 and IS-1311. A total of 30 primer pairs 
were screened against DNA from the reference isolate mycobacteria; M. tuberculosis H37Rv, 
M. bovis AF2122/97, M. bovis-BCG Pasteur (the present tuberculosis vaccine strain), MAP 
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type strain K10 and M. smegmatis type strain ATCC 607. The final panel of primers (Table 
2.1) were selected as those which produced only a single PCR product which matched the 
predicted size (determined by agarose gel electrophoresis, Figure 2.2), with no amplification 
under no template control conditions or from the feline tissue sample not infected with 
mycobacteria. In addition, when the amplified product was extracted and sequenced, it was 

































Figure 2.2: Products produced by the final six-gene mycobacterial panel primers selected 
analysed by 2% agarose gel electrophoresis alongside a 1Kb DNA ladder (L, black arrows 
indicate 500bp marker). The anticipated pattern of bands was found to be present in the 
DNA extracted from M. tuberculosis H37Rv (A), M. bovis AF2122/97 (B), M. bovis-BCG 
Pasteur (C) MAP strain K10 (D) and M. smegmatis type strain ATCC 607 (C); 16s rRNA 
(lane 1, 279bp), hsp65 (lane 2, 439bp), Ag85-B (lane 3, 355bp), ESAT-6 (lane 4, 233bp), 
Rv1506c (lane 5, 290bp) and IS-1311 (lane 6, 201bp).  
 
L             1           2           3        4           5           
L         1        2         3         4        5 
L               1           2             6          
L         1        2         3         4        5 
L         1        2          
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A total of 346 feline samples where amplifiable DNA was extracted were analysed using the 
six-gene mycobacterial panel and produced gene products (Figure 2.3); 59 (17.1%) produced 
an hsp65 gene product whilst 270 (78.0%) were positive for 16s rRNA. All samples giving rise 
to an hsp65 product also produced a 16s rRNA amplicon. 
Of the 346 samples, 145 (41.9%) were positive for Ag85-B, diagnosing tuberculosis, of which 
no (0%) samples gave an Rv1506c product (i.e. there were no M. tuberculosis infections) 
whilst 39 (11.3% of 346) samples were also positive for ESAT-6, consistent with a diagnosis 
of M. bovis. These results indicate that 106 samples (30.6%) were infected with M. microti (i.e. 
they were Ag85-B positive but ESAT-6 negative). All of the samples from which Ag85-B and 
ESAT-6 products were amplified also produced 16s rRNA amplicons. Only two (0.9%) cat 
biopsies amplified DNA for IS-1311 (consistent with MAC infections); both also produced 16s 
rRNA products, but only one amplified hsp65.  
 
Figure 2.3: A flow diagram demonstrating the results generated from sequential PCR 
amplification of feline GAPDH and the six-gene mycobacterial panel for the feline biopsy 





In total, 59 of the feline samples analysed produced an amplicon for the hsp65 gene fragment 
that has been used in previous studies to speciate mycobacterial infections (Telenti et al. 1993, 
Figure 2.4). The hsp65 PCR products were extracted from the agarose gels, purified and 
sequenced using the forward primer sequence by the University of Dundee (Figure 2.5). The 
consensus nucleotide sequence generated was entered into a BLAST search to match it back 
to any registered genomes. Of the 59 hsp65 sequences generated, 19 sequences most closely 
matched the sequences for M. tuberculosis H37Rv, Beijing 2014 and similar clinical isolates, 
M. tuberculosis variant bovis strain 1 (more commonly referred to as strain AF2122/97) and 
M. bovis-BCG, as the hsp65 gene has a conserved sequence across the MTBC organisms 
(Borgers et al. 2019). An additional nine hsp65 sequences matched to specific mycobacterial 
sequences in the NCBI database; three M. malmoense; three M. smegmatis, two M. kansasii 
and one M. fortuitum. For all 28 samples matched to a species, the nucleotide sequence 
identity was high, ranging from 85.71% to 96.22% (median 95.99%). 
 
Figure 2.4: A representative image of hsp65 gene products amplified from template DNA 
extracted from feline FFPE biopsy tissues, analysed by 2% agarose gel electrophoresis 
against a 1Kbp DNA ladder (500bp markers are indicated by white arrows). In this image, nine 




Figure 2.5: A representative hsp65 gene sequencing trace displayed using FinchTV software. 
The trace was obtained from extracting and sequencing the hsp65 gene product from agarose 
gel as shown in Figure 2.4. The consensus nucleotide sequence for the sequencing trace was 
extracted and matched to recorded sequences in the NCBI database by BLAST search.  
Of the remaining hsp65 gene products, nine sequences could only be identified to the genus 
level as belonging to a Mycobacterium species, but the species was not identifiable, and for 
the final 22 samples, no significant similarity was found between the consensus nucleotide 
sequence and any genome within the NCBI database.  
As described above, 119 cats with biopsy material available to this study had previously 
received a species diagnosis from independent mycobacterial testing; of the 60 diagnosed 
with M. microti infections, 53 (88.3%) were similarly diagnosed in this study. A group of 36 cats 
were previously diagnosed with M. bovis infections, which was matched in this study for 30 
(83.3%) of them. For 14 cats, where previous diagnostic testing only identified their infections 
as belonging to the MTBC group, this study, based on the PCR results for ESAT-6, identified 
nine as M. bovis and five as M. microti. Therefore, this study identified MTBC infections to the 
species level in 97 cases of the 110 (88.2% sensitivity) biopsies that had previously been 
independently diagnosed as MTBC. The remaining 13 samples were in the group of biopsies 
which produced a 16s rRNA gene product, confirming mycobacteriosis, but no additional 
mycobacterial genes were identified.  
Eight cats had been previously diagnosed with non-tuberculous mycobacterial infection to the 
species level. Four cats had been diagnosed with MAC infections of which two (50%) were 
found to be PCR positive for IS-1311 in this analysis. The individual cats with M. fortuitum and 
M. malmoense infection were both successfully identified as these species in this study by 
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hsp65 gene sequencing in this study. This meant that the protocol developed in the current 
had a 75% sensitivity for identifying non-tuberculous mycobacterial infections.   
Of the eight canine samples from dogs previously diagnosed with M. bovis infections, just one 
produced an hsp65 gene product (12.5%). When sequenced, this shared 99.98% sequence 
identity with M. tuberculosis variant bovis strain 1 (i.e. M. bovis AF2122/97). All eight samples 
(100%) produced 16s rRNA, Ag85-B and ESAT-6 amplicons but not Rv1506c or IS-1311.  
2.3.2 Bacillary Grading 
All tissue samples were assigned a mycobacterial burden grade based on i) evaluation by a 
single diagnostic laboratory (Finn Pathologists, Norfolk) or ii) the number of AFB visible on ZN 
stained slides examined by light microscopy under oil emersion. A five point system was 
developed for slides stained as part of this study (exemplified in Figure 2.6) from paucibacillary 
infections with no visible AFB (Grade 0) or sporadic individual bacilli (Grade 1) to multibacillary 
infections associated with very large numbers of AFB (Grade 5).  
Figure 2.6: Images taken from representative sections of slides assigned different 
mycobacterial grades. Slide A was scored at Grade 1 as it only contains a single AFB (white 
arrow). Slide B was assigned Grade 3, a number of cells with macrophage morphology contain 
moderate numbers of AFB (red arrow). Slide C was assigned Grade 5 due to the large 
accumulations of AFB (black arrows) within multiple aggregates of macrophages throughout 
the section. All sections were stained following the ZN protocol. Slides were visualized under 
oil emersion x100 magnification for sections A and B or x40 magnification for section C and 
images were taken with Zen Blue software.  
For 44 of 380 (11.6%) feline FFPE tissue samples, there was insufficient tissue remaining 
following PCR analysis to complete the ZN stain and to assign a mycobacterial grade. A small 
number (11, 2.9%) of tissue sections did not contain any visible AFB. Of the AFB containing 
A B C 
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sections 44 (11.6%) were assigned Grade 1, 122 Grade 2 (31.9%), 62 Grade 3 (16.4%), 36 
(9.5%) were given a Grade 4 and 61 (15.9%) were allocated Grade 5.  
In order to test the hypothesis that higher grade samples would be more likely to give a positive 
PCR result, the percentage of samples within each grade from which a 16s rRNA PCR product 
(as the most frequently identified gene) was successfully obtained was compared using the 
Chi-squared (χ2) statistical test. Statistical analysis showed significantly unequal distribution of 
positive results (χ2 = 131, p<0.001) with samples graded 0 and 1 significantly less likely to give 
a positive PCR product for 16s rRNA than samples assigned higher grades.  
2.4 Discussion  
The data presented in this study represents the first reported attempt to develop a PCR assay 
for the speciation of mycobacterial infections focussing on the UK companion animal 
population. Previously published PCR protocols developed for companion animal 
mycobacteriosis have primarily been used for diagnosing lepromatous diseases; in particular 
canine leproid granuloma (CLG) and feline leprosy syndrome (Foley et al. 2002; Huges, et al. 
2002; Conceicao et al. 2011; Reppas et al. 2013; O’Brien et al. 2017). Both of these clinical 
entities are frequently diagnosed in countries without endemic tuberculosis in cattle or wildlife 
(and therefore cats), such as Australia, and so there has not been a need for assays which 
include MTBC targets (Malik et al. 2013; Reppas et al. 2013; O’Brien et al. 2017). By contrast, 
MTBC infections represent the most commonly identified feline mycobacterial infections in UK 
cats (Gunn-Moore et al. 2011a). 
In each of the previously described protocols, the majority of DNA samples were extracted 
from fresh tissue, methanol-fixed stained or unstained cytology samples (typically aspirates of 
cutaneous nodules) with a minority being derived from FFPE tissue (; Foley et al. 2002; Huges, 
et al. 2002; Conceicao et al. 2011; Reppas et al. 2013; O’Brien et al. 2017). In the UK, samples 
suspected of originating from animals with mycobacterial disease are nearly always formalin 
fixed due to the concern that they may contain viable M. bovis or M. microti which are defined 
by the UK Health and Safety Executive as Hazard Group 3 organisms, which demarcates 
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pathogens that can cause severe human disease and can spread through the community 
easily (HSE, 2013). The fixation of tissue in formalin can lead to a reduction in the sensitivity 
of DNA based diagnostic techniques due to the damage and fragmentation of DNA which 
inevitably occurs, especially when the contact time between the tissue and fixative exceeds 
48 hours (Malik et al. 2013). However, a molecular assay for the detection of Mycobacterium 
spp. DNA within CLG FFPE specimens was successful in all 24 samples tested (Reppas et 
al. 2013). 
Nearly half of the samples used in this study were FFPE samples acquired retrospectively 
from a variety of diagnostic laboratories from across the UK and so tissue processing, and 
notably the duration of tissue fixation, was not a controllable factor. Despite this, GAPDH was 
amplifiable from 91.1% of feline samples and 100% of canine samples. Similarly, the sensitivity 
for MTBC genes within feline tissues was relatively high; 88.3% for M. microti, 83.3% for M. 
bovis and 88.2% for the MTBC overall, and 100% for canine samples, though the canine 
sample size was very small. Compared to the currently available feline IGRA, this PCR test 
has a lower sensitivity for MTBC which is reported as 100% for the IGRA but has comparable 
sensitivity for M. bovis which one study found to be 80% for the IGRA (Rhodes et al. 2008; 
Rhodes et al. 2011). Similar to the IGRA, the sensitivity of the assay developed in this study 
only identified 50% of the cats infected with MAC organisms (Rhodes et al. 2008; Rhodes et 
al. 2011). The reason for this is not immediately clear but it may be a result of choosing a 
single IS (IS-1311) as the target to identify this group; due to the documented problems of 
sensitivity and specificity of IS PCR targets for the MAC it may be necessary to include a 
combination of several such targets into the gene panel to improve the test accuracy (Englund 
et al., 2002; Keller et al. 2002; Sohal et al. 2002; Johansen et al. 2005; Semret et al. 2006). 
Although the LUMRL PCR is used clinically for feline mycobacterial samples in the UK, its 
performance has not been systematically evaluated for companion animal tissues and so it is 
not currently possible to compare sensitivities with the PCR panel developed here.  
Further work to enhance the sensitivity of this assay would be beneficial if this test were to be 
used clinically. As formalin fixation fragments DNA, targeting smaller regions of the genes of 
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interest may yield higher rates of positive results. The PCR products used in this assay are 
currently between ~200bp and ~450bp in size, which is relatively large. One possibility for 
future development would be to target internal regions of the current gene products by 
quantitative PCR (qPCR), as this typically amplifies much smaller segments of DNA (e.g. 
between 80bp and 150bp) and a similar qPCR approach has already been successful for the 
diagnosis of CLG. A potential drawback of a qPCR approach however would be the probable 
loss of sequencing ability. Whilst it would still be possible to purify and sequence any gene 
products, the smaller size would inevitably reduce the potential number of nucleotide variations 
present, so there would be a reduction in the ability of the product sequences to assign a 
species diagnosis. As is currently the case with the hsp65 gene sequencing in this study, the 
MTBC genome homology means that sequencing these products is less useful than 
determining the presence,  or absence, of specific RD, this reduction in gene product size 
could be limiting in terms of identifying the less commonly speciated mycobacteria i.e. those 
outside the MTBC and MAC.  
However, hsp65 gene sequencing was only possible from 15.5% of feline tissues and 12.5% 
of canine samples in this study. The sequence data obtained did not add diagnostic 
information in more than half of these (31/59) as the sequence was either not found in the 
NCBI database or was only identifiable to the genus level, which had already been 
demonstrated by the amplification of the product. Furthermore, for cases where hsp65 gene 
sequencing identifies MTBC sequences (19 cats and all eight dogs in this study population), 
further molecular diagnostics are needed to discriminate between M. tuberculosis, M. bovis 
and M. microti as these organisms pose markedly different zoonotic risks to the owners of 
infected animals, so this further distinction is critical. The results of hsp65 gene sequencing 
were most beneficial for the nine cases of non-tuberculosis mycobacteriosis caused by M. 
malmoense, M. smegmatis, M. kansasii and M. fortuitum that would not have otherwise been 
identified by this study. However, these nine cats only represent 2.4% of the total population 
of 380 samples. Consequently, it may be considered a worthwhile trade off to move to a qPCR 
based system with an overall increase in sensitivity but losing the ability to speciate some of 
the less commonly encountered mycobacteria in UK cats. It may also be possible to identify 
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gene targets that could be specific to these organisms and add them to any new diagnostic 
panel, especially as M. malmoense and M. fortuitum represent the most abundantly identified 
species from the mycobacterial culture of feline biopsies after the MTBC and MAC organisms.  
Only one published study has examined the results of mycobacterial culture in relation to feline 
samples in the UK and none have examined canine submissions. In that publication, Gunn-
Moore et al. (2011a) examined 339 culture results which is a comparable size to the findings 
presented here (n=380). The study reported that M. microti was isolated from 18.6% of 
submissions, M. bovis from 15.3% and MAC from 7.4% (including both M. avium and M. 
intracellulare). These organisms accounted for 41.3% of all submissions and 88% of culture-
positive samples, whilst 53.1% of submissions yielded no growth (Gunn-Moore et al. 2011a). 
In contrast, the data presented in this study identified gene patterns consistent with M. microti 
in 30.6% of the tissues tested which is significantly higher than the results produced from 
tissue culture, meanwhile the frequency with which M. bovis infections were identified is similar 
between the two methods, 15.3% compared to 11.3% respectively.  
One reason for the discrepancy in prevalence with respect to M. microti could be the relative 
difficulty in culturing this organism, which has remained problematic since the original studies 
by Wells from the late 1930’s (Wells and Oxon, 1937; Wells, 1946). The very slow in vitro 
growth of M. microti compared to other organisms within the MTBC, and its variable tolerance 
to glycerol means that to be sensitive, culture methods require markedly extended incubation 
times for clinical samples, typically 12-16 weeks compared to the 4-8 weeks for M. bovis, plus 
the use multiple media types, both with and without glycerol (Wells and Oxon, 1937; Wells, 
1946; Xavier et al. 2007).  It is therefore likely that the previously reported prevalence of M. 
microti in UK cats based on culture results is an underestimate and it may in fact be 
significantly higher than previously thought. Although M. microti is relatively avirulent in 
humans, a number of people have been infected and of particular concern is that a number of 
these patients were immunocompetent (as far as their physicians could assess) which raises 
questions with regards to the potential for zoonotic transmission from cats (Pym et al., 2002; 
Xavier et al. 2007). Despite these concerns, it remains the case that to date there are no 
instances of zoonotic transmission of M. microti from cats in the literature.  
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Importantly in this study, no M. tuberculosis infections were identified in any of the feline 
samples tested. This is likely to be because cats seem to be resistant to developing clinical 
disease due to M. tuberculosis, as has been demonstrated in experimental challenge studies, 
but whether or not they can carry latent infections remains unproven (Francis, 1958). Similarly, 
no dogs in this study were found to have M. tuberculosis infections. However, the canine 
sample size was very small and so may not be representative of all canine mycobacterial 
infections in the UK. Tuberculosis in dogs has historically been reported following both M. 
tuberculosis and M. bovis infections, with canine cases of M. microti occurring only very rarely 
(Snider and Cohen, 1972; Deforges et al. 2004). It is therefore an important benefit of this 
assay that the distinction between M. tuberculosis and M. bovis can be accurately made. For 
the first time, the MTBC organisms were identified in more than half of the feline samples; 
54.0% of the 270 that were positive for at least one mycobacterial gene demonstrating that 
veterinary clinicians in the UK should have a high suspicion of tuberculosis in cases with 
compatible lesions.  
Organisms of the MAC were rarely identified in this study, only 0.5% of the total 380 samples 
were positive for IS-1311, significantly lower than the percentage diagnosed by culture results.  
However, this probably reflects a lack of sensitivity of this marker rather than any significant 
decline in prevalence. For example, independent testing (IGRA and/or LUMR PCR) had 
already identified that twice the number of cases included in this study were infected with MAC 
organisms than this assay indicated. Further work is therefore needed to improve the 
sensitivity to detect MAC infections before any conclusions can be made regarding this result.  
In agreement with previous studies considering feline mycobacterial diseases, the number of 
AFB in these sections was highly variable (Gunn-Moore et al. 2011b; Malik et al. 2013). Herein, 
the overwhelming majority (97%) of samples collected from the primary diagnostic lab (Finn 
pathologists) contained visible AFB which likely reflects the time given by these veterinary 
pathologists to search granulomatous sections for foci of AFB. This is a significant increase 
on a previous UK study in which primary diagnostic laboratories found AFB in 64% (125/195 
cats) of the cases tested (Gunn-Moore et al. 2011b), suggesting pathologists may be more 
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aware of the significance of mycobacterial disease in UK cats and therefore they might be 
more likely to persist in examining suspect sections for AFB. 
This study found that although AFB numbers were inconsistent between sections, when ZN 
slides were scored, by far the most frequently attributed grade was Grade 2, defined as those 
slides that contained few or scattered organisms and/or up to ten AFB per high power field 
under oil emersion light microscopy. This finding is consistent with the large prevalence of 
tuberculous infections in this study population that are typically paucibacillary. As was initially 
hypothesised, those sections which were graded as Grade 1 or 2 were significantly less likely 
to give a positive PCR result for the 16s rRNA gene than sections that scored a higher grade, 
probably because the amount of mycobacterial DNA in the template material was greater for 
these samples. Importantly however, it was possible to amplify genes from some samples in 
every group, including those assigned Grade 0 (negative for AFB). This has also been 
demonstrated for samples analysed by LUMRL and in terms of culture, 41% of samples that 
were AFB negative were successfully cultured (Gunn-Moore et al. 2011a; Sharp et al. 2019). 
This may reflect either the imperfect sensitivity of the ZN method for staining all mycobacteria 
present in a sample or it may be simply that the section stained and examined contained no 
organisms but that they existed elsewhere in the lesion, so scoring sequential sections may 
have given different results. In either case, it is clinically important that a molecular diagnosis 
can still be possible even with a negative ZN stain, particularly if the entire lesion has been 
fixed and so mycobacterial culture is impossible.  
In conclusion, this study successfully developed a molecular method for the diagnosis of feline 
and canine mycobacterial infections in the UK. This six-gene mycobacterial assay identified a 
significantly higher proportion of cats with M. microti infections than previous studies, indicating 
that the prevalence of this infection may have been underestimated previously. Critically, no 
M. tuberculosis cases were identified and so the current UK wide advice that companion 
animal mycobacterial infections pose very low risk to their owners appears to be justified. This 
assay was found to have high sensitivity (88.2%) for the MTBC group of mycobacteria but was 
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Mycobacteriosis is an emerging zoonotic disease of domestic cats and timely, accurate 
diagnosis is currently challenging. To identify differential cytokine/chemokine concentrations 
in serum/plasma of cats, which could be diagnostic biomarkers of infection we analysed 
plasma/serum from 116 mycobacteria-infected cats, 16 healthy controls and six cats 
hospitalised for unrelated reasons using the Milliplex MAP Feline Cytokine Magnetic Bead 
multiplex assay. Three cytokines; sFAS, IL-13 and IL-4 were reduced while seven; GM-CSF, 
IL-2, PDGF-BB, IL-8, KC, RANTES and TNF-α were elevated in mycobacteria-infected cats 
compared to healthy controls. However, IL-8 and KC concentrations were not significantly 
different from cats hospitalised for other reasons. Elevations in TNF-α and PDGF-BB could 
have diagnostic potential to identify M. bovis and M. microti infected cats specifically while 
GM-CSF, IL-2 and FLT3L were increased in MTBC infected cats. This study demonstrates 
potential use of feline tuberculosis as a spontaneously occurring model of this significant 
human disease. Cytokine profiling has clear diagnostic potential for mycobacteriosis of cats 
and could be used discriminate tuberculous from non-tuberculous disease to rapidly inform on 
zoonotic risk. Future work should focus on the in-field utility of these findings to establish 









3.1 Introduction  
Tuberculosis has been the cause of considerable morbidity and mortality in the human 
population for centuries, and remains the leading cause of death from any single infectious 
agent (Mycobacterium (M.) tuberculosis) worldwide 1–3. Historically, the significance of this 
disease has resulted in extensive biomedical research interest and, due to the growing threat 
of drug resistance, tuberculosis is a major focus of collaborative global healthcare investment 
4–8. Meanwhile, tuberculosis in domestic cats receives relatively little research attention, 
despite being more common and clinically significant than previously thought 9–11. In the UK, 
approximately 1% of all feline biopsies submitted for routine histopathological analysis show 
changes consistent with mycobacteriosis and a third of these contain Ziehl-Neelsen (ZN) 
positive organisms when stained, with morphology indicative of the presence of mycobacteria 
10,12.  
The various mycobacterial species that have been identified in companion animals, including 
cats, can be grouped into the same two major categories as human mycobacterial disease; 
those belonging to the Mycobacterium tuberculosis-complex (MTBC) and the non-tuberculous 
mycobacteria (NTM, also referred to as ‘atypical mycobacteria’ or ‘mycobacteria other than 
tuberculosis’, MOTT) 11,13–19. 
The MTBC consists of ten highly genetically related species of mycobacteria which are 
capable of causing tuberculosis in both man and other animals, and are some of the oldest 
recorded zoonotic diseases known to both human and veterinary medicine 20–26. All member 
species of the complex share identical sequences across the 16s rRNA gene and 99.5% 
sequence homology across the remainder of the genome 27. The most discriminating features 
between the species at the nucleotide level are genomic deletions, termed regions of 
difference (RD) 28–31. The MTBC organisms which infect cats, Mycobacterium microti and 
Mycobacterium bovis, differ by RD-1 12,32–34. This region is absent from M. microti but present 
in all other MTBC organisms 28. It has been shown to encode a variety of molecules which act 
as virulence factors which are also immuno-dominant proteins such as; 6kDa early-secreted 
antigenic target (ESAT-6) and the 10kDa culture filtrate protein (CFP-10) 35–37.   
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In companion animals, such as cats, MTBC infections pose a potential zoonotic risk to their 
owners; additionally these cases may act as a potential source of environmental contamination 
with mycobacteria such as M. bovis, a pathogen of major animal health significance in the UK 
and other countries as the causative agent of bovine tuberculosis (bTB) 38–41.  
In stark contrast to human tuberculosis cases, the majority of feline tuberculosis cases present 
with localised nodular cutaneous disease, frequently with a degree of ulceration and 
occasionally with a draining sinus tract 9,13,14,34. The lesions are typically distributed around the 
face, extremities and tail base – the so-called “fight and bite sites” 15,34. Skin lesions may be 
accompanied by a localised or even generalised lymphadenopathy, or lymphadenopathy 
(usually of the submandibular, pre-scapular or popliteal nodes) may be the only presenting 
sign, termed an incomplete primary complex 14,33,34.  
Pulmonary lesions do occur in cats, but rarely, and result from bacteria being inhaled and 
causing typical tubercle formation in the lungs and hilar lymph nodes 9,14. Much more 
commonly, pulmonary disease is secondary to the putative haematogenous spread of bacteria 
from the site of inoculation in the skin 12,14. This generates a diffuse interstitial pattern of 
disease which eventually becomes bronchial and is clinically observable as progressive 
dyspnoea followed eventually by a soft productive cough 14,34. Radiographically this presents 
interstitial patterd differs from primary pulmonary infection which more frequently causes the 
“classical” tuberculous cavitating lesions 34. Disseminated disease can cause a range of 
clinical signs including hepato-splenomegaly, pleural and pericardial effusions, generalised 
lymphadenopathy, weight loss and pyrexia 9,13,33,34,42.    
With such variable clinical presentation and non-specific clinical signs, diagnosing feline 
mycobacterial infections rapidly and accurately is challenging. Mycobacterial culture 
conducted by the Animal and Plant Health Agency (APHA), is currently the recognised ‘gold 
standard test’ for the diagnosis of mycobacterial disease in UK companion animals; however, 
it has several limiting features. Firstly, it has been shown to have a relatively poor sensitivity 
of ~50%, secondly it requires weeks from the time that a contaminated tissue biopsy is 
submitted for results to be obtained e.g. the average culture time is 12-16 weeks for M. microti 
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- the most frequently cultured organism 9,34,43. During this time, if untreated, a patient will 
remain a potential source of infection to both its owner and the local environment.  
As such, alternative diagnostic tests have been developed which aim to reduce the amount of 
time between clinical presentation and a definitive diagnosis being reached. Interferon-gamma 
(IFN-γ) release assays (IGRA) were developed on the principle of quantitatively evaluating 
IFN-γ production by peripherally circulating antigen-specific effector T-memory cells upon in 
vitro stimulation, in order to aid the diagnosis of bTB in cattle 44–47. These have subsequently 
been adapted to identify both active and latent tuberculosis in human patients with both greater 
sensitivity and specificity than the previously utilised tuberculin skin test 48–50. Where 
intradermal testing has been shown to be of unreliable clinical utility in the cat, the IGRA has 
been used successfully 14,46.  
The IGRA tests have several advantages over other diagnostic techniques; they are 
significantly quicker at generating results than culture and are cheaper than many 
commercially available PCR and subsequent sequencing methods, they are also relatively 
non-invasive requiring only a single peripheral blood sample 46,49. Unlike intradermal skin 
testing, they can be repeated if necessary as conducting the assay does not alter the systemic 
immune response 45,51,52. In 2008, an adapted methodology of the IGRA was validated for 
diagnostic use in cats; this assay has a reported 100% sensitivity to indicate MTBC infection 
46.   
Recently, within the field of human diagnostics of mycobacterial diseases, and of tuberculosis 
in particular, there has been a marked increase in research focussed on the identification of 
circulating cytokine biomarkers for the diagnosis of both active and latent MTBC infections in 
humans 53–58. The goal of such assays is to cheaply, sensitively and rapidly identify infected 
and infectious individuals, in order to combat what remains one of the most incident infectious 
diseases of man 59. Such studies have utilised multiplex cytokine assays, most commonly 
Luminex xMAP technologies, with promising results 55,60,61. Studies of multiple assays have 
found circulating cytokine concentrations and combinations of cytokines which can sensitively 
and specifically diagnose both active and latent tuberculosis in humans 53–58. For example; 
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CXCL10 and CCL2 plasma concentrations can be combined with circulating levels of IFN-γ to 
more accurately discriminate between active and latent TB states, whilst the quantification of 
vascular endothelial growth factor can help differentiate patients with tuberculous pleural 
effusion from those with neoplastic pleural effusion 58,62. Similar assays have also been used 
successfully in the study of a limited number of companion animal diseases, including canine 
lymphoma and feline cystitis 63–66.  
As the timely and accurate diagnosis of feline mycobacteriosis, and the identification of the 
causative species is currently challenging, the aim of this study was to evaluate whether 
cytokine profiling from peripheral blood samples of infected cats demonstrate the same clinical 
utility as has been shown for humans. We therefore hypothesised that a number of cytokines 
would be differentially detectable in cats infected with mycobacterial infections when compared 
to both healthy controls and sick cats hospitalised for other reasons. We further hypothesised 
that the cytokine response would differ according to the species of mycobacteria present in 
the patient.  
3.2 Materials and Methods 
3.2.1 Blood Sample Collection from Mycobacteria spp. Infected Cats 
Blood samples analysed in this study were either heparinised plasma or separated serum. 
Archived remnant samples obtained opportunistically by vets and donated by the cats’ owners 
were used in this project. Cats diagnosed with mycobacterial infection by histological 
identification of (pyo)granulomatous inflammation in lesion biopsy material with the presence 
of AFB morphologically indicative of mycobacteria were considered eligible for inclusion in this 
study. Private veterinary surgeons who contacted the Royal (Dick) School of Veterinary 
Studies (RDSVS) for clinical assistance with case management were asked to retain any blood 
samples remaining after diagnostic procedures had been performed. With the owner’s 
consent, these samples were then sent directly to the RDSVS where they were retained frozen 
prior to the analysis of chemokine and cytokine concentrations.  
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Cats were excluded from the study if, prior to blood sample collection, they had been known 
to be treated with immunomodulatory medications e.g. non-steroidal anti-inflammatory drugs 
(NSAIDs), chemotherapeutic agents or corticosteroids within 14 days of sample collection. 
Cats were additionally excluded if they were pre-treated with antibiotics with efficacy against 
mycobacteria, including fluoroquinolones, macrolides/azides or doxycycline within the same 
time period. Cats were not excluded if they had been treated with antimicrobial agents if these 
were likely to be ineffective against mycobacteria, such as a penicillin or cephalosporin. 
Similarly, cats were not excluded if they had been treated with non-immunomodulatory 
analgesic medications e.g. opioids.     
3.2.2 Speciation of Mycobacteria Infecting Case Animals  
All 116 cats included in this study had positive histological diagnoses of mycobacterial infection 
as outlined above (see Section 2.2.1). Of these, cases which had undergone additional IGRA, 
PCR or culture testing were sub-classified by the species of infecting organism identified.  
Cases were defined as being infected with an MTBC mycobacteria if the cat had an IGRA test 
which showed an antigen specific IFN-γ response biased to purified protein derived from M. 
bovis (PPDB) above that generated in response to purified protein derived from M. avium 
(PPDA). The MTBC cases which additionally responded to the ESAT-6/CFP-10 peptide 
combination were classified as M. bovis infected. Cats which did not respond to the ESAT-
6/CFP-10 peptide cocktail but showed a PPDB biased response were defined as being 
infected with M. microti. Cats with a positive IGRA test that did not meet the criteria for MTBC 
infection were classified as being infected with NTM. Both the test method and interpretation 
have previously been described by Rhodes et al. (2008). 
In addition to IGRA testing, where available the results of specialist mycobacterial culture 
conducted at Weybridge reference laboratory by the APHA from tissue biopsies were used to 
speciate infections. In some cases, PCR results were used to speciate infections: these were 
conducted by Leeds University Mycobacterial Reference Laboratory (LUMRL). In total, 80 of 
the 116 cats tested could have the infecting species of mycobacteria identified.  
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3.2.3 Collection of Control Cat Blood Samples  
Remnant serum samples from 16 healthy control cats were kindly gifted from the Waltham 
Centre for Pet Nutrition. At the time of sampling each control animal underwent its annual 
routine health check comprising compete physical examination by the attending veterinary 
surgeon, plus full haematological testing and serum biochemical analyses. All cats were 
required to have been found to be healthy and their blood test results to be unremarkable to 
be included as control animals in this study. Separated serum were aliquoted, sent directly to 
the RDSVS and stored -80°C prior to analysis of chemokine and cytokine concentrations.  
3.2.4 Collection of Hospitalised Cat Blood Samples 
Remnant serum was obtained from six cats under treatment at the RDSVS. These cats had 
no clinical signs consistent with mycobacterial disease and were only included if an alternative 
definitive diagnosis had been reached. Once obtained, samples were kept at 4°C and assayed 
within 12 hours. 
Cats were excluded from this group for any one or more of the following: a diagnosis of stage 
V neoplasia (i.e. bone marrow involvement was confirmed), myelodysplastic disorder, 
exogenous retroviral (FIV/FeLV) infection, or if they had received treatment with any 
immunomodulatory medicines including NSAIDs, corticosteroids or chemotherapeutic agents.  
3.2.5 Cytokine and Chemokine Measurements  
Cytokine and chemokine concentrations were measured in all of the samples using a 
commercial, feline specific, antibody-coated microsphere-based multiplex cytokine 
immunoassay shown to be able to quantify 19 cytokines contemporaneously using 25µL of 
each patient’s serum (FCTYOMAG-20K MILLIPLEX MAP Feline Cytokine/Chemokine 
Magnetic Bead Panel, Premix 19 Plex Kit, MERCK Millipore Corporation, Billerica, MA, USA).  
The cytokines measured were; cluster of differentiation (CD) 95 (also known as sFas), Fms-
related tyrosine kinase three (Flt-3) ligand, granulocyte-macrophage colony-stimulating factor 
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(GM-CSF), IFN-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-12-(p40), IL-13, IL-18, 
keratinocyte chemoattractant (KC), monocyte chemoattractant protein (MCP)-1, platelet 
derived growth factor dimeric for subunit β (PDGF-BB), C-C motif ligand 5 (CCL-5, also known 
as ‘regulated on activation, normal T-cell expressed and secreted’ or RANTES), stem cell 
factor (SCF), stromal-cell derived factor (SDF)-1 and tumour necrosis factor (TNF)-α.  
All reagents as well as the serum/plasma samples were initially brought to room temperature. 
The pre-mixed bead solution was sonicated for 30 seconds and then vortexed for one minute. 
Quality Control vials 1 and 2 (FCTYOMAG-20K Kit) were each reconstituted with 250µL of 
deionised water. Serum Matrix (FCTYOMAG-20K Kit) was made by the addition of 1mL of 
deionised water and lyophilised Serum Matrix which was allowed to reconstitute at room 
temperature for ten minutes before a further 2mL of Assay Buffer (FCTYOMAG-20K Kit) was 
added. Patient and control animal sera were diluted in a 1:3 in Serum Matrix before analysis. 
The standard curve panel was produced by conducting a seven step 4-fold dilution series of 
the Feline Cytokine Panel Standard (FCTYOMAG-20K Kit) in Assay Buffer following 
reconstitution in 250µL of deionised water. Each assay plate was initially coated with 
200µL/well of Assay Buffer which was left for ten minutes on a plate shaker prior to the Buffer 
being removed.  
An aliquot of 25µL of appropriate Standard, Quality Control or diluted serum sample was 
added to each well as appropriate; all samples were assayed in duplicate and mean values 
analysed. An additional 25µL of Assay Buffer was added to the 0pg/mL standard (background) 
wells and to each well containing test serum, whilst the same volume of serum matrix was 
added to the Standard and Control wells. Finally, 25µL of the pre-mixed bead solution was 
added to each well before the plate was covered with aluminium foil and incubated overnight 
(16 hours) at 4oC on a plate shaker.   
The following day, the contents of each well was removed and each well was washed twice 
with 200µL of Wash Buffer. The Detection Antibody solution (FCTYOMAG-20K Kit) was 
allowed to warm to room temperature before 25µL was added to each well. The plates were 
sealed, covered with aluminium foil and incubated at room temperature on a plate shaker for 
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an hour; 25µL of streptavidin-phycoerythrin (FCTYOMAG-20K Kit) was then added to each 
well and the plate was incubated at room temperature on a plate shaker for an additional half 
an hour. The contents of each well was removed and each well was washed twice with 200µL 
of Wash Buffer (FCTYOMAG-20K Kit).  
The plates were read with a multiplex plate reader and companion software (Luminex 200). 
All cytokine and chemokine concentrations were calculated from the median fluorescent 
intensity (MFI) prior to statistical analysis and the results are therefore reported in pg/mL.  
3.2.6 Statistical Analysis  
Statistical analysis was performed using commercially available statistical software (GraphPad 
Prism 7.0). Mean MFI values of duplicate samples for each cat were used for analysis. For the 
purposes of statistical analysis, values that fell below the limit of detection of the assay were 
assigned a concentration of 0 pg/mL.  
Initially, to compare all mycobacteria positive samples (n=116) to healthy control cats (n=16), 
the D’Agostino & Pearson omnibus test was used to confirm a Gaussian distribution of the 
control group data for each of the cytokines/chemokines measured. As no reference intervals 
currently exist for these biomarkers in the cat, these were generated from the healthy control 
cat population to include values 1.96 standard deviations above and below the mean of the 
control group (i.e. to encompass ~95% of the healthy population) for each cytokine/chemokine 
measured. The mean concentration, standard deviation and reference interval (RI) generated 
for each molecule measured. 
For mycobacteria-infected cats, 95% confidence intervals (CI) around the mean were 
generated by logarithmic-transformation of the cytokine values so that the data conformed to 
a Gaussian distribution. On this basis, a 95% confidence interval was then generated for the 
transformed data which was then reverse transformed to give the confidence intervals 
provided in Table 3.1.  
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Cytokine concentrations were considered to be statistically significantly different between 
mycobacteria-infected and healthy control cats if there was no overlap between the RI 
generated from the control data and CI of data generated from infected cats (shown in bold in 
Table 3.1).  
A second comparison was made between mycobacteria-infected, healthy control cats and 
hospitalised cats. Confidence intervals for the cytokine levels of hospitalised cats were 
generated in the same way as described for mycobacteria-infected cats and are shown in 
Table 3.1. Again, cytokine levels were considered to be significantly different between groups 
if there was no overlap between the RI generated from the control data and CI of the 
concentrations measured in serum from sick cats or mycobacteria infected cats.  
A sub-group analysis was conducted to compare healthy control (n=16), M. bovis infected 
(n=22), M. microti infected (n=43) and NTM infected cats (n=15) with each other. Of these four 
groups, only cytokine concentrations within the healthy control group followed a Gaussian 
distribution as assessed by D’Agostino & Pearson omnibus test. Therefore, a Kruskal-Wallis 
test by ranks was used to determine if differences existed between the groups for each 
cytokine measured. Where significant differences were found (defined as p<0.05), each group 
was compared in a consecutive pairwise manner using Mann-Whitney U tests with post-hoc 
Bonferroni correction applied to accommodate for multiple comparisons. This resulted in a 
value of p≤0.003 being considered statistically significant for sub-group analyses. The median, 
range and 95% confidence interval for the cytokine concentrations measured within each sub-








3.3 Results  
Table 3.1: Cytokine concentrations detected for each group of cats; healthy controls, 
cats infected with Mycobacteria spp. and cats hospitalised for other reasons. All 
concentrations are given in pg/ml. Rows in bold denote a statistically significant 
difference between at least two of the three groups. Legend: N; total number of cats per 
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Hospitalised cats (N=6) 
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Table 3.2: Cytokine concentrations detected for each sub-group of cats infected with 
Mycobacteria spp. designated into those cases infected with M. bovis, M. microti or non-
tuberculous (NTM) mycobacteria. All concentrations are given in pg/ml. Rows in bold denote 
a statistically significant difference (P≤0.003) between at least one of these groups and the 
healthy control cats (Table I). Legend: N; total number of cats per group.  
Cytokine/ 
chemokine 
M. bovis-infected cats 
N=22 
Median 
(95% confidence interval) 
M. microti-infected cats 
N=43 
Median 
(95% confidence interval) 
NTM infected cats 
N=15 
Median 
























































































































3.3.1 Patient Characteristics  
All cats included in this study were adult cats from the UK. In total, serum/plasma from 116 
cases of feline mycobacterial disease met the inclusion criteria for the study, and serum from 
16 healthy control cats and six hospitalised cats was also analysed.  
Within the group of cats with clinical mycobacteriosis, the infecting organism was speciated 
based on IGRA, culture and/or PCR for 80 of the 116 (69.0%) cats. Of these, 22 (27.5%) were 
infected with M. bovis, 43 (53.8%) were infected with M. microti and the remaining 15 (18.7%) 
infected with NTM.  
For the cats hospitalised for other diseases the final diagnoses were established as 
hyperthyroidism (n=2), congestive heart failure due to hypertrophic cardiomyopathy (n=1), 
hepatic lipidosis (n=1), lysosomal storage disease (n=1), chronic kidney disease (n=1) and 
diabetes mellitus (n=1).  
3.3.2 Cytokine and Chemokine Concentrations 
All mycobacteria-infected cats compared to healthy control cats  
The mean/median and standard deviation/range for each cytokine concentration for each of 
these groups is shown in Table 3.1. Three cytokines; sFAS, IL-13 and IL-4 were found to be 
significantly reduced in the mycobacteria-infected group compared to healthy control cats 
(Figure 3.1). By contrast, seven cytokines; GM-CSF, IL-2, PDGF-BB, IL-8, KC, RANTES and 
TNF-α were present in significantly elevated concentrations within the peripheral circulation of 




Figure 3.1: Cytokines found to have significantly reduced concentrations in the peripheral 
blood of cats with mycobacterial disease compared to healthy controls. Data are shown as the 
median for the group with error bars indicting the 95% confidence interval. 
 
 
Figure 3.2: Cytokines found to have significantly increased concentrations in the peripheral 
blood of cats with mycobacterial disease compared to healthy controls. Data are shown as the 
median for the group with error bars indicting the 95% confidence interval. 
There was no significant difference between the two groups in their circulating concentrations 




Comparison of all mycobacteria-infected cats to hospitalised cats and controls 
To begin to assess the specificity of changes in cytokine concentrations between feline 
mycobacteriosis patients and healthy controls, serum from six hospitalised cats was analysed 
and compared to both of these groups, data shown in Table 3.1.  
The cytokines GM-CSF, IL-2, PDGF-BB, RANTES and TNF-α were found at significantly 
elevated concentrations in mycobacteria infected cats, whilst IL-4 and sFAS were detected at 
reduced concentrations in mycobacteria infected cats compared to both hospitalised non 
mycobacteria-infected cats and healthy controls (Figure 3.3).  
 
Figure 3.3: Cytokines found to have significantly altered concentrations in the peripheral blood 
of cats with mycobacterial disease compared to healthy controls and/or cats hospitalised for 
other reasons. Data are shown as the median for the group with error bars indicting the 95% 
confidence interval. 
The concentrations of IL-13 and IL-1β were found to be significantly reduced in hospitalised 
cats when compared to both control cats and those with mycobacterial infections (Figure 3.4). 
Whilst differences in the concentrations of IL-8 and KC were observed between healthy cats 
and those infected with mycobacteria, there was no difference in the concentrations of these 
cytokines between cats infected with mycobacteria and cats hospitalised for unrelated 




Figure 3.4: Cytokines found to have significantly altered concentrations in the peripheral blood 
of cats with mycobacterial disease compared to healthy controls and/or cats hospitalised for 
other reasons. Statistically significant differences between groups were determined by 
Kruskal-Wallis test by ranks (P<0.05), each group was compared in a consecutive pairwise 
manner using Mann-Whitney U tests with post-hoc Bonferroni correction applied to 
accommodate for multiple comparisons (P≤0.003). Data are shown as the median for the 
group with error bars indicting the 95% confidence interval. 
Comparison of cats infected with different mycobacterial species  
Of the 116 cats enrolled in the study, 80 had their mycobacterial infections definitively 
speciated to one of three causative agents, or group of causative agents; M. bovis, M. microti 
and NTM infections. These groups were compared to one another and also against the healthy 
control group. This analysis revealed the concentration of TNF-α to be significantly increased 
in the M. bovis-infected group when compared to all other groups; while the concentration of 
PDGF-BB was found to be significantly increased in cats infected with M. microti compared to 
all remaining groups (Figure 3.5). Concentrations of GM-CSF, IL-2 and Flt3-L were 
significantly increased in both MTBC groups (M. bovis and M. microti) when compared to the 




Figure 3.5: Cytokines found to have significantly altered concentrations in the peripheral blood 
of cats with mycobacterial disease due to M. bovis or M. microti, respectively, compared to 
healthy controls and cats infected with non-tuberculous mycobacterial (NTM) species. Data 
are shown as the median for the group with error bars indicting the 95% confidence interval.  
 
Figure 3.6: Cytokines found to have significantly altered concentrations in the peripheral blood 
of cats with mycobacterial disease due to TB-complex infections (M. bovis or M. microti 
respectively), compared to healthy controls and cats infected with non-tuberculous 
mycobacterial (NTM) species. Data are shown as the median for the group with error bars 
indicting the 95% confidence interval. 
The group of cats infected with NTM species had a significant reduction in the concentration 
of MCP-1 in comparison to the healthy controls (data not shown).  
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Concentrations of cytokine IL-8 were increased in all three mycobacteria-infected groups when 
compared to healthy control animals (data not shown), with the greatest increase observed in 
the cats with NTM infections, though this trend was not statistically significant (p=0.07).  
3.4 Discussion  
Current routine clinical methods for the diagnosis of feline mycobacterial disease, and 
tuberculosis in particular, have a number of drawbacks. Multiplex immunoassays have proven 
to be sensitive, specific, rapid, require very small sample volumes, and show a broad analytical 
and dynamic range 67-71. The benefits of the multiplex assay approach used in this study 
include more rapid availability of results than is currently achievable with culture or IGRA, and 
that this analysis requires only a small volume of serum or plasma to analyse (25uL) 67–71.  
This population of cats consisted of adult cats resident in the UK; previous studies have shown 
that male cats are over-represented in the population of cats presenting with mycobacterial 
infections and cats are usually younger when they present with M. bovis compared to M. 
microti infections 13,34. It was not possible for us to determine if any such bias existed within 
our study population as signalment data was infrequently reported to us by primary veterinary 
clinicians. The reasons for this are unclear but it may be a reflection of the predominately 
outdoor and semi-feral lifestyles of many of these cats meaning that there is limited information 
definitively known about them.   
All samples used in this study were opportunistically obtained remnants collected as part of 
other diagnostic investigations and processed by primary veterinary clinicians. This approach 
meant that samples could be sourced ethically and provides demonstrable ‘proof of concept’ 
that such methodology is potentially practicable and achievable within a clinical setting. Due 
to the remnant nature of samples analysed in this study, one must be cognisant of the 
possibility that post-collection processing may not have been consistent across samples e.g. 
storage temperature, which may have influence on individual findings 72,73. However, it seems 
reasonable to presume that such adverse effects would not impact any one group of cats in 
this study in particular, but occur randomly throughout the dataset generated and so the results 
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obtained in this study are still (clinically) interpretable. Similarly, due to the opportunistic nature 
of sample collection, this study included two different types of sample media; serum and 
heparinised plasma. Previous work with the same commercially available multiplex assay kit 
has demonstrated strong correlation between cytokine/chemokine concentrations obtained in 
paired serum and heparinised plasma samples taken from the same cat 71,74, and so again it 
would seem the results obtained in this study remain reliable and interpretable.  
The inflammatory cascade induced by mycobacterial infection is complex and is poorly 
characterised in the cat. The hallmark lesion of mycobacterial infections, including TB, is the 
granuloma which is a compact, organised aggregate of immune cells formed as part of the 
host immune response to the persistent stimuli of the pathogen 15,75–77. Upon phagocytosis, 
inhibition of phagosome-lysosome fusion enables the intracellular survival of mycobacteria 
within these phagocytes 78. The internalised bacilli are then believed to stimulate the infected 
macrophage to invade the local tissues 79,80. The stimulation of macrophage Toll-like receptors 
(TLR) by mycobacteria induces the production of numerous cytokines, predominantly TNF-α, 
which drives the recruitment of mononuclear cells and neutrophils from surrounding blood 
vessels. In particular, there is recruitment of activated T-cells which interact with activated 
macrophages and secrete IFN-γ leading to mycobacterial killing 81–85. Additionally, each group 
of recruited cells also release their own assortment of cytokines and chemokines which 
perpetuate the inflammatory cascade and the formation of a stable granuloma structure 82,86. 
In this study, we demonstrated that changes in the concentrations of eight critically important 
cytokines gave a sensitive and specific indication of mycobacterial infection in this feline 
population. Elevated concentrations of the cytokines GM-CSF, IL-2, PDGF-BB, IL-8, KC, 
RANTES and TNF-α in mycobacteria infected cats with concurrent reductions in sFAS, IL-13 
and IL-4 are suggestive of a pro-inflammatory process occurring in these patients, which is 
dominated by the recruitment and maturation of monocyte-macrophage lineage cells, the 
recruitment of cytotoxic T-cells, the proliferation of fibroblasts and T-cells and the suppression 
of humoral immunity.  
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Granulocyte-macrophage colony-stimulating-factor (GM-CSF) is a critically important cytokine 
involved in the innate immune response against mycobacteria, specifically via influencing 
macrophage and dendritic cell function 87–93. GM-CSF deficient mice are extremely susceptible 
to mycobacterial disease and their macrophages fail to effectively inhibit intracellular pathogen 
replication 91. Similarly, humans with detectable titres of anti-GM-CSF auto-antibodies show 
an increased susceptibility to pulmonary tuberculosis compared to healthy controls, whilst GM-
CSF immunotherapy can contribute to the resolution of disease due to drug-resistant M. 
tuberculosis 94,95. GM-CSF activated cells, principally macrophages, go on to propagate the 
inflammatory cascade in particular via the production of TNF-α 87. 
GM-CSF has been shown by previous multiplex cytokine analyses to be critical in the early 
response and possible clearance of M. tuberculosis in humans and mice, so that the use of 
recombinant GM-CSF as an adjunctive therapy for TB has been posited; the findings of this 
study suggest that this may also be of benefit to feline patients.  
TNF-α is an agonist of both NF-kB and mitogen-activated protein kinase (MAPK) which lead 
to downstream upregulation of pro-inflammatory immune functions including but not limited to; 
increased cell adhesion (e.g. giant cell formation) and macrophage apoptosis which are 
beneficial to the control of mycobacterial infections 96–98. One such downstream effect is the 
increased expression and secretion of chemokines including RANTES and interleukin IL-8 99–
101. These molecules are major drivers in the recruitment and migration of leukocytes towards 
an inflammatory focus 99–101. Additionally, RANTES can combine synergistically with other 
locally secreted cytokines, such as IL-2 released from T-cells and IL-12(p40) released from 
pathogen-activated antigen-presenting cells e.g. mature dendritic cells, in order to stimulate 
the activation and proliferation of natural killer (NK) cells, which ultimately leads to a local 
increase in mycobactericidal activity 99–101.  
TNF-α, one of the most studied cytokines in the human mycobacterial response, has been 
repeatedly shown to be of significant diagnostic utility for mycobacterial infections in humans, 
with concentrations varying between TB and non-TB patients as well as being discriminatory 
between active and latent infections and generally being found to decline with successful 
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therapy 54–57. Similarly, a number of patients receiving TNF-α antagonists such as infliximab 
have been reported to contract and even die from mycobacterial infections 102–104. In this study, 
it is notable that this cytokine was the only one to be uniquely indicative of infection with M. 
bovis. This is potentially due to the secretion of RD-1 proteins during the course of these 
infections generating a more pro-inflammatory state in M. bovis infected cats. The possibility 
that cats infected with mycobacteria and with elevated TNF-α could have more severe or active 
disease and hence pose a more serious zoonotic threat to humans is one that warrants further 
investigation.  
An essential step in the formation of an effective granuloma structure is fibroblast proliferation, 
mediated at least in part by the local production of PDGF-BB 105. Similar to TNF-α, it has 
recently been demonstrated that circulating levels of this cytokine are elevated in human 
patients with active pulmonary tuberculosis, and that these levels decline significantly over a 
six month course of therapy 55. However, in contrast to TNF-α, within our feline population, 
PDGF-BB was only detected at significant levels in cats infected with M. microti. This may 
indicate a difference in the immune response by cats to this species of mycobacteria, which 
was used as the human vaccine strain prior to the availability of M. bovis-BCG, and may 
therefore be considered attenuated 106. Future analysis and comparison of the granuloma 
structures of M. microti and M. bovis infected cats may show physical manifestations of such 
differences, and may be useful to identify prognostic features of relevance to feline disease.  
The Fas/Fas-ligand (FasL) system is an important molecule for immunological regulation; 
specifically it maintains T-cell homeostasis by the induction of apoptosis in order to limit T-cell 
expansion following antigenic stimulation 107,108. It has been reported that mycobacteria exploit 
this system in order to subvert and evade the adaptive immune response of an infected animal 
by generating an immune-privileged niche 107,109. Soluble Fas (sFAS) can antagonise cell 
surface FasL by competitive inhibition and so allow continued T-cell proliferation, a 
phenomenon shown to be significant in lymphoproliferative disorders such as non-Hodgkin’s 
lymphoma 110.  
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This is the first time, to our knowledge, that evidence of such an extensively conserved 
systemic immune response to these infectious agents, directly comparable to that seen in 
many human and animal models of mycobacterial disease, has been demonstrated in the cat. 
This suggests that the occurrence of mycobacterial infections in this species could act as a 
naturally occurring model of human disease. This capacity could be particularly significant in 
overcoming the known shortcomings of murine models of mycobacterial disease, particularly 
as feline cases occur with relatively high clinical frequency and so could provide a naturally-
occurring reliable source of study data. 
Within the variety of mycobacterial species which are known to infect cats; those belonging to 
the MTBC, and M. bovis in particular, pose the greatest risk of zoonotic spread to in-contact 
humans 39–41. Currently the gold standard diagnostic test to identify these organisms which 
can threaten human health is mycobacterial culture; however, M. bovis takes a minimum of 
six to eight weeks to confirm by culture and M. microti requires even longer at 12-16 weeks 
9,14,43. Within the cytokines analysed in this study; Flt-3L, GM-CSF and IL-2 were all 
significantly elevated in cats with a diagnosis of infection with an MTBC organism compared 
to all other groups. Therefore, it may be possible that these cytokines in particular could be 
used to more rapidly identify those infections that pose zoonotic risk to owners and the general 
public, allowing for earlier intervention.   
Cytokine profiling in companion animal medicine has been the subject of a number of recent 
studies 63,65,66. One limitation of such studies to date is the study design to compare cytokine 
profiles in animals with the designated diagnosis of interest and apparently healthy animals as 
controls. In our investigations, we additionally included a small number of cats that had been 
hospitalised for reasons unrelated to mycobacterial disease. This allowed us to identify that 
the changes in concentration of the cytokines KC and IL-8 were not specific to mycobacterial 
infection, but rather may simply occur when cats were ill or stressed. These findings indicate 
that including such a group in experimental design is and will be important for the assessment 
of diagnostic accuracy, including sensitivity and specificity, of cytokine profiling in the future. 
Greater accuracy would be achieved by expanding on our small sample size (n=6) and also 
159 
 
by matching the diagnoses in this group to those with similar aetiopathogenesis to the 
diagnosis of interest. For example, such a study could include cats with other infectious 
granulomatous disease such as feline infectious peritonitis (FIP), where multiplex expression 
profile analysis of serum samples have also shown elevations in RANTES and GM-CSF 
concentrations 65.  
A limitation of the study we report here is its retrospective nature; this meant that it was not 
possible to have a standardised diagnostic assessment of each cat and samples from each 
cat did not undergo the gold standard test of mycobacterial culture. The majority of cats in this 
study were diagnosed by IGRA which has been shown to have a higher sensitivity for MTBC 
than NTM infections, which may have introduced some bias towards MTBC infected 
individuals in our population 46. Similarly, the amount of time elapsed between the time of 
infection, the infective dose received, and the time of blood sampling was not known for these 
cats. It is therefore possible that the changes seen could reflect different stages or magnitude 
of the feline response to mycobacteria; for example, MTBC infections may be diagnosed 
earlier in the course of infection than NTM infections and so the differences seen may simply 
reflect an early compared to late immune response. It was therefore not possible for us to 
generate sensitivity or specificity data for these cytokines nor to assess their diagnostic 
capacity in combination as has been achieved in human medicine. To further investigate the 
potential for cytokine profiling in feline mycobacterial disease, the prospective recruitment of 
cases would allow for additional control over the time of blood sampling in relation to patients 
being presented to a veterinary surgeon. Such a study would additionally further allow changes 
in cytokine concentrations to be tracked over time, and in response to treatment. This would 
allow much greater accuracy regarding the cessation of antimicrobial therapy in these cases, 





In this study, we demonstrate a conserved immunological response to mycobacteria by 
domestic cats analogous to that of other species. Further research into feline tuberculosis as 
a spontaneously occurring model of a significant human disease is now required. These data 
show that cytokine profiling has the practical and immunological potential to be developed as 
a sensitive and specific diagnostic test for the presence of mycobacteria in feline infections, to 
readily speciate them and help inform on zoonotic risk to exposed humans. The Milliplex MAP 
Feline Cytokine Magnetic Bead multiplex assay was shown to be a practicable and reliable 
platform for these measurements and further work should focus on the prospective diagnostic 
utility of the findings reported in this study.  
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Chapter 4: A Feline Outbreak of M. bovis in the UK 
Associated with Feeding a Commercial Raw Food Diet.  
 
Preface 
The following Chapter presents the findings of a study, conducted as part of this studenship 
programme investigating an unprecedented outbreak of tuberculosis in domestic cats 
putatively due to the contamination of a raw pet food product. The findings are presented in 
four parts; the first three parts are presented as a chronological assembly of publications which 
document the outbreak and investigation in real time. Each publication contains a statement 
detailing the contribution of each author. 
The fourth part of this Chapter comprises a detailed retrospective analysis of the outbreak; at 
the time of writing no new cases had been confrmed in the preceeding three months. Part four 
(O’Halloran, manuscript in preparation), joins together the epidemiological evidence 
established at the time of submission of this thesis with the clinical investigation findings to 
identify the most likely risk pathways by which the outbreak occurred; this would not have been 
possible without the assistance and resources of Tony Roberts of the Animal and Plant Health 
Agency who was instrumental in the epidemiological investigation.    
Acknowledgments 
Thanks go to all of the owners and veterinary surgeons of the cats in this study for donating 
samples and cadavers to us to allow the investigations to be conducted and for giving 






Mycobacterium bovis in pet cats 
Veterinary Record, October 2018 
Dear Editor,  
We are writing with regard to three clinical cases of feline tuberculosis due to Mycobacterium 
(M.) bovis recently confirmed in two households in England. What makes these cases unusual 
is that these cases occurred in young pedigree cats (under two years old) with no history of 
outdoor access since they were adopted as kittens. Furthermore, both households are located 
well within areas of the country deemed to be low risk for M. bovis in cattle and other species 
including cats. These cases are therefore not typically consistent with how we currently think 
most cats become challenged with M. bovis – by hunting infected prey. Notably all cats were 
fed a commercial raw food diet but the significance of this in the epidemiology of these cases 
is not yet clear. Given the clinical particulars of these cases, it may be possible to prioritise 
differential diagnoses such as gastrointestinal lymphoma, or feline infectious peritonitis (FIP), 
but we would like to urge clinicians to be aware of the possibility of tuberculosis in young 
pedigree cats, even with a lack a history of outdoor access and that may have been fed on a 
raw food diet. If colleagues are suspicious of any cases, or have diagnosed any similar cases, 
we would be very interested in hearing from them.  
Yours sincerely,  
Conor O’Halloran & Danièlle Gunn-Moore; Royal (Dick) School of Veterinary Studies and The 
Roslin Institute, University of Edinburgh 
Nicki Reed; Wear Referrals, Stockton-on-Tees 
Julie Vickers; TDDS Ltd, Exeter 
Eili Dettmering; Top Cat Veterinary Centre, Brighton 
Olympia Ioannidi & Kevin Murtagh; Anderson Moores Veterinary Specialists, Winchester 
Author contributions:  
C. O’Halloran (the candidate), collated the case data and wrote the publication. Drs Reed, 
Vickers, Dettmering, Ioannidi and Murtagh provided case details. Professor Gunn-Moore 





Tuberculosis due to Mycobacterium bovis in pet cats associated 
with feeding a commercial raw food diet.  
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Author contributions:  
O’Halloran, C. conducted investigations, collated the clinical case details, supervised the 
clinical management of cases and wrote the manuscript.  
Drs Ioannidi, Reed, Murtagh, Dettemering, Van Poucke, Gale and Howe diagnosed cases 
in practice, provided case details for publication and clinically managed cases in 
collaboration with the Univeristy of Edinburgh. Drs Vickers and Dobromylsky are 
experienced veterinary pathologists and provided diagnostic assistance for these cases. 
Dr Paul Burr, supervised the IGRA testing whilst Dr Gascoyne-Binzi conducted the PCR 





Objectives: Mycobacterium bovis, a member of the Mycobacterium tuberculosis-complex, 
can infect cats and has proven zoonotic risks for owners. Infected cats typically present with 
a history of outdoor lifestyle and hunting behaviour, and cutaneous granulomas are most 
commonly observed. Six young cats, living exclusively indoors in five different households 
across England were presented to separate veterinarians across the UK with various clinical 
signs due to tuberculous disease. 
Methods: Investigations into the pyogranulomatous lesions, lymphadenopathy and/or 
pulmonary disease of these cases consistently identified infection with Mycobacterium bovis. 
Infection was confirmed by PCR where possible or was indicated with a positive interferon 
gamma release assay (IGRA) where material for PCR was unavailable. In-contact, cohabiting 
cats were screened by IGRA and follow-up testing undertaken/advised where these were 
positive. A lifestyle investigation was undertaken to identify the source of infection. 
Results: Six clinically sick cats and seven in-contacts have been identified with evidence of 
M. bovis infection. Five clinical cases were either too sick to treat or deteriorated despite 
therapy, giving a mortality rate of 83%. Lifestyle investigations revealed the common factors 
between clusters to be; that affected cats had mycobacterial infections speciated to M. bovis, 
were exclusively indoor cats and were fed a commercially available raw food product produced 
by a single manufacturer. The Food Standards Agency, Animal and Plant Health Agency, 
Public Health England and the food manufacturer concerned have been notified/informed.  
Other possible sources of exposure for these cats to M. bovis were explored and were 
excluded; including wildlife contact, access to raw milk, the presence of rodent populations 
inside the buildings in which the cats lived, and exposure to known infectious humans. 
Conclusions and relevance: Upon investigations, our results provide compelling, if 
circumstantial, evidence of an association between the commercial raw diet of these cats and 





4.1 Introduction  
The increasing importance of mycobacterial infections in companion animals in the UK has 
become apparent in recent years1,2. It has been demonstrated that approximately 1% of all 
feline biopsies submitted for histopathological analysis show changes consistent with 
mycobacteriosis (pyo/granulomatous inflammation dominated by epithelioid macrophages) 
and at least one third of these have demonstrable Ziehl-Neelsen (ZN) positive organisms when 
stained, with a thin rod-like appearance, indicative of mycobacteria; these are also referred to 
as acid or alcohol fast bacilli (AFB)3-5. 
Clinically, about a third of feline mycobacteriosis cases in the UK are caused by 
Mycobacterium tuberculosis-complex (MTBC) pathogens, with Mycobacterium (M.) microti 
being cultured from 19% of all cases of feline mycobacteriosis, and a further 15% caused by 
M. bovis6,7.  
There is a strong geographical predisposition to feline infections with members of the MTBC6. 
M. bovis infections are strongly co-incident with where there are high levels of endemic 
infection in local bovine and wildlife populations, such as the South-West of England6-8. Feline 
MTBC infections, particularly those caused by M. bovis, pose a potential zoonotic risk to their 
owners9;  they may also act as a potential source of environmental contamination, which is 
critically important, as M. bovis is a pathogen of major animal health significance in the UK 
and other countries as it is the causative agent of bovine tuberculosis (bTB)10.  
In contrast to human tuberculosis, the majority of feline tuberculosis cases present with 
localised nodular cutaneous disease, frequently with a degree of ulceration and occasionally 
with draining sinus tracts1,2,6,7,11,12. The lesions are typically distributed around the face, 
extremities and tail base; the so-called “fight and bite sites” 1,2,6,7,11,12. Skin lesions may be 
accompanied by a localised or occasionally generalised lymphadenopathy, or 
lymphadenopathy (usually of the submandibular, pre-scapular or popliteal lymph nodes) may 
be the only presenting sign, termed an incomplete primary complex1,2,6,7,11,12.  
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Primary pulmonary lesions do occur in cats, but rarely1,6. They can result from bacteria being 
inhaled and causing tubercle formation in the lungs and hilar lymph nodes1,2,6,7,11,12. However, 
much more commonly, pulmonary disease is secondary to the putative haematogenous 
spread of bacteria from the site of inoculation in the skin1,2,6,7,11,12. This generates a diffuse 
interstitial pattern of disease that eventually becomes bronchial, and is clinically observable 
as progressive dyspnoea followed eventually by a productive cough1,2,6,7,11,12. Disseminated 
disease can cause a range of clinical signs including hepato-splenomegaly, pleural and 
pericardial effusions, generalised lymphadenopathy and weight loss1,2,6,7,11,12. Historically, 
tuberculosis in cats commonly presented as alimentary disease, caused by cats drinking 
tuberculous cow’s milk, but following the introduction of milk pasteurisation, this form of 
tuberculosis is now only seen extremely rarely1,2,6,7,11,12.  
Due to the putative transmission of M. bovis and M. microti to cats by hunting infected prey, 
tuberculosis is most frequently diagnosed in adult cats, with a consistent history of hunting 
reported in almost every instance6. Male cats are over-represented, possibly secondary to 
contamination of fight-inflicted wounds6. The median age of infection is three years for M. bovis 
and eight years for M. microti1,2,6,7,11,12. There appears to be no link between MTBC infection 
and classical immunosuppression i.e. feline immunodeficiency virus (FIV) and feline 
leukaemia virus (FeLV) infection in cats6.   
The diagnosis of mycobacterial disease in cats is challenging; the traditional tuberculin skin 
testing technique has been shown to be ineffective in domestic cats13. Molecular techniques 
such as PCR and DNA hybridisation1,14,15 are available through human Mycobacterial 
Reference Laboratories in the UK but remain expensive, and in some circumstances 
prohibitively so. These techniques also require the organism to be present, and are most 
sensitive when performed on a cultured isolate. Where this is not possible for a cat, then an 
IGRA is available16,17. This test uses specific mycobacterial proteins to stimulate peripheral 
immune cells in order to determine if a patient has been infected with an organism which either 
contains or secretes those peptides16-18. The production of interferon gamma in response to 
protein purified derived (PPD) from M. bovis (PPDB) at a greater concentration than that 
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produced in response to PPD from M. avium (PPDA), confirms infection with an MTBC 
organism16,17. A further peptide cocktail of the 6kDa early-secreted antigenic target (ESAT-6) 
and 10kDa culture filtrate protein (CFP-10) can be used to determine if a patient has been 
infected with an MTBC organism which encodes the genetic region RD-1; M. tuberculosis and 
M. bovis do encode this region, whilst M. microti does not19,20. Experimental challenge studies 
have shown that M. tuberculosis does not cause clinical disease in cats, so a positive response 
to ESAT-6/CFP-10 and PPDB in a feline patient indicates infection with M. bovis21. This is not 
the case for canine patients which can present with disease due to M. tuberculosis22.   
Contrary to the common presentation of feline tuberculosis as cutaneous lesions on non-
pedigree adult cats that hunt, we recently published our findings that we had become aware 
of three highly unusual systemic/abdominal cases of tuberculosis caused by M. bovis that had 
occurred in young pedigree cats with no outdoor access in two households in England. Of 
particular note, both of these households are located well within areas of the country deemed 
to be low risk for M. bovis in cattle and other animal species. However, we noted that all three 
cats had been fed a commercially available complete raw food diet and that the 
epidemiological significance of this was unclear at the time. Following the publication of letters 
in the Veterinary Record23 and Veterinary Times24, we have now identified and investigated a 
total of five households infected with M. bovis involving 13 cats; here we report on all of the 
households and show that the raw food diet is epidemiologically implicated as a possible 
source of these infections. Further to these cases, we have investigated a continually growing 
number of cases diagnosed since our original publication which has allowed us to begin a 
more extensive epidemiological investigation into this outbreak which will be published 







4.2 Case details  
Each cluster is designated by its regional geographical location which are represented on the 
map below; the locations given are not exact (county level) in order to comply with client data 
protection (Figure 4.1). Furthermore, a timetable of the key dates for the outbreak are given in 
Table 4.1.  
 
Figure 4.1: A map of the UK showing the approximate location of each of the clusters 
throughout England. Exact locations are withheld for client data protection. The map is 
adapted from TBhub (https://www.tbhub.co.uk accessed 3 April 2019), a joint industry 
initiative, supported by the Agriculture and Horticulture Development Board (AHDB), the 
Animal & Plant Health Agency (APHA), the British Cattle Veterinary Association (BCVA), the 
Department for Environment, Food and Rural Affairs (DEFRA), Landex and the National 




Table 4.1: A timetable of the dates on which the first cat in each cluster was diagnosed with 
tuberculosis and when the relevant government authorities were alerted to our concerns.  
Date (2018) Event 
15th August First cat in Cluster 1 diagnosed by NR, Wear Referrals 
21st September First cat in Cluster 2 diagnosed by ED, Top Cat Veterinary Centre 
24th September University of Edinburgh (DGM/COH) notify Animal and Plant Health 
Agency (APHA) and begin a collaborative epidemiological 
investigation. 
29th September University of Edinburgh (DGM/COH) open investigations with Public 
Health England 
10th October  University of Edinburgh (DGM/COH) contact food manufacturer with 
concerns 
29th October First cat in Cluster 3 diagnosed by RH, Wymondham Vet Clinic 
3rd November First cat in Cluster 4 diagnosed by JG, City Vets 
14th November First cat in Cluster 5 diagnosed by SVP, Millenium Veterinary Practice 
11th December Food manufacturer recalls suspect product 
 
Cluster 1: Durham  
A two year old, male neutered Siamese cat was referred with lethargy, hyporexia and pyrexia 
(40.5°C) of two weeks’ duration. The cat had been acquired from a breeder at 12 weeks of 
age, had not received any vaccinations since the kitten course, and was indoor-only with one 
other cat (see below). The cat had been fed only a single commercial frozen raw food diet 
since acquisitiona. Routine haematology and serum biochemistry (Table 4.2) documented a 
mild non-regenerative anaemia. The cat tested negative for FeLV antigen and anti-FIV 
antibodies. An abdominal mass attributed to an enlarged mesenteric lymph node was palpated 










Table 4.2: Abnormalities identified on routine haematology and serum biochemistry analysis 
of the presenting cat in each Cluster of cats.  
 Analyte Measured value Reference Interval 
Cluster 1 Haematocrit 25.8% 27.0-45.0% 
 Red blood cell count 4.7x1012/L 5-10x1012/L 
 Neutrophil count 12.85x109/L 2.5-12.8x109/L 
 Urea 15.4mmol/L 2.8-11mmol/L 
 Glucose 8.1mmol/L 4.5-8mmol/L 
Cluster 2 Haematocrit 21.8% 27.0-45.0% 
 Neutrophil count 25.00x109/L 1.48-10.29x109/L 
 Monocyte count 2.00x109/L 0.07-0.85x109/L 
Cluster 3 Packed cell volume 
(PCV) 
14% 25-45% 




16µg/dL Less than 14µg/dL 
Cluster 4 Haematocrit 25.2% 30.3-52.3% 
 Total white blood 
cell count 
18.16x109/L 2.87-17.02x109/L 
 Neutrophil count 13.49x109/L 1.48-10.29x109/L 
Cluster 5 Haematocrit 21.0% 27.0-45.0% 
 Neutrophil count 24.32x109/L 1.48-10.29x109/L 
 
On presentation at the referral centre, a thin body condition was noted (body condition score 
3/9; weight 4.3kg). The respiratory rate was elevated at 42 breaths/min, with wheezing 
detected on inspiration and expiration. An 8cm firm mass was palpable in the mid-abdomen, 
without evidence of pain.  
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Repeated routine haematology and serum biochemistry (Table 4.2) identified marginal mature 
neutrophilia, mild hyperglycaemia and mildly elevated urea. A computed tomography (CT) 
scan of the thorax showed a diffuse ground-glass appearance to the lung parenchyma, which 
also contained disseminated micro-nodular lesions (Figure 4.2).  The sternal lymph node was 
mildly enlarged. A CT scan of the abdomen showed the enlarged and lobulated appearance 
of the mesenteric lymph nodes (Figure 4.3).  
 
Figure 4.2: Transverse computed tomography (CT) scan of the thorax of the first clinical case 
from Cluster 1 showing an extensive multifocal nodular and alveolar lung pattern, consistent 
with mycobacteriosis. 
 
Figure 4.3: A transverse CT scan of the abdomen of the first clinical case in Cluster 1. The 
scan shows a large, multinodular mass occupying approximately 2/3 of the abdominal cavity. 
Lymph node biopsies showed pyogranulomatous lymphadenitis with no infectious organisms 
seen on Zeihl-Neelson staining. To begin to investigate the differential diagnoses of 
pyogranulomatous lymphadenitis in the cat, feline coronavirus (FCoV) antibodies, serum 
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alpha-1-acid glycoprotein and serum albumin:globulin ratio were tested; they were not 
suggestive of feline infectious peritonitis (FIP), Toxoplasma gondii serology was negative, and 
Bartonella species serology was weakly positive (6 [RI <5.5]).  On suspicion of mycobacterial 
infection, an IGRA was conducted at Biobest Laboratories and indicated infection with M. 
bovis. 
The cat is currently being treated with the recommended anti-mycobacterial triple antibiotic 
therapy1,2, comprising pradofloxacin (Veraflox™, Bayer, 3mg/kg every [q] 24 hours by mouth 
[PO]), azithromycin (Zithromax™, Pfizer, 9mg/kg q 24 hours PO) and rifampicin (generic, 
11mg/kg q 24 hours PO). Two months after starting medication the abdominal mass was no 
longer palpable and the cat’s weight had increased to 5.12kg. Treatment is on-going at the 
time of writing. 
A two-year-old female neutered Oriental cat that resided in the same household as the case 
described above was referred to the same centre with a chronic intermittent cough, and a three 
week history of increased respiratory rate and effort, lethargy and hyporexia. The cat was 
acquired from a different breeder at the same time as the above cat, had not received any 
vaccinations since the kitten course, and was indoor-housed only. Both cats were fed 
exclusively on the same commercial complete raw dieta. Prior to referral, pyrexia (39.8°C) had 
been recorded and routine serum biochemistry had identified a significant hyperbilirubinaemia 
(64 μmol/L; RI 0-12 μmol/L), whilst haematology was unremarkable.  
On presentation at the referral centre, the cat’s respiratory rate was 100 breaths/min, with 
bilateral moist rales on thoracic auscultation and a tracheal wheeze on auscultation of the 
cervical neck. A thoracic CT scan showed a marked diffuse nodular lung pattern with areas of 
alveolar infiltrate and an IGRA test confirmed infection with M. bovis. 
This cat was not amenable to medication for behavioural reasons, and her evident respiratory 
signs increased the risk of transmission to the owners, so she was euthanased. No post-






Cluster 2: Sussex 
A 12-month-old female neutered, indoor only domestic short haired cat was presented for a 
history of lethargy, hyporexia and significant weight loss (reduced by 12.5% over four months, 
(body condition score 2/5). This cat, and three other co-habiting cats, were fed on the same 
commercial raw fooda as those in Cluster 1 since acquisition as kittens. On presentation this 
cat was pyrexic (41.1°C) and an abdominal mass was palpable cranial to the bladder. The cat 
was referred for further investigation which revealed mild generalised peripheral 
lymphadenopathy and diffuse bilateral wheezes and crackles on lung auscultation. Routine 
haematology and serum biochemistry (Table 4.2) showed non-regenerative anaemia, a 
mature neutrophilia and monocytosis. Serum biochemistry revealed elevated globulin levels. 
As for the above Cluster the differential diagnoses included FIP, a lymphoproliferative disease, 
mycobacterial disease or other infectious agents. The cat tested negative for FeLV antigen 
and anti-FIV antibodies. A chest and abdominal CT scan revealed multifocal pulmonary 
nodular-like lesions, alveolar foci and partially consolidated left and right cranial lung lobes, 
generalised severe lymphadenopathy, a multi-lobulated multi-cavitated right cranial abdominal 
mass around the ileum with perilesional peritonitis and moderate splenomegaly.  
A fine needle aspirate from the enlarged nodes revealed extensive pyogranulomatous 
inflammation, containing numerous AFB with typical mycobacterial morphology (Figure 4.4a 
and b). Unstained sections were submitted to Leeds University Mycobacterial Reference 
Laboratory (LUMRL) for mycobacterial PCR which identified MTBC DNA; subsequent 
speciation using the GenoType MTBC kit (Hain LifeScience GmbH, Nehren, Germany) 






Figure 4.4a: A fine needle aspirate from the inguinal lymph node of the clinically affected cat 
in Cluster 2. The slide is stained with Wright’s stain (40x magnification). It shows reactive, 
vacuolated “foamy” macrophages (red arrow) and mature neutrophils (black arrow). 
 
Figure 4.4b: A Ziehl–Neelsen stain of a second slide made from a fine needle aspirate (as 
shown in Figure 6.3a) viewed under oil emersion (x100 magnification). The slide similarly 
shows reactive, vacuolated “foamy” macrophages (red arrows). Throughout the slide there are 
positively stained (fuschia coloured) extracellular rod shaped bacilli with typical mycobacterial 
morphology. 
Given the severity of disease the cat was euthanased on welfare grounds. On IGRA testing, 
the three co-habiting cats had results indicative of infection with M. bovis. They remain 
clinically well though due to financial restrictions further investigation (e.g. diagnostic imaging) 




Cluster 3: Norfolk 
A 15-month-old, male neutered domestic long-haired cat was presented, it had been 
exclusively indoor housed since acquisition as a kitten along with a female sibling. Both cats 
were fed exclusively the same brand of raw fooda as the other Clusters from the time that they 
were kittens. The cat was presented with diarrhoea and on examination had pale mucus 
membranes, abdominal distention, poor muscle condition, and marked generalised superficial 
lymphadenomegaly involving the submandibular, prescapular and popliteal lymph nodes, in 
addition to an abdominal mass assumed to be enlarged mesenteric lymph node(s). The cat 
was borderline pyrexic (39.5°C). Routine haematology and serum biochemistry (Table 4.2) 
revealed anaemia, a mature neutrophilia and a mild increase in SMDA. Fine needle aspirates 
of the abdominal mass/lymph node showed large numbers of macrophages (Figure 4.5) and 
intracytoplasmic AFB; confirmatory mycobacterial PCR and speciation at LUMRL on the 
remaining slide, confirmed MTBC DNA was present but as the slide had been previously 
stained the DNA was of insufficient quality to differentiate between MTBC organisms i.e. M. 
bovis or M. microti. An IGRA test showed a weakly positive result suggestive of M. bovis 
infection. Treatment was attempted with pradofloxacin (Veraflox™, Bayer, 3mg/kg q 24 hours 
by mouth PO), azithromycin (Zithromax™, Pfizer, 9mg/kg q 24 hours PO) and doxycycline 
(generic, Summit, 10mg/kg PO q 24 hours). Unfortunately, the cat continued to deteriorate 
and was euthanased on welfare grounds. The sibling remains clinically well at the time of 






Figure 4.5: A Ziehl–Neelsen stain of a slide made from a fine needle aspirate of the abdominal 
mass from the case in Cluster 3 viewed under oil emersion (x100 magnification) containing 
high numbers of AFB.  
 
Cluster 4: Devon 
A six-year-old female neutered Bengal-cross cat was presented to its primary veterinary 
surgeon for lethargy and hyporexia. The cat was an indoor-only cat and had been in the 
owner’s possession since it was seven weeks old. This cat lived with another exclusively 
indoor-housed cat, a four-year-old male neutered Abyssinian cat that had asthma; both were 
fed the same commercial raw food dieta as the other Clusters since they has been acquired, 
although they were also given occasional meals of commercial cooked processed fish-based 
foodsb,c. On presentation, the cat was pyrexic (39.9°C) with an enlarged inguinal lymph node 
and localised overlying cellulitis. Routine haematology (Table 4.2) revealed non-regenerative 
anaemia and leukocytosis due to a mature neutrophilia. The cat tested negative for FeLV 
antigen and anti-FIV antibodies. Histopathology of the lesion biopsy revealed marked 
necrotising panniculitis containing AFB with mycobacterial morphology. Unstained sections 
were submitted to LUMRL for mycobacterial PCR and speciation as described above, and 
confirmed M. bovis. Pending these results, the necrotic area of the lesion was surgically 
debrided and the cat was given potentiated-amoxicillin (Clavaseptin™, Vetoquinol at 18mg/kg 
q12 hours PO) and marbofloxacin (Marbocare™, Animalcare at 2mg/kg q24 hours PO). 
Unfortunately, the wound broke down irreparably; the cat was euthanased on welfare grounds. 
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A post-mortem examination was conducted within the Containment Level 3 facility of the 
Roslin Institute, University of Edinburgh; there was a surgical defect in the right inguinal area 
where the affected skin, fat and lymph node had been removed as well as pathological tissue 
break down (Figure 4.6a and b). On examination of the abdomen many small white, well 
demarcated hard lesions were present throughout the spleen on both the visceral and cut 
surfaces. Within the thorax, similar lesions were visible in the caudal lung lobes and 








Figure 4.6a: Post-mortem examination of a six-year-old female neutered Bengal-cross cat 
(Cluster 4) shows evidence of the extensive nature of surgical resection required to remove 








Figure 4.6b: Evidence of the breakdown of the surgical wound and surrounding tissue 




Grossly pathological tissues were taken from the lung and spleen, homogenised in 1% 
collagenase solution containing 10% penicillin-G, decontaminated with 4% NaOH for 30 
minutes and sown onto OADC supplemented 7H11 (Middlebrook, UK) slopes, Löwenstein–
Jensen medium with pyruvate and Stonebrink slopes in order to isolate and genotype the 
causative strain.  After nine weeks, small colonies were visible on the plates with typical 
morphological appearance of M. bovis. In-house PCR testing at Edinburgh followed by PCR 
performed at LUMRL confirmed the colonies to be M bovis; the APHA was notified and sent a 
second tissue sample for independent culture analysis, which is pending. The in-contact cat 
remains clinically well at the time of writing but the results of a screening IGRA test indicate 
M. bovis infection. Thoracic radiographs and abdominal ultrasound have identified no 
pathology. However, this cat has experienced significant recent weight loss (~12% 
bodyweight), so the owner has elected to treat with standard anti-mycobacterial therapy (drugs 
as dosages as above in Cluster 1).  
Cluster 5: Essex 
A 15-month-old, indoor-only, male neutered Maine Coon cat was presented for lethargy and 
constipation of approximately 48 hours. The cat had been fed exclusively on the same dieta 
as the other Clusters since it was acquired at 12-weeks-old. Physical examination revealed 
pyrexia (40.0°C) and a palpable, mobile, non-painful abdominal mass in the region of the 
mesentery. Ultrasound examination confirmed the presence of a 9x13cm mass adjacent to an 
enlarged mesenteric lymph node and a small amount of free fluid. Fine needle aspirates of the 
mass revealed large, foamy macrophages, mesenchymal cells and histiocytic infiltration. 
Routine haematology and serum biochemistry (Table 4.2) revealed non-regenerative anaemia 
and marked mature neutrophilia. 
An exploratory laparotomy was performed and the fluid, mass and mesenteric lymph node 
were resected (Figure 4.7) and submitted for histological examination. Large numbers of 
macrophages were observed and a presumptive diagnosis of FIP was made. However, further 
investigation to confirm FIP, including immunohistochemistry on the biopsy material, reverse 
transcription quantitative PCR (RT-qPCR) for mutated FCoV on the abdominal fluid, and 
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serum FCoV titre quantification and alpha-1 acid glycoprotein was not compatible with FIP. 
During this investigation, retrospective staining of the original biopsy revealed individual AFB 
with mycobacterial morphology scattered in large areas of necrosis. The cat improved clinically 
post-surgery but six weeks later developed a cough; thoracic radiography revealed a mass 
dorsal to the carina (Figure 4.8), whilst a repeat abdominal ultrasound revealed a 2cm mid-
ventral mass caudal to the spleen. Cytology of the abdominal mass again revealed a 
predominance of macrophage infiltration with intracellular non-staining rods present. Cytology 
with ZN-staining revealed AFB, initial PCR testing at the University of Edinburgh indicated 
infection with M. bovis (protocol as outlined in Chapter 2) and the remaining slides were 
submitted for mycobacterial PCR and speciation at LUMRL but it was not possible to isolate 
sufficient mycobacterial DNA for definitive speciation. The IGRA screening tests on the two 
co-habiting domestic short haired cats which ate mainly commercial dry food, separately from 
the Maine Coon cat, showed positive responses indicative of M. bovis infection though they 
were clinically well.  
 
Figure 4.7: The Maine Coon in Cluster 5 had a large abdominal mass (centre) measuring 
8x13cm removed during an exploratory laparotomy. The local draining mesenteric lymph node 
(left) was also removed during surgery as was the ~12ml of ascitic fluid (right). The fluid was 
tested for mutated feline coronavirus by RT-qPCR but was negative. Retrospective 




Figure 4.8: A left latero-lateral of the thorax of the Maine Coon cat from Cluster 5. There is a 
mass (total diameter 1.2cm) at the level of the carina. A cough had become clinically evident 
at the time this radiograph was taken. It resolved within three days of anti-mycobacterial triple 
antibiotic therapy.  
The Maine Coon was treated with the recommended anti-mycobacterial triple antibiotic 
therapy1,2 comprising marbofloxacin (Marbocyl™, Vetquinol, 2mg/kg every [q] 24 hours PO), 
azithromycin (Zithromax™, Pfizer, 9mg/kg q 24 hours PO) and rifampicin (generic, 11mg/kg q 
24 hours PO). Two months after starting medication the abdominal mass was no longer 
palpable and the cat’s weight had increased. However, following owner-led cessation of 
therapy at this stage, the cat subsequently relapsed and was euthanased on welfare grounds 
and has been submitted to APHA officials for post-mortem examination, the results of which 
are pending at the time of writing. Due to the owner being immunocompromised, the two in-







4.3 Follow-up investigations  
The current legislation applicable to England (The Tuberculosis (England) Order 2014) Article 
625 states that suspicion of tuberculosis in the carcass of any pet mammal is notifiable, and as 
such the Secretary of State has been duly notified of all of the cases presented here via the 
APHA. However, there is no statutory obligation of investigation in non-bovine animals and so 
current investigations have been led by the University of Edinburgh and largely financed, 
where conducted, by the University and/or owners.  
Public Health England (PHE) have similarly been informed of the cases and all owners have 
been offered the opportunity to discuss the zoonotic aspects that these cases present should 
they wish to do so with PHE. PHE are currently adopting a precautionary public health 
approach similar to that which has been described previously26. The owners of two of the 
affected cats were found to be IGRA and Mantoux test (tuberculin skin test) positive 
respectively, one has required the instigation of anti-tuberculosis medical therapy.  
Potential sources of exposure to M. bovis were explored with the owners; all except the raw 
commercial food were excluded. Excluded sources included wildlife contact (all cats were 
solely indoor cats), the presence of rodent populations inside the buildings in which the cats 
lived, access to raw milk, and exposure to any known infectious humans.  
As the only common factors between all clusters are that they were diagnosed with the same 
infection (M. bovis), were exclusively indoor cats and were fed a commercially available raw 
food product produced by a single manufacturera, the Food Standards Agency (FSA) have 
similarly been informed and they are investigating appropriately.  
The authors at the University of Edinburgh have been sent detailed batch information and 
photographs of and/or actual samples of the diet from three of the five clusters, as was being 
fed to the cats at the time the diagnoses were made (Figure 4.9a-c). Notably, all three of these 
samples were the venison product produced by the same company. On questioning the 
owners; the venison product from the single manufacturer comprised ~80% of the ration of 
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one cat (Cluster 4), the sole intake of another (Cluster 5) and the “vast majority” of the diet of 
a third (Cluster 2). The remaining two clusters (Cluster 1 and 3) fed a variety of the products 
from the same company, including the venison product.  
As such, the evidence we have collected during our investigations of these cases provide 
compelling, if only circumstantial, evidence of an association between the diet of these cats 
and their M. bovis infections.  
The company was alerted, and an internal investigation by them led to the voluntary withdrawal 
of the venison version of their food from sale; ‘because some of the ingredients were not 
inspected in line with EU requirements. The absence of inspection means the safety of the 
product cannot be confirmed and may therefore carry a potential risk.’ The batches withdrawn 
are those dated as best before between March 2019 and August 2019 and pre-date those 
submitted for testing at the University of Edinburgh. The FSA are now undertaking this area of 
the outbreak investigation independently.  
 
Figure 4.9: Three of the five Clusters had retained the food product that the affected cats were 
being fed at the time that they became ill. One owner sent photos taken by themselves (4.9a 
- left), the other two owners sent the food to the University of Edinburgh by refrigerated courier 
and the photos were taken inside the Containment Level 3 facility prior to further testing (4.9b 






This outbreak currently includes 13 cats, in five separate Clusters, that were found to be 
infected with M. bovis; six cats were clinically unwell at diagnosis (five of these are now dead), 
while seven were found to be positive by IGRA i.e. they had evidence that they have been 
infected with M. bovis, although how many of these latter cats’ are likely to become ill is 
unclear. Three have not been assessed further by their veterinarian (Cluster 2), and one 
(Cluster 4) has already lost a great deal of weight, potentially related to M. bovis infection (this 
cat has been treated for M. bovis infection and has since recovered all its previously lost 
weight). While still circumstantial, the only probable source of the infection is that M. bovis 
infected the cats when they were all exposed to the same commercially available raw food. 
New cases are still occurring and further data collection is in progress at the time of writing, 
but the authors intend to make readers aware of the details and the scale of this problem as 
soon as practically possible. The cases reported here appear to be limited to cats which have 
been fed this feline-specific food (i.e. no dogs have yet been affected) and no owners are self-
reporting as unwell. 
The feeding of commercial raw meat based diets (RMBD) to companion animals has increased 
substantially in popularity in recent years, not just in the UK but globally27,28. In the USA, sales 
of RMBD doubled in the five years to October 2017 and have expanded by 15.9% in last year 
alone, making the industry worth an estimated US$195 to the United States economy29. In 
Europe, a recently published study from the Netherlands found that 51% of dog owners fed 
their animals either completely or partially on RMBD30. A similar increase has been seen in 
the UK, with what were only a handful of companies registered as producers of RMBD a few 
years ago having increased to a current excess of 80 registered with the Department for the 
Environment, Farming and Rural Affairs (DEFRA)27. Shapiro et al (2017)31 found in a survey 
of Australian cat breeders that raw meat was fed as an integral constituent of the diet by 89% 
of respondents. The reasons behind so many people adopting RMBD feeding are numerous 
and complex. Some owners feel that it is physiologically more “natural” for their pet to consume 
food similar to that they would have eaten at an earlier stage in their evolution (i.e. pre-
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domestication)31-33. There have been speculative suggestions that RMBD feeding may be 
beneficial in preventing the onset of dental disease, food responsive inflammatory bowel 
disease and atopy, and a recent paper has shown that the microbiome of dogs fed RMBD is 
more diverse than when fed processed diets31-34. The topic of what the veterinary profession 
should be advising clients with respect to RMBD is highly emotive on both sides of the debate, 
and the evidence for and against is frequently either low quality or simply anecdotal reports 
with a lack of rigorous, properly controlled trials31-35. There is however, consensus that home-
prepared RMBD should be generally avoided as it is extremely difficult to make them 
nutritionally balanced35. This concern has been overcome by the introduction of commercially 
available complete RMBD which comply with the strict legislative requirements, overseen by 
the European Pet Food Industry Federation (FEDIAF), to ensure nutritional and energy 
requirements are met if any given product was provided as the sole ration for the life time of 
the animal in question36-38.   
Unfortunately, statutory regulations governing RMBD only account for the presence or 
absence of a limited number of infectious organisms39. It is one of the few areas regarding 
RMBD on which there is agreement; that there is a significant increase in the risk of infectious 
diseases to both pets and owners through the consumption and handling of such products on 
a regular basis40-46. Almost all RMBD are sold frozen in order to extend their expiry dates and, 
in the case of some organisms (e.g. nematodes such as Trichinella species) reduce or 
eliminate contamination47. In studies of the zoonotic infectious agents present within thawed 
RMBD, Salmonella species have received the most attention44-46. Although subclinical 
infections occur frequently in animals, Salmonella species can cause gastroenteritis and even 
septicaemia48-50. For example, Stiver et al. reported fatal septicaemic salmonellosis after 
RMBD feeding in two cats51. Other studies have successfully recovered a variety of viable 
zoonotic pathogens including Escherichia (E.) coli serotype O157:H7, Listeria 
monocytogenes, Sarcocystis spp. Campylobacter spp. and Toxoplasma gondii from RMBD44-
46,52. At least one such RMBD contaminant, Shiga Toxin releasing E. coli (STEC) has been 
linked to human deaths in the UK, and Public Health England are attempting to educate 
owners about the risks associated with RMBD53. In the USA, raw cat food has similarly had to 
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be recalled due to contamination with Listeria monocytogenes54. At this stage, as cases are 
continuing to be diagnosed there is insufficient evidence to ascertain if this is a single, one off 
event or an ongoing problem. However, in either instance this outbreak raises concerns over 
the strength of current regulation with regards to meat inspection procedures and may 
necessitate an increase in trained veterinary meat inspection of a carcass before it is passed 
as fit for animal consumption. With particular reference to wild venison, one such alteration 
could be that the entire gralloch (all viscera) be brought to the slaughter-house for veterinary 
inspection.  
Our study is the first to report infection of companion animals with an MTBC pathogen which 
appears to be associated with feeding a RMBD, with 13 cats in five households infected, as 
identified to date. Not only does this imply that the owners were handling contaminated 
material, but the gastrointestinal presentation means that the cats may have been shedding 
M. bovis into their home environment, creating the potential for even greater exposure to 
owners. Of further concern, the Pet Food Manufacturers Association guidance to owners 
handling RMBD is that they should clean surfaces, utensils and animal food bowls with “soap 
and hot water”55. Pasteurisation requires milk to be heated to 71.5°C and held at that 
temperature for a minimum of 15 seconds to inactivate M. bovis56; it is highly unlikely that 
owners would be able to achieve this in a domestic setting, so M. bovis is very likely to be able 
to persist on kitchen surfaces even after the owners feel that they have been “cleaned”. 
Furthermore, M. bovis is able to survive for at least 60 days in standing water57, such as might 
be found in or around a kitchen sink, over which time further organisms may be added with 
each prepared meal making it highly plausible that the small dose needed to infect a human 
could be reached.  
The severity of clinical disease that was seen in the cats we report here is much greater than 
we would typically expect to see through infections acquired through hunting infected rodents. 
The clinical signs of pyrexia, anaemia and leukocytosis (caused by a mature neutrophilia) are 
not typically present in feline tuberculosis cases and the young age of many of the cats affected 
is also striking, as is that the cats were indoor only, and not from areas of England known to 
193 
 
have endemic M. bovis in rodents, badgers, other wildlife and cattle58-60. These factors may 
mislead clinicians presented with future cases to not consider tuberculosis as a potential 
differential diagnosis, delaying the time until correct diagnosis and thus exposing owners to 
possible infection for extended periods.  
Many of the cats presented in these clusters were either too sick to attempt treatment, or 
clinically deteriorated despite attempted therapies giving a case fatality rate, to date, of 83% 
compared to our more usual 70-80% successful treatment rate2. The severity of infection was 
similar to that which we previously reported in an outbreak of M. bovis tuberculosis in a pack 
of working Foxhounds where it was concluded that the source of infection was most likely the 
feeding of contaminated raw meat61. That outbreak resulted in a higher than typical clinical 
attack rate for tuberculosis (approximately 10% of the group) and when the hounds started to 
display clinical signs, they deteriorated so rapidly that euthanasia was required on welfare 
grounds within hours to days61. Additionally, feline abdominal M. bovis infections acquired in 
a nosocomial setting and cats with disseminated M. bovis infection that appeared to have 
followed extensive ingestion, also displayed rapid clinical progression, and severe signs such 
that euthanasia on welfare grounds was quickly required62,63. The parallels between these 
fulminant outbreaks suggests that there may be an underlying difference in the 
immunopathogenesis of the disease, whereby gastrointestinal/peritoneal challenge of 
companion animals with M. bovis results in more severe disease that is less amenable to 
treatment and may thus have implications for the clinical management of gastrointestinal 
tuberculosis cases in comparison to the more typical dermal presentation. Alternatively, or 
additionally, it may be that strains of M. bovis which are capable of establishing infections in 
companion animals following gastrointestinal/peritoneal challenge may have or may utilise 
additional virulence factors which make these infections clinically more aggressive. The latter 
scenario would have profound implications on the zoonotic risk to owners if they were being 
exposed to M. bovis with inherently greater virulence.  
The IGRA was used to detect M. bovis infection in all six of the unwell and a further six of the 
in-contact cats. However, one in-contact cat (Cluster 3) was IGRA tested and found to have a 
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greater response to PPDA than PPDB, i.e. a pattern not consistent with that expected of M. 
bovis infection. It may be that this cat has not been challenged with M. bovis but has co-
incidentally and/or previously been sensitised to antigens of the M.avium-intracellulare-
complex. However, studies in calves sensitised to environmental mycobacteria and infected 
with M. bovis, have concluded that M. bovis infection may be concealed for some time in this 
situation64. It is therefore possible that this cat may develop a different response, i.e. that 
typical of M. bovis, if it were to be retested in the future.  
Work by our team at the University of Edinburgh is ongoing to develop a rapid PCR assay 
which we hope can be performed on tissue lysates, (unstained) cytology slides and formalin-
fixed biopsy tissues. Where this was used in these cases it proved extremely useful; but, its 
use outwith a research capacity will require more extensive evaluation before this is made 
available to clinicians. Similarly, the team is continuing to work with Biobest Laboratories to 
validate to use of the feline IGRA in the detection and monitoring of tuberculosis in cats.  
Urgent work is now needed to establish the extent of any contamination of the RMBD pet food 
chain in the UK, and a full epidemiological investigation is underway to establish where lessons 
can be learned in order to future safeguard animals being fed RMBD.  
Management of suspect cases 
The team at the University of Edinburgh are always keen to hear from clinicians who may 
have, or have had, suspicions about similar cases and can offer our experience in both 
diagnosing and managing these patients. Currently, we are advising that animals known to 
have been exposed to the recalled food, or who have been exposed to a confirmed case but 
are displaying no clinical signs should be tested by IGRA at least four weeks after the last 
known exposure. If these tests are positive then diagnostic imaging should be undertaken to 
assess for structural (i.e. active) disease (full body CT or radiographs and, ideally, abdominal 
ultrasonography). Where present, active disease should be treated appropriately; as outlined 
in O’Halloran and Gunn-Moore, 20171. There is currently no evidence on which to base the 
appropriate course of action for animals that are IGRA test positive but lack evidence of 
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structural disease. It may be appropriate in these cases to closely monitor body weight, 
condition score and resting respiratory rate and to investigate further if these decline. 
Alternatively some owners may elect to give prophylactic therapy; isoniazid (which is 
occasionally used in humans for this purpose) can be used for six months but experience of 
its use in cats is limited and toxicities may occur. Instead, some owners may choose to treat 
using the triple combination of anti-tuberculous therapy for three months, given that the use of 
this protocol is well established and potential side effects are well documented.   
4.5 Conclusion  
This report follows our initial alert regarding an ongoing outbreak of M. bovis tuberculosis in 
pet cats across the UK. It describes six clinically sick cats and seven in-contacts with a 
mortality rate of 83%. Lifestyle investigation revealed the common factors between clusters 
were that the cats were exclusively indoor only and fed a commercially available raw food 
product produced by a single manufacturer. The Food Standards Agency, Animal and Plant 
Health Agency, Public Health England and the food manufacturer concerned have been 
notified/informed. Our results provide compelling, if circumstantial, evidence of an association 
between the commercial raw diet of these cats and their M. bovis infections.    
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Tuberculosis in UK cats associated with a commercial raw food 
diet. 
Editorial, Journal of Feline Medicine and Surgery, August 2019 
Conor O’Halloran & Danièlle Gunn-Moore  
Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, 
Easter Bush Campus.  
Johann Schonlein coined the term “tuberculosis” in the year 1834, 48 years before the 
causative agent Mycobacterium (M.) tuberculosis was first visualised by Robert Koch. At that 
time, one in seven of the world’s population was thought to be infected and despite significant 
efforts in the intervening almost two hundred years, this prevalence has actually increased to 
an estimated one in three. Whilst M. tuberculosis may have been the first tuberculous 
organism identified, it is restricted to infecting a very small number of species. By comparison, 
the causative agent of ‘zoonotic tuberculosis’, i.e. M. bovis, has a very wide host range. So 
named for is predilection for bovine hosts, M. bovis can actively infect an exceptionally broad 
range of species which include but are not limited to; cattle, badgers, deer, camelids, a variety 
of rodents, human and non-human primates, racoons, possums, and coyotes. Not surprisingly, 
our feline patients are also susceptible.  
Last year, we were alerted to a highly unusual group of feline M. bovis tuberculosis cases 
(O’Halloran et al. 2018a). Initially, the striking feature was that these cases presented with a 
rare manifestation of disease; alimentary tuberculosis (Figure 4.10): this compares to most 
‘typical’ cases of tuberculosis in cats in the UK, which are cutaneous and/or pulmonary. The 
investigation became even more complex when diagnostic tests confirmed M. bovis infections; 
this was unexpected as these cats were living in areas of the UK which have either a very low 
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prevalence of M. bovis in cattle and badger (such as Lancashire) or are officially M. bovis free 
(such as Scotland).  
 
Figure 4.10: The grossly abnormal intestine and associated lymph nodes removed for 
specialist mycobacterial culture from a one year old, male neutered Persian cat who was 
weaned onto the Natural Instinct Wild Venison product and continued to eat it as a sole ration 
until developing marked chronic weight loss, hyporexia and an expiratory wheeze. He was 
euthanased on welfare grounds due to the severity of clinical signs.   
We investigated the lifestyle histories of the cases to try and identify any possible routes of 
exposure to M. bovis. We discovered that all of the cats were indoor-only (i.e. they were at 
negligible risk from wildlife or rodents), they were of different breeds and were mostly young, 
none had been fed raw (unpasteurised) milk, or lived with people with active tuberculosis. The 
only common feature was that all were fed (in varying proportions) a commercial raw food diet; 
Natural Instinct, Wild Venison (Figure 4.11). On discussion with the company and from their 
subsequent investigations, it was concluded that some of the ingredients had not been meat-
inspected in line with EU requirements so the safety of the product could not be confirmed; 






Figure 4.11 The Natural Instinct product linked to this outbreak.  
The EU requirements in question (predominately EU Regulation 853/2004) state that a wild 
venison carcass (including its gralloch, or innards) must be inspected by a trained person 
(which can be the stalker) after the deer’s death to look for any signs of disease, parasites or 
contamination. However, the stalker does not have to bring the gralloch ‘off the hill’, so 
infections could be missed. In addition, the supply by hunters of small quantities of wild game 
meat directly to local retailers is not covered by these regulations and therefore is not subject 
to any of the defined rules for food of animal origin. 
In this case, possible contamination could have been avoided if this Regulation had been 
correctly adhered to. However, in order to reduce the risk of a similar incident occurring in the 
future it is our view that examination of entire game carcasses (including the gralloch) should 
be undertaken by a qualified, specially trained veterinary surgeon in an abattoir if the meat 
from the carcass is intended for consumption as a raw food product (for either people or pets). 
Such a policy change could be applied across England and Wales, or limited to regions within 
the high risk and edge areas for endemic M. bovis infections in cattle and wildlife. Additionally, 
we feel it would be sensible to prevent the feeding of raw offal to any companion animal. This 
policy is already in effect for packs of working hounds; since October 2017 the feeding of offal 
from livestock species to registered kennel hounds has been banned in England following our 
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previous work investigating another raw-food associated M. bovis outbreak and no new cases 
have since been reported (Anonymous, 2017; O’Halloran et al. 2018b). 
Our initial investigation into this current outbreak has been reported in this publication 
previously (O’Halloran et al. 2019) and new cases continue to occur. To date we have 
diagnosed 45 cases with active clinical disease, 73 with inactive (i.e. latent) infection and 
screened in excess of 50 well cats where owners are concerned regarding historical exposure 
to the contaminated product. A more up to date report of our findings is in preparation and will 
be published as soon as possible.  
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Mycobacterium (M.) bovis can infect cats and has proven zoonotic risks for owners. We 
describe an outbreak of M. bovis in cats from across England and Scotland associated with 
feeding a commercial raw food diet. Investigations of (pyo)granulomatous lesions, 
lymphadenopathy, and pulmonary and/or alimentary disease of 45 affected cases over one 
year identified infections with M. bovis genotype 10:a. 
Infection was confirmed by culture in a small number of cases (n=5); PCR was used in 
combination with or as an alternative to culture (n=12) and/or infection was indicated by 
positive interferon gamma release assay (IGRA; n=34). At-risk cats were screened by IGRA; 
follow-up testing identified 77 sub-clinically infected cats.   
The five culture-positive cases were distributed across England and Scotland, within areas of 
the UK considered to be low-risk for endemic M. bovis. Whole genome sequence analysis of 
recovered isolates revealed identical nucleotide sequences providing evidence that these 
infections are epidemiologically linked.   
Lifestyle investigations revealed that affected cats were mainly indoor-only, all of whom had 
been fed Natural Instinct’s Wild Venison food as at least part of their diet. As far as possible, 
other possible sources of infection were explored and were excluded; including wildlife contact, 
access to raw milk, the presence of rodent populations inside the buildings in which the cats 
lived, and exposure to known infectious humans.  
Owners and examining vets of test-positive cats were referred to their local health 
professionals; four owners and one veterinary surgeon were found to have a high likelihood of 
latent tuberculosis infections. One pregnant owner underwent prophylactic treatment. Though 
it is not possible to conclusively demonstrate a zoonotic origin for these infections, the potential 
for this should be considered when possible cases are identified.   
Our results provide strong evidence that the commercial raw diet of these cats was the likely 
route of their M. bovis infections.    
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4.7 Introduction  
Mycobacterium (M.) bovis is one of the member species of the Mycobacterium tuberculosis-
complex (MTBC) which are capable of causing tuberculosis across a broad taxonomy of 
species including but not limited to humans, cattle, deer, dogs and cats (Sales et al. 2001; 
Philips et al. 2003; Allen, 2017).  
Feline infections with M. bovis are strongly co-localised to areas of the UK with a high 
prevalence of infections in cattle (Gunn-Moore et al. 2011); termed high risk areas (HRA) of 
the UK by the Department for Environment, Food and Rural Affairs (DEFRA). Conversely, M. 
bovis infections are very rare in low risk areas (LRA) and somewhat higher incidence in the 
edge zones between LRA and HRA regions as evidenced by a culter of M. bovis infections in 
cats in Berkshire in 2013 (Roberts et al. 2013).  
Within the MTBC group of pathogens, M. bovis stands out as the least host restricted and thus 
has significant zoonotic potential (Sales et al. 2001; Biet et al. 2005; Suzuki et al. 2010). 
Disease in humans due to infection with M. bovis, termed ‘zoonotic tuberculosis’ by the World 
Health Organisation (WHO), is a major global public health priority which resulted in nearly 
150,000 cases and at least 12,500 deaths worldwide in 2010 (World Health Organisation, 
2017). Clinically, about a third of feline mycobacteriosis cases in the UK are caused by MTBC 
pathogens; in the only published study, M. microti was cultured from 19% of all submitted 
cases of feline mycobacteriosis, and 15% were caused by M. bovis (Gunn-Moore et al. 2011a; 
O’Halloran and Gunn-Moore, 2017). 
Characterisation of the typical clinical manifestations of feline mycobacterial diseases in the 
UK has shown that 74% of cases present with single or multiple cutaneous lesions, and 10-
16% with pulmonary or systemic signs (Gunn-Moore et al. 2011a). The remainder of cases 
are small numbers of relatively rare presentations such as alimentary, joint or ocular 
mycobacteriosis (Gunn-Moore 2014; Lalor et al. 2017; Stavinohova, et al. 2019).   
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We have previously reported on a highly unusual group of 13 feline M. bovis tuberculosis 
cases (O’Halloran et al 2018a; O’Halloran et al. 2019). Initially, the striking feature was that 
these cases all presented with one of the rarest manifestations of disease, alimentary 
tuberculosis. The investigation became more complex when diagnostic tests indicated M. 
bovis infections as these cats were living in areas of the UK which have either a very low 
prevalence of M. bovis in cattle and badger (such as the North East of England) or Scotland, 
which holds officially M. bovis free status (for cattle (APHA, 2017; O’Halloran et al. 2019). 
Suspicions were raised with regards to a possible link to diet as all cats were indoor-only, had 
no access to alternative sources of infection as far as we could determine, and they were all 
fed a single commercial raw food product, Natural Instinct Wild Venison (Food Standards 
Agency, 2018; O’Halloran et al. 2019).  
We concluded that these initial findings provided circumstantial evidence of an association 
between the commercial raw diet of these cats and their M. bovis infections. Since then, further 
cases have been diagnosed and an epidemiological investigation undertaken; the purpose of 
this publication is to outline in full our findings and conclusions from both the clinical and 
epidemiological investigations.   
4.8 Clinical Investigations  
4.8.1 Clinical Presentation of Cases  
Forty-five cats from 41 households have been diagnosed with active tuberculous disease 
linked to this outbreak at the time of writing. All 45 cases were presented to their primary 
veterinary surgeons over the course of one year (July 2018 to July 2019). The majority of 
affected cats (39/45, 86.7%) were pedigree breeds including; eight Bengal cats, seven 
Persians, seven Maine Coons, six Siamese, four British Shorthairs, two Ragdolls and one 
each of Burmese, Toyger, British Blue, Sphinx and one Bengal cross cat. The remaining six 




The age at presentation ranged from three-month-old kittens to 13 years, with a median age 
of two years. There was no statistical difference between the number of male or female cats 
presenting with disease (Χ21=1.48, p>0.05); half of the cats (22/45, 48.8%) were neutered 
males, ten cats were neutered females (22.5%), whilst nine were entire females (20.0%) and 
four (8.9%) were entire males.  
Clinical signs noted by the owners of these cats were most frequently non-specific signs of ill 
health, including combinations of lethargy (18/45 cats, 40.0%), hyporexia (15/45 cats, 33.3%) 
and poor or declining body weight/condition (15/45 cats, 33.3%). 
The clinical abnormality most frequently reported by examining vets was “respiratory signs”, 
which was recorded in 75.6% (34/45) of cases. The severity of these signs ranged from mild 
increases in respiratory rate and/or effort through to a persistent cough and pneumonia 
causing life-threatening dyspnoea; it was the recorded reason for euthanasia in two cases 
(Figures 4.12a and 4.121b). In a further three cases (6.7%) thoracic lymphadenomegaly of the 
peribronchial, sternal and/or mediastinal lymph nodes was the only gross lesion detected on 
investigation of the primary presenting complaint (lethargy in two cats and hyporexia in one 
cat).  
 
Figure 4.12a: A latero-lateral thoracic radiograph of an affected cat (a four-year-old female 
neutered indoor-only Bengal cat) showing two cavitating lesions (red box) within the lower 





Figure 4.12b: Post mortem examination of the same cat radiographed in Fig. 4.12a revealed 
extensive fibrinopurulent exudate (black arrows) in the thoracic cavity and the extent of the 
granulomatous lesions. Lung samples submitted for mycobacterial culture were positive for M. 
bovis. 
 
Abdominal masses (granulomas) were palpable in 23 of the 45 cats (51.1%), whilst the 
abdominal viscera (excluding lymph nodes) were found to be structurally abnormal (either 
enlarged or containing granulomatous lesions, Figure 4.13) in a further four cases (8.9%) as 
visualised by abdominal radiography, ultrasonography and/or computed tomography (Figure 
4.14). The abdominal lymph nodes associated with the alimentary system (Figure 4.15) were 
enlarged in four cats (8.9%) and enlarged as part of a generalised lymphadenomegaly in a 
further eight cats, hence 12 cases (26.7%) had abdominal lymphadenomegaly. Overall, the 
alimentary tract and associated structures were found to contain gross pathology in 31 of the 
45 cases (68.9%), but clinical signs directly relatable to the gastrointestinal system (vomiting, 




Figure 4.13: The spleen of an 18-month-old male neutered Burmese cat at laparotomy 
surgery showing multifocal raised white-pink circular lesions later confirmed as granulomatous 
on histopathology and containing acid-fast bacilli with mycobacterial morphology. The liver of 
this cat was similarly affected 
 
 
Figure 4.14: An ultrasound examination of an 18-month-old male neutered indoor only Maine 






Figure 4.15: A markedly enlarged mesenteric lymph node (black arrow) from the same cat as 
Figure 4.14 visualised during the laparotomy surgery.  
 
Uncommon clinical signs included non-healing skin lesions (Figure 4.16) in four cats (8.9%), 
orthopaedic involvement in two cats (4.4%) and optic disease (Figure 4.17) in two cats (4.4%).   
 
Figure 4.16: The non-healing skin wound over the left pelvis of a two-year-old male, indoor 





Figure 4.17: Optic examination of a two-year-old indoor only female neutered British Shorthair 
cat presented for conjunctival hyperaemia revealed a mass over the optic nerve, later 
diagnosed as granulomatous chorio-retinitis with acid-fast bacilli as well as the observable 
retinal detachment that was also confirmed histologically following enucleation.  
 
At clinical examination pyrexia was present in 17 cats (37.8%); where recorded, the 
temperature ranged from 39.8ºC to 41.1ºC, with a median of 40.0ºC (normal range 37.7°C - 
39.1°C). Routine haematological evaluation revealed a non-regenerative anaemia in a further 
ten cats (22.2%) and a mild to moderate mature neutrophilia in six cats (13.3%). Serum 
biochemistry was largely unremarkable; only two cats (4.4%) showed increased liver enzyme 
activity, affecting both alanine aminotransferase and alkaline phosphatase. One of these cats 
had a large hepatic granuloma extending into the biliary duct, whilst the cause of these 
elevations was not identified in the second cat.  
When tested, all cats were found to be negative for Feline Leukaemia Virus antigen and anti-
Feline Immunodeficiency Virus antibodies.  
4.8.2 Mycobacterial Testing   
Specialist mycobacterial culture and subsequent genotyping at a national reference laboratory 
(Animal and Plant Health Agency [APHA], Weybridge in the UK) remains the only test that can 
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result in official confirmation of M. bovis infection of companion animals (Middlemiss and Clark, 
2018). From this outbreak, 11 grossly diseased tissue samples were obtained at post mortem 
examination and submitted for mycobacterial culture at APHA Weybridge. All post mortem 
examinations were conducted either at APHA veterinary investigation centres by APHA 
pathologists or at the Roslin Institute, University of Edinburgh under Containment Level 3 
conditions by the authors (COH/JH). The results of ten cultures are available at the time of 
writing with the results from one case still pending. Five of these ten cultures (50.0%) resulted 
in positive results and genotype analysis has identified all five isolates as genotype 10:a. The 
five cats were resident across the UK in LRA locations. Subsequent whole genome analysis 
of the cultured isolates revealed them to be identical at the nucleotide level.  
Although it is the gold standard test, mycobacterial culture does have a number of limitations. 
For example, as a prerequisite it requires the acquisition and submission of fresh biopsy 
samples; however, given the location of many of the lesions in these cases inside body cavities 
(i.e. the chest and abdomen) this made retrieving enough sample for culture ante mortem an 
invasive procedure that many of these cases were not clinically fit to undergo. For most of 
these cats it was only possible to obtain very small samples by needle aspiration or 
tracheal/bronchial wash samples for cytological examination (Figure 4.18). In a number of 
cases where larger biopsies had been obtained, they had been formalin-fixed and submitted 
for histopathological examination and as such were unavailable for culture. For these cats, we 
utilised molecular testing methods (GenoTypeMTBC; Hain Lifescience GmbH, Germany) at 
Leeds University Mycobacterial Reference Laboratory (LUMRL). This methodology is used as 
standard of care in the diagnosis of human tuberculosis, and although not specifically validated 
for companion animal tissue samples, this assay is able to diagnose human mycobacterial 
infections as being caused by MTBC organisms and then specific gene probes are used to 
determine the infecting species within this group, including the identification of M. bovis 
(National Institute for Health and Care Excellence, 2016). Twelve cat samples of the 15 tested 
generated positive PCR test results; one indicated infection with an MTBC organism but there 
was insufficient DNA for speciation and 11 were identified to the species level as M. bovis 
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infections. Two of the M. bovis positive test results were subsequently confirmed by 
mycobacterial culture of lesioned tissue samples. 
 
Figure 4.18: A cytological sample obtained by fine needle aspirate from the submandibular 
lymph node of a two-year-old entire, indoor-only female Bengal cat. The sample is stained with 
a commercial Romanowsky stain variant (Diff-QuikTM) and reveals pyogranulomatous 
inflammation typical of feline mycobacterial infections with non-staining ‘ghost’ bacilli typical of 
Mycobacteria spp. (black arrow). Image taken under oil emersion at x100 magnification.  
 
The cat identified by PCR as being infected with an MTBC organism was included in this 
outbreak investigation even though molecular testing did not identify M. bovis DNA. This cat 
was an 18-month-old indoor-only domestic shorthair which had been fed exclusively on the 
implicated diet since its acquisition by the owners at eight weeks of age, it had a 
contemporaneous interferon-gamma release assay (IGRA) result indicative of M. bovis 
infection, as well as lymph node aspirate cytology which confirmed the presence of acid-fast 
bacilli with mycobacterial morphology. Cumulatively these findings were taken to support its 
inclusion as an affected cat.   
Immunodiagnostic assays for the diagnosis of tuberculosis are used globally to test human 
and bovine populations (Wood and Jones, 2001; McCormick-Baw et al. 2018). The most 
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successful of these to date is the IGRA; first developed to aid in the eradication of M. bovis 
from cattle populations in Australia, the assay detects antigen-specific T-cell responses to 
mycobacterial antigens from circulating leukocytes to diagnose infection (Rothel et al. 1992; 
Wood and Jones, 2001). This first test, the BOVIGAMTM assay, is now widely used to detect 
the cell-mediated immune response to M. bovis in cattle, sheep, goats, buffalo and bison 
(Wood and Jones 2001; Pesciaroli, M. et al. 2014, Anusz et al. 2017). With small adaptations 
the test protocol has proved to be extremely useful in humans, and the WHO’s new 2018 
guidelines on the management of human tuberculosis now support the global use of IGRA 
testing at-risk populations (Chee et al., 2018, McCormick-Baw et al. 2018). In 2008, 
adaptations to the test procedure were undertaken by the TB Research Group at the then 
Veterinary Laboratories Agency, now APHA, to optimise the test for domestic cats (Rhodes et 
al. 2008a). The resultant feline IGRA is now commercially available via Biobest Laboratories, 
Edinburgh, UK and although the number of tested cats remains too small to allow official 
validation to World Organisation for Animal Health (OIE) standards, several publications have 
indicated that this is a useful test to generate rapid information on the infection status of cats 
(Rhodes et al. 2008b, Rhodes et al. 2011, Gunn-Moore et al. 2014). The methodology and 
interpretation of this test has been previously published and the same protocol has been used 
for cats involved in this outbreak (Rhodes et al. 2008a; O’Halloran et al. 2019).  
The advantages of IGRA tests compared to other mycobacterial tests are that they can be 
performed rapidly, only require venipuncture of the patient, rather than more invasive tissue 
biopsy, and they can support a diagnosis in the absence of an aetiological agent as is common 
in feline tuberculous granulomas, which are usually paucibacillary (Wood and Jones, 2001; 
Gunn-Moore et al. 2011b). It can be particularly useful for the diagnosis of cases where the 
lesion is completely inaccessible, such as the two cases of chorio-retinal disease. Of particular 
relevance to this investigation is that this test is currently the cheapest option available to 
owners. The combination of lack of invasiveness, speed of generating results, and lower cost 
are the likely reasons for the high number of IGRA tests in this instance rather than the 
validated gold standard culture.  
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During this outbreak 34 of the 45 clinical cases (75.6%) tested positive using the feline IGRA 
and gave test results indicative of M. bovis infection. Of these, eight cases (23.5% of positive 
IGRA tests) were supported/confirmed by either PCR test (five cats) or subsequent positive 
cultures (three cats).  
4.8.3 Sub-clinical Cases  
As the outbreak continued and the commercial raw diet was implicated, owners who fed the 
diet became concerned that their cats could be infected. In addition, some of the affected cats 
lived with other cats, so some owners were worried that their other cats could be at risk. Since 
the IGRA is the only test for mycobacterial infection that can be performed on an animal with 
no visible lesions many of these owners chose to have their cats tested using this assay. To 
date, 143 at-risk, clinically well cats have been tested by IGRA, of which 83 (58.0%) results 
indicate likely M. bovis infections.  
In a previous outbreak, we utilised an IGRA for screening kennel-housed Foxhounds with a 
similar test protocol to the feline IGRA (O’Halloran et al. 2018b). At that time, we considered 
that a positive interferon gamma response to mycobacterial proteins/peptides was indicative 
of a significant antigen specific T-cell response. Furthermore, such a response was thought to 
be suggestive of significant challenge and probable infection, rather than just exposure to 
these mycobacteria. We therefore applied the same criteria to these cats and advised that the 
83 cats that generated positive IGRA results should be further evaluated for the presence of 
lesions by full clinical veterinary examination and diagnostic imaging. In six cases (7.2%), 
imaging revealed mild interstitial pulmonary disease (Figure 7) and associated 
lymphadenomegaly that were not causing clinical signs, this allowed the clients to treat these 
cats at an early stage of infection (see below).    
The remaining 77 cats were IGRA positive with no detectable clinical disease. These cats 
were deemed to be likely to be sub-clinically infected and owners were advised that they 
should be closely monitored for the onset of clinical signs and/or prophylactic therapy could 
be instigated at their discretion.   
218 
 
4.8.4 Current Approach to Suspect Cases  
The team at the University of Edinburgh are always keen to hear from clinicians who may 
have, or have had, suspicions about similar cases to continue to gather evidence about this 
outbreak as well as offering our experience in the diagnosis and management of these 
patients. 
Currently, the number of newly diagnosed clinical cases appears to be in decline. The first 
cases were presented in July 2018 and peaked in June 2019, six months after the implicated 
product was recalled. No new clinically active cases have been diagnosed, to our knowledge, 
since the middle of July 2019.   
The ante mortem testing of any suspect cases can be performed as described earlier – by 
specialist mycobacterial culture at APHA Weybridge (the gold standard confirmatory test) or 
by PCR and/or IGRA.  Where present, the treatment of active feline tuberculous disease 
should be carefully considered; there is no requirement to euthanase M. bovis infected pets in 
the UK, but appropriate therapy requires long-courses (typically 3-6 months) of combination 
antibiotic administration which can be difficult to achieve in cats, can cause side effects and 
be costly for owners. If treatment is to be attempted then it must be done appropriately, 
consisting of a combination of a macrolide/azalide, a fluoroquinolone and rifampicin 
administered daily as outlined in O’Halloran and Gunn-Moore (2017), to prevent the induction 
of antimicrobial resistance to these medications and to protect public health.  
Veterinary clinicians in the UK should be aware that, under the Tuberculosis (England) Order 
2014 and equivalent Statutory Instruments in Scotland and Wales (Anon, 2014), in the event 
that non-bovine animals are euthanased or die when there is suspicion of M. bovis infection 
then this is notifiable to the Secretary of State (via APHA). The carcase must be detained on 
the premises pending APHA advice. 
It is currently advisable that animals known to have been exposed to Natural Instinct Wild 
Venison food, or who have been exposed to a confirmed case but are displaying no clinical 
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signs, should not be tested by IGRA for at least four weeks after the last known exposure. The 
time required for cats to mount a detectable T-cell response to M. bovis is unknown as no 
controlled challenge studies have been performed in this species; therefore the estimate of 
four weeks is extrapolated from bovine data where such time-course challenge studies have 
been conducted (Rhodes et al. 2000). If first line tests are positive then diagnostic imaging 
should be undertaken to assess for structural (i.e. active) disease; this should comprise full 
body computed tomography (CT) scan or thoracic radiographs and, ideally, abdominal 
ultrasonography or alternatively, abdominal radiographs. There is currently no evidence on 
which to base the appropriate course of action for animals that are IGRA positive but lack 
evidence of structural disease. It is likely appropriate in these cases to closely monitor body 
weight, condition score and resting respiratory rate, and to investigate further if these change. 
Alternatively, some owners may elect to give prophylactic therapy; isoniazid (which is 
occasionally used in humans for this purpose) can be given for six months, but experience of 
its use in cats is limited, it has a narrow therapeutic index (in humans and mice) and therefore 
toxicity may occur (El-Sayed et al. 2010; Fernandes, G. et al. 2017). Instead, owners may 
choose to treat these animals using the triple combination of anti-tuberculous therapy (above) 
for three months, given that the use of this protocol is well established and the potential side 
effects are well documented (O’Halloran and Gunn-Moore, 2017).  In this outbreak, the 
commonly reported side effects (defined as an incidence of between 1 in 10 and 1 in 100 
patients) to treatment included pruritic skin erythema caused by rifampicin and/or neutropenia 
induced by chronic fluoroquinolone administration.  
4.8.5 Public Health Considerations 
The incidence of zoonotic transmission of M. bovis from cats is very rare with only six cases 
reported in the literature (Lewis-Jonsson, 1946; Isaac, et al. 1983; Une and Mori 2007; Roberts 
et al. 2014). However, there may be particular risk to owners who have compromised immune 
function such as those receiving chemotherapy, radiotherapy or tumour necrosis factor alpha 
(TNF-α) inhibitors (Hofland, et al. 2013; Simonsen, et al. 2017). Therefore, owners of cats with 
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active disease should be advised to seek medical advice if they are at elevated risk and/or if 
cats have lesions that are discharging (purulent) material or if they have a productive cough. 
Owner screening tests (QuantiFERON GoldTM IGRA and/or tuberculin skin tests) conducted 
to date have identified likely latent tuberculosis infections (LTBI) in four owners and one vet. 
All of these people had been exposed to severe feline cases with purulent lesions, however, 
it is unclear at this time if this represents zoonotic transmission from these cats or if these 
individuals were infected at an earlier time. Public health agencies in the UK have previously 
assessed the risk to immunocompetent owners from M. bovis infected pets and have 
concluded that there is ‘very low’ risk of zoonotic transmission (Public Health England, 2014).   
4.9 Epidemiological Investigation 
In general terms, the only common factors linking these cases were the raw cat food consumed 
(Natural Instinct, Wild Venison) and being mostly indoor cats.  
Two breeding colonies were affected; one in the north of England had three clinical cases, two 
IGRA positive cats and two IGRA negative cats in the colony. Tracing rehomed kittens 
identified ten with clinically signs and two that were IGRA positive but clinically well. The 
second breeder, located in the south of Scotland, had eight breeding cats of which one was 
clinically sick and four were well but IGRA positive. Ten kittens from two litters rehomed from 
the second breeder were traced; half of these were tested by IGRA and all five were negative. 
There were no other common associations between the remaining cats. 
The alimentary tract and associated lymphoid structures were found to contain lesions in 31 
of the 45 cases (68.9%) which is consistent with challenge via the gastrointestinal route, 
supporting the hypothesis of food as the common source of infection. Five cats presented with 
large lung abscesses, which could be associated with spread via the retropharyngeal lymph 
nodes, inhalation of M. bovis from contaminated food during eating or may represent 
dissemination of disease.  
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All cases were presented to their primary veterinary surgeons between July 2018 and July 
2019. A working estimate for the incubation period is two and five months for alimentary 
infections of tuberculosis in cats. This estimate is based on experimental data from the 1900’s 
presented by Francis (1958) in which very large doses (1-10mg) of M. bovis when given by 
mouth and produced lesions 40 to 121 days later. However, extrapolating for more advanced 
pathology and the potentially lower doses encountered in any contaminated raw pet food could 
extend this significantly. Beyond this, the kinetics of feline M. bovis infection following oral 
challenge are unknown; however, it is likely that in at least some cats, a long sub-clinical phase 
is seen, as in cattle and humans (where it is termed latency), and this may extend the upper 
range of incubation to many months or even years.   
Identifying a likely infection window and determining whether the cats were all infected by one 
particular batch of contaminated food are difficult questions to answer. The earliest signs were 
reported in the first weeks of July 2018; if a minimum incubation period is approximately two 
months, then a contaminated batch of raw pet food manufactured in early May 2018 would be 
implicated. With the apparent last cases being identified in July 2019, this theoretically includes 
all batches of food made as late as January 2019 when the production of this product was 
ceased by Natural Instinct. The age of the cats affected limits the potential infection window to 
some degree; excluding kittens weaned directly onto Natural Instinct Wild Venison, the 
youngest case was one year old when signs were first seen in August 2018, which extends 
the potential time of potential challenge back into 2017.     
With the possibility of long sub-clinical chronic infections adding a considerable degree of 
open-endedness to the upper incubation period range, contaminated batches could 
theoretically have been produced during the whole of 2018, possibly 2017, or even earlier.  
The temporal clustering of the majority of the early cases from July to September 2018 
suggests a most likely possible common infection window of February to July 2018 (calculated 
from a most likely incubation period range of two to five months). Subsequent cases therefore 
either include a period of sub-clinical infection or represent the later consumption of stored 
food. The breeder in the north of England was clear about the infection window for their cats; 
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it had to be limited to June 2018 as this was the only time the cats had been fed Natural 
Instinct, Wild Venison. 
An important factor that potentially explains the extended period of this cluster is long storage 
of the pet food in home freezers. Since Natural Instinct, Wild Venison was marketed with 
‘Limited Availability’ owners reported that they tended to bulk purchase when it was available. 
The freezer shelf life was several months (calculated as nine months from data on packaging) 
and so a single contaminated batch could feasibly be responsible for this whole cluster. 
Overall, the most likely infection window was probably March to June 2018 and all cases 
associated with this raw pet food could plausibly fit within this window, with stored food and 
sub-clinical incubation giving rise to later cases. The estimated two to five month incubation 
period is supported by the currently observed decline in the presentation of new cases 
following the recall of the food in December 2018.  
Transmission to the cats from the local environment was considered to be very unlikely 
because a) the cats were kept indoors, with a few cats having limited usually supervised 
outdoor access, and b) the majority of cases were located in the LRA for endemic M. bovis. 
Infected vermin entering the houses cannot be ruled out for cases in only two households 
located in higher incidence bovine tuberculosis areas. However, they were not in regions with 
endemic M. bovis genotype 10:a infections.   
A contaminated raw commercial cat food (Natural Instinct, Wild Venison) is the most likely 
route of infection for these cats. However, alternative pathways cannot be completely ruled 
out. Most owners of pedigree cats were located in the LRA and obtained kittens from within 
the LRA, but other cats in the same households had prior ownership which could not be fully 
investigated, so they could have had previous outdoor access in the HRA. Some of the non-
pedigree cats had vague histories, including an in-contact cat that was obtained from a website 
with no history at all. Incomplete information creates some uncertainty for several of the cases 
and failure to confirm infection by the gold standard test for the majority of cases adds a degree 
of uncertainty as to the true number of M. bovis cases seen.  
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Within this group of 45 clinical cases, M. bovis genotype 10:a has been cultured from five 
cases from different areas of England and Scotland, with an additional Scottish sample where 
culture is still pending. Whole genome sequencing of the five M. bovis 10:a isolates by APHA 
Weybridge found them to be identical to the nucleotide level, i.e. they were identical isolates 
of M. bovis, which provides very strong evidence in support of the dietary infection hypothesis. 
Furthermore, the nearest cattle isolates with only one single nucleotide polymorphism (SNP) 
difference form a tight cluster of six farms in Oxfordshire. An M. bovis isolate from at least one 
of two wild fallow deer shot in this area had an identical genome sequence to these cattle 
isolates suggesting that wild deer from this area may be the origin of contaminated venison. 
Precise information detailing the source of venison meat and offal is needed to definitively tie 
the pet food and deer from this area together which is the subject of an ongoing investigation 
by the Food Standards Agency (FSA) and the local authority. However, an example record list 
for a known venison supplier to the pet food manufacturer includes one estate in west 
Buckinghamshire that is very close to the farm cluster and provides a tentative but plausible 
risk pathway for these cat cases consistent with the whole genome sequence analyses.  
Further analysis of pet food obtained from owners could provide definitive evidence of the 
transmission route. However, batches matching the earlier period of the most likely infection 
window are unsurprisingly not available and no M. bovis has been isolated from the few 
samples tested by APHA, the FSA or the University of Edinburgh to date.  
During this investigation, M. bovis was cultured from additional cats that were fed Natural 
Instinct Wild Venison and were euthanased, often with severe mesenteric lymph node 
pathology. However, the cultured isolates were found to be 11:e and 25:e. Therefore, there 
were thought to most likely represent alternative sources of infection. Conversely, M. bovis 
genotype 10:a was isolated from a cat during the timeframe of this outbreak which triggered a 
further investigation but this cat was located within the homerange of this genotype, had a 
superficial skin lesion consistent with inoculation via a bite wound and had no history of being 





This cluster of cases represents the only documented outbreak of feline tuberculosis putatively 
caused by feeding pet cats a contaminated commercial raw food diet. Previous examination 
of feline mycobacterial cases in the UK showed the highest frequency of infections in non-
pedigree, male cats with frequently reported hunting behaviour that then develop skin lesions, 
probably following inoculation of mycobacteria directly into the site of the lesion (Gunn-Moore 
et al. 2011a, Gunn-Moore 2014). By contrast, the majority of cases affected in this outbreak 
were pedigree or pedigree-cross breeds (86.7%) and there was no statistically significant 
predilection for males to be affected.  
The reason for the high proportion of pedigree cats affected is likely that owners of these cats 
are more likely to feed raw food diets. Although this has not been studied systematically, 
anecdotal evidence suggests that a growing number of pedigree cat breeders in the UK (and 
elsewhere) are advocating feeding so-called biologically appropriate raw food (BARF) diets to 
owners acquiring kittens (Handl, 2014; Waters, 2017). The evidence supporting the use of 
these diets remains poor despite their increasing popularity in recent years (Schlesinger and 
Joffe, 2011; EFSA, 2015). There have been speculative suggestions that BARF feeding may 
be beneficial in preventing the onset of dental disease, may alleviate food responsive 
inflammatory bowel disease and atopy, and a recent study demonstrated that the microbiome 
of dogs fed BARF diets is more diverse than when fed processed diets - though no health 
benefits were identified as a result of this diversity (Handl, 2014; Sandri et al. 2017). Kittens 
raised on a rabbit-based raw diet had better stool quality, assessed with a visual grading 
system, than their cooked diet fed peers, but both groups grew similarly (Glasgow et al. 2002). 
However, some of the kittens fed the rabbit-based diet developed dilated cardiomyopathy 
secondary to taurine deficiency after several months of feeding (Glasgow et al. 2002). A critical 
review by Schlesinger and Joffe (2011) concluded that the evidence advanced for the claimed 
health benefits of raw feeding amounted to opinions and claims that were, at best, supported 
by data that was of low relevance. 
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A major and growing concern relating to feeding pets these diets are the risks posed by 
microbiological contamination that are not addressed by cooking. The bacteriological quality 
of raw commercial pet foods, assessed by total bacterial, coliform or Escherichia (E.) coli 
counts, has been noted to fail threshold levels for raw human meat products in a high 
proportion of sampled foods in both Europe and North America (Freeman and Michel, 2001; 
Towell, 2008; Nemser et al. 2014; Kölle and Schmidt, 2015; Nilsson, 2015). The most recent 
systematic review, conducted by Davies et al. (2019), found evidence that the bacteria in these 
diets often encode resistance to critically important antibiotics such as extended-spectrum 
cephalosporins, and raw-fed pets create an elevated risk of shedding these resistant bacteria 
(Nilsson, 2015; Baede et al. 2017; Davies et al. 2019). Despite this evidence, the vast majority 
of owners interviewed (94%) in a separate survey believed raw diets to be “absolutely” safe 
for their dogs (Davies et al. 2019). During the current investigation, health screening of 
exposed individuals identified four likely LTBI owners and one veterinary surgeon. Although it 
has not been demonstrated that these likely infections originated from handling the implicated 
food or their affected cats, in light of these findings, the precautionary advice against raw 
feeding issued by various professional bodies, such as the World Small Animal Veterinary 
Association, appears to be justified. Both veterinary and public health practitioners need to 
continue to exercise their responsibility to communicate these risks clearly to consumers of 
raw pet food. 
More than half of clinical cases in this outbreak presented with palpable abdominal masses 
(granulomas) and gastrointestinal lymphadenopathy which supports the hypothesis that this 
outbreak was due to a contaminated food product. In a study reporting the clinical presentation 
of feline mycobacterial infections likely to have been acquired from hunting, the only alimentary 
associated sign reported was weight loss, identified in 15.8% of cases none of which had 
directly palpable masses (Gunn-Moore et al 2011a). In the current cluster, twice the proportion 
of affected cats (33.3%) showed declining body weight/condition. Additionally, cats in this 
cluster were frequently anaemic and pyrexic which suggests that there may be a more severe 
phenotype of disease associated with this cluster than would be expected from sylvatic 
infections (which are rarely pyrexic; data unpublished). This is also supported by the very high 
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mortality rate reported for the early cases (O’Halloran et al. 2019). The reasons for this are not 
immediately clear; it may be that these cats were exposed to the largest amount of 
contamination, or it may be that these cats, being largely pedigree breeds, responded 
differently to mycobacteria; for example, susceptibility to M. avium-intracellulare complex 
infection and disease has previously been reported in Abyssinian cats (Baral et al. 2006). 
Alternatively, it may be that genotype 10:a of M. bovis is particularly virulent in the context of 
companion animal infections; for example, when the same genotype infected a group of 
Foxhounds it caused fatal fulminant infections in a number of animals (O’Halloran et al. 
2018b). Further work investigating the host-pathogen interaction of M. bovis strains and 
companion animals is needed to examine this further as it may be significant in predicting 
patient prognosis and qualifying zoonotic risk to owners.  
Many of these cats presented with respiratory signs that was unexpected. The presence of 
individual demarcated granulomas (as shown in Figures 4.12a and 4.12b) appears to be most 
consistent with primary inhalation of bacilli into the lungs, presumptively as the cats were 
eating contaminated food. In a number of cases, the pattern of lung pathology was more 
suggestive of disease spreading from a separate focus (such as the gastrointestinal tract). The 
interstitial lung pattern seen when imaging these cases indicates likely haematogenous spread 
of infection and influx of inflammatory cells into the lung parenchyma. Importantly, many of the 
IGRA-positive cats with no detectable respiratory signs on owner history or clinical 
examination were found to have thoracic pathology on imaging, highlighting the need for 
veterinary surgeons to investigate cases thoroughly if there are concerns over potential 
exposure.  
The epidemiological investigation into this outbreak has demonstrated that the most likely 
source of infection of these cats was the consumption of a raw food diet (Natural Instinct, Wild 
Venison) and that one contaminated batch could have potentially been responsible for all of 
the cases diagnosed. In order to increase the certainty of these investigations it would be 
beneficial to have a greater number of samples submitted for the gold standard test of 
mycobacterial culture as genotyping and sequencing isolates adds significant clarity. However, 
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this was hindered here by the lack of state funding for most companion animal samples so 
that the cost to owners for official confirmation of infection through APHA are now estimated 
to be in excess of £500 (including post mortem examination). Many owners saw this as 
prohibitive and there was significantly greater uptake of this option when the decision was 
taken by APHA to relax the eligibility criteria for funded submissions after the initial cases 
presented. As an alternative, owners chose to use non-validated but less costly tests; further 
work to validate these tests would be beneficial for the investigation of any future outbreaks.  
Definitive proof that the implicated raw food was the source of infection in these cats would 
require the isolation of viable M. bovis organism from a sample of the food from the at-risk 
period. However, a small number of samples have been tested to date and have been found 
to be negative. This is likely to be because the food samples submitted were from the time 
that the cats were diagnosed rather than the point at which they were infected. Additionally, 
the bulk purchasing of food by owners further creates problems for test sensitivity when large 
batches of food need examining. 
In conclusion, this is the first report of an outbreak of M. bovis tuberculosis in pet cats where 
there is compelling evidence that a contaminated raw food product was the origin of infections. 
All culture positive tissues had a genetically identical genotype of M. bovis isolated, which has 
not been detected in the areas local to the cats. Based on our estimates of incubation times 
and from the epidemiological investigation, it is possible that a single batch of contaminated 
food produced in late 2017 or early 2018 resulted in the whole cluster of cases. Four cat 
owners and one vet were diagnosed with suspected latent TB, potentially due to exposure to 
infected cats with purulent lesions and/or their contaminated feed, though this remains 
unproven. Though the risk posed by M. bovis infected cats to humans is low, this outbreak 
demonstrates that clinicians and pet owners must continue to be made aware of the 
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Chapter 5: An outbreak of tuberculosis due to 
Mycobacterium bovis infection in a pack of English 
Foxhounds (2016-2017).  
Preface 
The following Chapter presents the findings of a study, conducted as part of this studenship 
programme that has been published in the journal Transboundary and Emerging Diseases.  
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Abstract 
Mycobacterium bovis can cause tuberculosis in social mammals including lions, cattle and 
man, but canine infections are considered rare.  
In 2016/17 we investigated a M. bovis TB outbreak in a pack of approximately 180 Foxhounds 
within the bovine tuberculosis Edge Area of England. We employed a combination of 
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immunological tests including an interferon gamma release assay (IGRA) and a serological 
assay (DPP VetTB, Chembio). Test-positive hounds were euthanased and subjected to post-
mortem examination (PME).  
Overall 164 hounds were tested; 97 (59%) responded positively to at least one test. Eighty-
five (52%) dogs responded to M. bovis antigens by IGRA whilst only 21 (12.9%) had detectable 
serological responses. At PME three hounds (3.1%) had visible lesions (VL) due to M. bovis 
infection, later confirmed by culture. Samples from 24 non-VL hounds were cultured and M. 
bovis infection was confirmed in a further three hounds (11%).  
This study is the first investigation and report of an outbreak of M. bovis TB in a canine species. 
We establish that, in principle, diagnostic tests used for identifying infected individuals of other 
species can effectively be used in the dog. Further work is urgently needed to establish the 






Mycobacterium (M.) bovis is one of the nine member species of the Mycobacterium 
tuberculosis complex (MTBC) which are capable of causing tuberculosis, across a broad 
taxonomy of social mammal including but not limited to humans, lions, elephant and meerkats 
(Parsons, 2013; Angkawanish, 2013; Miller, 2012; Drewe, 2010; Brosch, 2002). Within this 
group of pathogens, M. bovis stands out as the least host restricted and thus has significant 
zoonotic potential (Miller, 2013; Michel, 2013; Broughan, 2013; Palmer, 2007). Disease in 
humans due to infection with M. bovis, termed ‘zoonotic tuberculosis’ by the World Health 
Organisation (WHO), is a major global public health priority which resulted in nearly 150,000 
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cases and at least 12,500 deaths in 2010 worldwide (Olea-Popelka, 2017; Dürr, 2013). 
Additionally, the lack of diagnostic discrimination between M. tuberculosis and M. bovis in 
some human cases by reference laboratories means that the true mortality and morbidity 
caused by zoonotic tuberculosis is possibly underestimated (Olea-Popelka, 2017; Dürr, 2013). 
Discriminating between tuberculosis caused by different species of the MTBC is challenging 
as all member species share identical sequences across the 16s rRNA gene and 99.5% 
sequence homology across the remainder of the genome (Brodin, 2002). The most 
discriminating features between the species at the nucleotide level are genomic deletions, 
termed regions of difference (RD) (Teo, 2013). These have been shown to encode a variety 
of different virulence factors e.g. RD-1 is present on all MTBC mycobacteria other than M. 
bovis bacille-Calmette-Guérin (M. bovis-BCG) and M. microti and encodes for the 
immunodominant proteins and key virulence factors; a 6kDa early-secreted antigenic target 
(ESAT-6) and 10kDa culture filtrate protein (CFP-10) (Junqueira-Kipnis, 2006; Guinn, 2004; 
Gao, 2004).  
The human burden of disease is highest across Africa, South-East Asia and the Western 
Pacific. In South Africa, dogs have been shown to become infected with M. tuberculosis, as 
diagnosed using human interferon gamma release assays (IGRA), when exposed to high risk 
humans i.e. those with active tuberculous disease (Parsons, 2012). Similarly, African wild dogs 
(Lycaon pictus) have been found to be infected with M. bovis, presumptively from hunting 
exposure (Ayele, 2004). In the UK, however, the significance of M. bovis in companion animals 
is largely limited to domestic cats, were frequent diagnoses are made (Pesciaroli, 2014; Gunn-
Moore, 2014; Broughan, 2013). Canine incidence of tuberculosis in the UK is currently 
considered to be rare, and almost all reported cases are limited to individual sporadic infection 
or small numbers of epidemiologically unrelated cases (Szaluś-Jordanow, 2016; Park, 2016; 
Pesciaroli, 2014; Parsons, 2012; Posthaus, 2011; Van Der Bürgt, 2009; Shrikrishna, 2009; 
Ellis, 2006; Gay, 2000; Liu, 1980; Snider, 1971).  
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Between the end of 2016 and July 2017, a large outbreak of M. bovis infection occurred in a 
kennel of working Foxhounds within the Edge Area of England; which is a buffer zone of 
intermediate bovine tuberculosis incidence separating the high and low risk bovine 
tuberculosis areas and subject to additional surveillance and controls for this disease. This 
report describes the clinical features of the outbreak, the testing approach taken and the 
epidemiological aspects of the spread of disease as they are currently understood. Work to 
evaluate the testing approach further is currently ongoing and will be published separately 
(Chapters 7 and 8). We go on to explain the new statutory controls which have been 
implemented in England as a result of this incident to minimise the low risk of spreading 







5.2 Outbreak Investigation 
5.2.1 The Index Case 
The hunt kennel where this outbreak occurred is situated in the south of England, UK, and 
housed up to 180 working Foxhounds ranging in age from juvenile puppies (less than ten 
weeks old, n=32), young adults (up to and including a year old, n=21) and adults up to eight 
years old (median age of four years).  
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The kennel is situated within the designated Edge Area of bovine TB incidence. The hounds 
work across six counties, four of which are also within the Edge Area, and two in the Low Risk 
Area, up to three times weekly during the peak of their hunting season (August to April).  
In a similar fashion to many hunt kennels, the hounds were predominately fed raw meat, 
permitted offal and bone from fallen stock (so called “flesh feeding”), as permitted under 
Animal By-Products legislation (Article 18, Commission Regulation (EC) No. 1069/2009).  
The index case (Case 0) occurred in December 2016. The pack had experienced an outbreak 
of upper respiratory tract disease in the previous weeks, resulting in a number of individual 
hounds suffering from reduced body condition, lethargy and poor appetite. Two of these 
hounds developed marked polyuria and polydipsia and died. Clinical suspicion at this time was 
of leptospirosis infection as routine vaccination is not used and clinical signs were compatible 
(Rissi, 2014). The hounds were not subjected to any confirmatory diagnostic testing at this 
time and carcasses were disposed of. When a third hound, a four-year-old entire male 
Foxhound with no previous history of ill health, developed anorexia, plus marked polyuria and 
polydipsia, blood samples were taken for routine haematology, serum biochemistry and 
leptospirosis IgG titre testing. 
These tests revealed; an inflammatory leukocytosis (21.8x109/L [reference interval, RI, 6-
15x109/L]) consisting of a mature neutrophilia (17x109/L [RI 3.6-12x109/L]), lymphopenia (0.4 
x109/L [RI 0.7-4.8x109/L]), monocytosis (3x109/L [RI 0-1.5 x109/L]) and eosinopenia (0x109/L 
[RI 2-10 x109/L]). Serum biochemical analysis showed a marked azotaemia (urea 18.7mmol/L 
[RI, 1.7-7.4mmol/L], creatinine 457µmol/L [RI 40-132µmol/L]), hypoalbuminaemia (18g/L [RI 
26-35g/L]) and hypocalcaemia (total calcium 2.04mmol/L [RI 2.30-3.00mmol/L]). Serological 
testing returned only a very low positive combined leptospirosis IgG titre (1+), indicating that 
active leptospirosis was unlikely to be the cause of the azotaemia and other clinical signs.  
The dog was euthanased and subjected to post mortem examination (PME). Both kidneys 
were found to be grossly diffusely grey in colour and firmly textured. Across both the visceral 
and cut surfaces were multifocal to coalescing nodular, approximately round, areas containing 
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hard white and soft black material (Figure 5.1). Representative samples were collected and 
fixed in formalin for histological evaluation by one of the authors (MD, FRCPath and 
experienced veterinary pathologist). Additional samples were frozen and submitted for 
mycobacterial culture and PCR. 
 
Figure 5.1: The left kidney of Case 0, removed at PME, the visceral and cut surfaces show 
diffuse discolouration and there are observable granulomas on the visceral surface.  
Examination of haematoxylin and eosin stained sections showed extensive, multifocal to 
coalescing areas of severe, chronic-active, necrotising, granulomatous to pyogranulomatous 
nephritis (Figure 5.2). Silver staining for the identification of spirochetes was negative, as was 
periodic acid-Schiff staining for fungi (not shown), while a Ziehl-Neelsen stain revealed 
moderate numbers of positive staining (acid-fast) bacilli morphologically typical of 
mycobacteria within the cytoplasm of epithelioid macrophages, indicative of mycobacterial 




Figure 5.2: A section of kidney from case 0 (shown grossly in Figure 7.1), stained with 
haematoxylin and eosin. Image A shows the section at low power (x10 magnification) where 
multifocal areas of pathology (granulomas) are visible. Image B is a high power view of the 
same section (x40 magnification) and shows numerous epithelioid macrophages with 






Figure 5.3: A section of kidney from Case 0 stained with Ziehl-Neelsen stain shown under oil 
emersion x100 magnification which reveals moderate numbers of intracellular and 
extracellular acid-fast organisms morphologically typical of Mycobacteria spp.  
The Animal and Plant Health Agency (APHA) was notified of the findings and remaining fresh 
tissue was submitted for both routine mycobacterial culture (APHA, Weybridge) and for 
mycobacterial PCR (Leeds University Mycobacterial Reference Laboratory [LUMRL]), both of 
which confirmed infection with M. bovis subsp. bovis which was genotyped to 10:a.      
5.2.2 Testing Regime 
Once M. bovis infection had been confirmed a prospective test and cull policy was 
implemented at the kennels in order to contain the spread of infection within the pack and 
remove any potentially infected animals. This was combined with immediate voluntary 
movement restrictions implemented by the kennel and increased biosecurity measures e.g. 
increased kennel disinfection protocols, cessation of feeding fallen stock and immediate 
repairs to limit wildlife access to the hounds.   
a) Interferon-gamma (IFN-γ) release assays (IGRA) 
IGRA tests were originally developed on the principle of quantitatively evaluating IFN-γ 
production by peripherally circulating antigen-specific effector memory T-cells upon in vitro 
stimulation, in order to aid the diagnosis of M. bovis tubserculosis in cattle, where it has a 
reported sensitivity of 81.8-100% and specificity of 88-99% (Vordermeier et al., 2006; Schiller 
et al., 2009; Bezos, 2014; Wood, 2001). The IGRA has subsequently been adapted to identify 
active and latent tuberculosis in human patients with at least equivalent sensitivity and 
increased specificity than the tuberculin skin test, as well as being practically easier to perform 
(Thillai, 2014; Eisenhut, 2014; Zhou, 2011; Kim, 2011). An IGRA test has been validated for 
use in pet cats with up to 100% sensitivity for the detection of MTBC infections (Rhodes, 2011; 
Rhodes, 2008a; Rhodes 2008b). Whereas intra-dermal testing has been shown to be of 
unreliable clinical utility in the dog, an IGRA has been used successfully for the detection of 
M. tuberculosis infections in dogs in a high risk setting (Parsons, 2012). The in vitro nature of 
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the test allowed us to test individual animal responses to multiple antigen combinations with 
technical replicates.  
To interrogate the immune response of the hounds to mycobacteria, the antigens purified 
protein derived (PPD) from M. avium (PPDA), PPD from M. bovis (PPDB) and a cocktail of the 
RD-1 specific immunodominant proteins ESAT6 and CFP-10 were selected. The PPDA is 
frequently used in both IGRA and tuberculin skin testing to assess for exposure/sensitisation 
to, or infection with, environmental mycobacteria species (Rhodes, 2008a; Pai, 2007; Wood, 
2001). Infection with an MTBC mycobacteria is confirmed if the IFN-γ response of any animal 
is greater to PPDB than to PPDA (Rhodes, 2008a; Wood, 2001). The presence of a concurrent 
response to the immunodominant antigens ESAT-6/CFP-10 indicates infection with an RD-1 
positive MTBC mycobacteria (i.e. excludes infection with M. microti or previous vaccination 
with M. bovis-BCG) (Teo, 2013; Guinn, 2004).  
The IGRA assays were conducted at Biobest Laboratories, Edinburgh in line with the assay 
protocol validated and previously published for use in the cat (Rhodes, 2011; Rhodes, 2008a). 
A 5ml heparinised whole blood sample was taken from each hound and transported to the 
laboratory at ambient temperature within 18 hours. Upon receipt, peripheral blood 
mononuclear cells (PBMC) were removed; blood was diluted 1:1 with Hanks Balanced Salt 
Solution (HBSS, Gibco, UK) and layered over Histopaque 1077 (Sigma, UK) before 
centrifugation at 800 x g for 40 minutes at room temperature. PBMC were removed from the 
resulting interface, washed with HBSS and re-suspended in complete culture media (RPMI 
1640 containing 100µg/ml L-glutamine, 10% foetal bovine serum, 100µg/ml penicillin, 100U/ml 
streptomycin, 5x10-5M 2-mercaptoethanol and non-essential amino acids) to a density of 
2x106/ml. 100l of PBMC suspension were stimulated in duplicate with PPDA or PPDB 
(Lelystad, Prionics, Netherlands); both at a final concentration of 10µg/ml, as well as a peptide 
cocktail of ESAT-6/CFP-10 at a final concentration of 5ug/ml (Lionex, Germany), a mitogen 
positive control of phorbol myristate acetate plus calcium ionophore (PMA/Ca, Sigma, UK, 




Cells were incubated for 4 days at 37oC/5% CO2, after which the supernatants were removed, 
and duplicates pooled, for quantification of IFN-γ by ELISA. Supernatants were either directly 
assayed or stored at -80oC until required. The IFN-γ ELISA was conducted using a 
commercially available canine specific ELISA kit (DY781B, R&D Systems, Europe Ltd., UK) 
according to the manufacturer’s instructions. Supernatant from each cell culture condition was 
assayed in duplicate. Optical density (OD) values were measured at a wavelength of 450nm 
and the replicate values for each condition were averaged and standard deviations calculated. 
Where replicates differed by more than 30% from each other, the test was considered invalid.  
Prior to the instigation of testing, a prospective case definition was set to determine which 
hounds would be considered positive; it was decided that a statistically significant response to 
any of the three test antigens (PPDB, PPDA or ESAT6/CFP10) above the negative (medium 
control) condition was plausibly indicative of a biologically significant antigen specific T-cell 
response. Furthermore, such a response would be consistent with not just exposure to 
mycobacteria but rather would be suggestive of significant challenge and probable infection. 
To achieve maximum diagnostic sensitivity, and due to the fact that very little is known about 
the infection dynamics, clinical progression or probability of mycobacterial shedding by dogs 
once they are infected with mycobacteria, it was assumed that any hound with a significant 
IFN-γ response to at least one test antigen was infected and potentially infectious. Any such 
hound would therefore pose a risk to human and animal health as well as to the environment 
and so should be removed from the pack and euthanased.  
As no cut off values or reference intervals exist for the dog, we defined the threshold for 
responsiveness to antigen stimulation as the mean OD value of the negative control replicates, 
plus two standard deviations (?̅? + 2𝑆𝐷). Antigen responses were defined as the mean OD 
value of the replicates, minus two standard deviations ( ?̅? − 2𝑆𝐷). If a calculated antigen 
response value was greater than that calculated for the negative control, then the response 
was considered positive. For a test to be considered interpretable, the PMA/Ca (positive 




In total 164 hounds were tested by IGRA, only 11 tests failed and required repetition; the most 
frequent reason for this (n=6) was that there was insufficient response to the PMA/Ca positive 
control, followed by a clotted blood sample which precluded the isolation of PBMC (n=4) and 
only one test required repetition due to significant disagreement between replicate values. All 
IGRA test result data are provided in Appendix 1.1.  
Of the 164 hounds, 85 (52.0%) were found to be positive by the above case definition. Within 
those found to be positive, 77 (90.1%) displayed a significant response bias to PPDB which 
was greater than the PPDA response (which was also significantly elevated above the 
negative condition in 37, 48.1%, of these hounds), a pattern considered indicative of MTBC 
infection.  
Within the group of hounds displaying a typical MTBC infection response, 48 (62.3%) also 
responded to the peptide cocktail ESAT-6/CFP-10. Five of the test positive individuals (3.1%) 
responded to ESAT-6/CFP-10 and no other test antigens. These individuals were considered 
positive by the case definition and so were removed from the pack and euthanased. Similarly, 
only three individuals (1.8%) responded to PPDA and no other test antigens; whilst it was 
considered unlikely that these were infected with MTBC mycobacteria, they were removed 
from the pack, and euthanased, as a precaution.  
b) Serological testing  
Concurrently to the IGRA testing, serological assessment of each hound was conducted. 
Blood was taken from each hound at the same time as the whole blood was collected for IGRA 
testing, 5mls of whole blood was placed into plain blood tubes and left upright at room 
temperature to allow clot formation. On arrival at the laboratory, blood was centrifuged at 800 
x g for 15 minutes at room temperature. Serum was removed and frozen at -20oC in 500µL 
aliquots until needed.  
The Dual Path Platform (DPP) VetTB test for Cervids (Chembio Diagnostic Systems Inc., USA) 
consists of two nitrocellulose strips inside a cassette that allows independent delivery of the 
test sample and antibody-detecting reagent to the two test antigens (MPB83 and combined 
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ESAT-6/CFP-10) and the test control. One cassette was used per hound. Tests were carried 
out at APHA Starcross. Thirty microliters of serum was dispensed into the sample well followed 
by two drops of sample buffer. After five minutes, a further four drops of sample buffer was 
added to the buffer-only well. Cassettes were incubated for a further 20 minutes. This protocol 
is used by APHA for Eurasian badger (Meles meles) with preliminary test estimates of test 
sensitivity of 55.3% (38-71.4%) and specificity of 97.5% (86.8-99.9%).Test results were 
obtained by inserting each cassette into a hand-held optical reader device (Chembio 
Diagnostic Systems Inc., USA), measuring reflectance in relative light units (RLU). An RLU 
numerical value for the control band (to show the test was valid) and the test band was 
provided by the reader. 
Test results were obtained first qualitatively by visual inspection and to check the cassette 
quality control band and the presence/absence of antigen binding by serum antibody, and then 
quantitatively by inserting each cassette into an Optricon DPP Reader (Chembio Diagnostic 
Systems Inc., USA), to measure reflectance of antigen binding by antibody in relative light 
units (RLU).  
A total of 164 hounds were tested; of these 11 (6.7%) generated positive test bands visible by 
eye; of these, nine had antibodies directed against antigen MPB83 and two against ESAT-
6/CFP-10. No hounds were positive to both MPB83 and ESAT6/CFP10. Hounds which 
produced a visibly positive test were considered to be infected, removed from the pack and 
euthanised.  
Additionally, a further 10 hounds (6.1%) showed RLU values greater than that of the majority 
of the remaining population and were assigned as “intermediate positive” test results (Figure 
5.4). Whilst interpreting these results is challenging, these hounds were considered to be at 
increased risk of infection in comparison to the background population and so were also 
removed from the group and euthanased. All test result data for the Chembio DPP VetTB test 





Figure 5.4: Dual Path Platform (DPP VetTB, Chembio, USA) serology test results (given as 
Relative Light Units [RLU]) for each of 163 hounds tested. Responses (RLU) to the two test 
antigens MPB83 (circles) and ESAT6/CFP10 (squares) are shown. Hounds producing a 
visible/qualitative test-positive result are represented by red symbols, those giving an 
intermediate result are represented by orange symbols and test negative animals are shown 
as black open symbols. Negative samples scoring zero RLU were assigned as “0.1” to allow 







5.2.3 Screening of at risk, in-contact dogs  
During the course of the outbreak, a number of dogs were identified out with the pack which 
had considerable potential for exposure to the hounds at the affected kennels. These dogs fell 
into three groups; (1) those dogs kept as pets by individuals who lived at or worked closely 
with the kennels and who spent a considerable amount of time with the hounds, (2) individual 
bitches from the affected kennel, that had been sent within the previous 18 months to other 
kennels for the purpose of breeding and remained at those kennels, and (3) a group of bitches 
that were sent from the affected kennel during the 18 months prior to the outbreak, to other 
kennels for purposes of breeding and were then returned, possibly bringing the infection with 
them. 
After consultation with owners, 19 at-risk pet dogs (group 1) were subjected to IGRA testing 
according to the same protocol as the hounds, outlined above (Section 7.2.2 sub-section a). 
Of these dogs only two were found to produce significant responses to PPDB and with a 
PPDB>PPDA bias and neither of were responsive to ESAT-6/CFP-10. Retrospective 
investigation revealed that one of these dogs was a hound which had been retired from the 
affected pack due to age-related poor performance only a few weeks prior to Case 0 becoming 
clinically sick. The second was a terrier dog, used as a “cutting room scrap dog” i.e. it was 
regularly close to the preparation of carcasses before they were fed to the hounds.  
In total, 13 bitches were sent from the affected kennel to one of two other kennels for breeding 
purposes, (groups 2 and 3); both of these kennels are in the High Risk Area (HRA) of endemic 
bTB of England. Seven of these bitches were still away at the other kennels at the time of 
testing (i.e. group 2), where they were assessed by IGRA and DPP VetTB test assay (as 
outlined above) and found to be negative on both tests. Six bitches had been off site for 
breeding purposes in the 18 months preceding the outbreak and returned to the kennels before 
the first case occurred (i.e. group 3). Only three of these animals were still alive at the time of 
the outbreak; one was found to be IGRA positive (PPDB> PPDA) but was DPP VetTB test-
negative and had no visible lesions at PME. The remaining two live hounds were test negative 
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by both assays. The reason for, and timing of, euthanasia or death of the three untested 
hounds is not known as it was not recorded by kennel staff.   
5.2.4 Post-mortem examination of test positive animals and subsequent 
mycobacterial culture (Table 5.1) 
During the course of the outbreak, from December 2016 until July 2017, a total of eight hounds 
became clinically unwell. All hounds displayed similar clinical signs to Case 0 including acute 
onset anorexia, lethargy, polyuria and polydipsia. Only one of these hounds was subjected to 
IGRA testing ante mortem and was found to be responsive to the antigen cocktail of ESAT-
6/CFP-10, the remainder had to be euthanased for welfare reasons before samples could be 
obtained. 
All IGRA and serology test positive but clinically healthy animals were euthanased and 
carcasses disposed of by incineration. Prior to incineration, all carcasses were subjected to a 
minimum of a gross PME; the exterior of the carcass was assessed, the abdominal and 
thoracic cavities were opened and all viscera visually inspected. Overall, 97 of the 164 hounds 
tested in the initial screening tests were euthanased. Of these 97, three (3.1%) were found to 
have grossly visible renal pathology (visible lesions, VL) as described for Case 0; lesioned 
tissues were removed for mycobacterial culture and histological examination. In all cases, 
acid-fast bacilli were noted on histology and M. bovis was cultured from the fresh tissue (see 
below). 
Additionally, 24 (25% of the 97) non-visible lesioned (NVL) hounds were randomly selected to 
have a full PME with samples taken for mycobacterial culture and histological examination. 
For each of these hounds the submandibular, pre-scapular, axillary, bronchial and mesenteric 
lymph nodes were removed with one (left hand side for paired nodes) or one half (for unpaired 
nodes) formalin fixed and the other kept in sterile containers for mycobacterial culture. Given 
the frequency of renal lesions in previously confirmed cases, representative internal samples 




Post mortem samples were assessed by mycobacterial culture either at APHA, Weybridge 
(clinically sick animals only) or the Roslin Institute, University of Edinburgh (clinically sick and 
clinically well animals). Samples from two of the eight clinically sick animals (25%) were tested 
in both laboratories to check for culture agreement and both laboratories were able to grow M. 
bovis from both samples. 
All samples for mycobacterial culture were treated according to APHA's standard operating 
procedure by both laboratories. Briefly, inside a Containment Level 3 (CL3) laboratory up to 
20 g of tissue was homogenised, decontaminated with 5% oxalic acid or 10% sodium 
hydroxide, and centrifuged, the pellet was re-suspended in sterile phosphate-buffered saline 
(PBS) and centrifuged again. Urine was centrifuged and removed from the sediment. The 
homogenate or urine sediment respectively was then re-suspended in PBS and sown onto 
solid Middlebrook 7H11 OADC (Sigma, UK) and liquid Middlebrook 7H9 ADC (Sigma, UK) 
culture media. 
Cultures were read at six weeks of incubation and again at 14 weeks in order to allow sufficient 
time required for any MTBC organism (i.e. either M. bovis or M. microti) to grow in culture if 
present in the tissue sample.  
A total of 14 hounds (8.2%) were confirmed as infected with M. bovis by mycobacterial culture 
(Table 5.1). Of these; all eight hounds which showed signs of clinical disease were found to 
be culture positive at six weeks. Six hounds were sub-clinically infected; three were identified 
as being visible lesion positive at PME, in each case M. bovis was isolated from at least one 
lymph node, at least one kidney and from urine samples. All cultures in these animals were 
positive by six weeks. Three hounds were NVL at PME but were culture positive, as with the 
VL hounds, in each case M. bovis was isolated from at least one lymph node, at least one 
kidney and from urine samples, however, all cultures were only found to be positive at 14 
weeks.  
Positive cultures were harvested and heat killed before genotyping; M. bovis was identified on 
the basis of colony morphology and genotyping by APHA. Genotyping was performed using 
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spoligotyping (Kamerbeek et al. 1997) and VNTR typing (Exact Tandem Repeat loci A to F, 
Frothingham and Meeker-O'Connell, 1998). Positive cultures grown at the Roslin Institute 
were harvested and digested with enzymatic lysis buffer containing 20mg/ml lysozyme (Sigma, 
UK). Mycobacterial genomic DNA was obtained using a DNeasy Blood and Tissue kit (Qiagen, 
Germany) in accordance with the manufacturer’s instructions. Harvested DNA was used as a 
template for PCR identification (as developed in Chapter 2) of the mycobacterial genes; the 
65kDa heat shock protein (hsp65) and 16s rDNA. If these were positive further testing was 
conducted to look for the presence of the MTBC antigen 85-A, and the RD-1 specific gene 
ESAT-6. A summary of all PME and culture results is shown in Table 5.1. 
Table 5.1: Results of post mortem investigations compared to ante mortem test results. 








IGRA positive 4 5 76 86* 
IGRA negative 7 5 66 78 










IGRA positive 0 0 9 9** 
IGRA negative 0 0 57 57 
TOTAL 0 9 57 66 








Total Additional notes 
Clinical signs, no 
ante mortem 
testing 





IGRA positive, DPP 
test not done 
1 
 
0 0 1 Significant IFN-γ response was 
seen to ESAT-6/CFP-10 only. 
Lesions present at post-mortem 
examination. 
IGRA positive, DPP 
positive 
2 0 2 4 Visible lesions present at post-
mortem examination of culture-
positive hounds. 
IGRA positive, DPP 
“at risk”  
2 0 3 5  
IGRA positive, DPP 
negative 





1 2 4 7  
IGRA negative, 
DPP “at risk” 
0 2 3 5  
IGRA negative, 
DPP negative 
0 0 66 66  
TOTAL 14 21 136 171  
*One animal not DPP tested  **PME of these nine hounds were unremarkable 
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5.2.5 Repeat IGRA testing protocol  
Once the initial screening testing had been completed, the 66 hounds that remained were kept 
in isolation for 60 days. At this time, because the test accuracy of the two testing methods is 
unknown, the IGRA test was repeated. Nine hounds were found to be IGRA positive, none 
were visibly lesioned at PME.  
Following these results it was decided that the remaining 57 hounds were unlikely to be 
infected/infectious and so voluntary restrictions on the kennels were lifted. The hounds 
continue to be closely monitored for any change in appetite, body weight and body condition 
score. All of the remaining hounds remain well at the time of writing.  
5.3 Screening of at risk, in-contact humans  
M. bovis is a known zoonotic bacteria. Once infection was confirmed by laboratory culture from 
samples taken from the hounds, Health Protection England (HPE) was informed to assess the 
risk to human health. An in-depth risk assessment was conducted, and contacts were stratified 
in to risk pool. A ‘stone in the pond’ approach was adopted for screening, with those at highest 
risk of exposure screened initially. This investigation and its findings are the subject of an 
additional study, where 11 people were screened (Phipps et al., 2018). One asymptomatic 
exposed person has tested positive for tuberculosis on initial screening by IGRA and has since 
been diagnosed with latent tuberculosis. Due to the nature of the contact between this 
individual and the infected hounds, it remains possible but unproven that the person was 






5.4 Epidemiological assessment  
5.4.1 Risk pathway identification  
The APHA conducted an epidemiological investigation into the source of the outbreak to 
investigate possible transmission pathways. A qualitative risk assessment approach was used 
to address the likelihood of each of these routes of infection.  The more probable contenders 
in order of likelihood were: 
5.4.2 Movement of infected hounds into the kennels 
(inhalation/ingestion/biting) 
Thirteen female hounds moved to, and six returned from, other kennels for breeding purposes 
during the 12 months prior to clinical signs in case 0.  This included locations in the HRA that 
were also within the home-range for genotype 10:a of M. bovis, where infected carcases would 
have been more likely to have been fed. Within the previous three years, but prior to the 18 
months investigation in Section 5.2.3; three hounds, two male and one female, moved onto 
the premises from three other kennels in the HRA. The likelihood of these hounds becoming 
infected from fallen stock at these kennels or through other transmission pathways in the HRA 
was assessed as medium and therefore the most likely. This likelihood was somewhat 
mitigated by the fact that only one of the tested bitches was positive to the screening tests, 
and she had no visible lesions at PME.  However, not all animals could be followed up because 
of missing records or mortalities, only ten of the 16 traced animals were alive and available for 
testing at the time of the outbreak. 
5.4.3 Feeding of M. bovis-infected fallen stock (ingestion)  
Details of the fallen stock collected from farms and fed to the hounds in the kennels over the 
12-month period prior to the first hound death were examined to provide an evaluation of the 
likely risk posed. A total of 24 carcases were sourced from an Approved Finishing Unit (AFU) 
for negative-testing cattle from bovine tuberculosis restricted farms. However, no tuberculous 
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lesions had been confirmed at post mortem meat inspection in the abattoir in any cattle from 
the unit over the previous three years, reflecting the fact that most were sourced from low 
bovine tuberculosis incidence areas i.e. from across the Low Risk Area and/or low incidence 
parts of the Edge Area. Apart from the AFU, six carcases were collected from farms with a 
history of TB breakdowns caused by genotype 10:a of M. bovis – two dating back to 
breakdowns in 2014 and one in early 2016 due to the purchase of one infected cow. However, 
none of these incidents had ongoing infection within the herds in question and all had been 
subject to parallel IGRA and tuberculin skin testing, with negative results, which reduces the 
probability of residual infection.  
The feeding of fallen stock from local cattle herds with undisclosed M. bovis 10:a infection 
remains a low likelihood considering the low tuberculosis incidence in the area, annual 
tuberculosis testing of herds, and the herd level test sensitivity with a cut-off of one reactor. 
Only one farm was in a four year testing parish, but was assessed as low risk after considering 
its purchase history. No alpaca carcases or lungs had been fed. However, it is possible that 
kennel staff may not have recognised tuberculous lesions in carcases if present. The likelihood 
of feeding infected material to the hounds at this kennel was consequently assessed as low, 
but with a medium level of uncertainty regarding prevalence of carcase infection and dose-
response in dogs.  
5.4.4 Exposure to infected livestock or wildlife during exercising 
(inhalation/ingestion/biting) either directly or via M. bovis-contaminated 
environment 
About 85% of the geographical area to which the hounds were exposed had low cattle 
tuberculosis incidence and no indication of wildlife infection.  The remaining 15% had some 
tuberculous cattle breakdowns where APHA investigation indicated possible wildlife sources. 
The very infrequent reporting of M. bovis in farm dogs in UK suggests that farm-based 
transmission pathways are not very effective. Kennel staff reported that direct contact between 
wildlife and working hounds during exercise was unlikely. However, the worst case scenario 
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of an encounter with an infectious badger, or infected carcase could have been missed. The 
likelihood of infection whilst exercising was considered very low, but with high uncertainty 
associated with wildlife prevalence and general lack of quantification of the transmission 
pathways from the environment. 
5.4.5 Exposure to infected local wildlife at the kennels 
(inhalation/ingestion/biting)  
The kennels are located in an area of the country where cattle tuberculosis incidence is low 
and there is no evidence of wildlife infection.  Access to the kennels by larger wildlife such as 
badgers was very unlikely. Likelihood was considered very low with low uncertainty. 
Once in the kennels, infection appears to have spread horizontally between the hounds, 
suggesting that in certain conditions such as intensive housing of large packs, relatively high 
rates of transmission can occur within dog populations.  It is known that badgers can excrete 
up to 100,000 M. bovis colony forming units (CFU) per ml of urine where kidneys are infected 
(Corner, 2012). Dogs with similar pathology may have similarly high excretory rates. Inhalation 
of infected urine aerosols or ingestion of such high doses are valid and likely transmission 
pathways in this scenario to account for dog to dog spread.  However, the fact that no gross 
tuberculous pathology was found in the respiratory and digestive systems of the clinical cases 
or test positive dogs adds a level of uncertainty as to what the exact transmission route was. 
5.5 Statutory changes resulting from the assessment  
This outbreak prompted a policy review of the feeding of raw flesh from fallen stock to hounds, 
permitted under Article 18 of Commission Regulation (EC) No. 1069/2009.  A condition of this 
regulation is that fallen stock fed are not killed or have not died as a result of the presence or 
suspected presence of a disease communicable to humans or animals. An interpretation of 
this is that TB reactors, normally removed by APHA, and inconclusive reactors, should not be 
fed. The Department for Environment, Food and Rural Affairs (DEFRA) commissioned a risk 
assessment from APHA to consider the likelihood of M. bovis infection occurring in hounds at 
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Animal By-Products (ABP) registered kennels through the routine feeding of fallen stock 
sourced from farms in the HRA of England.   
The overall likelihood of at least one foxhound becoming infected with M. bovis within the next 
five years, if current practices remained unchanged, was considered to be medium. This 
assessment was subject to a high level of uncertainty associated with the true prevalence of 
M. bovis infection in fallen stock carcases in the HRA and the dose-response following 
ingestion of infected material in dogs.  However, the fact that this is the first reported case in 
a kennel in the UK, may suggest that the actual risk is lower. On one hand this conclusion is 
caveated by the possibility of under-reporting through lack of systematic surveillance for TB in 
dogs. Alternatively, the conclusion is supported by a survey of culled hounds from ten Irish 
hunting kennels, over a three year period (2003-2005), which identified M. bovis infection in 
one of 52 foxhounds submitted for PME as part of the survey (Jahns, 2011).   
As a proportionate risk mitigation strategy, DEFRA has introduced tighter restrictions on the 
collection and feeding of fallen stock to hounds in registered kennels. Since 10 October 2017 
the feeding of offal from livestock species to dogs from recognised kennels or packs of hounds 
has been banned in England (Anon. 2017). Hunt kennel operators must also carry out 
additional examinations for lesions of TB in fallen stock originating from ‘high risk’ premises 
(defined as farms under movement restrictions due to a bovine TB breakdown, or which have 
been released from such restrictions in the previous 12 months). Additionally, APHA has 
developed training materials and guidance on the identification of TB in carcases of cattle and 
other livestock, for collectors and kennels feeding fallen stock to hounds. This should raise 
awareness of TB and assist recognition of tuberculous lesions in fallen stock for notification of 
suspicion of TB in carcases to APHA, as legally required under The Tuberculosis (England) 
Order 2014. The hunt kennel industry is also strengthening the voluntary code of practice and 






To the authors’ knowledge this outbreak represents the only documented occurrence of 
tuberculosis in a canine species with evidence of onward dog-to-dog transmission within the 
affected group. Previous reports of tuberculosis in dogs have been of single sporadic cases 
or small case series of unrelated infections. The reason for, and source of, this outbreak 
remains unproven; however, given the known ability of M. bovis to spread readily between 
social animals, it is not surprising that a large group of kennelled hounds presented a pool of 
competent, susceptible hosts once the pathogen was introduced. Also remarkable in this 
outbreak was its fulminant nature, from the occurrence of the index case until the resolution of 
the outbreak (seven months), nearly one in ten animals on the premises became clinically 
sick. Tuberculosis is usually considered a chronic disease with only a small percentage of 
infected individuals becoming clinically unwell (Eisenhut, 2014). Therefore this rapid 
progression to disease in a relatively high proportion of animals can be considered unusual, 
although not unheard of, as sporadic fulminant human cases of renal tuberculosis leading to 
death by acute renal function impairment have been reported (Pathan, 2001; Dissanayake, 
2004; Adzic-Vukicevic, 2017; Punia, 2008; da Silva Junior, 2016; Isao, 2006).  
The reasons for the fulminant nature of this outbreak are likely to be multifactorial; a 
combination of pathogen virulence, host genetics and phenotype, as well as environmental 
conditions. There is a possibility that the pathogen became host-adapted. However, all animals 
from which viable organism was isolated were found to be infected with genotype 10:a. It may 
therefore also be the case that this strain of M. bovis in particular poses some genetic virulence 
with respect to the dog, or that it became tolerant to a new host and so spread amongst the 
hounds once introduced.  
From a host perspective of transmission dynamics, the kennel stocking density was higher 
than that recommended by the Masters of Foxhounds Association (MFHA). This would have 
created an ideal opportunity for spread of disease once the index case became clinically sick 
and infectious. Similarly, the physiological stress of overcrowding may have made individuals 
256 
 
more susceptible to infection. A number of the kennels were in suboptimal states of repair. 
This meant that once the kennels became contaminated, it was almost impossible to 
appropriately disinfect them. They have since been destroyed completely and the kennel has 
moved to a new, clean site. Foxhounds per se are known to be at risk of mycobacterial 
infections with outbreaks of canine leproid granulomas reported in New Zealand and Australia 
(Smits, 2012). These outbreaks all affected closely related individuals and so the high level of 
genetic relatedness between individuals within this pack could imply that if a genetic 
susceptibility, such as a defect in cellular immune response did exist, then it would likely have 
high penetrance.  
The majority of the clinical signs in sick hounds were non-specific and compatible with those 
seen due to M. bovis infections in other species; lethargy, anorexia, weight loss and 
lymphadenopathy (O'Halloran, 2017; Murray, 2015; Isaac, 1983). Unusually for companion 
animals, every clinically ill animal, those with lesions at PME as well as NVL hounds that were 
found to be culture positive, had renal infections. The kidney is not generally considered a so-
called “target organ” for mycobacterial infections in companion animals, however, it is the most 
common site of extra-pulmonary TB in humans, other than lymph nodes (O'Halloran, 2017; 
Adzic-Vukicevic, 2017; da Silva Junior, 2016; Murray, 2015; Pesciaroli, 2014). Renal 
tuberculous infections are often considered to be insidious and present with mild or even 
subclinical disease, a significant proportion of cases are incidental findings at PME (Punia, 
2008; Isao, 2006). In human cases of infection where irreversible kidney damage occurs, there 
are commonly co-morbidities. Amyloidosis is one such co-morbidity, particularly in India, which 
predisposes to glomerulonephritis and potentially fatal nephrotic syndrome (Sanz-Martín, 
2016; Chong, 2017). This may also be the case for dogs; Foxhounds have previously been 
reported to be affected by renal amyloidosis (Mason, 1996), and this kennel has had previously 
confirmed clinical cases, whilst at least one of the M. bovis hounds was found to be positive 
for renal amyloidosis (data not shown). 
Other conditions which adversely affect the outcome of renal tuberculosis are the deposition 
of anti-mycobacterial antibodies within the glomeruli and/or hypercalcaemia which is a 
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common complication of tuberculosis and is directly nephrotoxic (Zhao, 2017; Bellendir, 1978; 
Ko, 2004; Chan, 1994). It is possible that either of these conditions could have had an impact 
on the number of dogs affected and the severity of disease seen in this outbreak.   
The relatively high level of renal immune-privilege may have allowed mycobacteria to replicate 
there whilst avoiding immune surveillance and clearance (Kurts, 2001). All of the hounds with 
renal lesions also had positive urine cultures (where these were available), which suggests 
that this could be a major source of infection for onward dog-to-dog transmission. However, if 
contaminated urine was the main source of infectious material, e.g. via aerosolisation, then 
lung pathology would be expected, but there were no pulmonary lesions in any of the dogs 
subjected to PME. Additionally, the urine cultures were only found to be positive after 14 weeks 
of culture suggesting that the initial number of organisms present was low. Based on the 
distribution of lesions it would appear that the mycobacteria arrived in the kidney by 
haematogenous spread. If so this indicates a distant source of infection which has not been 
identified. 
Infected urine was identified as a key risk factor for potential human exposure during the risk 
assessment of kennel staff, predominately due to the use of power washers to clean excreta 
from the hard standing, which posed a significant risk of aerosolisation (Phipps et al., 
manuscript submitted). The outcome of tuberculosis screening for at-risk humans at the 
kennels was that a single individual was diagnosed with latent tuberculosis (Phipps et al., 
manuscript submitted). If urine from infected dogs was heavily contaminated with M. bovis it 
would have been likely that a higher proportion of individuals at risk would have been test 
positive. Based on these observational data, it is possible to conclude that M. bovis infected 
dogs are likely to be infectious to each other, and their urine may contaminate their local 
environment, but that this may not be the only or even the major route of transmission, and 
that the risk to human health is low.  
No ante mortem tests have been validated for the diagnosis of M. bovis infection in dogs; we 
therefore combined two established testing methods for other species to try and maximise our 
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diagnostic sensitivity and bring this outbreak under control. The tests used here target the 
disparate arms of the immune response, with the IGRA evaluating the cell mediated Th-1 
response whilst the serological assay used to detect a humoral Th-2 response. The 
percentage of tested animals deemed to be positive by each test was markedly different with 
52% of dogs classed as infected by IGRA at initial screening but only 12.9% of dogs classed 
as infected or “at risk” by serology. This difference is likely due to the dominance of cell 
mediated immunity in an animals’ response to mycobacterial infection (Khan et al. 2006) but 
further investigation of the canine immune response to M. bovis and mycobacterial antigens 
is needed before this can be shown conclusively, this work is currently ongoing and will be 
published separately.   
Whilst uncertainty exists with regards to the source of infection, it seems likely that 
contaminated fallen stock carcasses were involved. All culture positive animals had the same 
genotype isolated, which has not been frequently detected in the area local to the kennels. 
This suggests a single introduction with a large dose of infectious material was likely and that 
infection then spread between cohabiting hounds (Reynolds, 2006). One kennel worker was 
also diagnosed with latent tuberculosis, potentially due to exposure to infected hounds and/or 
their contaminated feed, though this remains unproven. Though the risk posed by M. bovis 
infected hounds to other hounds, cattle herds, local wildlife, their environment and their human 
keepers is low, this outbreak demonstrates that the risk is plausible and real. Resultantly, to 
try to prevent such an outbreak from occurring again, the conditions for the collection and use 
of animal by-products for feeding to dogs in recognised kennels or packs of hounds have now 
been amended to ban the feeding of offal from fallen stock. Similarly, health surveillance 
requirements for hounds have been increased by the MFHA. To be successful, these policy 
changes will need to be aided, however, by the future evaluation of diagnostic test accuracy 
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Chapter 6:  Bovine Tuberculosis in Working 




The following Chapter presents the findings of a study, conducted as part of this studenship 
programme that has been published in the journal Epidemiology and Infection.  
The manuscript derived from this Chapter is available as an eponymous Open Access article: 
Phipps, E., McPhedran, K., Edwards, D., Russell, K., O'Connor, C., Gunn-Moore, D.A., 
O’Halloran, C., Roberts, T. and Morris, J. (2019). Bovine tuberculosis in working foxhounds: 
Lessons learned from a complex public health investigation. Epidemiology and Infection, 147, 
E24. 
Author contributions: 
This public health investigation was devised and planned with input from the collective group 
of co-authors. The investigation was then implemented by Public Health England, supervised 























In 2017, Public Health England South East health protection team were involved in the 
management of an outbreak of Mycobacterium bovis (the causative agent of bovine 
tuberculosis) in a pack of working foxhounds. This paper summarises the actions taken by the 
team in managing the public health aspects of the outbreak, and lessons learned to improve 
the management of future potential outbreaks.  
A literature search was conducted to identify relevant publications on M. bovis. Clinical notes 
from the health protection database were reviewed and key points extracted. Animal and 
public health stakeholders involved in the management of the situation provided further 
evidence through unstructured interviews and personal communications.  
The PHE South East team initially provided ‘inform and advise’ letters to human contacts whilst 
awaiting laboratory confirmation to identify the infectious agent. Once M. bovis had been 
confirmed in the hounds, an in-depth risk assessment was conducted, and contacts were 
stratified in to risk pools.  Eleven out of twenty exposed persons with the greatest risk of 
exposure underwent tuberculosis screening and one tested positive, but had no evidence of 
active infection.  
The number of human contacts working with foxhound packs can be large and varied. Health 
protection teams should undertake a comprehensive risk assessment of all potential routes of 
exposure, involve all other relevant stakeholders from an early stage, and undertake regular 
risk assessments. Current guidance should be revised to account for the unique risks to 






Detected infections of dogs with Mycobacterium bovis, the causative agent of bovine 
tuberculosis (bTB), are extremely rare, with only seven cases being reported to the Animal 
and Plant Health Agency (APHA) between 2004 and 2010 (1). The risk of transmission of M. 
bovis from dogs to humans is also considered rare, with expert consensus concluding that 
dogs are a ‘spill over’ host and not a significant source of transmission (2). However, this 2017 
outbreak of M. bovis amongst a pack of working foxhounds in the South of England sparked 
considerable interest and concern from members of the public, media, veterinary and health 
professionals, and led to a co-ordinated response from Public Health England (PHE) health 
protection teams, the University of Edinburgh and the APHA (3; 4; 5; 6).  
This was the first recorded outbreak of M. bovis in working foxhounds in England. Although 
public health guidance on the management of M. bovis associated with animals in general is 
available, there is no specific guidance describing the management of the human health risks 
associated with an outbreak of M. bovis in working foxhounds and the complex exposures this 
context presents. Given the increased awareness of M. bovis infection associated with working 
dogs (including foxhounds as seen here or other farm dogs) amongst the veterinary 
community, it is likely that assessments of the risks to human health  will be required again in 
the future (1; 2). Such situations are likely to attract wider public interest due to concerns over 
the spread of bTB. 
Management of this unique outbreak in working foxhounds required PHE to work 
collaboratively with veterinary stakeholders to identify exposed persons and limit the spread 
of M. bovis amongst both humans and animals. This paper summarises the actions taken by 
PHE South East in managing the public health aspects of this situation, and lessons that can 
be learned to improve the management of similar situations following notification of potential 





A literature search was conducted on PubMed and CAB Abstracts to identify relevant 
publications on M. bovis in dogs ((dog OR pack OR foxhound OR hound) AND (TB OR 
tuberculosis OR mycobacterium), all papers available on databases with English language 
translation available). Additional papers of relevance to this case study not identified through 
the literature search were suggested by the authors of the publication that arose from this 
work.  
6.3 Results 
6.3.1 Background epidemiology of M. bovis in the UK 
Bovine tuberculosis is an important disease of cattle with a wide range of wild and domestic 
animal hosts (7; 8).The causative agent, M. bovis,  is a slow growing, aerobic bacterium that 
typically causes infection of the lungs in humans, but can affect any organ in the body (9). 
Human infection with M. bovis typically occurs through ingestion, inhalation or contact with 
mucous membranes or skin abrasions of an infected animal (7). The main sources of zoonotic 
transmission of M. bovis infection are the ingestion of unpasteurised milk and dairy products, 
or prolonged exposure to aerosolised bacilli excreted from the respiratory tract of diseased 
animals (7; 10). Localised non-pulmonary M. bovis lesions can occur rarely through handling 
infected animals or carcases and theoretically through aerosolised exposure in abattoirs (10). 
Human to human transmission is extremely rare (9). In the United Kingdom, infection in 
humans with M. bovis is much less common than M. tuberculosis; between 2002 and 2014 
there were 357 reported human cases of M. bovis compared to 96,887 cases of M. 
tuberculosis (9; 11). It is thought that most cases of M. bovis infection in humans in the UK are 
likely due to reactivation of latent infection acquired before compulsory pasteurisation of milk 
and bTB control programmes, contact with a human tuberculosis case, or infection acquired 
abroad (7; 9). 
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The incidence rate of M. bovis in cattle in England is one of the highest in Europe (11.0 new 
herd incidents per 100 herd-years at risk in 2017) (12). The UK government has implemented 
stringent controls to minimise the spread of bovine tuberculosis, with some counties in the 
South West and South East of England being deemed High Risk Area and separate adjacent 
buffer zone (Edge Area), and so cattle in these areas are subject to additional testing and 
surveillance (12). Non-bovine farmed animals such as South American camelids (alpacas), 
sheep, goats, pigs and deer are  also sporadically infected, usually through direct or indirect 
contact with cattle or badgers (the two maintenance hosts of the bacterium in the UK) (13; 14). 
Infection of companion animals does occur, and there have been numerous reported cases of 
pets testing positive for M. bovis over the past few years, predominantly domestic cats (2; 12; 
13; 15). The majority of cases of dogs infected with M. bovis in the literature come from 
countries other than England and have identified risk factors such as being strays or having 
exposure to infected non-domestic animals (1; 15; 16; 17). 
The potential for zoonotic transmission of M. bovis from companion animals to human contacts 
was confirmed in 2014 when cases of human M. bovis infection followed transmission from 
infected cats in Berkshire, England (18; 19; 20). Lessons learned from the management of 
exposure to infected companion animals in 2014 justified a measured and co-ordinated public 
health response in order to protect human health.  
6.3.2 Initial Risk Assessment 
The responsible health protection team in the South East of England were initially made aware 
in early 2017 of the potential risk of zoonotic transmission of M. bovis by a private veterinarian 
with clinical suspicion of this diagnosis in working foxhounds cared for at the practice. A 
number of veterinary staff may have come into contact with infected hounds during their 
routine work. Key questions asked by the public health team in the initial assessment are 
summarised in Box 6.1, based on core principles of health protection practice and adaptation 
of existing general guidelines on the management of human health risks of tuberculosis (7; 
21). Before implementing public health actions it is recommended to wait for laboratory 
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confirmation (7). Veterinary practice staff were therefore reassured and ‘inform and advise’ 
letters offered for distribution in the workplace, and the situation highlighted to the APHA in 
case of further action required.  
 
Box 6.1: Questions asked by the public health team in the initial assessment 
6.3.3 Confirming the Diagnosis 
Primary concerns regarding the health of the kennel hounds were first raised in late 2016, a 
number of hounds had been euthanased for welfare grounds for reasons of deteriorating 
health within the preceding months. When a new hound starting showing similar clinical signs 
(weight loss, lethaergy, hyporexia, polyuria and polydipsia) it was euthanased and submitted 
for post-mortem examination. Gross renal pathology was confirmed histopathologically as 
granulomatous, and the presence of acid-fast bacilli with mycobacterial morphology was 
confirmed by examination of Zeihl-Neelsen stained sections of diseased tissue.  
This finding instigated a veterinary disease outbreak investigation by the Univeristy of 
Edinburgh, Biobest Laboratories and APHA (detailed in reference 24). Briefly, 164 hounds in 
the kennel were tested using an experimental interferon-gamma release assay (IGRA) test at 
Biobest Laboratories and a serological assay originally developed for cervid species (Dual 
Path Platform VetTB test for cervids).  
Of the 164 hounds tested, 85 (52%) were diagnosed as being test positive as per the 
prospective case definition set. Test positive hounds and clinically sick hounds were 
euthanased and M. bovis infection was confirmed by culture in 14 cases. The isolated 
Box 6.1: Initial Assessment 
 What is the name of the hunt and where is it located 
 How many animals are involved and how many have undergone testing 
 What clinical signs did the hound(s) present with 
 What type of testing has been undertaken (e.g. PCR/culture/IGRA) 
 When are results available yet to confirm the diagnosis  
 Any at risk groups in contact with the hounds e.g. immunocompromised staff   
 Any symptomatic staff or household members? 
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organism was genetically tested confirming genotype 10:a with the first laboratory confirmation 
occurring in February 2017. 
6.3.4 Veterinary Epidemiological Investigation 
Once infection with M. bovis 10a had been confirmed evaluation of the risk to human health 
was undertaken (see below). Simultaneously, an epidemiological investigation began to 
identify the risk pathways by which the hounds may have initially become infected. These are 
detailed in (24) and comprised of, in order of considered likelihood; a) movement of infected 
hounds into the kennels b) feeding M. bovis infected fallen stock to the hounds c) exposure to 
infected livestock or wildlife during work and/or d) exposure to infected local wildlife at the 
kennels.  
Qualitative assessment of each pathway was undertaken with the evidence available. Tracing 
of hound movements indicated that 21 had been moved onto the affected premises within the 
three years prior to the diagnosis of the index case, of which 18 were moved in the preceding 
18 months. Some kennels of origin of these hounds were located within the geographical 
region of the UK designated as the High Risk Area (HRA) for M. bovis incidence with respect 
to bovine infections. Furthermore, a number of these were located within the home-range of 
M. bovis 10a.  It was therefore considered to be medium risk (and therefore most probable) 
that whilst at these kennels, hounds were fed fallen stock infected with M. bovis 10a and this 
was the source of infection.  
Due to the outbreak-kennel location within the Edge Area for M. bovis incidence, being out 
with the home range of M. bovis 10a and with no locally identified wildlife infections with M. 
bovis the remaining pathways were deemed to be possible sources of infection but low risk.  
6.3.5 Identifying At Risk Groups 
Following culture confirmation of M. bovis from the hound tissue samples, PHE undertook a 
formal risk assessment to identify potential routes of zoonotic transmission, understand levels 
of exposure and determine future public health actions, including possible screening of human 
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contacts. Available guidance related to M. bovis in livestock was reviewed and tailored to this 
specific situation (7). The key points of this risk assessment are summarised in Box 6.2, and 
involved collecting information from staff caring for the foxhounds, the local veterinary practice 
and the APHA.  Again, this risk assessment was undertaken based on key principles of health 
protection practice and adaptation of general guidance on the management of human health 
risks related to bTB (7; 21).  
 
Box 6.2: Outline of the agreed basis for HPE risk assessment  
6.3.6 Communications Strategy 
A multi-agency incident control team (ICT) was convened to facilitate effective information 
gathering and to agree on suitable actions for all involved stakeholders. This collective 
Box 6.2: Summary Details of the Public Health Risk Assessment 
Potential routes of exposure 
 Identify all persons who were in contact with the symptomatic foxhounds including temporary 
and previous staff members at the kennels and veterinary practice 
 Define the level of contact and activities undertaken e.g. preparing food, grooming, cleaning 
environment, dressing wounds, undertaking invasive procedures 
 Whether anyone may have been bitten by infected foxhounds 
Risk of exposure 
 Level of exposure – total time spent with infected foxhounds by each person involved 
 Use of personal protective equipment (PPE) during contact – consistency and type worn 
 Whether any contact could have generated aerosols 
Environmental factors 
 Environments in which contact takes place e.g. kennels, household, vehicles and veterinary 
practice 
 Condition of kennels e.g. cracked concrete and other porous surfaces  
 Ventilation and cleanliness of environments 
 Frequency and level of cleaning undertaken e.g. sweeping, pressure washing, disinfecting 
Veterinary assessment 
 List of veterinary practices caring for the working foxhound pack  
 Prevalence of bTB in the surrounding area amongst bovine and non-bovine animals 
 Potential route of initial infection e.g. contact with confirmed bovine cases or being fed 
potentially contaminated meat  
 Follow up being undertaken by APHA 
 Any plans to test the rest of the working foxhound pack  
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approach, also involving specialist communication colleagues from all agencies, ensured that 
consistent messages were delivered, with the aim of reducing misinformation and managing 
perceptions of risk amongst the public (22).  
The foxhounds were exercised on land and at events over several counties in the South East. 
Local health protection teams (HPTs) across the region received calls from members of the 
public, veterinary and public health professionals enquiring about the pack and associated 
risks of infection. Calls to HPTs were recorded on a case and incident management database 
HPZone (inFact Shipley, 2012). In order to facilitate co-ordination between teams and quick 
referencing, a unique identifier for the situation was created that could be linked to all incoming 
enquiries taken by the teams involved. The response was coordinated across several HPTs 
by the incident lead, and an email circulation list was used to keep the incident management 
team informed of all actions undertaken and updates on the situation. PHE and DEFRA 
communications teams were also involved at this point to agree on what proactive and reactive 
statements would be appropriate. DEFRA and veterinary colleagues experienced a higher 
volume of interview and statement requests than the public health teams, likely due to the high 
profile of fox hunting and bTB in the media.   
6.3.7 Screening & Further Public Health Actions 
A ‘stone in the pond’ approach was adopted in determining which human individuals should 
initially undergo screening for tuberculosis (23). Screening does not differentiate between M. 
bovis and M. tuberculosis infections, but does identify persons requiring further investigations 
and confirmatory testing. PHE identified close contacts with the highest risk of potential 
transmission for initial screening, and then planned to expand the screening pool to more 
casual contacts if the first round of screening suggested significant transmission had occurred.  
The individuals identified for the first round of screening were those with the greatest degree 
of contact with infected foxhounds, and included persons who had conducted invasive 
procedures on symptomatic dogs (such as post-mortem examinations and surgical 
procedures) without appropriate personal protective equipment (PPE), and kennel workers 
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involved with food preparation and cleaning of kennels using a pressure washer. These were 
hypothesised to be the highest risk exposures to potential sources of M. bovis, e.g. infected 
tissue, aerosolised fluids and potential contaminated fallen stock used as feed. The use of a 
pressure washer was of particular interest as the presence of kidney lesions in infected 
foxhounds (24) suggests that M. bovis bacilli could have been excreted in the hounds’ urine.   
Persons in the initial screening group were referred to their local tuberculosis service for 
screening. All other identified potential contacts were sent an ‘inform and advise’ letter whilst 
results from the initial round of screening were awaited (see Box 6.3 for outline summary). In 
addition, HPT staff visited the veterinary practice to discuss and allay staff concerns related to 
M. bovis and their risk of acquiring tuberculosis. 
 
Box 6.3: Agreed purpose of communication strategy with at risk individuals 
In total, eleven out of seventeen people were considered to have potential exposure to infected 
foxhounds as outlined in Figure 6.1 and were offered tuberculosis screening. Of these, one 
person tested positive for TB (using QuantiFERONTM TB Gold). Following a further 
assessment including computed tomography (CT) scanning and culture of tissue samples, 
there was no evidence of active tuberculosis infection and latent tuberculosis was diagnosed.  
This person had not had previous testing for tuberculosis, did not have other risk factors, but 
was involved in all high risk activities including post-mortem examination without PPE, 
preparation of fallen carcases for feeding, cleaning of kennels using a pressure washer and 
care of open wounds on infected animals. Seven contacts screened negative for tuberculosis, 
Box 6.3: Key information for inform and advise letters 
 Reassure that the risk of transmission from animals to humans is low  
 Some persons may be unusually susceptible such as immunocompromised  persons 
 Description of the symptoms of tuberculosis 
 Advice to contact GP if experiencing any of these symptoms, mentioning the possible route 
of exposure through the hunting pack  
 Screening of high risk persons is currently taking place and we may be in contact again  to 
arrange screening if initial tests indicate that transmission of bTB has occurred 
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and three declined the offer of screening. Based on this outcome of the first screening round, 
it was agreed by the ICT that further screening would not be offered to more casual contacts.  
 
Figure 6.1 Hierarchy of screening pools used during the public health investigation resulting 
from the kennel outbreak of Mycobacterium bovis tuberculosis in working foxhounds.  
Screening of the foxhounds continued over several months with two further screening rounds; 
a total of 164 hounds were tested with a 52% IGRA positivity rate (24). All foxhounds testing 
IGRA positive were euthanised. A second meeting of the original multi-stakeholder ICT was 
convened to discuss how to manage the ongoing exposure to IGRA positive hounds since the 
initial diagnosis. Staff members who had declined screening initially were encouraged to 
attend given this ongoing exposure. Three new staff members (bringing the total number of 
screened persons up to 20) who had joined the hunt since the initial diagnosis were identified 
and they were provided with ‘inform and advise’ letters to highlight their potential risk of 
exposure to infected foxhounds during both rounds of animal screening, and recommended 





The management of this situation has highlighted several learning points for veterinary and 
public health stakeholders. Outbreaks of potentially zoonotic infections amongst working 
foxhound packs are a unique challenge for both health protection teams and veterinary 
investigation teams, as they are comprised of large populations (in this case over 150) 
individuals, which are highly mobile (this kennel covered an area spanning six counties) and 
hounds are legislatively defined neither as companion animals nor agricultural livestock, 
meaning for example, that they can be fed fallen stock. The hounds from working packs may 
span both categories, spending time in both domestic and farming settings. This makes 
quantifying the unique exposures and risk of transmission associated with this context 
particularly difficult as they are not specifically covered by any existing guidelines. Moreover, 
IGRA testing is not validated for use in diagnosing M. bovis infections dogs, so the sensitivity 
and specificity of any results are unknown, adding some uncertainty to whether public health 
action should be warranted in light of a positive test (25). In this scenario, given the high 
number of positive IGRA tests, confirmatory tissue cultures and foxhounds with clinical signs 
consistent with tuberculosis, the decision to take action was relatively straightforward, but 
could be difficult in the face of less conclusive results.  
Bovine tuberculosis is an understandably emotive subject for many stakeholders, including 
kennel staff, farmers, veterinarians and the general public, and there was considerable media 
interest. It was crucial to ensure that confidentiality of the working foxhound pack was 
protected as much as possible by agencies involved, and that information sharing activities 
were coordinated and agreed on by all parties. The geographical area covered by the pack 
during outings spanned several counties, and required the involvement of multiple HPTs and 
tuberculosis services to coordinate a response. Effective communication between these teams 
is extremely important to ensure that resources are used efficiently and messages are 
consistent in order to address public concern. By visiting the veterinary practice in person, the 
health protection team were able to build relationships and foster trust from stakeholders to 
manage concern successfully. This also presented an opportunity for highlighting the 
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importance of appropriate wearing appropriate personal protective equipment when 
performing post-mortem examinations of animals, which would have significantly reduced the 
risk of exposure to M. bovis to veterinary and kennel staff. 
This situation highlighted how dynamic risk assessments should be undertaken frequently 
during the ongoing process of outbreak management, as the  foxhound pack is likely to come 
in to contact with new persons such as temporary staff and members of the public as well as 
those potential contacts identified in the initial assessment. IGRA testing of the whole pack 
was a significant undertaking for the kennel and University of Edinburgh staff, who were unable 
to secure additional funding for testing as the foxhounds were deemed to be non-livestock 
species, and took several months to complete. During this period, workers continued to be 
exposed to hounds that were eventually found to be IGRA positive.  Managing this unknown 
and unquantifiable risk of potential exposure whilst waiting for IGRA results was particularly 
challenging, and involved concerted effort from the HPT to communicate effectively with 
stakeholders to address and allay concerns.  Senior managers of the foxhound kennels were 
very receptive to both public health requirements and advice regarding animal health 
management. It is worth noting that as the hounds are not classed as livestock, the APHA 
have no regulatory powers to enforce euthanasia or other control methods.  
6.5 Conclusion 
This paper highlights the unique and unusual health protection scenario of managing potential 
working foxhound to human transmission of M. bovis. The number of human contacts with 
working packs can be large and varied, and the animals are not considered as domestic 
companion animals or livestock. Health protection teams involved in the management of such 
situations must ensure to undertake a comprehensive risk assessment of all potential routes 
of exposure, involve all other relevant stakeholders from an early stage in developing 
management and communication plans, and undertake regular risk assessments as new 
information becomes available. Current guidance should be revised to account for the unique 
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Assays for the Identification of Mycobacterium bovis-
Infected Domestic Dogs (Canis lupus familiaris). 
Acknowledgements 
Thanks go to all of the staff and management team of the kennels affected by this outbreak 
for facilitating the investigation and giving permission for its findings to be included in this 
thesis.  
Specific thanks go to Dr Shelley Rhodes (Senior Animal and Plant Health Agency Scientist 
and TB Test Consultant) who performed the commercial serological assays (Section 7.2.5). 
Additional funding for this project was provided by PetPlan Charitable Trust 
(OHALLORAN806: Validation of diagnostic assays for canine tuberculosis).  
 
Abstract 
The domestic dog (Canis lupus familiaris) is a competent host for Mycobacterium (M.) bovis 
infection but no ante-mortem diagnostic tests have been validated for this species. The aim of 
this study was to compare the performance of potential ante-mortem diagnostic tests across 
samples collected from dogs considered to be at high or low risk of sub-clinical M. bovis 
infection. We tested 164 dogs at high risk of infection and 119 dogs at low risk of infection with 
a combination of cell-based and/or serological diagnostic assays previously described for use 
in non-canid species. The interferon-gamma release assay (IGRA) using peripheral blood 
mononuclear cells (PBMC) identified the highest number of test positive animals (85, 52%), 
with a suggested specificity of 97.3%, whilst a whole blood IGRA was found to be unreliable. 
The production of antigen-specific tumour necrosis factor-alpha (TNF-α) by PBMC in response 
to a cocktail of ESAT-6 and CFP-10 antigens correlated very strongly with the overall IGRA 
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results and has future diagnostic potential. All three serological assays employed in this study 
(Idexx M. bovis Ab ELISA, [Idexx Laboratories, USA], DPP VetTB lateral flow assay [Chembio, 
USA] and comparative PPD ELISA [in-house]) identified seropositive dogs but, overall, the 
test-positive rate for the serological assays was only one third that of the cellular based assays. 
Circulating serum cytokine concentrations of interferon gamma (IFN-γ) and TNF-α were not 
statistically different between high and low risk groups of dogs. While many dogs in the high 
risk group had serum biochemical abnormalities, these did not correlate with the findings of 
other diagnostic tests.  
This study demonstrates, for the first time, the potential utility of two cellular and three 
serological assays for detecting sub-clinical M. bovis infections of dogs. Whilst the data 
suggest high test specificity for all assays evaluated, further work is needed to validate the 
sensitivity and specificity of individual or combinations of tests using sufficient numbers of dogs 
of known infection status. 
7.1 Introduction 
The domestic dog (Canis lupus familiaris) is, like many mammalian species, a competent host 
for Mycobacterium (M.) bovis infection (Snider et al. 1971; Ellis et al. 2006; Broughan et al. 
2013a). Although clinical cases of tuberculosis (TB) due to infection with M. bovis, or other 
members of the M. tuberculosis-complex (MTBC), are considered rare in the dog and generally 
only occur sporadically (Broughan et al. 2013b), we previously investigated a fulminant 
disease outbreak caused by M. bovis infection within a large group of kennel-housed working 
Foxhounds in the UK (O’Halloran et al. 2018). Investigation of this outbreak was impeded in 
its speed, and by the lack of available ante-mortem diagnostic tests for identifying M. bovis 
infections in domestic dogs (Snider et al. 1971; Snider et al. 1975; Broughan et al. 2013b). 
The tests employed therefore had to be adapted and interpreted in real time, based on 
extrapolation of performance data from non-canine species.  
Interferon gamma (IFN-γ) release assay (IGRA) tests have been developed on the principle 
of quantitatively evaluating antigen-specific IFN-γ production by peripheral circulating effector 
282 
 
memory T-cells following in vitro stimulation (Adams 2001; de la  Rua Domenach et al. 2006; 
Schiller et al. 2009). The first IGRA was designed to increase the sensitivity of M. bovis TB 
testing in cattle (Wood et al. 1990), and the resulting BOVIGAMTM assay holds World 
Organisation for Animal Health (OIE) validation, with a reported in-field sensitivity of 81.8-
100% and specificity of 88-99% (Wood, 2001; Vordermeier et al., 2006; Schiller et al., 2009; 
Bezos, 2014). IGRA tests have subsequently been adapted to identify active and latent TB in 
human patients with at least equivalent sensitivity and increased specificity when compared 
to the intradermal tuberculin skin test (TST) (Kim, 2011; Zhou, 2011; Eisenhut, 2014; Thillai, 
2014). Similarly, IGRA test protocols have been developed for use in domestic cats with a 
suggested high sensitivity and specificity for the detection of MTBC infections, and for the 
detection of M. tuberculosis infections in dogs in a high risk setting (Rhodes et al. 2011; 
Parsons et al. 2012; Broughan et al. 2013b); while the same study found the intradermal TST 
to be unreliable in the dog (Parsons et al. 2012). 
The IGRA used in this study was specifically developed to test dogs for subclinical M. bovis 
infection, and was based on the protocol used for testing domestic cats (Rhodes et al. 2011); 
the antigens purified protein derived (PPD) from M. avium (PPDA), PPD from M. bovis (PPDB) 
and a cocktail of proteins derived from the immunodominant proteins; 6kDa early-secreted 
antigenic target (ESAT-6) and 10kDa culture filtrate protein (CFP-10) were selected. PPDA is 
frequently used with PPDB as a comparator in both IGRA and TST tests to assess and mitigate 
for exposure/sensitisation to, or infection with, environmental mycobacteria species. Infection 
with a MTBC mycobacteria is confirmed if the IFN-γ response of an animal is greater to PPDB 
than to PPDA (Wood, 2001; Vordermeier et al. 2007).  
The proteins ESAT-6 and CFP-10 are both encoded on the RD-1 region of most MTBC, 
including M. bovis, and a small number of non-tuberculous mycobacteria (NTM) (Harboe et al. 
1996; Brosch et al. 2002). They are secreted proteins that form a heterodimeric complex in a 
1:1 ratio which has been consistently associated with phagocyte lysis and pathogen virulence 
(Gao et al. 2004; Guinn et al. 2004; Junqueira-Kipins et al. 2006). The presence of a 
concurrent response to the recombinant combination of ESAT-6/CFP-10, as well as PPDB, 
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indicates infection with an RD-1 positive MTBC mycobacteria (i.e. it excludes infection with M. 
microti or previous vaccination with M. bovis-BCG) (Harboe et al. 1996; Buddle et al. 2001; 
Brosch et al. 2002).  
A number of studies have tried to improve the sensitivity and/or specificity of IGRA tests. The 
overall performance of an IGRA, when used to test cattle for M. bovis or humans for M. 
tuberculosis infection, can be increased by the measurement of additional cytokines secreted 
by antigen specific cells within the blood (Jones; 2010; Elnagger et al. 2017). This includes 
tumour necrosis factor-alpha (TNF-α), which has a well described role in the mammalian host 
immune response to mycobacteria (Allie et al. 2013, Leem et al. 2018).  
The bovine (BOVIGAMTM) and human (QuantiFERONTM TB Gold) IGRA assays are both 
performed on whole blood without first needing to isolate peripheral blood mononuclear cells 
(PBMC), as is required for IGRA testing cats, camelids and the T-SPOT.TBTM test (Hesketh et 
al. 1994; Gutierrez, et al. 1998; Vordermeier et al. 2007; Rhodes et al. 2008a; Igari et al. 2018; 
Leem et al. 2018). The use of whole blood rather than PBMC makes the former assays quicker 
and cheaper to conduct and so would be an ideal development for canine TB testing.  
Both IGRA and TST assays evaluate the cell mediated adaptive immune response (CMI) of 
an animal which dominates the reaction to intracellular pathogens, including mycobacteria 
(Allie et al. 2013).  However, skin test responses in dogs have been shown to be unreliable 
(Parsons et al. 2012). Diagnostic serological assays, while generally recognised as having 
lower sensitivity than CMI assays, have been used both experimentally and commercially for 
the diagnosis of MTBC infections in a number of species (Min et al. 2011; Rhodes et al., 2012 
El-Seedy et al. 2013; Casal et al. 2014; Roos et al. 2016; Waters et al., 2017, Chambers et 
al., 2010). It is recognised that combining serological and CMI diagnostic tests may provide 
added value by increasing infection detection, e.g. Bezos et al. (2018) showed an increase in 
overall diagnostic sensitivity for both cattle and goats with MTBC infections.  
M. bovis is an endemic pathogen of major significance to the UK farming industry as the 
causative agent of bovine tuberculosis (bTB) (Vordermeier et al. 2007). In England and Wlaes 
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the regions with high prevalence of M. bovis, as defined by the incidence of bovine infections, 
comprise the High Risk Area (HRA), and lower but still significant disease prevalence occurs 
within counties of the Edge Area. Control measures implemented for cattle infections amount 
to an estimated cost of £100 million annually, and while the most recent government statistics 
show a decrease in herd incidence in England, there is a mixed picture, with an increase in 
the number of cattle slaughtered annually (DEFRA, 2018). 
Non-bovine reservoirs of infection are increasingly being investigated for their potential role in 
the epidemiology of the disease; either as possible reservoirs of infection or as sentinel 
species, but species-specific diagnostic tests are often lacking which impedes such 
investigations (Buddle et al. 2000; Delahay et al. 2002). As the UK moves towards its goal of 
M. bovis elimination, having diagnostic tests with known accuracy for such spill over species 
will be critical.  
The aim of this study is to compare the performance of ante-mortem diagnostic tests across 
samples collected from individual dogs considered to be at either high or low risk of sub-clinical 
M. bovis infection, and (presumed) TB-free dogs. 
7.2 Materials and Methods 
7.2.1 Sample collection 
Diagnostic blood samples from animals considered to be at high risk of sub-clinical infection 
with M. bovis (high risk group, HRG) were those taken from 164 kennel-housed foxhounds 
during an outbreak of TB due to M. bovis which occurred between December 2016 and July 
2017 (Table 7.1) (O’Halloran et al. 2018). Whole blood and PBMC stimulation assays were 
conducted at the time of sampling, whilst serological assays were performed subsequently on 
aliquots of serum separated and frozen at -80ºC within 24 hours of collection. 
To allow for a comparison of test performance in populations with predicted differences of 
infection prevalence, we also tested a total of 119 opportunistically collected blood samples 
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(i.e. remnant blood from samples taken for clinical reasons unrelated to this project); 77 from 
presumed TB-free dogs (TB-free group) and 42 dogs with some degree of potential exposure 
to cats or dogs with a mycobacterial infection (low risk group, LRG). The TB-free group 
provided 45 serum samples and 18 PBMC samples, an additional 42 PBMC samples were 
available from the LRG dogs, as shown in Table 7.1. 
Table 7.1: Origin of blood samples used in this study: *serum was unavailable for one 
Foxhound, HfSA; Hospital for Small Animals; **All samples from dogs resident in Scotland 
which has held Officially TB Free (OTF) Status since 2009.  
High risk or 
Low risk 
groups 






High risk Kennel Foxhounds 
where the M. bovis 
outbreak occurred 
164 163* 164 
     
TB-free Canine patients at 
the HfSA, University 
of Edinburgh** 
45 45 0 
TB-free Blood donor dogs at 
the HfSA, University 
of Edinburgh** 
24 0 24 





8 0 8 
Low risk Pet dogs in contact 
with a household 
(animal) case of 
mycobacterial 
disease 
10 0 10 
Low risk  Pet dogs of kennel 
staff where a 
previous M. bovis 
outbreak occurred 




Remnant samples were only included in this study if, prior to blood sample collection, the dog 
had not been treated with immunomodulatory medications e.g. non-steroidal anti-inflammatory 
drugs (NSAIDs), chemotherapeutic agents or corticosteroids within 14 days prior to sample 
collection. Dogs were excluded if they were pre-treated with antibiotics with efficacy against 
mycobacteria, including fluoroquinolones, macrolides/azides or doxycycline within the same 
14 day period. Dogs were not excluded if they had been treated with antimicrobial agents if 
these would be ineffective against mycobacteria, such as a penicillin or cephalosporin. 
Similarly, dogs were not excluded if they had been treated with non-immunomodulatory 
analgesic medications e.g. opioids.    
This study was conducted following approval from the School of Veterinary Medicine Ethical 
Review Committee at the University of Edinburgh; all relevant guidelines and regulations were 
adhered to throughout.   
7.2.2 IGRA using isolated PBMC 
The IGRA assays for the 164 dogs in the HRG were conducted as previously reported 
(O’Halloran et al. 2018). The same assay was used to test PBMC isolated from the 74 dogs in 
the TB-free and LRG groups (Table 7.1). The assay protocol had been validated and 
previously published for use in the domestic cat and was modified for use in the dog (Rhodes 
et al. 2011). A sample of up to 5ml heparinised whole blood was taken from each animal and 
transported to the laboratory at ambient temperature within 18 hours. Upon receipt, blood was 
diluted 1:1 with Hanks Balanced Salt Solution (HBSS, Gibco, UK) and layered over Histopaque 
1077 (Sigma, UK) before centrifugation at 800 x g for 40 minutes at room temperature. The 
PBMC were removed from the resulting interface, washed with HBSS and re-suspended in 
complete culture media (RPMI 1640 containing 100µg/ml L-glutamine, 10% foetal bovine 
serum, 100µg/ml penicillin, 100U/ml streptomycin, 5x10-5M 2-mercaptoethanol and non-
essential amino acids) to a density of 2x106/ml. A 100l sample of the PBMC suspension was 
stimulated in duplicate with PPDA or PPDB (Lelystad, Prionics, Netherlands); both at a final 
concentration of 10µL, as well as a peptide cocktail of ESAT-6/CFP-10 at a final concentration 
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of 5ug/ml (Lionex, Germany), a mitogen positive IFN-γ control of phorbol myristate acetate 
plus calcium ionophore (PMA/Ca, Sigma, UK, 50ng/ml and 1µg/ml respectively), and finally a 
complete culture medium only (i.e. negative) control.  
Cells were incubated for four days at 37oC/5% CO2, after which the supernatants were 
removed for quantification of IFN-γ by ELISA. Supernatants were either directly assayed or 
stored at -80oC until required. The IFN-γ ELISA was conducted using a commercially available 
canine specific ELISA kit (DY781B, R&D Systems, Europe Ltd., UK) according to the 
manufacturer’s instructions.  
Supernatant from each cell culture condition was assayed in duplicate. Optical density (OD) 
values were measured at a wavelength of 450nm and 630nm; the replicate OD (450nm-
630nm) values for each condition were averaged to give the final OD values and standard 
deviations were calculated. Where replicates differed by more than 30% from the mean, the 
test was considered invalid.  
During the outbreak, a prospective case definition was set to determine which hounds would 
be considered IGRA test positive (O’Halloran et al. 2018). It was determined that a statistically 
significant response to any of the three test antigens (PPDB, PPDA or ESAT6/CFP10) above 
the negative condition (media control) was indicative of a biologically significant T-cell 
response. The responsiveness threshold for each dog was defined as the mean OD value of 
the media negative control plus two standard deviations (2SD). The mean antigen-specific 
response minus two standard deviations must exceed this for response to be considered 
positive test (i.e. there must be non-overlapping 2SD). Similarly a PPDB-biased response was 
one where the mean PPDB response minus 2SD was greater than the mean PPDA response 
plus 2SD. For the test to be considered valid, the PMA/Ca (sample positive control) response 
must also be positive by the same criteria when compared to the negative sample control. As 
many of the PBMC positive control and antigen specific response values were above the linear 
range of the test kit standard curve, the OD values were used for test result interpretation. 
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7.2.3 TNF-α assay 
The concentration of TNF-α was measured in PBMC IGRA supernatants. Cell supernatants 
from a randomly selected subset of 45 dogs from the HRG were assayed by commercial ELISA 
(DY1507, R&D Systems, Europe Ltd., UK) according to the manufacturer’s instructions. Since 
PMA/Ca stimulation, as used as a positive control for the production of IFN-γ from lymphocytes 
in the IGRA, did not induce TNF-α in any dog sample tested, and antigen-specific TNF- 
responses were observed, Concanavalin A (ConA) was added to the positive control mitogen 
mix in a supporting experiment using three healthy dogs (from the TB-free blood donor subset, 
Table 7.1). The PBMC were isolated and incubated with PMA/Ca in the same conditions as 
described above but with the addition of ConA at a final concentration of 25µg/ml. After 
incubation for four days at 37ºC/5% CO2, the culture supernatant was assayed for TNF-α and 
IFN-γ by ELISA following the manufacturer’s instructions.  
Samples from the selected 45 dogs were interpreted as positive where the mean antigen-
specific TNF-α response minus 2SD was greater than the mean media sample negative 
control plus 2SD. Similarly a PPDB-biased response was one where the mean PPDB 
response minus 2SD was greater than the mean PPDA response plus 2SD.   
7.2.4 IGRA using antigen stimulated whole blood  
To compare the diagnostic results of whole blood and PBMC stimulation assays, a whole blood 
assay was conducted on the same subset of 45 dogs in the HRG tested in Section 7.2.3. 
Whole blood stimulation was performed using heparinised whole blood. One millilitre of 
heparinised whole blood was added to each of five separate wells of a 12-well tissue culture 
plate (ThermoFisher Scientific, USA) to which the following had been added; (a) 25µL 
phosphate-buffered saline (PBS, pH 7.2) (b) 25µL PMA/Ca (Sigma, UK) to a final 
concentration of 50ng/ml and 1µg/ml respectively (c) PPDA or PPDB, to a final concentration 
of 10µg/mL (Lelystad, Prionics, Netherlands), (d) 25µL of purified ESAT-6 to a final 
concentration of 5µg/ml and (e) 25µL of combined ESAT-6/CFP-10, to a final concentration of 
5µg/ml each. The plates were incubated overnight (approximately 16 hours) at 37ºC/5% CO2. 
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The following day, the plates were centrifuged at 800 x g for 15 minutes and the plasma was 
removed from the cellular fraction before being stored frozen at -80ºC. The concentration of 
IFN-γ in the samples was subsequently determined by ELISA (DY781B, R&D Systems, 
Europe Ltd., UK). Plasma samples from each condition were assayed in duplicate. The mean 
replicate OD (450-630nm) values were used to determine the concentration of IFN-γ against 
a recombinant canine IFN- standard curve (R&D Systems) and values are reported in pg/ml.  
7.2.5 Serological testing with commercial tests; the DPP VetTB Assay and 
Idexx M. bovis antibody ELISA 
Sera from each of the 163 HRG dogs and the 45 sera from TB-free dogs were tested by Dr 
Shelley Rhodes (APHA) using the DPP VetTB test (Chembio Diagnostic Systems, Inc., 
Medfords, New York, USA) as previously reported (O’Halloran et al. 2018). Briefly 30l of 
serum was applied to a single cassette and washed across two antigen lines (MPB83 and 
ESAT-6/CFP-10) with the kit buffer. After five minutes a further buffer application was applied 
as per the manufacturer’s instructions to wash the colloidal gold detecting reagent across the 
antigen and test control lines. After 15 minutes each cassette was visually inspected for QC 
purposes (to confirm the presence of a visible positive control line) and the antigen-specific 
antibody binding was quantified by inserting the cassette into an optical reader (Optricon DPP 
Reader, Chembio) which measures the reflectance of the response produced to both antigens, 
MPB83 and ESAT-6/CFP-10, individually as relative light units (RLU).   
Sera from the same animals (HRG and TB-free) were also tested by Dr Rhodes using the 
Idexx M. bovis antibody (Ab) ELISA (Idexx Laboratories, Inc., Westbrook, ME), performed with 
minor modifications to detect canine antibodies. ELISA plates pre-coated with mycobacterial 
antigens (MPB83 and MPB70) were supplied by Idexx, together with positive and negative 
controls and a secondary antibody to bovine IgG antibody. The kit secondary antibody, while 
retained for the kit-positive and -negative bovine plate controls, was replaced with Protein-G 
conjugated to horseradish peroxidase (HRP) which binds the constant region of antibodies of 
numerous species. Serum samples were diluted 1:50 and added to the ELISA plate in 
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duplicate, together with plate positive and negative controls, and ELISA plates were incubated 
for one hour at room temperature. Plates were washed with wash buffer (supplied with the kit), 
and then incubated with Protein-G-HRP for 30 minutes at room temperature and then washed 
again. Substrate (supplied with kit) was added to each well (100µL per well), the plates were 
developed for 15 minutes at room temperature, and the reaction was stopped by adding 100µL 
per well of stop buffer (supplied with kit). Absorbance values were read at 450nm as per the 
manufacturer’s instructions and the mean of each sample replicate calculated as a final OD 
value test result.  
The HRG and TB-free group results were compared by Mann Whitney U test with a P value 
of less than 0.05 considered to be significant.  
7.2.6 Serological testing by in-house comparative PPD ELISA 
ELISA test plates (NUNC Maxisorp Immmunoplate F96, Scientific Laboratory Supplies Ltd., 
UK) were coated with 100µL of test antigen (PPDA or PPDB) diluted to 10µg/mL in carbonate-
bicarbonate buffer (pH 9.6, Sigma Aldrich, UK). Plates were sealed and incubated at room 
temperature (RT) overnight. Plates were washed with PBS containing 0.05% Tween 20 and 
were blocked for one hour at RT with blocking buffer comprised of 4% bovine serum albumin 
(BSA; Sigma Aldrich, UK) in PBS. Serum from each dog (HRG, n=163 and TB-free, n=45) was 
diluted 1:50 in 2% BSA in PBS. After the plates were washed, 50µL of diluted serum was 
added to test wells in duplicate, blocking buffer was added to two wells on each plate (blank 
control). Plates were sealed and incubated at RT for two hours. Plates were washed again 
and 50µL of detection antibody (HRP-conjugated goat-anti-canine IgG; Euroimmun, Lübeck, 
Germnany) was added to each well and incubated for 45 minutes at RT. Following incubation, 
plates were again washed and 50µL of 3,3’,5,5’-tetramethylbenzidine (TMB; Sigma Aldrich, 
UK) added. After a 15 minute incubation, 25µL of 2M H2SO4 stop solution was added.  
Absorbance was read at 450nm and 630nm, test results for each dog were calculated as mean 
OD (450-630nm) of replicate wells with the mean OD (450-630nm) of blank control wells from 
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that plate subtracted. For the comparative test, the final OD value for PPDA was subtracted 
from the value for PPDB, giving an overall PPD OD value.   
The HRG and TB-free group results were compared using Mann Whitney U test with a P value 
of less than 0.05 considered to be significant.  
7.2.7 Serum IFN-γ and TNF-α ELISA 
Serum  from sampled dogs (HRG, n=163 and LRG, n=45) was assayed for IFN- and TNF- 
by commercial ELISA as described above (Sections 8.2.2 and 8.2.3); 50µL of serum diluted 
1:10 in PBS was assayed in duplicate for each dog. The calculated OD value (mean of the 
replicate OD (450-630nm) values) was used to determine the concentration of IFN-γ or TNF-
α respectively, against the standard curves. Values were calculated in pg/mL; the results were 
statistically compared by Mann Whitney U test with a P value of less than 0.05 considered to 
be significant.      
7.3 Results 
7.3.1 IGRA and TNF-α PBMC stimulation assays 
In total, 164 dogs at high risk of subclinical M. bovis infection were tested by PBMC IGRA, 
results are shown in Figure 7.1a. Only 11 tests failed and required repetition to provide a viable 
result; the most frequent reason for this (n=6) was that there was a statistically insignificant 
response to the PMA/Ca positive control; in some cases there was clotting of the blood sample 
which precluded the isolation of PBMC (n=4), and one test required repetition due to significant 
disagreement between replicate ELISA values.  
Of the 164 high risk dogs, 85 (52.0%) were found to be test positive by the case definition 
(positive to any of PPDA, PPDB or ESAT-6/CFP-10). Seventy seven (90.1%) of these dogs 
displayed a significant response bias to PPDB over the PPDA response, i.e. 47% of all HRG 
dogs tested displayed a response pattern indicative of MTBC infection. Within this group of 77 
dogs, 48 (62.3%) also responded to the ESAT-6/CFP-10 combination, i.e. a response pattern 
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highly suggestive of M. bovis. In addition, five test positive individuals responded to ESAT-6 
and CFP-10 and no other test antigens whilst another three responded only to PPDA.  
The IGRA results for the 74 LRG and TB-free dogs are shown in Figure 7.1b. Among these 
dogs 14 (19.4%) showed a significant antigen-specific response according to the case 
definition (positive to any of PPDA, PPDB or ESAT-6/CFP-10). However, in contrast to the 
HRG, 12 (85.7% of these 14) of these responses were biased to PPDA compared to PPDB, 
suggestive of exposure to/infection with environmental mycobacteria rather than MTBC 
species. Only two animals in this group showed a positive bias to PPDB above PPDA, 
indicative of MTBC infection, suggesting a test specificity might be 97.3%. Neither of these 
dogs responded to the ESAT-6/CFP-10 peptides. Retrospective investigation identified that 
these two dogs had been previously cohabitant with the HRG. Were these dogs to be removed 



















































































































































Figure 7.1: Results of the PBMC IGRA test for 164 HRG (Δ) (Fig. 7.1a), and 32 dogs from the 
LRG (○) and 42 from the TB-free group (□) (Fig. 7.1b) dogs. Each symbol shows the mean 
OD value of duplicate IFN- ELISA absorbance measurements for an individual dog. Solid 





The PBMC culture supernatants from 45 of the HRG dogs were assessed for antigen-specific 
TNF- (Figure 7.2). Three of the 45 dogs had statistically significant quantities of TNF-α in the 
supernatant of cells stimulated with PPDB compared to the negative control condition. The 
same three animals, along with an additional 25 individuals, were found to have significant 

































































Figure 7.2: Results of TNF-α ELISA conducted on the same PBMC supernatant as the IGRA 
tests in a randomly assigned sub-group of 45 high risk group dogs. Each symbol shows the 
mean OD value of duplicate TNF-α ELISA absorbance measurements for an individual dog. 
Solid symbols show a positive test to ESAT-6/CFP-10 or where PPDB>PPDA. 
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Comparing the concentration of antigen-specific TNF-α produced in response to ESAT-6/CFP-
10 stimulation only with the overall IGRA results (positive with either a PPDB bias or ESAT-
6/CFP-10 response), showed that these two tests, interpreted in parallel, identified 29 (64.4%) 
test positive and 16 test negative individuals. These tests showed very strong agreement 
(Cohen’s kappa coefficient, κ, =0.83).      
However, the mitogen PMA/Ca used as a sample positive control for the IGRA test did not 
stimulate the production/secretion of canine TNF-. As the HRG dog stimulations could not 
be re-run to include an additional mitogen, we compared the IFN- and TNF- production from 
three healthy dog PBMC samples stimulated with a cocktail of PMA/Ca and ConA. In this 
instance TNF-and IFN-were both produced (Figure 7.3). Therefore the lack of TNF- 
response to the PMA/Ca positive control in the HRG group does not invalidate the positive 
antigen-specific responses observed to PPDB and ESAT-6/CFP10, rather it indicates that the 
positive control was not optimal and that future assays to measure this, and potentially other 
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Figure 7.3: Concentration (replicate mean; error bars show standard deviation) of TNF-α (left) 
and IFN- (right) produced by PBMC stimulated for four days at 37ºC/5% CO2 with 
PMA/Ca/ConA. Addition of Con A to the mitogen mix induced TNF- in all three dogs, whereas 
all previous PBMC incubations with PMA/Ca did not induce detectable TNF-. 
The same subset of 45 HRG dogs was tested using a whole blood IGRA (Figure 7.4). Overall 
responses were low, with three individuals showing responses indicative of MTBC infection 
(PPDB>PPDA), two of which also showed responses to peptide cocktail and ESAT-6 protein. 
Comparing these results with those from the PBMC IGRA showed poor agreement between 
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Figure 7.4: Results of the whole blood IGRA test for a randomly assigned sub-group of 45 of 
the high risk group of 164 dogs. Concentrations are calculated using the mean of duplicate 
IFN- ELISA absorbance measurements against the standard curve. Solid symbols show a 
positive test to ESAT-6/CFP-10 peptides or ESAT-6 or where PPDB>PPDA. 
7.3.2 Serological Assays 
The Idexx M. bovis Ab ELISA (Figure 7.5) showed a statistically significant difference between 
the OD values for the HRG (n=163) and TB-free (n=45) dog groups (Mann Whitney U = 880.5, 
P<0.001). In deciding upon a preliminary test cut-off for the canine samples tested with the 
Idexx M. bovis Ab assay, we took into account both the cattle Idexx test protocol and the 
modified Idexx test as applied to camelid TB testing at APHA, both of which approximate to 
an OD cut-off value of 0.3 to provide high test specificity. Application of a cut off value of 0.3 
to the canine samples tested with the Idexx M. bovis Ab test, the data resulted in 100% test 
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Figure 7.5: Serology results for dogs in the high risk group (HRG, n=163) and TB-free group 
(n=45) obtained using the Idexx M. bovis Ab test. Results shown are the mean OD values of 
duplicate measurements for individual dog samples at 450nm absorbance. The test-positive 
cut off value of OD 0.3 is shown by a horizontal line. Solid symbols show test-positive samples. 
The DPP VetTB test (Figure 7.6) showed significantly higher RLU results for the HRG 
compared to the TB-free dogs (Mann Whitney U = 2731, P=0.003). In deciding upon 
preliminary cut-offs for the MPB83 and ESAT6/CFP-10 antigens in this test, a preliminary ROC 
analysis for the MPB83 RLU values suggested a cut-off of >95 to provide a specificity of 100%. 
A similar analysis for ESAT-6/CFP-10 was not viable due to the very low number (n=2) of sero-
positives; however, there was a clear divide between these two sero-positives and test-
negatives, of between 40-80 RLU, therefore >60 RLU was chosen as the cut-off for the ESAT-
/CFP-10 antigen line for the purpose of this study. Applying these cut-offs to the study cohorts 
provided a 100% specificity, and identified 11 HRG dogs (6.7%) as test-positive; nine of these 













































1 0 0 0




F IG .6  -  D P P  V e tT B  a s s a y
M P B 8 3  c u t-o ff
E 6 /C F P  c u t-o ff
 
Figure 7.6: Serology results for dogs in the high risk group (HRG, n=163) and TB-free group 
(n=45) obtained using the DPP VetTB Assay. Results given as Optricon relative light units 
(RLU). The test-positive cut off values for each antigen are shown by the horizontal lines at 95 
RLU for MPB83 and 60 RLU for ESAT-6/CFP-10 (E6/CFP). Solid symbols indicate a positive 
sample. As the axis is logarithmic, only values greater than zero can be plotted. For this graph, 
291 values overall were zero or negative and are therefore not included on the graph. 
The comparative ELISA (Figure 7.7) found generally higher responses to PPDA than to PPDB 
in the TB-free population. The test cut-off was calculated as the mean OD [PPDB-PPDA] of 
the TB-free group plus three standard deviations, providing a cut-off value of 0.14. Using this 













































Figure 7.7: Serology results for dogs in both the high risk group (HRG, n=163) and TB-free 
group (n=45) obtained using a comparative PPD antibody ELISA. Results shown are mean 
values of duplicate measurements calculated by subtracting the PPDA OD480-630 from the 
PPDB OD480-630 values. The test-positive cut off (OD 0.14) is shown by a horizontal line. Each 
symbol represents one dog sample. Test-positives are shown as solid symbols. 
7.3.3 Serum IFN-γ & TNF-α ELISA  
No statistical difference was found between the quantities of either TNF-α or IFN-γ present in 
the peripheral circulation of the dogs comprising the HRG and LRG (data not shown).  
7.3.4 Haematology and Serum Biochemistry 
Standard haematological and serum biochemical analysis was conducted on samples 
collected from half (n=83) of the HRG dogs, selected at random. The only haematological 
abnormality identified frequently was an increase in the total leukocyte count (n=22, 26.5%); 
in most cases this was due to the presence of a mature neutrophilia (n= 18, 81.2%) while band 
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neutrophils were also present in a minority of cases (n=4, 4.8%). One dog was found to have 
each of eosinophilia, monocytosis and reticulocytosis.  
Only five dogs of the 83 tested (6.0%) were found to have all serum biochemical tests within 
the reference interval (RI). The most frequently detected abnormality was elevated serum urea 
which was above RI in 44 of the dogs (53.0%), three of which also had elevated bile acid 
concentrations. Total calcium was low in 18 samples (21.7%) whilst alkaline phosphatase 
(ALP) activity was reduced in 25 samples (30.1%) and increased in six. More than a quarter 
(22, 26.5%) of dogs were found to have elevated globulin levels; 20 of them were elevated 
enough to increase the total protein concentration of the serum to greater than RI with normal 
albumin concentrations. No association was found between these changes and the results of 
the other tests.  
7.4 Discussion 
Almost every species of mammal, including the domestic dog, is susceptible to infection with 
MTBC organisms, including M. bovis (Brosch, 2002; Drewe, 2010; Miller, 2012; Parsons, 
2013; Angkawanish, 2013). Canine disease due to M. bovis has been documented in a 
number of clinical case reports over many decades, with several reports demonstrating inter-
species transmission, including to and from humans (Snider, 1971; Liu, 1980; Gay, 2000; 
Ayele, 2004; Ellis, 2006; Van Der Bürgt, 2009; Shrikrishna, 2009; Posthaus, 2011; Pesciaroli, 
2014; Park, 2016, Szaluś-Jordanow, 2016). Despite this, ante-mortem diagnostic testing for 
TB in the dog is limited. There is a single study describing the use of an IGRA for the detection 
of M. tuberculosis in a group of 40 dogs living in close contact with sputum-positive pulmonary 
TB owners (Parsons et al. 2012).  To our knowledge, no other ante mortem tests have been 
evaluated as effective for the diagnosis of canine MTBC infections; intradermal TST for both 
M. bovis and M. tuberculosis is unreliable, as are complement fixation and haemagglutination 
methods (Snider et al. 1971; Snider et al. 1975; Parsons et al. 2012 Broughan et al. 2013b).  
In the UK, M. bovis infection is endemic, with the highest prevalence in the counties comprising 
the HRA, and lower but still significant prevalence within the Edge Area, defined by the 
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incidence of bovine infections. In these areas many species other than cattle are also infected 
with M. bovis and it was from within the Edge Area that we previously reported an outbreak of 
M. bovis disease in a pack of kennelled foxhounds (Delahay et al. 2002, O’Halloran et al 2018). 
The lack of reliable diagnostic assays meant that the prevalence of subclinical M. bovis 
infection within the group of exposed animals was challenging to determine, and potentially 
led to the outbreak lasting longer, and costing more to bring under control, than if such a test 
or tests had been available.  
To begin to address this shortcoming, we have in this study applied commercially available 
tests produced for other species (Idexx for cattle, DPP VetTB for cervids) with an in-house 
serology test, and cellular cytokine release assays (IFN- and TNF-) using commercial 
reagents, for their ability to detect subclinical infections in dogs from both high and low 
expected prevalence populations. All of the tests chosen evaluate the host immune response 
rather than relying on direct pathogen identification or isolation. Previous studies have 
demonstrated that the major immunological consequences of MTBC infections are broadly 
conserved across host species (Cousins and Florisson, 2005; Broughan, et al. 2013b). Once 
mycobacteria are phagocytosed, macrophages and dendritic cells present antigen from lysed 
bacilli to CD4+ and CD8+ αβ as well as γδ T-cell subsets in the context of cell surface MHC 
class II molecules. The reciprocal activation between cells of these immunophenotypes, 
through the secretion of IFN-γ and TNF-α along with other cytokines, generates the classical 
cell mediated response required for the control of an intracellular pathogen.  
The first diagnostic test we assessed was an adapted IGRA, identifying animals with IFN-γ 
producing antigen-specific T-cells. Similar to domestic cats, lion, alpaca and other new world 
camelids, we found that it was necessary to isolate PBMC prior to antigen stimulation in order 
to reliably generate interpretable test data under these conditions (Hesketh et al. 1994; 
Gutierrez et al. 1998; Cousins and Florisson, 2005; Rhodes et al. 2008a; Leem et al. 2018). 
This was due to the failure of cells within the whole blood of these species to respond 
significantly to either positive control or antigen stimulation, unlike the whole blood responses 
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observed in cattle, goats and humans (Vordermeier et al. 2006; Vordermeier et al. 2007; Bezos 
et al. 2018; Leem et al. 2018).   
Examining the responses generated by the HRG dogs, we found that 77 (47.0%) showed a 
PPDB biased response indicating subclinical MTBC infection; compared to the LRG groups 
where only two animals (2/32, 6.3%) showed this response; interestingly, these were the two 
dogs most in-contact with the HRG hounds whilst no animals in the TB-free group showed an 
MTBC response. These results suggest this test method and interpretation has a high 
specificity of 97.3-100%, which is within the range of 90-100% consistently reported for IGRA 
assays in cattle, cats and goats (Vordermeier et al. 2006; Rhodes et al. 2012; Bezos et al. 
2018). Of the 77 HRG dogs showing a PPDB biased response, 62% simultaneously showed 
a significant response the ESAT-6/CFP-10, strongly suggestive of infection with an RD-1 
positive MTBC organism; this is slightly lower than the proportion reported for  both cattle 
(~85% in the high specificity IGRA where both PPD and peptide must be positive, and 82% 
for peptide alone as a diagnostic, Vordermeier et al., 2016) and cats (80% but only ten cats 
were tested, Rhodes et al., 2011). This difference may reflect a lesser immunological 
significance of these antigens in canine infections and/or may be an artefact of the unknown 
incubation time from infection to blood sampling in the HRG dogs; had infections been allowed 
to continue to incubate, the number of dogs responding to these peptides may have increased.    
A further five dogs in the HRG only responded to the peptide cocktail ESAT-6/CFP-10. With a 
lack of an antigen-specific PPDB response, it is questionable whether these animals are truly 
infected with M. bovis or not, since some NTM (notably M. kansasii and M. leprae, among 
others), encode orthologs of these proteins, and as the HRG in this study comprised working 
Foxhounds there was significant potential for them to be exposed to/infected with confounding 
NTM.  However, infected cattle are known to respond to ESAT6/CFP-10 in the absence of a 
positive PPD response, and in a setting of confirmed M. bovis infection such as the HRG dogs, 
a positive response to these peptides suggests an individual at high risk of being infected. 
Furthermore, no animals in the LRG/TB-free groups demonstrated ESAT-6/CFP-10 
responses, despite many having similar opportunity for NTM sensitisation as the HRG. So, 
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whilst the potential for confounding influence of NTM is important for interpreting individual 
animal responses, at a group level the data presented here would suggest that a response to 
ESAT-6/CFP-10, even alone, is sufficient to indicate high risk of M. bovis challenge.  
In our previous assessment of test responses, individual dogs with a significant response to 
any test antigen were considered test-positive (O’Halloran et al. 2018); this included three 
dogs that responded to PPDA alone. Analysis of the LRG tests found that this response 
occurred in 12 of the 74 dogs (16.2%) suggesting that this should not be seen as indicative of 
being at risk of M. bovis infection. Therefore, the definition of IGRA-positive animals in the 
context of subclinical M. bovis infections, should be revised to consider only individuals that 
show a statistically significant response above the media control to PPDB that is greater than 
the PPDA response, and/or those who respond significantly to the ESAT-6/CFP-10 
combination. 
The diagnostic sensitivity of assessing antigen-specific TNF- responses has only recently 
been tested clinically and on relatively small populations of M. tuberculosis-infected people, 
with inconclusive results; however, it shows promise for discriminating between active and 
latent disease (Harari et al. 2011; Wang et al. 2013). The approach we used, combining two 
ELISA cytokine measurements (IFN- and TNF-) on the same stimulated cell supernatants, 
identified additional test-positive individuals suggesting that a dual cytokine test approach may 
have a higher diagnostic sensitivity without the need to take any additional blood from the 
animals being tested. However, going forward there would need to be a modification of the 
positive mitogen control to include ConA, since PMA/Ca alone did not stimulate canine TNF-
 release.   
The detection of specific antibody responses has been useful in the development of new 
diagnostic tests for mycobacterial infections, particularly for species where repeat capture of 
the same individual at a fixed time point is difficult, and therefore precludes the use of TST 
(Gao et al. 2007; Lesellier et al. 2008; Bezos et al. 2018) or where reagents for IGRA tests are 
304 
 
not available. We therefore examined the antibody responses of dogs using a combination of 
serological tests already in use for other species.  
As expected, the total number of test-positive animals identified by the serological assays was 
significantly lower than for the PBMC IGRA; 16.5%, 7.4% and 6.7% for PPD ELISA, Idexx 
ELISA and DPP VetTB tests respectively, compared to 52% IGRA-positive in the HRG dogs).   
However the simplicity of the antibody tests compared with the IGRA test does provide relative 
speed and a lower test cost compared to the IGRA, which could facilitate an initial blood test 
screening of large numbers of animals in confirmed breakdown situations, and/or provide a 
serological option where blood sampling and rapid, temperature controlled transport (for IGRA) 
may not be possible.  
Of the three antibody tests the comparative PPD ELISA found a much higher number of test-
positive dogs, 27 compared to 12 (Idexx) and 11 (DPP VetTB). Whether this is due to PPD 
providing the largest epitope repertoire of all assays tested, or whether the test cut-off is not 
optimal remains to be explored. Many LRG/TB-free dogs had a PPDA-biased response 
resulting in a very low test-cut-off (0.14) compared to the Idexx ELISA (cut-off 0.3). However, 
25 of the 27 comparative PPD positive dogs were positive to at least one other test (PMBC 
IGRA [20], DPP VetTB Assay [7] and/or Idexx ELISA [6]) and so this does provide confidence 
in the PPD ELISA results. 
Evaluating all of the test responses for each individual dog, it became clear that a small 
minority of individuals showed much higher responses to the tests than the rest of the test 
positive population on each assay. Further examination showed that this was consistently due 
to three individuals for the cell based and cytokine assays, and a single individual for the 
antibody based assays. The relevance of the magnitude of this test response is unclear. There 
is conflicting evidence in the scientific literature as to whether the concentration of cytokine in 
serum and/or produced in in vitro diagnostic assays is proportionate to the severity or 
progression of clinical disease in vivo (Hasan et al. 2009; Ruhwald et al. 2009; Jonnalagadda 
et al. 2013; Xu et al. 2018), whilst there is some evidence indicating that ESAT-6/CFP-10-
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specific IFN-γ responses correlate with disease severity in cattle (Vordermeier et al. 2002) and 
that the titre of detectable antibody correlates with the occurrence of a lesioned phenotype 
(Roos et al. 2016). This may be true for dogs; however, data in this study did not support this 
view, possibly because of to the subclinical nature of the HRG tested. 
Haematological abnormalities were identified infrequently in the 83 dogs in the HRG that were 
tested. The high total leukocyte counts, mature and band neutrophilia seen in a small number 
of dogs did not correlate with any of the mycobacteria-specific diagnostic tests; they probably 
reflect an unknown inflammatory stimulus in these dogs.  
Serum biochemistry of the same dogs revealed multiple frequent abnormalities. The most 
frequent, elevated urea concentration, likely reflects the high protein diet of the working hounds 
as they were fed raw meat, rather than any underlying pathology. Half of the 22 dogs with 
hyperglobulinaemia were also found to be positive to at least one of the serology assays 
indicating that in some cases hyperglobulinaemia may have been related to the presence of 
antigen-specific antibodies. However, the overall specificity of hyperglobulinaemia with 
respect to the remainder of the tests was poor.  
This study was unable to evaluate test sensitivity as too few confirmed infections were 
identified – in total seven confirmed clinical cases of M. bovis infection occurred during the 
course of the kennel outbreak. Due to the severity of the disease, these affected animals were 
euthanased on welfare grounds before diagnostic blood samples could be taken. The 
diagnosis of M. bovis infection in these animals was confirmed by mycobacterial culture of 
visibly lesioned tissues collected post-mortem in each of these cases. The rate of false 
negative test results (type II error) in this study is therefore also unknown.   
In summary, this study demonstrates, for the first time, the utility of two cellular (IGRA and 
TNF-) and three serological assays (DPP VetTB, Idexx and comparative PPD ELISA) for 
detecting sub-clinical M. bovis infections of dogs. Whilst the data suggest high test specificity 
for all assays evaluated, further work is needed to robustly validate the specificity of the tests, 
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Chapter 8: Bayesian Latent Class Estimation of the 
Performance Parameters of Diagnostic Tests to 
Identify Mycobacterium bovis Infected Dogs. 
Abstract 
There are currently no diagnostic tests available for the ante-mortem identification of 
Mycobacterium (M.) bovis infections in domestic dogs (Canis lupus familiaris). We previously 
reported the use of a combination of eight tests to identify infected individuals during an 
outbreak of M. bovis tuberculosis in a pack of Foxhounds (Chapters 5 and 7); four of these 
tests were shown to be promising for the detection of infected animals. A retrospective 
Bayesian latent class analysis of the combined four test results of 164 hounds was conducted 
in order to estimate the sensitivity, specificity, positive and negative predictive values of each 
test as well as the prevalence of infection in the pack. The cell-based interferon gamma release 
assay (IGRA) was shown to be the most sensitive test and had the highest positive and 
negative predictive values with moderate specificity. The three serological assays were shown 
to have higher specificities but lower sensitivities than the IGRA. Of the serological tests, the 
comparative purified protein derivative (PPD) ELISA performed best for all parameters 
estimated, followed by the Idexx M. bovis Ab ELISA with the DPP VetTB assay performing 
least well. This differential performance between the cell-based IGRA and serological assays 
suggests that testing protocols combining both approaches may be most useful for identifying 
and controlling future outbreaks.The model was improved by the addition of informed priors 
but was not significantly affected by the inclusion of covariance between the serological 
assays. This study provides useful test performance data that could not have been derived 
using a traditional frequentist approach. Further work is now needed to improve the credibility 
of the initial estimates produced in this analysis by expanding the population of dogs with test 




Tuberculosis due to infection with Mycobacterium (M.) bovis is a chronic zoonotic infectious 
disease currently endemic among cattle and wildlife populations in England and Wales1-3. The 
major impact of infection is within the production cattle population and disease control 
measures cost the UK government in excess of £100 million annually3,4. Despite the 
implementation of a strict statutory testing policy, disease elimination has proven difficult; likely 
due to the complex and multifactorial nature of the host, pathogen and environmental 
interaction which results in disease transmission before infected animals can be detected3-5. 
Further to this, there are a number of significant maintenance and spill over hosts including 
the Eurasian badger (Meles meles)4, various deer species6,7, North American camelids8,9 as 
well as companion animals including both the domestic cat (Felis catus)10 and dog (Canis 
lupus familiaris)11. 
Recently, we investigated a large outbreak of M. bovis tuberculosis in a large working pack of 
Foxhounds in England12. At the time there was discussion in the veterinary and national press 
regarding whether working hounds contribute to the contamination with M. bovis of the 
environment where cattle and other susceptible species may be co-habitant or use as grazing 
pasture13-17. A complete and robust epidemiological investigation conducted jointly by our 
group and the Animal and Plant Health Agency (APHA) concluded that there was no evidence 
to suggest that dogs play a significant role in the persistence of M. bovis in England and Wales 
or that scent and drag hunting with dogs contributes to the spread of bovine tuberculosis 
amongst cattle or wildlife (reported in this thesis, Chapter 5)12.  
Whilst the risk posed by hounds was being evaluated, there was a concurrent time delay in 
establishing control over the outbreak as there are no validated ante-mortem diagnostic tests 
for canine M. bovis infections12. The only diagnostic test recognised in statute, and therefore 
the test designated as the ‘gold standard’, is post-mortem specialist mycobacterial culture of 
visibly lesioned (granulomatous) tissues18. However, the concept of a “gold standard” in this 
case can be considered misleading; the term was only intended to be applied to a test which 
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has (near) perfect performance relating to both sensitivity (Se) and specificity (Sp)19. Logically, 
the isolation of viable M. bovis organisms from lesions obtained from cadavers gives culture 
an assumed (near) perfect Sp for infection with that organism, provided rigorous laboratory 
protocols are in place to prevent sample contamination during handling. The Se of culture for 
canine derived samples has not been assessed, but in domestic cats the overall Se of all 
mycobacterial culture is under 50%20 whilst the Se of M. bovis culture is reported to be 
approximately 80% in cattle21. These data suggest that it may be inappropriate to refer to post-
mortem tissue culture as the ‘gold standard’ test in the outbreak of M. bovis studied herein. 
Furthermore, during the investigation, it was only practically possible to conduct post-mortem 
examinations on a subset of the hounds that were euthanased, meaning that in most cases 
‘gold standard’ test data were not available. In addition, in a number of samples no growth of 
M. bovis was observed from tissue samples after 16 weeks12 which is difficult to interpret for 
a test with unknown Se.  
Taking this into account made accurate estimation of the performance parameters for the 
testing strategy that we used challenging whilst relying on frequentist analytical methods to 
compare our results to mycobacterial culture. An alternative method for such an analysis in 
the absence of an appropriate or accurate gold standard test is to use a Bayesian latent class 
modelling approach22-24. This statistical methodology does not require the true infection status 
of an individual to be known but instead models this as a latent (unknown) variable along with 
the test performance parameters22-24. Methods adhering to a Bayesian rather than frequentist 
framework have been successfully utilised since the development of the two-test, two-
population model introduced by Hui and Walter in 198024. Since then, the World Organisation 
for Animal Health (the OIE) has encouraged the use of these models; particularly in cases, as 
presented here, where the acquisition of sufficient numbers of samples from animals of known 
infection-status would be extremely difficult due to the low prevalence of disease, where 
current gold standard diagnostic testing methods have known limitations and/or the 
experimental infection of animals to produce robust test performance data would be 
considered unethical25.  
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The methodology established by Hiu and Walter is dependent on the critical assumptions that; 
a) when comparing multiple populations, the underlying disease prevalence differs between 
them, but that b) the test performance is the same across them and, c) the (two) tests are 
conditionally independent from one another24. In our outbreak scenario, however, there was 
only a single epidemiological population without a second that we could be sure adequately 
satisfies these assumptions. This limitation is not uncommonly encountered when studying 
infectious diseases as it is inherently challenging to sample populations of animals which have 
differing infection prevalence but do not respond differently to the tests being conducted26. 
Therefore, an extension to the original methodology has been proposed whereby three or 
more tests are performed on a single study population26,27, an approach which has previously 
been adopted for the estimation of test performance relating to bovine M. bovis infections5.  
The aim of the study presented here was to analyse a panel of four tests that we have 
previously established as promising in their application to detect subclinical M. bovis infections 
in dogs using samples collected ante mortem28 (reported in Chapter 7) and employ a Bayesian 
latent class analysis to estimate the performance parameters (Se, Sp, positive predictive value 
[PPV] and negative predictive value [NPV]) of each test and the underlying infection 
prevalence in the population. 
We demonstrate that the cell-based interferon gamma release assay (IGRA) was shown to be 
the most sensitive test and had the highest positive and negative predictive values with 
moderate specificity. The three serological assays were shown to have higher specificities but 
lower sensitivities than the IGRA. 
8.2 Materials and Methods:  
8.2.1 Study Population & Test Data 
We previously investigated a fulminant disease outbreak caused by M. bovis infection within 
a large group of kennel-housed working Foxhounds in England12 (Chapter 5). A total of 164 
hounds were sampled over the course of the outbreak and so had test data available for 
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analysis in this study12. The samples were previously analysed using eight test protocols that 
were either previously developed for the detection of M. bovis infections in non-canid species 
or newly developed by our group12,28.  
We demonstrated that four of these assays produced results which overall gave were able to 
distinguish between high and low risk groups of individuals, indicating that they had good 
potential to be developed into diagnostic assays28. These included a cell-based interferon 
gamma release assay (coded here as “IGRA”), the Idexx M. bovis Ab ELISA (Idexx, USA; 
coded as “Idexx”), the DPP lateral flow VetTB Assay for Cervids (Chembio, USA; coded as 
“DPP”) and a newly developed comparative purified protein derivative (PPD) ELISA (coded as 
“CompPPD”)28.  
8.2.2 Bayesian Latent Class Analysis 
As previously described, we tested 119 M. bovis-free and M. bovis-‘low risk’ dogs using the 
same protocols as the high risk dogs in order to determine specific cut-off values for each test 
methodology28. We therefore ascribed each of the 164 hounds a binary positive or negative 
status for each of the four tests allocating each individual to one of 16 possible combinations 
of positive and negative test results.  
Bayesian latent class models were used to estimate diagnostic test Se, Sp, PPV, NPV and 
the prevalence of infection. The computations were implemented using WinBugs version 1.4.3.  
All models utilised a four-test one-population approach. As no data are available on the 
performance of these assays in domestic dogs, model one was coded (Appendix 2) to include 
uninformative flat uniform priors; beta (1, 1). Throughout the study all models were run for 
100,000 iterations with the first 5000 discarded as a “burn in”. Chain convergence after the 
initial burn-in was assessed by visual inspection of the Markov chain Monte Carlo outputs. 
For tests to be of potential benefit to clinicians, the PPV and/or NPV of a test needs to at least 
be greater than 50% (i.e. better than chance) or else no decisions can be made based on the 
test result. Subsequently to evaluating model one, informed priors were included into a second 
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model in order to improve the clinical utility of the posterior estimates. The values assigned 
were based on data obtained from a review of relevant bovine literature29-35. The sensitivity of 
IGRAs reported in the literature ranged from 55% to 93% with 74% most frequently reported 
and their specificity ranged from 89% to 100% with a consensus around 95%29-35. These 
values were converted into beta (15.04, 5.28) and beta (64, 3.7) values respectively; the beta 
distributions and designated initial values used for all parameters in model two are provided in 
Table 8.1.  Where published data were unavailable, such as for the in-house comparative 
ELISA, the posterior estimates obtained from model one were used as a priori information for 
models two and three.  
Table 8.1: The beta distributions and designated initial values for each variable used in models 




In models one and two, we had followed the implicit model assumption that the different tests 
are conditionally independent of one another. However, as three of the four tests are 
serological assays, albeit of different types, we included undefined covariance terms into 
model three to allow for possible interdependence between these test results to be accounted 
for. Model three included the same prior distributions as model two which are provided in Table 
8.1.  
Variable Beta Distribution  Initial value 
SeIGRA (15.04, 5.28) Se=0.74 
SpIGRA (64, 3.7) Sp=0.95 
SeDPP (1, 1) Se=0.65 
SpDPP (1, 1) Sp=0.98 
SeCompPPD (1, 1) Se=0.10 
SpCompPPD (1, 1) Sp=0.20 
SeIdexx (98.77, 261.40) Se=0.5 
SpIdexx (137.64, 6.81) Sp=0.97 
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8.3  Results 
Between December 2016 and August 2017 we tested a total of 164 Foxhounds kept at a single 
kennel premises to try and identify all of the individual dogs infected with M. bovis during a 
tuberculosis outbreak12. The combination and frequency of the results generated by the four 
testing protocols retrospectively analysed in this study are shown in Table 8.2.  
Table 8.2: Test result categories for the 164 dogs included in this study in descending order 
of frequency.  
IGRA Idexx Ab ELISA DPP VetTB 
assay 
Comparative PPD ELISA Frequency 
(Total = 164) 
Negative Negative Negative Negative 66 
Positive Negative Negative Negative 62 
Positive Positive Negative Negative 15 
Positive Positive Positive Positive 4 
Negative Positive Positive Negative 3 
Negative Negative Negative Positive 3 
Positive Positive Negative Negative 2 
Negative Negative Positive Negative 2 
Positive Positive Positive Negative 2 
Positive Negative Positive Negative 1 
Positive Negative Negative Positive 1 
Negative Negative Positive Positive 1 
Negative Positive Positive Positive 1 
Positive Positive Negative Positive 1 
Negative Positive Negative Positive 0 
Positive Negative Positive Positive 0 
The posterior parameter estimates for all three models generated in this study are provided in 
Table 8.3. In model one, the IGRA test had the greatest Se with a median posterior estimate 
of 51% (95% credibility interval [CrI] 42-59%). The IGRA and the comparative PPD ELISA 
were the only assays shown to have a clinically useful PPV, defined as greater than 50%, with 
a median estimate of 89% (CrI 69-96%) and 55% (CrI 5-79%); however, only the IGRA had 
the full 95% credibility interval above 50%. The Idexx M. bovis Ab ELISA was shown to have 
a specificity estimate of 56%, however the PPV (40%) and NPV (6%) estimates were too low 
for this to be considered a clinically useful test. All of the remaining test parameter estimates 
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in model one had posterior parameter estimates below 50% and broad credibility intervals 
which further indicated the need to include a priori information into the model. 
Table 8.3: Interferon gamma release assay (‘IGRA’), Idexx M.bovis Ab ELISA (‘Idexx’), DPP 
VetTB assay (‘DPP’) and Comparative PPD ELISA (‘CompPPD’) diagnostic test parameter 
estimation based on the test results of 164 individuals. Posterior parameter estimates are 
given as proportions. 95%CrI: 95% credibility interval, Se: test sensitivity, Sp: test specificity, 
PPV: test positive predictive value, NPV: test negative predictive value.  
Variable Model one Model two Model three 
 Mean Median 95% 
CrI 
Mean Median 95% 
CrI 
Mean Median 95% 
CrI 




















































































































Model two and three both included informed priors with respect to test performance. The 
parameter estimates generated from model two indicate, in agreement with model one, that 
the IGRA is the most sensitive of the tests analysed (median estimate 64%, CrI 51-90%) 
followed by the comparative PPD ELISA (median estimate 36%, CrI 10-77%), with the DPP 
lateral flow assay and the Idexx M. bovis Ab ELISA performing very similarly for this parameter 
estimate (DPP lateral flow median sensitivity estimate 15%, CrI 2-83%; Idexx M. bovis Ab 
ELISA median sensitivity estimate 14%, CrI 3-74%). By contrast, all three of the antibody 
detection assays were estimated to have greater specificities than the IGRA, which was 
estimated by this model to have a specificity of 55% (CrI 43-79%), ranging from 76-89% but 
with wide 95% credibility intervals such as 1-99% for the DPP lateral flow assay.  
In model two, all tests were shown to meet our definition of a clinically useful test. The model 
two analysis again showed that the IGRA was the best performing test with a PPV estimate of 
74% (CrI 39-98%) and a NPV estimate of 82% (CrI 8-99%). By these estimated performance 
measures the comparative PPD ELISA (PPV 63%, CrI 19-89%; NPV 67%, CrI 4-98%) and the 
Idexx M. bovis Ab ELISA (PPV 64%, CrI 35-92%; NPV 61%, CrI 4-98%) performed similarly 
to one another with the DPP lateral flow assay appearing to be the least useful with the lowest 
predictive value estimates (PPV 56%, CrI 17-96%; NPV 59%, CrI 4-98%).  
In model three, covariance terms were included to allow for the possibility of conditional 
dependence between the antibody-based test assays. Overall bivariate correlations were very 
low between these three assays (ρ=0.16, 0.17 and 0.26 respectively) and including the terms 
into the model did not significantly alter most of the posterior parameter estimates; only the 
sensitivity estimate of the IGRA increased to a median estimate of 77% (CrI 53-92%) while 
the remaining median estimate values remained within 5% of those generated in model two. 
Further comparison of the deviance information criterion (DIC) values between model two and 
three showed only a small change (less than three) indicating that the inclusion of the 
covariance terms did not significantly improve the fit of the model to the data.  
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8.4  Discussion  
Bayesian latent class analysis provides an accepted alternative methodology for estimating 
diagnostic test performance when an affordable, reliable and/or non-invasive reference 
standard does not exist23-27. These methods are particularly useful for cases of infectious 
disease which have long subclinical latent periods, such as tuberculosis; this is because the 
latent class models do not require the true infection status of any of the animals in the test 
population to be known22. The OIE has continuously endorsed the use of latent class models 
for the assessment of novel diagnostic test performance in animal populations in recent 
years25. Using this technique we modelled the test performance of four previously unevaluated 
diagnostic tests for their ante mortem accuracy to diagnose subclinical M. bovis infections in 
domestic dogs.  
All three of the latent class models that we developed during this study consistently showed 
that the cell based IGRA test had the greatest sensitivity for detecting subclinical infections. 
As an ex vivo T-cell stimulation assay, this IGRA test detects an antigen-specific cell mediated 
immune response to mycobacteria which is typically formed in response to intracellular 
pathogens including M. bovis36,37. The IGRA test assays are therefore considered to be both 
sensitive and relatively specific indicators of infection36,37. Model three produced a median 
posterior sensitivity estimate for the canine IGRA of 77% (CrI 53-92%) for the detection of 
subclinical M. bovis infections. This result is similar to those reported for the approved human 
test to detect both latent and active M. tuberculosis infections, the QuantiFERONTM-TB Gold 
IGRA test36,38,39. Two recent studies independently evaluated the Se and Sp of the 
QuantiFERONTM-TB Gold test comparing its performance to the gold standard of tuberculin 
skin testing and found it be 75% (95% confidence interval 53.1–88.8%) sensitive and 80% 
(95% confidence interval 64.1–90.0%) specific respectively38,39. In addition, a study evaluating 
the sensitivity of IGRA testing in cats for culture positive M. bovis infections, using almost 
exactly the same methodology as the test evaluated here, found the Se to be 80% compared 
to the gold standard of specialist mycobacterial culture40. It is not possible to compare these 
performance data to cattle sensitivity studies evaluating the BOVIGAMTM assay as recent 
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bovine sensitivity data was used as prior information to build model three. Overall therefore, 
this study demonstrates that the canine IGRA here performs in line with assays designed to 
detect tuberculous infections in other animals and can therefore be considered a sensitive test.  
This study also analysed the performance of three serological assays for their use in canine 
populations. Almost all antibody tests for the detection of M. bovis infections to date have 
suffered from a relative lack of Se in comparison to T-cell based assays because infected 
animals less frequently mount a significant humoral immune response to infection41-43. 
However, bovine data suggests that positive antibody test results can correlate with the 
presence of a visibly lesioned phenotype at post mortem carcass inspection and therefore 
likely reflect an animal which is not only infected, but also infectious to naïve animals and the 
environment that the animal is in42. A number of these heavily infected cattle will also not 
respond positively to the BOVIGAMTM test (an IGRA assay) due to T-cell anergy following 
prolonged antigenic stimulation42,43. Serological assays have additional technical advantages 
compared to IGRA tests in that they are simpler and are therefore quicker and cheaper to 
perform42,43. As well as this, because serological assays can be developed to include a small 
number of very specific antigen targets, the specificity of these assays can be greater than 
those seen for T-cell assays which frequently utilise antigen cocktails. These antigen cocktails 
may have shared epitopes with other mycobacteria which impedes the test specificity44. These 
factors mean that a combination of testing methods can be maximally effective in bringing M. 
bovis outbreaks under control, a strategy which has recently validated in an outbreak of M. 
bovis in cattle and goats45,46. Our previous study showed that the comparative PPD ELISA that 
we have developed identified the largest number of test-positive dogs of the serological assays 
tested with high Sp (set at 99% in that study). Here, we show that the same test retains a 
higher test Se than the other two serological assays with a median estimate of 32% (CrI 12-
74%) compared to the DPP lateral flow VetTB assay and the Idexx M. bovis Ab ELISA which 
performed approximately half as well with median Se estimates of 17% and 18% respectively. 
This suggests that a combination of the IGRA and the comparative PPD ELISA might be the 
most efficient combination of two tests to use when investigating any similar outbreaks in the 
future though further research would be needed to confirm this.  
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Both of the assays shown to be the least sensitive in this analysis have contrastingly been 
shown to have much greater sensitivities in the species for which they were originally 
developed for use. For example, the DPP lateral flow VetTB assay performed with a sensitivity 
of 84.6% in a group of naturally and experimentally infected red deer (Cervus elaphus)47 whilst 
the Idexx M. bovis Ab ELISA has a reported sensitivity of 63%48. The reasons for the 
differences in performance of these tests across the different species are not immediately 
obvious, however, the higher sensitivity of the comparative PPD ELISA which contains the 
greatest number of proteins suggests that the peptides included in the assays do not contain 
the immunodominant epitopes of M. bovis as recognised by the canine adaptive immune 
response. Therefore, the development of more sensitive serological assays will require greater 
interrogation of which antigen or antigen combinations are the most frequently recognised 
within M. bovis infected dogs.  
An approach of combining serological testing subsequent to intradermal tuberculin injections 
may further increase the sensitivity of serological assays, as has been shown in other 
species46,48, making this a useful area of focus for future research.  
As would be predicted, all three of the serological assays demonstrated high specificities with 
median posterior Sp estimates of 76%, 77% and 89% respectively. These Sp values were all 
higher than the Sp estimate of the IGRA, estimated at 59% (CrI 44-80%). However, though 
lower than the serological assays, the Sp of the IGRA is within the range of values that would 
be expected for T-cell test assays, for example it is not significantly different to the specificity 
reported for the QuantiFERONTM-TB Gold test in human populations with high tuberculosis 
burdens (70.8%; 95 % confidence interval 67.5–73.9 %)36,39.  
Because the data used in this study referred to a single outbreak we were able to estimate the 
prevalence of infection and we were also able to effectively estimate the positive and negative 
predictive values of the tests to give a clearer evaluation of the clinical utility of the tests.  
The median posterior prevalence estimate produced from models two and three was 55%; this 
is similar to the percentage of animals that tested positive to at least one of our diagnostic 
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tests in the original outbreak investigation12, however, this estimate was also linked to very a 
high degree of uncertainty with a 95% credibility interval of 5-96%. 
As would be predicted, the IGRA was found to have both the highest estimated predictive 
values of the tests studied (median PPV 75%, median NPV 82%) whereas the serological 
assays had lower predictive values and performed comparably with one another. The posterior 
parameter estimates for the PPV and NPV produced from model three indicated that all of the 
tests we evaluated in this study met the criteria for being clinically informative by having values 
greater than 50%. This further demonstrates that these tests have the potential to be used in 
the diagnosis of canine M. bovis infections. Further work is needed to build on this analysis; 
the estimates for most of the modelled parameters sit within relatively wide credibility intervals 
due to the small size of the population of dogs tested (n=164), these can be improved by the 
inclusion of additional test data and would particularly benefit from data from dogs of known 
infection status.  
8.5 Conclusion 
This is the first study to analyse the test performance parameters of a number of diagnostic 
tests to detect M. bovis infections in domestic dogs. These results show that the IGRA test 
has the greatest Se, SP, PPV and NPV of the tests evaluated, it therefore has the greatest 
potential to be useful as a clinical diagnostic test. The three serological assays had markedly 
reduced Se estimates compared to the IGRA but despite this all three had predictive values 
which indicate they also have potential for use as diagnostic test. The comparative PPD ELISA 
assay that we developed was shown to be the best performing of the serological assays, 
possibly due to the inclusion of a broader pool of antigens. The development of serological 
tests for canine M. bovis infections could therefore benefit from the identification of specific 
immunodominant antigens in dogs and their inclusion in any novel assay development. 
The use of a Bayesian latent class modelling approach was critical to this analysis given the 
lack of a gold standard test and that the true status of the individuals tested is unknown, 
however, it proved necessary to include informed priors to produce reliable posterior 
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parameter estimates. Future research evaluating the diagnostic test performance of these 
assays should include a greater number of animals, particularly those of known infection 
status, to establish greater credibility in the estimates produced. Additional work to assess the 
use of tests in combination with intradermal tuberculin injections may be beneficial to 
establishing the optimal testing strategies for future outbreak investigation and control. 
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Chapter 9: Characterising Antigen-specific Cytokine 
Profiles for the Diagnosis of Canine Mycobacterium 
bovis Infections.  
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Abstract 
Tuberculosis (TB) has been the cause of considerable morbidity and mortality in the human 
population and zoonotic TB caused by Mycobacterium (M). bovis is an increasingly recognised 
pathogen of domestic companion animals. There are currently no validated ante mortem tests 
to diagnose TB in dogs. We previously measured mycobacterial-antigen specific interferon 
gamma (IFN-γ) as a marker of infection in a group of M. bovis exposed Foxhounds. The 
measurement of cytokines in addition to IFN-γ has been shown to improve TB diagnostic 
sensitivity in other species. Therefore we assessed the cytokine profile of antigen-stimulated 
peripheral blood mononuclear cells derived from M. bovis infected and uninfected (control) 
dogs to determine whether this might be of diagnostic potential for dogs. Supernatants from 
antigen stimulated cells were assessed using the Milliplex MAP Canine Cytokine Magnetic 
Bead multiplex assay. The pro-inflammatory cytokines, IL-8 and keratinocyte-derived 
chemokine (KC) concentrations were not significantly different between infected and control 
dogs whilst three cytokines; TNF-α, IL-6 and IL-10 showed potential for use as canine TB 
diagnostic markers along with IFN-γ. Future work should focus on the in-field utility of these 
findings to establish diagnostic sensitivity and specificity of these markers. The study also 
identified a number of similarities in the cytokine profile of TB affected dogs when compared 
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with more commonly studied species such as humans and cattle, indicating that further work 
studying the kinetics of canine TB infections could have translational benefits. 
9.1 Introduction  
Tuberculosis (TB) has been the cause of considerable morbidity and mortality in the human 
population for centuries, and remains the leading cause of death from any single infectious 
agent (Mycobacterium (M.) tuberculosis) worldwide 1–3. Historically, the significance of this 
disease has resulted in extensive biomedical research interest and, due to the growing threat 
of drug resistance, TB is a major focus of collaborative global healthcare investment 4–8. 
Meanwhile, TB in domestic companion animals receives relatively little research attention, 
despite being more common and clinically significant than previously thought 9–11. In the UK, 
approximately 1% of all feline biopsies submitted for routine histopathological analysis show 
changes consistent with mycobacteriosis and a third of these contain Ziehl-Neelsen (ZN) 
positive organisms when stained, with morphology indicative of the presence of mycobacteria 
10,12. Culture results indicate that a third of these infections are tuberculous in cats 10,12, whilst 
equivalent data do not currently exist for dogs.  
The various mycobacterial species that have been identified in companion animals, including 
dogs, can be grouped into the same two major categories as human mycobacterial disease; 
those belonging to the Mycobacterium tuberculosis-complex (MTBC) and the non-tuberculous 
mycobacteria (NTM, also referred to as ‘atypical mycobacteria’ or ‘mycobacteria other than 
tuberculosis’, MOTT) 11,13–19. 
The MTBC consists of ten highly genetically related species of mycobacteria which are 
capable of causing TB in both man and other animals, and are some of the oldest recorded 
zoonotic diseases known to both human and veterinary medicine 20–26. All member species of 
the complex share identical sequences across the 16s rRNA gene and 99.5% sequence 
homology across the remainder of the genome 27. The most discriminating features between 
the species at the nucleotide level are genomic deletions, termed regions of difference (RD) 
28–31. The MTBC organisms which frequently infect dogs, M. tuberculosis and M. bovis, both 
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encode RD-1 12,32–34. This region is absent from M. microti and the vaccine strain; M. bovis 
bacille Calmette-Guérin (M. bovis-BCG) but present in all other MTBC organisms 28. It has 
been shown to encode a variety of molecules which act as virulence factors such as the 6kDa 
early-secreted antigenic target (ESAT-6) and 10kDa culture filtrate protein (CFP-10) 35–37.   
In companion animals, MTBC infections pose a potential zoonotic risk to their owners due to 
the close contact between owners and their pets and additionally these cases may act as 
potential sources of environmental contamination with mycobacteria such as M. bovis, a 
pathogen of major animal health significance in the UK as the causative agent of bovine 
tuberculosis (bTB) 38–41.  
Although relatively rare, in contrast to human TB cases, all clinical canine TB cases diagnosed 
in an outbreak in a kennel displayed advanced renal pathology (reported in Chapter 5) 71. Urine 
samples collected from these animals were shown to be culture positive for M. bovis which 
further increases the risk of environmental contamination and zoonotic transmission 71. 
Pulmonary lesions in dogs have been reported to result from bacteria being inhaled, causing 
typical tubercle formation in the lungs and peri-bronchial lymph nodes 9,14. Additionally, 
pulmonary disease is thought to occur secondarily to the putative haematogenous spread of 
bacteria from a site of inoculation elsewhere e.g. in the skin 12,14. This generates a diffuse 
interstitial pattern of disease which eventually becomes bronchial and is clinically observable 
as progressive dyspnoea followed eventually by a productive cough 14,34. Disseminated 
tuberculous disease has been reported to cause a range of clinical signs in dogs, including 
hepato-splenomegaly, pleural and pericardial effusions, generalised lymphadenopathy, weight 
loss and pyrexia 42.    
With such variable reported clinical presentations and non-specific clinical signs, diagnosing 
canine MTBC infections rapidly and accurately is challenging. Mycobacterial culture 
conducted by the Animal and Plant Health Agency (APHA), is currently the recognised ‘gold 
standard test’ for the diagnosis of mycobacterial disease in UK companion animals; however, 
it has several limiting features. Firstly, when feline submissions were analysed it was shown 
to have a relatively poor sensitivity of less than 50% 9,34,43. Secondly, it requires weeks from 
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the time that a contaminated tissue biopsy is submitted for results to be obtained e.g. the 
average culture time is 6-8 weeks for M. bovis 9,34,43. During this time, if untreated, a patient 
will remain a potential source of infection to both its owner and the local environment.  
As such, alternative diagnostic tests have been developed which aim to reduce the amount of 
time between clinical presentation and a definitive diagnosis being reached. Interferon-gamma 
(IFN-γ) release assays (IGRA) were developed on the principle of quantitatively evaluating 
IFN-γ production by peripherally circulating antigen specific effector T-memory cells upon in 
vitro stimulation, in order to aid the diagnosis of bTB in cattle 44–47. These have subsequently 
been adapted to identify both active and latent TB in human patients with greater sensitivity 
and specificity than the previously utilised tuberculin skin test 48–50. Where intra-dermal testing 
has been shown to be of unreliable clinical utility in the dog, the IGRA has been used 
successfully 14,46,71. IGRAs have several advantages over other diagnostic techniques; they 
are significantly quicker at generating results than culture and are cheaper than many 
commercially available PCR and subsequent sequencing methods, they are also relatively 
non-invasive requiring only a single peripheral blood sample 46,49. Unlike intra-dermal skin 
testing, they can be repeated if necessary as conducting the assay does not alter the systemic 
immune response 45,51,52.  
Recently within the field of human diagnostics of mycobacterial diseases, and of TB in 
particular, there has been a marked increase in research focus on the identification of cytokine 
biomarkers for the diagnosis of both active and latent infections 53–58. The goal of such assays 
is to cheaply, sensitively and rapidly identify infected and infectious individuals, in order to 
combat what remains one of the most incident infectious diseases of man 59. Such studies 
have utilised multiplex cytokine assays, most commonly Luminex xMAP technologies, with 
promising results 55,60,61. Studies of multiple assays have found cytokine concentrations and 
combinations of cytokines which can sensitively and specifically diagnose both active and 
latent TB in humans 53–58. For example; the concentration of IL-2 within the IGRA supernatant 
can be combined with circulating levels of IFN-γ to more accurately discriminate between 
active and latent TB states 58,62. Similar assays have also been used successfully in the study 
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of a limited number of companion animal diseases, including canine lymphoma, feline cystitis 
and feline mycobacterial infections (reported in Chapter 2) 63–66.  
As the timely and accurate diagnosis of canine mycobacteriosis as well as the identification of 
the causative species is currently challenging, the aim of this study was to evaluate whether 
cytokine profiling using supernatants from stimulated peripheral blood mononuclear cells 
(PBMC) in dogs would demonstrate the same clinical utility as has been shown for humans. It 
was hypothesised that a number of cytokines would be differentially detectable in samples 
from dogs infected with M. bovis compared to uninfected controls. Since previous studies have 
shown that a proportion of TB affected dogs had antibodies specific for M. bovis antigens 
(Chapters 5 and 7), this study analysed whether the cytokine profile also differed in these 
individuals.   
9.2 Materials and Methods  
This study was conducted with prospective approval from the School of Veterinary Medicine 
Ethical Review Committee at the University of Edinburgh and all relevant guidelines and 
regulations were adhered to throughout.   
9.2.1 Sample Collection 
Cell based IGRA assays for the 164 kennel hounds which were tested as part of an outbreak 
of TB caused by M. bovis infection were conducted as previously described (Chapter 5) 71. 
The stored supernatants from PBMC stimulated by purified protein derived from M. bovis 
(PPDB) or a combined peptide cocktail of ESAT-6 and CFP-10 antigens were compared to 
supernatants from unstimulated PBMC. Samples from 60 hounds were selected for analysis. 
The hounds were classified into one of three groups based on the combined outcome of the 
diagnostic tests performed previously. As detailed in O’Halloran et al. (2018) 71, dogs with 
significant mycobacterial antigen specific IFN-γ responses were classed as IGRA positive. In 
addition to the IGRA, the sera were tested with the DPP lateral flow assay, the Idexx M. bovis 
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Ab ELISA and a comparative PPD antibody ELISA 72. Here, these results were combined to 
class hounds as either seropositive if they were shown to have responded positively in at least 
one of the antibody tests, or seronegative if they did not.  
The previous test results were used to establish the three groups of dogs analysed in this 
current study. Firstly, dogs which were test-negative by IGRA and all three serological assays 
on two occasions 30 days apart (uninfected hounds, control group). This group was used as 
the control group against which the cytokine responses of the other groups could be 
compared. Secondly, dogs which were found to be positive to the IGRA test but which were 
negative to all of the serological assays (IGRA+, seronegative) and thirdly, dogs which were 
IGRA test positive and positive to at least one serological assay (IGRA+, seropositive). No 
dogs in this study were test positive on the serological assays and test negative by IGRA.   
9.2.2 Cytokine and Chemokine Measurements  
Cytokine and chemokine concentrations were measured in supernatant samples diluted 1:2 in 
RPMI 1640 cell culture media (Gibco, Thermo Fisher Scientific, UK) using a commercial, 
canine specific, antibody-coated microsphere-based multiplex cytokine immunoassay shown 
to be able to quantify 13 cytokines contemporaneously using 25µL of each sample 
(CYTOMAG-90K MILLIPLEX MAP Canine Cytokine/Chemokine Magnetic Bead Panel, 
Premix 19 Plex kit, MERCK Millipore Corporation, Billerica, MA, USA). 
The following cytokines were measured: granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IFN-γ, interleukin (IL)-2, IL-6, IL-7, IL-8, IL-10, IL-15, interferon gamma-induced 
protein (IP)-10, IL-18, keratinocyte-derived chemokine-like protein (KC-like), monocyte 
chemoattractant protein 1 (MCP-1, also known as CCL2) and tumour necrosis factor (TNF)-α.  
All reagents as well as the supernatant samples were brought to room temperature. The pre-
mixed bead solution was sonicated for 30 seconds and then vortexed for a minute. Quality 
Control vials 1 and 2 (CCTYOMAG-90K Kit) were each reconstituted with 250µL of deionised 
water. The standard curve panel was produced by conducting a seven step 4-fold dilution 
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series of the Canine Cytokine Panel Standard in Assay Buffer (CCTYOMAG-90K Kit) following 
reconstitution in 250µL of deionised water. Each assay plate was initially coated with 
200µL/well of Assay Buffer which was left for ten minutes on a plate shaker prior to being 
removed. An aliquot of 25µL of kit Standard, Control or supernatant sample was added to each 
well as appropriate; all samples were assayed in duplicate and mean values analysed. An 
additional 25µL of Assay Buffer was added to the 0pg/mL standard (background) wells and to 
each well containing test sample whilst the same volume of Assay Buffer was added to the 
Standard and Control wells. Finally, 25µL of the pre-mixed bead solution was added to each 
well before the plate was covered with aluminium foil and incubated overnight (at least 16 
hours) at 4oC on a plate shaker.   
The following day, the contents of each well were removed and each well was washed twice 
with 200µL of Wash Buffer. The Detection Antibody solution (CCTYOMAG-90K Kit) was 
allowed to warm to room temperature before 25µL was added to each well. The plates were 
sealed, covered with aluminium foil and incubated at room temperature on a plate shaker for 
an hour before 25µL of streptavidin-phycoerythrin (CCTYOMAG-90K Kit) was then added to 
each well. The plate again was incubated at room temperature on a plate shaker for an 
additional 30 minutes. The contents of each well was removed and each well was washed 
twice with 200µL of Wash Buffer.  
The plates were read with a multiplex plate reader and companion software (Luminex 200). 
All cytokine and chemokine concentrations were calculated by the software prior to statistical 
analysis and the results are reported in pg/mL. 
9.2.3 Statistical Analysis  
Statistical analysis was performed using commercially available statistical software (GraphPad 
Prism 7.0). Mean concentration values of duplicate samples for each condition were doubled 
prior to analysis to allow for the dilution factor. For the purposes of statistical analysis, values 
that fell below the limit of detection of the assay were assigned a concentration of 0 pg/mL.  
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The amount of antigen specific cytokine was determined by subtracting the concentration in 
the unstimulated cells from both the PPBD stimulated and ESAT-6/CFP-10 stimulated wells. 
The 60 dogs tested were divided into three groups based on their previous test results; IGRA 
negative and seronegative (controls, n=22), IGRA+ seronegative (n=22) or IGRA+ 
seropositive (n=16).  
A D’Agostino & Pearson omnibus test was used to assess the data. This showed that the data 
did not conform to a Gaussian distribution and therefore non-parametric tests were used for 
the analysis; Kruskal-Wallis tests were used to determine if there were significant differences 
between the three groups of dogs. If this was significant then pairwise Mann-Whitney tests 
were performed to determine which groups of dogs were significantly different. The two sets 
of data, from the PPDB stimulated samples and the ESAT-6/CFP-10 samples were analysed 
independently. Statistical significance for all tests was set a p<0.05.  
9.3 Results  
Cytokine concentrations were measured in the supernatants from antigen-stimulated PBMC 
from three groups of dogs; IGRA negative seronegative (uninfected controls), IGRA+ 
seronegative and IGRA+ seropositive. The median concentration and associated 95% 
confidence intervals (CI) are given for all cytokines separated into each of the three groups of 
dogs; Table 9.1 shows the cytokine concentrations measured from the supernatant of PPDB 
stimulated cells and Table 9.2 shows the equivalent values present within the supernatants of 
ESAT-6/CFP-10 stimulated cells. The concentrations of cytokines that were found to be 







Table 9.1: Cytokine concentrations measured from the supernatant of PPDB stimulated cells; 
values are given as the median and associated 95% confidence interval (CI). All 
concentrations are presented in pg/mL.  
 IGRA negative & 
Seronegative (controls) 
IGRA positive & 
Seronegative 
IGRA positive & 
Seropositive 












GM-CSF 0.00 0.00 0.00 0.00 158.50 0.00 0.00 412.60 0.00 
IFN-γ 0.33 9.10 0.00 252.30 503.20 204.30 13.65 185.90 0.00 
IL-2 0.00 0.00 0.00 0.00 1.05 0.00 0.00 0.00 0.00 
IL-6 0.00 33.45 0.00 34.39 110.40 6.92 25.45 61.01 8.42 
IL-7 0.00 0.00 0.00 0.00 2.63 0.00 0.00 2.05 0.00 
IL-8 5939.00 19115.00 0.00 29215.00 52803.00 4135.00 14607.00 59728.00 0.00 
IL-15 0.00 0.58 0.00 0.00 7.74 0.00 0.00 7.60 0.00 
IP-10 0.00 0.00 0.00 0.00 1.72 0.00 0.00 0.00 0.00 
KC-like 521.90 1220.00 0.00 649.10 814.50 177.10 1430.00 1764.00 434.20 
IL-10 5.49 20.45 0.00 24.93 81.44 0.00 30.05 120.30 8.93 
IL-18 0.00 0.00 0.00 0.00 1.05 0.00 0.00 0.43 0.00 
MCP-1 0.00 1633.00 0.00 0.00 4154.00 1081.00 3087.75 82857.00 2077.00 
TNFα 3.11 8.68 0.00 39.77 118.30 29.81 36.90 139.00 1.94 
 
Table 9.2: Cytokine concentrations measured from the supernatant of ESAT-6/CFP-10 
stimulated cells; values are given as the median and associated 95% confidence interval (CI). 
All concentrations are presented in pg/mL. 
 IGRA negative & 
Seronegative (controls) 
IGRA positive & 
Seronegative 
IGRA positive & 
Seropositive 





 95% CI 
Lower 
 95% CI 




GM-CSF 0.00 0.00 0.00 0.00 11.22 0.00 0.00 60.78 0.00 
IFN-γ 1.93 10.83 0.00 102.70 330.40 9.10 6.54 81.38 0.00 
IL-2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
IL-6 0.93 17.35 0.00 13.27 31.39 0.00 2.87 40.09 0.00 
IL-7 0.00 0.00 0.00 0.00 0.32 0.00 0.00 0.50 0.00 
IL-8 2715.00 21803.00 0.00 9074.00 22250.00 4.74 7485.00 45612.00 0.00 
IL-15 0.00 3.99 0.00 0.00 2.79 0.00 0.00 7.08 0.00 
IP-10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
KC-like 330.20 1229.00 0.00 206.70 696.10 32.22 371.10 1003.00 0.00 
IL-10 9.13 36.32 0.00 14.44 26.90 0.00 7.01 29.89 0.00 
IL-18 0.00 0.00 0.00 0.00 0.97 0.00 0.00 0.50 0.00 
MCP-1 0.00 0.00 0.00 256.00 2163.00 0.00 4659.50 68135.00 3721.30 
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Figure 9.1: Cytokines identified in the supernatant of peripheral blood mononuclear cells 
stimulated with either PPDB (A), or ESAT-6/CFP-10 (B). Cells were taken from dogs 
previously diagnosed as uninfected (green), M. bovis IGRA+ and seronegative (orange) or M. 
bovis IGRA+ and seropositive (red). Data are displayed as the median concentration for the 
group with error bars indicting the 95% confidence interval. 
Cells stimulated with either PPDB or ESAT-6/CFP-10 generated significantly different 
concentrations of IFN-γ between all three groups of dogs (p<0.0001). The IGRA+ seronegative 
animals were found to produce significantly greater concentrations of IFN-γ from PBMC 
stimulated with both PPDB and ESAT-6/CFP-10 antigens when compared to the other groups 





significantly higher concentrations of IFN-γ in response to both antigens than the control group 
(p<0.001). 
In response to PPDB stimulation, cells from both groups of IGRA+ dogs produced higher 
concentrations of IL-6 than the IGRA negative group (Figure 9.1 A, p=0.002). There was no 
significant difference between the concentration of IL-6 produced by PBMC from the IGRA+ 
seronegative dogs and the IGRA+ seropositive dogs (Figure 9.1 A, p=0.136). However, in 
response to ESAT-6/CFP-10 stimulation, cells from both groups of IGRA+ dogs produced a 
greater concentration of IL-6 than the IGRA negative control group (Figure 9.1b, p=0.007) 
whilst the PBMC of IGRA+ seropositive dogs produced significantly less IL-6 than those taken 
from IGRA+ seronegative dogs (Figure 9.1b, p=0.03). 
The cytokine IL-10 was found to be secreted to higher concentrations by cells from IGRA+ 
dogs than from IGRA negative dogs in response to both antigens (Figure 9.1, p<0.001). Whilst 
there was no difference between the concentrations of IL-10 produced by PBMC from IGRA+ 
seronegative and IGRA+ seropositive dog PBMC stimulated with PPDB (Figure 9.1 A). There 
was significantly less IL-10 produced by cells from IGRA+ seropositive dogs in response to 
ESAT-6/CFP-10 than by IGRA+ seronegative dogs, but the former was not then significantly 
different to the concentration produced by cells from control dogs (Figure 9.1 B, p=0.06).   
The concentration of TNF-α was significantly higher in the supernatant of cells from IGRA+ 
seronegative dogs compared to the control dogs in response to both PPDB and ESAT-6/CFP-
10 antigens (Figure 9.1, p=0.01). The cells from IGRA+ seropositive dogs produced an 
equivalent concentration of TNF-α as the IGRA+ seronegative dogs when stimulated with 
PPDB but did not produce consistently detectable concentrations of TNF-α when cells were 
stimulated with ESAT-6/CFP-10 (Figure 9.1).  
The cytokines IL-8 and KC-like were found to be produced in response to both antigens by 
cells from all three groups of dogs, however, no significant differences were found between 
any of the groups (Figure 9.1, p=0.3293, p=0.8698 respectively).  
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No significant difference was found in the concentration of MCP-1 produced under any of the 
conditions or groups (p=0.5). However, three dogs within the control group had very high levels 
(>10,000pg/mL) of MCP-1 in response to ESAT-6/CFP-10 stimulation which skewed these 
data considerably.  
Based on previous study findings of good agreement between the amount of antigen specific 
TNF-α and IFN-γ in IGRA+ dogs (Chapter 7, Section 7.3.1) 71,72, the concentration of TNF-α 
was compared to the amount of IFN-γ in the same supernatants. There was near perfect 
positive correlation between the two cytokines in the cells stimulated with PPDB from all three 
groups of dogs (R2=0.95, Figure 9.2 A) but only weak positive correlation was seen in cells 













Figure 9.2: The concentration of TNF-α plotted against the concentration of IFN-γ in the 
supernatants of peripheral blood mononuclear cells obtained from all 60 dogs included in this 
study stimulated with either PPDB (9.2 A) or ESAT-6/CFP-10 (9.2 B). A line of best fit plotted 
on both figures shows a strong positive correlation for PPDB stimulated samples (R2=0.95) 
whilst there is only weak association for cells stimulated with ESAT-6/CFP-10 (R2=0.34).  
The cytokines GM-CSF, IL-2, IL-7, IL-15, IP-10 and IL-18 were not found at concentrations 






































































9.4 Discussion  
Tuberculosis due to M. bovis in dogs represents a zoonotic risk for owners but the diagnostic 
options are currently limited 71,72. Whilst the concentration of the cytokine IFN-γ produced by 
PBMC or whole blood stimulated with mycobacterial antigens has long been used to diagnose 
infections in a number of species, recent studies in human patients infected with M. 
tuberculosis and cattle infected with M. bovis have shown that a number of other cytokines are 
produced under these conditions and can be used to infer more information about the state of 
a patient’s infection such as whether or not there is active disease, or to estimate prognosis 
73-75. The aim of this study was to analyse the concentration of multiple cytokines produced by 
canine PBMC in response to mycobacterial antigens from dogs previously diagnosed as 
infected or uninfected with M. bovis. The findings were related to the IGRA and serological 
status of dogs in relation to anti-mycobacterial antibodies measured as part of previous studies 
(Chapter 5 and Chapter 7) 71,72. All dogs were adult working Foxhounds co-habitant in the 
same kennel at the time of an M. bovis outbreak.  
Samples from 60 dogs were analysed in three groups; IGRA negative seronegative (controls, 
n=22), IGRA+ seronegative (n=22) or IGRA+ seropositive (n=16). These samples were 
chosen based on the results of previous tests to keep the size of each group proportionally 
similar to those seen when the entire pack was tested 71,72. We previously showed that more 
than half of the kennel hounds were positive by IGRA test, here 63% of dogs were IGRA+, 
whilst approximately a third of the hounds were previously shown to have anti-mycobacterial 
antibodies and 37% of dogs included in this study were seropositive 71,72. Initial analysis of the 
concentration of IFN-γ using this assay matched the results found previously when the 
supernatants were tested by conventional ELISA, validating the classification of dogs in this 
study. 
Notably, the level of antigen specific IFN-γ and IL-6 detected here showed a broadly similar 
pattern of secretion to each other. The concentrations of both cytokines were lower in the 
supernatant of cells stimulated with ESAT-6/CFP-10 than with PPDB. There are several 
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reasons that this may be the case; firstly, ESAT-6 and CFP-10 proteins are released from M. 
bovis via the ESX-1/typeVII secretion system that is not always active 76-78. This consistently 
gives rise to a number of animals that are infected with M. bovis but lack an antigen-specific 
response to these proteins. In experimentally infected cattle, studies show this to be 
approximately 18% and one feline study found it to be the case in two of ten (20%) M. bovis 
infected cats 46,76-78. Alternatively, these proteins may not be immunogenic to every animal due 
to genetic differences such as polymorphisms in MHC class II genes, or more subtle 
differences in antigen processing and presentation. This would in turn lower the median value 
measured across the group. Furthermore, PPDB contains a great number of peptides, all of 
which may provide stimulation to primed T-cells compared to just two proteins in the ESAT-
6/CFP-10 cocktail and this may lead to the secretion of a lower overall concentration of IFN-γ 
in these samples. 
The concentration of IFN-γ and IL-6 was also found to be lower in the supernatants derived 
from seropositive dogs compared to seronegative dogs in response to both antigens (PPDB 
and ESAT-6/CFP-10). As IFN-γ is secreted by, amongst other cells, activated T-cells and IL-
6 is released from blood monocytes and tissue macrophages, this likely reflects the activation 
of a Th-1 immune response classically triggered by intracellular pathogens such as 
mycobacteria 79. The decreased levels seen in seropositive animals may indicate that these 
dogs are moving towards a weaker Th-1 but stronger Th-2 biased immune response, which in 
human TB patients has been shown to be associated with active disease 80. Quantifying 
cytokines more typically associated with a stronger Th-2 response such as IL-4 and IL-13 may 
help to identify dogs at risk of developing clinical signs of TB so that they can be more quickly 
targeted for intervention.  
The cytokine IL-10 is a major immunoregulatory factor, particularly in the context of TB, and in 
humans and cattle has been shown a negative feedback effect on the production of IFN-γ with 
the effect of limiting the pro-inflammatory response to avoid excessive immune-mediated 
pathology 81-85. It was therefore unexpected to see higher levels produced by PBMC from 
IGRA+ dogs than cells from dogs that were IGRA negative. However, it has recently been 
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demonstrated that Th-1 CD4+ T-cells will secrete both IFN-γ and IL-10 following prolonged 
antigenic stimulation 81-85. Given the pattern of detection for both of these cytokines shown 
herein this suggests significant antigen specific T-cell responses are ongoing in the IGRA+ 
group of dogs.  
No IL-2, IL-7 or IL-15 was recovered from any of the supernatants in this study despite human 
and bovine studies suggesting that IL-2 concentrations can be indicative of more severe 
disease phenotypes 74,75. These three cytokines are a closely related group with a shared 
gamma chain (γc) structure allowing them to share some cellular receptors and regulate 
immune cell differentiation 86-88. In particular, they can modulate naïve, effector, and memory 
CD4+ T-cell function and IL-2 was initially identified as an autocrine cytokine necessary for the 
in vitro expansion of T-cells 86-88. In the context of the IGRA, IL-2 is detectable in bovine blood 
samples where antigen specific T-cells are expanding eight hours after antigen is added 74. In 
our study, we assayed the supernatants after four days of incubation and so any of the three 
γc-cytokines produced will likely have bound back onto cell receptors to induce continued 
activation/proliferation and so not be available for detection in the supernatant. Future studies 
examining the kinetics of cytokine production and secretion in this assay would be beneficial 
to determine the time point of optimum test sensitivity.  
No GM-CSF was consistently detected in any of the canine samples we analysed. A recent 
study of health care workers with exposure to patients with M. tuberculosis infections found no 
significant differences in the quantity of antigen specific GM-CSF produced by stimulated 
whole blood samples until exposure was prolonged (more than five years) where it was shown 
to be protective against active disease in these individuals 89. A number of in vitro studies have 
shown that GM-CSF has a limiting effect on M. tuberculosis replication and study of human 
PBMC demonstrated that activated NK cells improve γδ T-cell proliferation by secreting GM-
CSF, along with other cytokines, when stimulated with M. tuberculosis antigens 90,91. Given 
these previous studies, it was unexpected that little or no GM-CSF would be identified in our 
samples; however, very little is known about the biology of canine NK cells, and an exact 
definition of a canine NK cell is lacking from the literature 92. The lack of antigen specific GM-
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CSF in this study may further indicate that canine NK cells display different behaviour or 
functionality in the context of tuberculosis than in other species such as humans and mice. 
Alternatively, this finding may reflect an earlier stage of infection in these dogs compared to 
human studies where GM-CSF was only identified after years of exposure; whereas all of the 
canine samples were taken within three months of the first clinical case being diagnosed which 
may be too soon in a chronic disease process to identify this marker of protection.  
The pro-inflammatory cytokines IL-8 and KC-like were present at equivalent concentrations in 
all groups that we tested. Our research (Chapter 3) has previously shown that whilst these 
cytokines are present in higher concentrations in the sera of mycobacteria infected cats when 
compared to controls, this increase is non-specific and is found in cats with non-infectious 
health problems 93. Therefore, the cytokines detected in this study may similarly reflect a non-
specific response.   
As we have previously shown for a small number of dogs (Chapter 7) 72, the cytokine TNF-α 
showed a similar pattern of secretion to IFN-γ with a very strong correlated response in the 
supernatant of cells stimulated with PPDB. This suggests that within the assay there is 
reciprocal activation of canine monocytes by IFN-γ likely produced by (CD4+) T-cells and 
subsequent agonism of TNF-receptors expressed by T-cells. Although this process may be 
dependent on other cytokines produced from other PBMC subsets, this may facilitate the 
development of an in vitro co-culture system for studying the canine immune response to 
mycobacteria more closely in future studies.  
In conclusion, this study is the first to analyse the cytokine production profiles of canine PBMC 
derived from M. bovis infected or uninfected dogs. It confirms that measuring antigen specific 
IFN-γ production is a robust mechanism for the classification of the infection status of dogs 
whilst it is the first suggesting that determining antigen specific concentrations of the cytokines 
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Chapter 10: Canine Tuberculosis - A review of 19 new 
UK cases and 993 global historical cases.  
Abstract 
Canine tuberculosis has been recognised as a disease of dogs since shortly after the 
identification of M. tuberculosis itself at the end of the 19th century. The intimate relationship 
that has been built between humans and dogs during their millennia of domestication means 
that the zoonotic and reverse zoonotic transmission of diseases to and from domestic canines, 
including tuberculosis, if of significant public health significance.  
This analysis considered 1012 canine tuberculosis cases including 19 previously unreported 
cases and 993 from the historical literature. This study found that all cases were caused by 
infections with one of three MTBC organisms, M. tuberculosis, M. bovis or M. mircroti. This 
study found that during the last decade (2009-2019), the pattern of infections has changed; 
with a relative decline in the significance of M. tuberculosis as compared with M. bovis and the 
first documented canine infections with M. microti.  
The diagnosis of canine tuberculosis remains challenging as all of the three most frequently 
used tests; culture, interferon gamma release assay (IGRA) and PCR have unproven 
sensitivities with respect to dogs. Specialist culture remains the gold standard method to 
establish a diagnosis but the time required (weeks to months) means that an adjunctive test 
method such as and IGRA and/or PCR test may be necessary whilst culture results are 
pending.  
All cases conformed to one of four clinical groups based on the presenting signs; primary 
pulmonary, primary abdominal, disseminated or miscellaneous. For all presentations of cases, 
other than dogs with disseminated disease, treatment with triple combination antimicrobial 
therapy lead to good clinical outcomes but the treatment of dogs with M. tuberculosis remains 




Clinical tuberculosis has been documented in a variety of mammalian species as the result of 
infection with members of the Mycobacterium tuberculosis-complex (MTBC) group of 
mycobacteria (Brougham et al. 2013). This group of bacteria are non-motile, non-spore 
forming, intracellular, Gram-positive aerobic bacilli that are characteristically acid-alcohol fast 
when visualised by special stains, typically Ziehl-Neelsen staining, of tissue sections 
(Deforeges et al. 2014).  
The MTBC comprises phylogenetically related mycobcateria that share remarkable levels of 
genomic nucleotide sequence homology and share many identical gene sequences (Warner 
et al. 2013). The complex includes Mycobacterium (M.) tuberculosis, M. bovis, M. bovis  bacile 
Calmette–Guérin (M. bovis-BCG), M. microti, M. canettii, M. africanum, M. pinnipedii, M. 
caprae, M. suricattae and M. mungi, with all but the latter two having been reported as causing 
disease in humans (Pinsky et al. 2008; Warner et al. 2013). 
The domestic dog (Canis lupus familiaris) has a unique affiliation with human society that has 
developed since their domestication circa 40,000 years ago (Horard et al. 2014). This 
relationship has placed the dog in a position to be both the recipient and origin of transmission 
for many human pathogens including the mycobacteria of the MTBC. Clinical tuberculosis 
caused by the human adapted M. tuberculosis was first confirmed in a dog in 1892, merely 
seven years after the organism was first identified by Robert Koch (Moore, 1928; Gradman, 
2006). Canine tuberculosis received significant attention in the UK in the late 1920s and early 
1930s when it was first shown that companion dogs can act as both spill-over hosts and as a 
sentinel species for human infections (Moore, 1928; Thayer et al. 1930; Adams and Vokwald 
et al. 1932; Steinbach and Deskowitz, 1933). Throughout the 1930’s and beyond, dogs were 
used as an experimental model for human tuberculosis and canine serum was even explored 
as a potential therapeutic for patients in the pre-antimicrobial era (Beretta, 1891; McFadyean, 
1891; Manwaring, 1913; Adams and Volkard, 1932)  
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In the last 75 years, the incidence of tuberculosis in the human population throughout the UK 
as declined by 90% and the mortality rate has fallen by 98% (Glaziou et al. 2018). Throughout 
the same period, reports of canine tuberculosis in the literature saw a similarly dramatic decline 
and began to reflect individual and sporadically occurring canine cases whilst reports of feline 
mycobacteriosis became largely limited to incidental findings during post mortem surveys 
(Dodd, 1952, Cordes et al. 1963; Birn et al. 1965).  
In recent years, however, there appears to have been an anecdotal increase in the number of 
diagnoses of canine tuberculosis being made in the UK. Since December 2016, the author is 
aware of more than 120 cases; including one major outbreak in a kennel of Foxhounds 
(O’Halloran et al. 2018). There has also been increasing awareness in the last decade of the 
significance of mycobacterial infections in cats in the UK (Gunn-Moore et al. 2011; Gunn-
Moore et al. 2013). Meanwhile, the incidence of bovine tuberculosis (caused by infection with 
M. bovis) has also been increasing. It therefore seems that canine tuberculosis cases are likely 
to re-emerge as a clinical entity in the UK but this disease remains poorly characterised.  
It is the purpose of this study to review a series of both previously unreported cases of canine 
MTBC infections as well as those previously presented in the literature. This study discusses 
their clinical presentations, the challenge of diagnosis, potential treatment options as well as 
the zoonotic and reverse zoonotic potential of these bacteria.  
10.2 Materials and Methods 
Data relevant to the cases discussed in this study were obtained by literature review using 
online resources (PubMed, Web of Knowledge, CAB Abstracts, Medline and Google Scholar) 
with the search terms ‘dog or dogs or canine’, ‘tuberculosis or TB and mycobacteri*’. Cases 
were only included if infection with MTBC organisms were demonstrated i.e. cases of infection 
with other mycobacterial species were omitted.  
In instances of previously unpublished cases, all were managed under the supervision of the 
author. The primary care veterinary surgeon for each case was contacted and asked to provide 
clinically relevant data and to obtain consent from the owners for the data to be used in this 
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study. The study was conducted with ethical approval from the University of Edinburgh, 
Veterinary Ethical Review Committee.  
For each case where data were available signalment data including; location (country), breed, 
age at diagnosis, sex and neuter status were recorded. The method/s by which each diagnosis 
was made and the causative organism was recorded to the species level wherever this was 
available; however, in some cases it was only possible to diagnose infections to within the 
MTBC. Any treatment given to cases (where this was done) and the outcome was also 
recorded.  
10.3 Results 
A total of 1012 instances of canine tuberculosis were examined in this study; 19 cases were 
treated under the supervision of the author and a further 993 cases were identified by 
reference to previously published studies. The major details of the cases are summarised in 
Table 10.1. The amount of detail pertaining to the clinical particulars of each case presented 
in historical publications was variable. Therefore, where possible data are presented 













Table 10.1: Key details of the canine tuberculosis cases included in this study. No,: number 
of cases in each publications; Country: country of residence of the dogs at the time of the 
diagnosis; Year: year that the diagnosis was made; Age: age at the time of the diagnosis, 
Method: method by which the diagnosis was made and the species confirmed. NR: details not 
recorded/detailed in publication. 
No. Country Year  Age Sex Breed Organism  Method Source  
1 UK 2018 7 MN Cross-breed M. bovis PCR This study 
1 UK 2017 9 FN German 
Shepherd 
M. bovis PCR This study  
1 UK 2017 9 FE Labrador M. bovis  PCR This study  
1 UK 2018 3 MN Cavalier King 
Charles 
Spaniel  
M. bovis PCR This study 
1 UK 2019 6 MN Beagle MTBC PCR This study 
1 UK 2018 4  ME Springer 
Spaniel 
M. microti PCR This study  
1 UK 2016 1 FE Staffordshire 
Bull Terrier 
MTBC PCR This study 
1 UK 2019 4 MN Greyhound M. bovis PCR & 
culture 
This study  
1 UK 2015 4 FN Staffordshire 
Bull Terrier 
MTBC IGRA  This study 
1 UK 2013 2 FN Italian 
Spinone 
M. bovis IGRA + 
history 
This study 
1 UK 2013 5 ME Italian 
Spinone 
M. bovis Culture This study 
1 UK 2015 7 FN Catalunyan 
Sheepdog 
M. microti PCR This study 
1 UK 2015 4 FN Mixed M. tuberculosis IGRA + 
history 
This study  
1 UK 2012 6 FE Jack Russell 
Terrier 
M. bovis Culture This study  
1 UK 2013 6 FN Lurcher M. bovis IGRA + 
history 
This study  
1 UK 2013 2 ME Lurcher M. bovis IGRA + 
history 
This study  
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1 UK 2009 7 ME Patterdale 
Terrier 
M. bovis Culture This study 
1 UK 2008 6 ME Jack Russell 
Terrier 
M. bovis Culture This study  
1 UK 2007 3 ME Mixed Terrier M. bovis Culture This study  
1 UK 2014 4 MN Mixed Breed M. tuberculosis Culture Englemann et 
al. 2014 
97 UK 2017 2-4 
years 
Mixed Foxhound M. bovis IGRA, 
PCR & 
culture  
O’Halloran et al. 
2018 
1 UK 2004 6 ME Border Collie  M. bovis Culture Ellis et al. 2006 




NR NR NR M. bovis Culture Broughan et al. 
2013 
1 Eire 2004 3 ME Fox Terrier M. bovis Culture Bauer et al. 
2004 
1 France 2013 NR NR NR M. microti Culture Michelet et al. 
2015 
1 France 2011 NR NR NR M. microti Culture Michelet et al. 
2015 
1 Switzerland 2011 7 MN Podengo 
Iberico 
M. tuberculosis PCR Posthaus et al. 
2011 
1 France 2004 NR NR NR M. microti Culture Michelet et al. 
2015 




2008 NR ME Maltese 
cross 




2012 Mixed Mixed Mixed  
 
M. tuberculosis Culture Parsons et al. 
2012 
1 Norway 1982 NR NR NR M. tuberculosis Culture Saxegaard, 
1982 
1 USA 2004 3.5 ME Yorkshire 
Terrier 






Mixed Mixed Mixed M. bovis Culture Thacker et al. 
2013 
1 Belgium 1991 6 ME Red 
Setter/Cocker 
Spaniel cross 
M. tuberculosis Culture Clercx et al. 
1992 
5 USA 1987 Mixed Mixed Basset 
Hound 
M. tuberculosis Culture Carpenter et al. 
1988 
1 USA 1982 6 ME Cross breed M. tuberculosis Culture Ferber et al. 
1983 
1 UK 1964 5 FE Yorkshire 
Terrier 
M. tuberculosis Culture Birn et al. 1965 
1 USA 2004 3.5 MN Yorkshire 
Terrier 
M. tuberculosis Culture Hackendahl et 
al. 2004 
1 USA 1986 0.5 FE Mixed M. tuberculosis Culture Foster et al. 
1986 
1 Germany 2007 6 NR Golden 
Retriever 






2011 5 FE Doberman M. tuberculosis Culture 
& PCR 




2000 8 ME German 
Shepherd 
M. bovis Culture 
& PCR 
Gay et al. 2000 
1 South 
Korea 
1992 8 ME Cross Breed M. tuberculosis PCR Park et al. 2016 
1 Czech 
Republic 
1990’s NR NR NR M. bovis Culture Pavlik et al. 
2002 
1 UK 2002 5 NR Golden 
Retriever 
M. bovis  Culture Barber et al. 
2004 
2 UK 1992 NR NR NR M. bovis  Culture DeLisle, 1992 
1 New 
Zealand 




1952 NR NR NR M. bovis Culture Dodd, 1952 
1 Hungary 2004 2 ME West 
Highland 
White Terrier  





2004 5.5 FE Doberman 
 




2012 Mixed Mixed Mixed  
 
M. tuberculosis IGRA Parsons et al. 
2012 
14 UK 1955 Mixed Mixed Mixed M. tuberculosis Culture Hawthorne et al. 
1957 





Mixed Mixed Mixed 
 
M. tuberculosis Culture Snider et al. 
1971a 





Mixed Mixed Mixed 
 
M. bovis Culture Snider et al. 
1971a 
22 UK 1940 Mixed Mixed Mixed M. tuberculosis Culture Lovell and 
White, 1940 












M. bovis Culture Van der Burgt et 
al. 2009 
20 Italy 1929 Mixed Mixed Mixed M. tuberculosis Culture Paltrinieri, 1930 
16 UK 1910’s Mixed Mixed Mixed M. tuberculosis Culture Stableforth 1914 
25 UK 1930’s Mixed Mixed Mixed M. tuberculosis Culture Innis, 1940 
13 Finland 1910-
1935 
Mixed Mixed Mixed M. tuberculosis Culture Hjarre, 1939 
1 USA 2004 9 FN Golden 
Retriever 
 




Mixed Mixed Mixed 
 
M. bovis Culture Snider, 1971b 
8 USA 1962-
1972 
Mixed Mixed Mixed M. tuberculosis Culture Liu, 1980 
1 UK 1928 NR NR NR M. tuberculosis Culture Moore, 1928 




1 UK 1932 NR NR NR M. tuberculosis Culture Adams and 
Vokald 1932 






Mixed Mixed Mixed MTBC  Culture  Cheyrolles 1951 
10.3.1 Signalment  
Within the cohort of 1012 dogs identified as being infected with MTBC organisms, 515 (50.9%) 
were definitely speciated. Only three organisms of the MTBC were identified; M. tuberculosis 
(n=297, 57.7%), M. bovis (n=212, 41.2%) and M. microti (n=6, 1.2%).  
The median age of dogs infected with M. tuberculosis was five years (range 0.5-9 years), M. 
bovis was six years (range 1-9 years) and M. microti four years (range 4-7 years). Included in 
this study are a single group of 97 Foxhounds (9.6% of 1012 cases) affected during the same 
outbreak of M. bovis disease in a working kennel. The breed of the dog was only recorded in 
an additional 28 instances (2.8%) comprising; five cross-breeds, three Yorkshire terriers, three 
Golden Retrievers, two Doberman Pinchers, two German Shepherds, two Fox terriers, and 
one each of Patterdale terrier, Border terrier, West Highland White terrier, Basset hound, 
Beauceron, Podengo Iberico, Springer Spaniel, Beagle, Cavalier King Charles Spaniel, 
Labrador and Catalunyan sheepdog.  
10.3.2 Clinical Signs  
Of the 1012 cases identified in this study 156 (15.4%) were individually described with 
accompanying clinical detail; 96 dogs were infected with M. tuberculosis, 57 were infected with 
M. bovis and three were infected with M. microti. The clinical presentation of tuberculosis in 
these cases falls into four major categories based on the clinical presentation of the disease, 
which in order of frequency comprise; primary pulmonary, primary abdominal, disseminated 
or miscellaneous signs. Notably, pyrexia was an intermittently reported feature found amongst 
all presentations of this disease. 
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Primary pulmonary tuberculosis was described in 62 of 96 cases (64.6%) of M. tuberculosis, 
34 of 57 (59.6%) cases of M. bovis and one of three (33.3%) of cases of M. microti infections, 
where the clinical presentation is detailed (Figure 10.1). Furthermore, it was frequently referred 
to as the most commonly noted form of disease in publications detailing groups of cases that 
did not reproduce individual case details. 
 
Figure 10.1: A latero-lateral radiograph of a Labrador infected with M. bovis displaying peri-
bronchial pathology typical of primary pulmonary pathology. Image courtesy of Scott Lawson 
MRCVS. 
The pulmonary manifestations of canine tuberculosis was shown to begin, as expected, with 
respiratory signs; typically a husky, non-productive cough persisting for a number of weeks. 
This then often progressed to a more severe cough which typically then became productive. 
Eventually dogs became dyspnoeic with a restrictive breathing pattern and at this point 
frequently developed pulmonary effusion and (occoasionally) a secondary pneumothorax. The 
lymph nodes in the thoracic cavity of these cases wre ubiquitously enlarged and it was usual 
for them to contain an internal area of necrosis when examined at post mortem examination 





Figure 10.2: An incised bronchial lymph node removed post-mortem from a four-year-old male 
entire Foxhound dog infected with M. bovis demonstrating the lymphademomegaly and 
internal necrosis typical of canine pulmonary tuberculosis.  
Cases presenting with primary abdominal tuberculosis represented approximately one third of 
cases. This form of disease was documented in 32 of 96 (33.3%) dogs with M. tuberculosis 
infection, 17 of the 57 M. bovis cases (29.8%) and one of the three (33.3%) M. microti cases 
described.  
Lethargy, hyporexia/anorexia and the loss of body weight and condition were ubiquitous 
clinical signs reported among the dogs affected by primary abdominal tuberculosis (Figure 
10.3). The weight loss recorded was frequently both rapid and marked; often reported as 
between 20% and 25% in just a small number of weeks. The liver was most frequently reported 
as the affected abdominal organ. The liver was often found to contain palpable abnormal 
(granulomatous) structures later in the course of disease in a very large proportion of cases. 
Other structures affected have been recorded to include; the pancreas, the stomach, the 
mesentery and the associated gastrointestinal lymph nodes. It has been noted that palpation 
of these abdominal granulomas often becomes easier to detect as the granuloma expands in 
size and the patient loses body condition. Associated with this, there may be intermittent 




Figure 10.3: The loss of muscle condition from the temporal muscles (red box) of a three-
year-old male neutered Ladrador dog infected with M. bovis. Image courtesy of Sheena Lewis 
MRCVS.  
Disseminated disease was found in two M. tuberculosis cases (2.1%), four M. bovis cases 
(7.0%) and one M. microti case (33.3%). This form of the disease was often reported to have 
arisen insidiously and without any characteristic pattern to the clinical signs so that in all of 
these cases, these infections initially went undiagnosed. Eventually, all of these cases were 
euthanased due to the severity of disease which had developed. All seven cases presented 
at times with variable appetite, and protracted weight loss (though significantly slower and less 
severe than was seen with primary abdominal cases). At at least one assessment of routine 
haematology and serum biochemistry was abnormal in these cases; all cases displayed a 
pattern typical of a stress leukogram (mature neutrophilia, monocytosis, lymphopenia and 
eopsinopenia) though the neutrophilia was often described as marked or severe, non-
regenerative anaemia and azotaemia. Notably, these abnormalities were not present every 
time that blood was evaluated and when the dogs were initially presented routine 
haematological and serum biochemical assessment was normally round to be unremarkable.  
Four of these seven cases of disseminated tuberculosis (57.1%), including both of the M. 
tuberculosis infected dogs, one of the M. bovis infected dogs and the M. microti infected dog, 
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were diagnosed with dystrophic calcification, primarily affecting the kidneys of three dogs and 
primarily affected the liver in one case. All seven dogs were found to have elevated serum 
concentrations of ionised calcium, marked azotaemia and were presented to their primary 
veterinary surgeons for severe polyuria and polydipsia.  
The remaining two M. bovis cases of the 57 with specific details available (3.5%) that did not 
fit into any of the three categories of tuberculous disease and are therefore classed as 
‘miscellaneous presentations’.  
One case, an adult (exact age unknown) male neutered rescue Doberman presented with two 
focal ulcerated lesions, one on the flank (Figure 10.4) and one on the lateral digit of the right 
forelimb. Histological examination of the biopsied flank lesion revealed coalescing areas of 
granulomatous inflammation with central necrosis surrounded by large epithelioid 
macrophages and some neutrophils. Ziehl-Neelsen staining realed moderate numbers of acid-
fast bacilli with mycobacterial morphology. Subsequent PCR testing of frozen biopsy tissue 
confirmed the presence of M. bovis DNA in the lesion. The dog was successfully treated with 
the surgical removal of the lesions, including amputation of the affected digit, followed by eight 
weeks of anti-tuberculous therapy (see below) and remains clinically well at the time of writing. 
 
Figure 10.4: The ulcerated granulomatous lesion on the flank of a neutered male Doberman 
of unknown infected with M. bovis. Image courtesy of Helen Dixon MRCVS.  
The final case in this series is a three-year-old male neutered Springer Spaniel with a three 
month history of chemosis, blepharospasm and epiphora following a superficial corneal injury 
of unknown cause. A superficial corneal lesion (Figure 10.5) developed over a number of 
weeks and slowly increased in size. It was non-responsive to therapy with fusidic acid eye 
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drops (FuscithalmicTM [1% fusidic acid]; LEO Pharma, Denmark). Cytological examination of 
a fine needle aspirate of the lesion revealed granulomatous inflammation with non-staining 
“ghost” bacilli. Additional aspirates were found to contain acid-fast bacilli and one was PCR 
positive for M. bovis DNA. During this time the dog developed three dermal lesions (one on 
the lower lip and two on the cranial portion of the dorsum). Systemic treatment was instigated 
with anti-tuberculous therapy (see below) and topical therapy for the ocular lesion with 
moxifloxacin drops (VigamoxTM; Alcon, UK). The lesions completely resolved within six weeks 
and the dog remains well at the time of writing.   
 
Figure 10.5: The corneal granuloma of a thee-year-old male neutered Springer Spaniel dog 
infected with M. bovis. Image courtesy of Jess Florey MRCVS (Dick White Referrals).  
 
10.3.3 Diagnostic Tests  
The diagnosis of mycobacterial infections, and MTBC infections in particular, are notoriously 
challenging to make as all of the available diagnostic tests have limitations of sensitivity and/or 
specificity.  
For the majority of cases, evaluation of routine haematology and serum biochemistry were 
used as a first-line test when clinicians were presented with an unwell dog, however, the 
findings were typically unrewarding. The results, in the vast majority of cases for which they 
are available, were found to be within reference intervals. Occasionally, generally as the 
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severity of the disease advanced, non-specific changes occured, such as a stress leukogram 
(mature neutrophilia, monocytosis, lymphopenia and eopsinopenia). The mature neutrophilia 
seen has occasionally been described as marked or severe and in rare cases there is a band 
neutrophilia (a ‘left-shift’). A number of tuberculous dogs have been found to have a non-
regenerative anaemia; which may result from chronic inflammation. Organ specific changes, 
for example elevations in liver enzyme activity, were typically only found to occur when the 
relevant organ system was implicated in the disease process. 
Diagnostic imaging (computed tomography, radiography and ultrasonography) were used in a 
number of cases, particularly those diagnosed in recent years. The findings were useful for 
establishing the extent of the pathology associated with infections and changes in diagnostic 
imaging was reported in a number of cases as an aid to monitoring response to therapy and 
as an indicator of when treatment could be discontinued.   
Accessible lesions were often sampled by fine needle aspiration and cytological evaluation 
has additionally been conducted on bronchial alveolar lavage fluid (N.B. this procedure should 
only be undertaken in cases where tuberculosis is suspected after careful consideration and 
with appropriate protective equipment). Cytological findings from these cases represent the 
typical mammalian inflammatory response to mycobacteria; active macrophages dominate, 
variable numbers of neutrophils and lymphocytes and fewer plasma cells. Routinely used 
Romanovsky-type stains (e.g. DiffQuickTM; Richard Allen Scientific, UK) may highlight intra- 
and extracellular mycobacteria as non-staining, so called “ghost” bacilli as their lipid walls 
precent the uptake of stain. Acid-alcohol protocols (e.g. Ziehl-Neelsen) are needed to actively 
stain mycobacteria. 
A similar inflammatory infiltrate to cytological findings was ubiquitously reported in histological 
evaluations of lesioned tissue sections taken from tuberculous dogs but in addition the 
granulomatous structure was also visible. Canine granulomas of various structure have been 
described; the most commonly identified were well structured granulomas comprising large, 
often circular or ovoid, encapsulated areas of densely packed epithelioid macrophages, 
Langerhan’s cells and multinucleated giant cells. The peripheral macrophages were frequently 
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reported as admixed with lymphocytes that were occasionally seen to form small aggregates. 
In the central regions, irregular areas of necrosis containing cell debris, intact and degenerate 
neutrophils were variably recorded. The areas of central necrosis were notably missing from 
all three cases of M. microti infection where the histological assessment of tissue was 
available. In a small number of cases, the (pyo)granulomatous inflammation was found to 
occur outwith a typical granulomatous structure but instead macrophages and neutrophils 
simply infiltrated the affected organs in large numbers and only formed small aggregates. The 
histological findings in cases that were highly suggestive of mycobacterial infections were 
examined by specialist stains to look for aetiological agents. The Ziehl-Neelsen protocol 
identified variable numbers of acid-fast bacilli in the sections were this was reported, in line 
with findings reported for mycobacterial infections in other species (Brougham et al. 2013. In 
many of the cases reviewed in this study, the detailed findings of acid-fast staining were 
frequently omitted from case reports (i.e. they were often simply referred to as either positive 
or negative) and so a more detailed analysis was not possible.  
A number of the examined reports noted that these granulomatous structures and/or 
histological findings may also arise in the absence of an infectious agent but due to foreign 
body, canine histiocytic disorders, canine sterile granuloma syndrome or neoplasia (e.g. 
histiocytoma). 
In the UK and the USA, the only diagnostic test which can lead to official confirmation of a 
tuberculous infection in a dog is specialist mycobacterial culture conducted by the Animal and 
Plant Health Agency, Weybridge or the United States Department of Agriculture, Animal and 
Plant Health Inspection Service respectively (USDA, 2017; Middlemiss and Clark, 2018). 
Despite this, no sensitivity data are publically available for this technique with respect to canine 
submissions. Logically, culture tests are assumed to have perfect (100%) specificity for all 
submissions processed at these laboratories.  
In human medicine, tuberculosis is increasingly being diagnosed with the use of molecular 
assays; either PCR or quantitative PCR (qPCR). This has, in large part, been driven to 
decrease the time taken to make a diagnosis compared to culture which can take 2-4 weeks 
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for M. tuberculosis, 6-8 weeks for M. bovis and up to 12-16 weeks for M. microti (Reuter et al. 
2006; Emmanuel et al. 2007). In the UK, Mycobacterial Reference Laboratories, such as the 
one at Leeds University Teaching Hospital, are offering veterinary clinicians the most robust 
PCR assays for mycobacterial infections. This laboratory utilises the GenoType MTBC assay 
(Hain LifeScience, Germany) which allows the discrimination between all members of the 
complex in one rapid (five hours) assay (Hain LifeScience, 2019). However, this assay is 
validated for the assessment of liquid starting material (typically liquid cultures or expectorated 
sputum samples) where most veterinary submissions are cytological aspirates or tissue 
biopsies and this may have an, as yet, effect on the test sensitivity. In addition, veterinary 
submissions may also be formalin-fixed tissues being tested following routine histological 
examination and whilst this process is known to fragment extracted DNA, the effect that this 
may have on test sensitivity is as yet unknown. Despite this, positive results have been 
obtained from formalin-fixed canine tissue, even without visible acid-fast bacilli (Sharp et al. 
2019).  
Parsons et al. (2012) were the first to use a commercial interferon gamma release assay 
(IGRA) to test dogs for M. tuberculosis infections. This test, the QuantiFERONTM TB Gold 
assay is used to diagnose latent tuberculosis infections (LTBI) in people (Tilahun et al. 2019). 
The IGRA assays incubate whole blood or isolated cells (peripheral blood mononuclear cells 
[PBMC]) with mycobacterial antigens; if patients are infected with mycobacteria that posess 
those same antigens then antigen-specific T-cells will recognise those antigens, produce and 
secrete interferon-gamma (Wood and Jones, 2001). This can then be quantified by ELISA and 
compared to unstimulated samples from the same patient; a significant difference indicates to 
infection (Wood and Jones, 2001). In humans, the QuantiFERONTM TB Gold assay is reported 
to have a sensitivity of 82.3% (95% confidence interval; 77.7% to 85.9%) and specificity of 
82.6% (95% confidence interval; 78.6% to 86.1%) for LTBI (Takwoingi et al. 2019). The study 
by Parsons et al. (2012) screened high risk dogs (resident with humans that had active M. 
tuberculosis infections) and showed that a number generated positive results to the 
QuantiFERONTM TB Gold assay.  
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The QuantiFERONTM TB Gold test contains three combined MTBC antigens; 6kDa early-
secreted antigenic target (ESAT-6), 10kDa culture filtrate protein (CFP-10) and Tb7.7 (Bernitz 
et al. 2019). Only the latter of these is specific to M. tuberculosis, the former two are both 
common to MTBC organisms which encode the RD-1 region of the MTBC genome (i.e. all 
MTBC organisms excluding M. bovis-BCG and M. microti) (Leem et al. 2018; Bernitz et al. 
2019). Therfore a positive response of a dog to these antigens likely indicates infection with a 
RD-1-positive MTBC mycobacteria rather than just M. tuberculosis as implied by Parson et al. 
(2012), for example buffalo infected with M. bovis have been shown to give positive results to 
the same test (Bernitz et al. 2019). No further studies have expanded on the use of the 
QuantiFERONTM TB Gold test for dogs and, to the author’s knowledge, it is not currently 
available to veterinary clinicians.  
Another IGRA, based on the protocol used for the feline assay, was developed during an 
outbreak of M. bovis in a kennel of Foxhounds (Chapter 5; O’Halloran et al. 2018). This assay 
uses three separated antigen pools; purified protein derived (PPD) from M. bovis (PPDB), PPD 
from M. avium (PPDA) as well as a combination of ESAT-6 and CFP-10. This separation of 
antigens theoretically allows for the discrimination between canine infections with M. 
tuberculosis and M. bovis (both of which would give rise to the same pattern of response) and 
M. mircoti. However, no dogs infected with M. microti have been tested with this assay to date. 
Additionally, as with cats (Rhodes et al. 2008), a number of the Foxhounds tested that were 
infected with M. bovis did not give a significant interferon gamma response to the ESAT-6 and 
CFP-10, as would be expected from animals infected with M. microti. Therefore, whilst this 
test would appear helpful in diagnosing MTBC infections in dogs, it may not always 
discriminate between the different species. This IGRA test is now available to clinicians at 
Biobest Laboratories, Edinburgh. 
Serological assays are for the identification of tuberculosis infections in humans and other 
animal species (Waters et al. 2017; Bezos et al. 2018; Chen et al. 2018; Infantes-Lorenzo et 
al. 2019). The advantages of these assays is that they are comparatively inexpensive and 
rapid in relation to other tests (Waters et al. 2017; Bezos et al. 2018). In the context of cattle 
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and wildlife species, the acquisition of the small volume of serum required to run the assay is 
practically easier than conducting tests such as the tuberculin skin test which requires the 
same individual to be handled twice, usually 72 hours apart (Infantes-Lorenzo et al. 2019). Of 
the available commercial assays, the Chembio Dual Path Platform VetTB Assay for Cervids 
has been used in dogs but using a test cut-off point that maintains a high specificify, the 
sensitivity was found to be poor (O’Halloran et al. 2018). Therefore it is likely that, for the 
forseeable future, this and similar serological tests currently only used in research, will only be 
useful for screening large groups of at-risk animals rather than being a reliable tests for 
individual dogs.  
10.3.4 Treatment and Outcome 
The treatment of canine tuberculosis is contentious as all of the MTBC organisms isolated 
from the cases considered in this review can cause human disease and the inappropriate 
treatment of pets may inadvertently lead to drug resistant isolates, further risking public health. 
Indeed, the treatment of M. tuberculosis infected pets has been strongly discouraged on public 
health grounds and owners of such animals should be referred to the appropriate public or 
general health professionals (O’Halloran and Gunn-Moore, 2017).   
By contrast, M. microti has only ever been identified in six dogs and although a small number 
of people have developed disease due to this organism, no cases have been linked to 
transmission from a dog (Emmanuel, 2007).  
The public health risk from infections with M. bovis may be considered to sit somewhere 
between that of M. bovis and M. tuberculosis. Unlike M. tuberculosis which represents the 
major cause of human disease, M. bovis now causes only approximately 1% of human 
tuberculosis cases in the UK (Glaziou et al. 2018). However, zoonotic cases due to dogs have 
been confirmed or strongly suspected in recent years (Ellis et al. 2006; O’Halloran et al. 2018). 
Despite this, Public Health England deem the risk of zoonotic tuberculosis due to pets to be 
“very low” (Public Health England, 2014).  
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Treatment details for tuberculosis was reported in 22 cases recorded cases in this study; 
including the 19 cases were management was supervised by the author and nine previously 
published reports. In 20 cases the dogs were infected with M. bovis and one dog was infected 
with M. microti. All except one M. tuberculosis infected dog euthanased at the time the 
diagnosis was confirmed.  
The treatment protocol for the 19 dogs supervised by the author was based on a triple 
antimicrobial combination of drugs, adapted to dogs from the published guidance for cats 
(O’Halloran and Gunn-Moore, 2017). This outlines combination therapy comprising rifampicin, 
a macrolide and a quinolone administered daily. This class combination has been chosen for 
several reasons. Firstly, streptomycin should be kept as a last‐resort antibiotic for human 
patients and should not be used in dogs (Engelmann et al. 2014). Secondly, isoniazid can 
cause severe adverse neurological effects that has led to euthanasia of a dog (Sykes et al. 
2007). Thirdly, pyrazinamide is useful ineffective for the treatment of M. bovis infections (de 
Jong et al. 2005). And quinolones, which have documented anti-mycobacterial activity are well 
tolerated by dogs (Govendir et al. 2011).  
All 19 dogs received rifampicin (generic), an essential component of anti-tuberculous therapy, 
at a dose rate of 10-15mg/kg by mouth (PO) every (q) 24 hours (Munir et al. 2019). Three 
dogs (15.8%) subsequently developed pruritic skin eruptions (Figure 10.6), putatively due to 
the rifampicin as a similar reaction has been reported for cats (O’Halloran and Gunn-Moore, 
2017), though these cases appeared more severe than has been documented in cats, and the 
lesions healed subsequent to the withdrawal of the drug. In these cases, rifampicin was 
replaced with doxycycline (RonaxanTM; Boehringer Ingelheim, Germany) at a rate of 10mg/kg 




Figure 10.6: A skin eruption on the back of a 6-year-old neutered male Bealge dog with an M. 
microti infection five weeks after starting therapy with rifampicin at 11.5mg/kg po q24 hours. 
The lesion extends craniodorsally (top to bottom of the picture) approximately 5cm by 2cm 
laterally. Image courtesy of Alex McInroy MRCVS.  
One dog receiving rifampicin became inappetant and evaluation of serum biochemistry 
revealed a serum alkaline phosphatase (ALP) to ten-times the upper reference interval. 
Rifampicin therapy was discontinued immediately, doxycycline was started at previously 
stated doses and the dog’s appetite returned within 24 hours. Serum biochemistry was not 
repeated but the dog made a full clinical recovery.  
All 19 dogs either received a macrolide alongside the rifampicin; ten dogs (52.6%) were treated 
with the drug azithromycin (ZithromaxTM; Pfizer, UK) at a dose rate of 10-15mg/kg po q24 
hours and the remaining nine dogs (47.4%) were treated with clarithromycin (generic) at a 
dose rate of 7.5-15mg/kg po q12 hours. Azithromycin was chosen for smaller sized dogs 
(~15kg or less) as this drug is available as a reconsitited suspension allowing the amount 
administered to be accurately measured. By comparison, clarithromycin is available as 250mg 
or 500mg tablets (NHS, 2019), and the former size is an optimal size for a ~16kg dog.  
In cases with respiratory tuberculosis, azithromycin has been argued for as the optimal 
macrolide drug choice. This drug characteristically concentrates in lung tissue at 100-fold 
greater levels than in the circulation (Hand et al. 2001). A further interesting characteristic is 
the ability of azithromycin to concentrate within inflammatory cells, particularly neutrophils and 
monocytes within the bloodstream, and tissue macrophages (Mandell et al. 2001). The 
ongoing inflammatory process in the lung of these dogs may recruit azithromycin-laden 
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neutrophils from the circulation which might then unload the drug in the presence of 
mycobacteria within inflammatory sites (Hand et al. 2001). Inflammatory cells can therefore 
act as “Trojan horses” delivering local concentrations of azithromycin that are several orders 
of magnitude greater than that in plasma (Blumer, 2005). 
The final drug in the triple combination is a quinolone. Pradofloxacin is recommended in cats 
due to its increased safety profile in this species (Sykes and Blondeau, 2014). Pradofloxacin 
has proven efficacy against mycobacteria and also has an excellent safety profile in dogs and 
so was used to treat seven of these 19 cases (Govendir et al. 2011; Boothe et al. 2018). The 
dose rates ranged from the UK licensed dose of 3-5mg/kg PO q 24hrs up to include the USA 
licensed dose of 7.5mg/kg PO q24hrs (Anon, 2018; Boothe et al. 2018). One dog, a four-year-
old male neutered Greyhound developed neutropenia after being on the higher dose of 
pradofloxacin and was transitioned onto marbofloxacin (Marbocare PTM; Animalcare, UK) at a 
dose of 2mg/kg PO q24 hours and the neutropenia resolved. Five of the dogs had been given 
empricial marbofloxacin therapy (at the previously stated rate) before the diagnosis of 
tuberculosis was made and so this was continued. Six dogs were treated with enrofloxacin 
(BaytrilTM; Bayer, Germany) at 5-10mg/kg PO q24hrs. One of the treated dogs was a one-
year-old Staffordhire Bull terrier and there were concerns about using quinolones in a dog of 
this age due to the potential for damage to developing cartilage, especially given the 
anticipated duration of therapy (Sebastian, 2007). For this dog, doxycycline was subsitituted 
for the quinolone component of the triple antibiosis (RonaxanTM; Boehringer Ingelheim, 
Germany) at a rate of 10mg/kg PO q 24 hours. 
Three dogs with pulmonary disease also presented with productive coughs. Due to concerns 
that this might pose a zoonotic risk to their owners, anti-tussive therapy was instigated. The 
dogs received 0.5-1mg/kg codeine phosphate PO q6-8 hours.  
These 19 cases were treated for a minimum of 12 weeks and for at least eight weeks following 
complete resolution of clinical signs. Where internal pathology had been noted then the 
treatment was extended until this had either resolved or had remained unchanged for at least 
six weeks i.e. any changes were no longer actively improving or deteriorating. Treatment 
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duration ranged from 14 weeks to 38 weeks (median 20 weeks). All dogs responded 
favourably to therapy and to the authors’ knowledge are still alive at the time of writing.  
The treatment protocols for three dogs are presented in the literature. One dog with abdominal 
tuberculosis was treated with rifampicin (generic) at 10 mg/kg administered PO q24h, 
clarithromycin (generic) at 12 mg/kg PO q12h, and enrofloxacin (BaytrilTM; Bayer, Germany) 5 
mg/kg administered PO q12h for three months when the enrofloxacin was discontinued and 
the remaining two former drugs were continued for a further three months (Englemann et al. 
2014). The dog fully responded to therapy and the authors report it was well 31 months after 
the initial diagnosis (Englemann et al. 2014).  
The second dog also presented with abdominal tuberculosis (due to M. bovis infection) but 
was only treated with enrofloxacin monotherapy (dose rate unknown) (Shrikrishana et al. 
2009). The dog only partially responded to therapy and was euthanased shortly after therapy 
was instigated.  
The final dog was resident in Brazil and it was initially based on the presumptive diagnosis of 
Ehrlichiosis and so was treated with chloramphenicol (50 mg/kg PO q12 hours), 
dexamethasone (0.30 mg/kg PO q24 hours), and fluids (Rocha et al. 2017). However, the 
treatment was ineffective and the dog progressed to death; M. bovis was confirmed at post 
mortem examination. 
10.4 Discussion  
This study, the largest review of canine tuberculosis, evaluated 1012 cases and markedly 
improves the current knowledge of this disease.  
Infecting Mycobacteria 
Historical reviews have suggested a 3:1 ratio of infections caused by M. tuberculosis and M. 
bovis (Birn et al. 1965; Clerx et al. 1992; Liu, 1980). However in this study found a decrease 
in this ratio to just 2:1. If only cases diagnosed in pet dogs (i.e. excluding the single large 
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outbreak of M. bovis in working Foxhounds in the UK) within the last ten years (2009-2019) 
are examined, then there is a clear inversion of this trend; there are twice the number of M. 
bovis cases compared to M. tuberculosis. Additionally, all six M. microti cases were diagnosed 
in this same ten year period. This likely reflects the continuing decline in human M. tuberculosis 
cases in the countries/regions from which these cases originated (mostly Europe, North 
America and New Zealand). The most common risk factor for a dog to present with an active 
M. tuberculosis infection in this study was still an exposure to a human with active tuberculous 
disease. The increase in M. bovis and M. microti cases may also reflect the increasing 
prevalence of these infections in countries such as the UK and/or increased diagnostic 
capacity (e.g. PCR) to separate out infections within the MTBC.  
Signalment 
This analysis found that young to middle aged adult dogs formed the majority of those infected 
with MTBC organisms with a range from six months to nine years. There was no significant 
difference between the age distributions of the dogs infected with M. tuberculosis, M. bovis or 
M. microti.  There was no sex predeliction for infection in the group of cases where this 
information was available, though this was only a minority of cases. This distribution, with a 
complete absence of older and geriatric dogs, may suggest that dogs may develop a degree 
of immunity as they age, potentially through exposure to environmental mycobacteria.  
Although the breed was only recorded in a very small group of cases (<3%), it is notable that 
most of the pedigree breeds reported were hound or terrier types. This may indicate that these 
hound and terrier type breeds have an increased susceptibility to MTBC infection, or it may 
reflect an increase in exposure e.g. to wildlife reservoirs due to the natural behaviours of these 
breeds such as scavenging and/or hunting small mammals. However, the very small number 
of cases where breed information is available makes it difficult to draw firm conclusions.  
Interestingly, there was no representation of breeds previously reported as susceptible non-
tuberculous mycobacterial infections such as Miniature Schnauzer’s or Boxers (Malik et al. 
1998; Sharp et al. 2019). Identification of the underlying genetics of these susceptibilities 
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would allow a greater understanding of the pathogenesis of mycobacterial infections and could 
lead to improvements in diagnosis and the development of new treatments.  
Clinical Signs 
For the first time, the clinical presentations of canine tuberculosis were grouped into four 
different clinical presentations which could be helpful as clinicians can detail the zoonotic 
implications e.g. pulmonary cases, which were found to be the most common are likely to pose 
the greatest risk of zoonotic transmission. The classification can also help with the prognosis 
e.g. all cases presenting with disseminated disease were fatal. The miscellaenous 
presentations reported here are critically important as this form of disease is almost certainly 
the most likely to be missed by clinicians who may not be suspicious of cases that do not 
present with the more commonly expected pulmonary form.  Delays in making a diagnosis can 
increase the risk to owners by extending the period of exposure to an infectious dog but also 
might mean that the opportunity to successfully intervene is lost.  
Diagnostics 
Specialist mycobacterial culture remains the gold standard diagnostic test but it not always 
practically possible and action (such as the instigation of therapy or euthanasia of the dog) 
may need to be taken prior to the availability of the results. Further work to validate PCR and 
IGRA methods would be helpful so that all stakeholders (owners, clinicians, public health 
officials and veterinary health officials) can have a clearer understanding of the test 
performance under normal field conditions and so interpret results appropriately. Although 
serological assays remain an attractive option for future development, it appears likely that 
they will remain too insensitive for use in individual patients.  
Treatment 
The very small percentage of cases (2.0%) were treatment was attempted implies that canine 
tuberculosis may be seen as carrying a poor prognosis but this analysis found that it is in 
reality a readily treatable infection; a good outcome (i.e. long term remisison of clinical disease) 
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was achieved in 86% of cases and 100% of cases were triple combination therapy was utilised. 
However, treatment was often of long duration and onwers must be aware of this before 
therapy is instigated. Also of significance, all cases of disseminated disease were euthanased 
on welfare grounds due to the severity of clinical signs and treatment would likely be 
unsuccessful in these dogs.  
Although there is a report of the successful treatment of a case of M. tuberculosis infection 
with triple combination antimicrobial therapy, this should be discoraged based on the risk to 
public health from these dogs.  
Side effects were reported with rifampicin therapy in a minority of cases which were severe 
including skin eruptions and both inappetance and induction of ALP activity. One dog was also 
reported as neutropenic, possibly due to chronic high dose pradofloxacin administration, but 
as this was a Greyhound, this may simply have been an incidental finding (Zaldívar-López et 
al. 2011). Dogs receiving anti-tuberculous therapy require careful monitoring and some 
clinicians may consider repeating haematological and serumbiochemical evaluation at regular 
interval (e.g. monthly) or if the dogs appear to become unwell whilst on treatment.  
Conclusion  
This analysis over over 1000 canine tuberculosis cases found that all cases were caused by 
infections with one of three MTBC organisms, M. tuberculosis, M. bovis or M. mircroti. This 
study found that in recent years the pattern of infections has changed with a relative decline 
in the significance of M. tuberculosis as compared with M. bovis and the first documented 
canine infections with M. microti. All cases conformed to one of four clinical groups based on 
the presenting signs; primary pulmonary, primary abdominal, disseminated or miscellaneous. 
For cases other than dogs with disseminated disease, treatment with triple combination 
antimicrobial therapy lead to good clinical outcomes but the treatment of dogs with M. 
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Abstract  
Murine bone marrow derived macrophages (BMDM) and human monocyte derived 
macrophages grown in colony stimulating factor 1 (CSF-1) have been widely used to study 
macrophage responses to infectious agents as well as Toll-like receptor (TLR) agonists. It was 
hypothesised that recombinant CSF-1 could be used to reliably generate canine BMDM in 
order to characterise them, examine the effect of TLR agonism and investigate the early (initial 
24 hours) response of these cells to mycobacterial infection. The culture of canine bone 
marrow cells for 10 days in recombinant human, porcine or canine CSF-1 at appropriate 
concentrations produced a pure population of BMDM that were adherent, morphologically 
resembled macrophages and expressed surface proteins typical of macrophages (as 
described in other species: the CSF-1 receptor, CSF-1, ADGRE-1, CD172a, CD163, CD16 
and CD14). Canine BMDM could be generated from bone marrow cells that had been 
cryopreserved so that multiple experiments could be conducted on cells from a relatively small 
number of animals. The canine BMDM produced were phagocytic and therefore permissive to 
mycobacterial infection whereupon they produced the pro-inflammatory cytokines TNF-α and 
IL-6 but not nitrite. The BMDM were also found to display mycobactericidal activity during the 
early phase of infection. Gene expression and cytokine production of canine BMDM in 
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response to the TLR4 agonist lipopolysaccharide, attenuated M. bovis bacille Calmette-Guérin 
and virulent M. bovis showed significant differences to the canine macrophage-like DH82 cell 
line indicating that the latter is not a good resource for the study of canine mycobacterial 
infections.  
11.1 Introduction  
Cells of the monocyte-macrophage lineage (MML) and their response to mycobacterial 
infection is considered in Section 1.6. These MMLcells include bone marrow progenitor cells, 
circulating cells of the MML and tissue resident macrophages. The  process of differentiation 
and maturation of macrophages from their progenitors is driven and regulated by the 
haemopoietic growth factors colony stimulating factor 1 (CSF-1) and interleukin (IL)-34 which 
share a common receptor (Hume, 2008; Fairbairn et al. 2011).  
Cells of the MML are frequently the first cells of the innate immune system to interact with any 
potential pathogen and their early response can have profound effects on the outcome of 
infection including pathogen killing and clearance, or persistence and the development of 
clinical disease (Burkey et al. 2009; Szatmary, 2012; Pahari et al. 2018). Macrophages 
represent the immunological niche for the persistence of mycobacteria, to this end they have 
evolved a number of mechanisms for the subversion of mycobacterial killing; some of which 
are considered in Section 1.6.5, making tem one of the most critical central cells to the host-
pathogen interaction and pivotal in the aetiopathogenesis of mycobacterial infections.    
Microbial pattern-recognition receptors (PRRs) are an essential early component of innate 
immunity, they detect and recognise conserved pathogen-associated molecular patterns 
(PAMPS), resulting in the activation of stimulated MML cells (and neutrophils) as part of the 
host response to eradicate invading pathogens whilst maintaining immunological tolerance by 
recognition of self (Burkey et al. 2009; Szatmary, 2012; Pahari et al. 2018). An important class 
of mammalian PRRs is the Toll-like receptor (TLR) family which recognise a wide range of 
microbial pathogens and pathogen-related products (Schneberger et al. 2011).  
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A number of studies which investigated the response of macrophages to mycobacteria in 
humans and mice demonstrated that stimulation of TLR2 and TLR4 receptors, as well as TLR1 
and TLR6 by mycobacteria-derived ligands results in downstream activation of the nuclear 
transcription factor NF-κβ which in turn leads to the up-regulation of genes encoding pro-
inflammatory cytokines such as TNF-α, IL-1β and IL-6 (Underhill et al. 1999; Quesniaux et al. 
2004; Bulut et al. 2005).  
While methods exist for the isolation and/or culture of MML cells from bone marrow across 
several species, this requires post mortem material which is not always readily accessible 
(Kapetenovic et al. 2012). Therefore, utilisation of a cell line that accurately mimics the 
response of ex vivo MML would be beneficial. The DH82 cell line was established from the 
neoplastic progenitor cells of canine malignant histiocytosis and was characterised as 
histiocytic in origin based on light microscopic and ultrastructural morphology (Wellman et al. 
1988). Since then it has been used as a model to investigate the canine response to 
intracellular pathogens including Leishmania spp., canine distemper virus and extracellular 
pathogens such as Mycoplasma canis (Puff et al. 2009; Michaels et al. 2016; Soto et al. 2019) 
The aim of this study was to utilise recombinant CSF-1 to generate canine macrophages from 
bone marrow (BMDM) in order to characterise them, examine the effect of TLR agonism and 
investigate the early (initial 24 hours) response of these cells to mycobacterial infection whilst 
comparing them to the established DH82 cell line in order to evaluate the usefulness of both 








11.2 Materials and Methods 
11.2.1 Isolation of Bone Marrow Cells 
Bone marrow was acquired from dogs and cats that were euthanased at the Royal (Dick) 
School of Veterinary Studies for reasons unrelated to this project. All animals came from the 
Edinburgh Dog and Cat Home and were euthanased because of a history of human-directed 
aggression or severe animal-directed aggression which precluded the rehoming of these 
animals to members of the public. No animals showed clinical signs of infectious disease, 
including mycobacterial infection, on veterinary examination prior to euthanasia. 
All euthanasias were performed by intravenous injection of pentobarbitone at a dose of 
≥1mg/kg administered by the author (a UK qualified and registered veterinary surgeon), 
following prior administration of oral sedation (acepromazine, ACP, 0.05mg/kg [ACP; Elanco, 
UK], phenobarbitone 3mg/kg [Epiphen, Vetoquinol, UK] and diazepam 1mg/kg [generic]) by 
the attending handlers, or by intramuscular injection of butorphanol 0.2mg/kg [Torbugesic; 
Zoetis, USA], 0.05mg/kg ACP and 0.05mg/kg medetomidine [Sedator; Dechra, UK] 
administered by the author.  
The sedation and euthanasia procedures as well as the use of cadavers for research purposes 
had prospective ethical approval from the University of Edinburgh Veterinary Ethics Research 
Committee and was adhered to throughout.  
The long bones; femur, humerus and ribs, were removed post-mortem from euthanased 
animals within one hour of euthanasia; the fascia and connective tissues were removed with 
a size 22 scalpel blade and the bones were then stored in PBS on ice until further processing 
(within four hours of euthanasia). The bones were surface decontaminated by immersion in 
70% ethanol for five minutes which was then removed by rinsing the bones in sterile PBS. A 
hand saw with a sterile blade attached was used to trisect the bones by incising through the 
diaphysis twice in order to expose the medullary cavity.  
392 
 
Bone marrow cells were removed by flushing the central cavity with warmed (37°C) RPMI 
1640 media supplemented with anticoagulant; sterilised sodium citrate, added to a final 
concentration of 3.2% by volume, through a 20mL syringe and 22 gauge needle. The flushed, 
cell-containing media was collected into 50mL sterile plastic tubes which were centrifuged at 
600 x g for five minutes before the supernatant was removed and discarded. The cell pellet in 
each tube was re-suspended in approximately 10mL of an ammonium chloride erythrocyte 
lysis buffer (composed of 8.26 g ammonium chloride, 1.0 g potassium bicarbonate, and 
0.037 g EDTA in 1dL of water), the suspension was transferred to a clean tube and incubated 
in the dark for seven minutes before the tube was filled with RPMI 1640 media supplemented 
with 20% foetal bovine serum. The suspension was passed through a 40µm Corning cell 
strainer (Corning Life Sciences, Germany) to remove any remaining debris and the flow 
through was again centrifuged at 600 x g for five minutes before the supernatant was removed.  
The cell pellets were re-suspended in a single mL of non-supplemented RPMI 1640 media 
and all suspensions were combined into a single clean tube at which time 10µL was removed 
and mixed with an equal volume of 2% Trypan blue stain prior to counting the number of live 
cells using a haemocytometer.  
11.2.2 Cryopreservation and Recovery of Bone Marrow Cells 
Cells were centrifuged at 600 x g for five minutes and the supernatant was discarded. Cold 
(4oC) cell freezing media comprised of heat inactivated FBS (Gibco, UK) containing 20% 
dimethyl sulfoxide (DMSO; Sigma Aldrich, UK) by volume was added dropwise to the cell pellet 
with manual agitation of the tube throughout. The volume added was sufficient to give a final 
cell concentration of 5x107 cells/mL. This cell suspension was divided into 1mL cryovials 
(Thermo Fisher Scientific, USA) which were placed into a pre-chilled (-20oC) Mr FrostyTM cell 
cooler containing isopropanol.  
The Mr FrostyTM cell coolers containing the cell vials were placed at -80oC for 72 hours after 
which time the cell vials were removed and transferred to a liquid nitrogen tank for long term 
storage. When needed, each vial was defrosted in a water bath pre-warmed to 37oC. The 
393 
 
thawed cells were transferred to a 15mL Falcon and 10mL of warmed complete culture media 
was added dropwise with agitation. The cells were centrifuged at 600 x g for five minutes and 
the supernatant was removed. Cells were re-suspended in 10mL of complete culture media 
(RPMI 1640 containing 100µg/ml L-glutamine, 10% foetal bovine serum, 100µg/ml penicillin, 
100U/ml streptomycin, 5x10-5M 2-mercaptoethanol and non-essential amino acids). Cell 
viability counts were performed using Trypan blue staining (Section 11.2.1).  
11.2.3 Culture of Bone Marrow Derived Macrophages  
When recovered from cryopreservation or removed from long bones, viable bone marrow cells 
(as determined by Trypan blue staining; Section 11.2.1) were diluted to a density of 1x106/mL 
in complete culture media. The cell suspension was plated into appropriately sized SterilinTM 
treated tissue culture plastic dishes (Thermo Fisher Scientific, UK). The growth factor 
recombinant colony stimulating factor 1 (r-CSF-1) was added at an appropriate concentration 
(see Section 11. 3). An equal volume of fresh complete culture media was added to cells after 
three days in culture at 37°C/5% CO2 along with sufficient r-CSF-1 so as to reach the same 
final concentration as on Day 0. After six days in culture, all media was removed, discarded 
and replaced with the same volume and quantity of r-CSF-1 as at time Day 0. 
11.2.4 Determination of Cell-surface Molecule Expression by Single and Dual 
Colour Flow Cytometry 
At four time points during macrophage differentiation; Day 0, 3, 6 and 10 the media was 
removed from the bone marrow cell cultures and transferred into 50mL Falcon tubes. The 
adherent cell layer was washed twice with sterile PBS to remove serum remnants. Following 
this, 10mL of non-enzymatic cell dissociation solution (Sigma Aldrich, UK) was added to the 
flask and incubated at 37oC until the cells visibly detached from the plastic. The cell solution 
was also transferred to a 50mL Falcon tube. All tubes were centrifuged at 600 x g for five 
minutes at room temperature, the supernatant was discarded and the cell pellets were each 
re-suspended in 1mL of complete cell culture media and combined into a single tube. Cell 
viability counts were performed using Trypan blue staining (Section 11.2.1). Cells were diluted 
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to a final concentration of 5x106/mL in complete culture media and 200µL (i.e. 1x106 cells) was 
added to the required number of wells of a round-bottom CELLSTAR® 96W Microplate (Sigma 
Aldrich, UK). The plate was centrifuged at 600 x g for five minutes at room temperature and 
the supernatants were discarded. Cells were washed twice in 100µL of sterile PBS and re-
suspended in block buffer (PBS containing 2% heat inactivated normal goat serum [Abcam, 
UK]) for half an hour at room temperature. Cells were washed twice in 100µL of sterile PBS to 
remove any serum remnants. The fixable cell viability stain Zombie Violet™ (Zombie Violet™ 
Fixable Viability Kit; Biolegend, USA) was added to all wells, other than the unstained control 
well, at a dilution of 1:1000 (as recommended by the manufacturer) in 50µL per well of sterile 
PBS without serum. Unstained control cells were re-suspended in 50µL of sterile PBS. The 
plate was incubated in the dark for 20 minutes at room temperature.  
Cells were washed twice in blocking buffer before primary antibodies including relevant isotype 
controls (Table 11.1) were added to the appropriate wells, diluted to the required concentration 
in 50µL of sterile PBS without serum. The plate was incubated in the dark for 30 minutes at 
room temperature. Cells were washed twice in blocking buffer before isotype- and species-
matched secondary antibody was added to the appropriate wells (Table 11.1), including a well 
with just secondary antibody added with no primary antibody, diluted in 50µL of sterile PBS 
without serum. The remaining control cells were re-suspended in 50µL of sterile PBS only. 
The plate was incubated in the dark for 30 minutes at room temperature and cells were then 
washed twice in sterile PBS and re-suspended in 100µL of 2% paraformaldehyde solution and 
left for 10 minutes at room temperature. Cells were washed twice in sterile PBS and re-
suspended in 100µL of flow cytometer buffer (sterile PBS containing 2% BSA, 2nM EDTA and 
2nM sodium azide). The plate was sealed with an adhesive plate sealant to prevent 
evaporation and kept refrigerated at 4oC overnight (approximately 16 hours) wrapped in foil to 
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The method for dual-colour staining was similar to that described above for single-colour 
staining, except that two isotype mis-matched primary antibodies were added to each sample 
(Table 11.1). Additionally, sequential wells of cells were stained with a single one of each of 
the fluorochromes used to act as compensation controls. Analysis of all stained cells was 
carried out using the BD Fortessa X20 flow cytometer and FlowJo software; 10,000 events 
(live cells) were collected. A representative gating strategy is demonstrated in Figure 11.4.  
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11.2.5 The Comparative Efficacy of Recombinant Canine, Porcine and 
Human CSF-1 for Generating Canine Macrophages  
A previous study has demonstrated that circulating canine and feline monocytes are capable 
of maturation into macrophage-like cells when grown in vitro in culture media supplemented 
with 104IU/mL of recombinant human (rh)-CSF-1 (Gow et al., 2013; Heinrich et al. 2017). 
Therefore, the same concentration (a gift from Professor David Hume) was initially used here 
to determine if macrophage cells could be derived from canine bone marrow. The resulting 
cells were assessed as being macrophages based on their morphology by light microscopy, 
expression of macrophage-associated cell surface molecules during the differentiation time 
course (Section 11.2.4) as well as adherence to treated tissue culture plastic and phagocytic 
capacity at the culmination of differentiation.  
The biological efficacy of recombinant canine (rc) and recombinant porcine (rp) CSF-1 (gifts 
from Dr Lissa Herron, The Roslin Institute) was assessed by testing cell viability via MTT (3-
4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay. In this assay the relative 
activity of NAD(P)H-dependent cellular oxidoreductase enzymes reflects the number of viable 
cells present in the well of a 96-well cell culture plate. These enzymes are capable of reducing 
the tetrazolium dye MTT to its insoluble formazan, which has a purple colour. 
Bone marrow was recovered from cryopreservation and viable cells (determined by Trypan 
blue staining) were diluted to a concentration of 2x107 cells/mL in complete culture media 
before 100µL was added to each well of a 96-well cell plate (NuncTM; Thermo Fisher Scientific, 
USA) i.e. 2x106 cells were added per well. A serial two-fold dilution series of each r-CSF-1 
were made in complete culture media, starting at a concentration of 2000ng/mL and ending at 
32ng/mL. A negative control condition was included by adding 100µL of complete culture 
media without r-CSF-1 supplementation to triplicate wells of bone marrow cells from each dog. 
A positive control condition was included by the addition of rh-CSF-1 diluted to a final 
concentration of 104IU/mL in complete culture media to triplicate wells of bone marrow cells 
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from each dog. The remainder of the cells had 100µL of the CSF-1 dilutions added in triplicate 
so that the final concentration of cells was 1x106/well.  
Plates were incubated at 37oC/5% CO2 for ten days with media changes (as described above 
in section xx) and the addition of fresh growth factor at Day 3 and Day 6. At Day 10 the media 
was removed and discarded, following this 100µL of RPMI-1640 media containing MTT at a 
final concentration of 1mg/mL was added to each well. The plates were returned to the 
incubator for three hours. At the end of the incubation period the MTT containing media was 
aspirated and discarded. To solubilise the formazan produced, 150µL of 4mM HCl in 
isopropanol was added to each well. The plate was covered in aluminium foil to protect the 
contents from light and incubated at room temperature on a plate shaker for 30 minutes. At 
the end of the 30 minutes the plate was visually checked to ensure that all of the formazan 
was in suspension, if not then the plate was returned to the plate shaker and rechecked at 10 
minute intervals until this was achieved.  
The optical density was quantified by measuring the absorbance at OD570nm; the data was 
exported to Microsoft Excel and analysed using GraphPad Prism 7. 
11.2.6 Phagocytosis Assay 
Following harvest of adherent BMDM cells after 10 days of differentiation in CSF-1 
supplemented complete culture media, 1x106 cells/ml were plated per well of a 6-well tissue 
culture plate in duplicate and cultured overnight at 37°C/5% CO2. Phagocytosis was initiated 
by the addition of fluorescein isothiocyanate (FITC)-conjugated Zymosan bioparticles 
(Molecular Probes, USA) at a particle to cell ratio of approximately 5:1, followed by further 
incubation for one hour. A negative control well was included where PBS was added to the 
complete culture media without Zymozan particles. Phagocytosis was stopped by the addition 
of 500 μL/well of ice-cold sterile PBS, followed by two further washes in ice-cold sterile PBS 
to remove extracellular particles.  
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All cells were fixed with the addition of 2% paraformaldehyde solution for 30 minutes at room 
temperature. The culture wells were washed twice with sterile PBS before 1mL of 0.1% Triton 
X100 solution (Sigma Aldrich, UK) in PBS was added for five minutes at room temperature in 
order to permeabilise cells. Blocking buffer comprising 3% bovine serum albumin in PBS was 
added to the cell monolayer and incubated at room temperature for one hour. After this 
incubation, blocking buffer was replaced with a solution of phalloidin Texas RedTM (Molecular 
Probes, USA) diluted 1:500 by volume in blocking buffer and incubated in the dark at room 
temperature for one hour.  
The cell plates were washed twice with PBS. Nuclear material was counterstained with the 
addition of 300nM 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Molecular Probes, 
USA) solution for five minutes at room temperature. The wells were washed five times with 
1mL deionised water which was not removed after the final wash. Cells were analysed for 
Zymosan particle uptake using fluorescence microscopy (Zeiss LSM710). 
11.2.7 Culture of Mycobacterial Reference Strains  
Reference strains of Mycobacterium (M.) bovis bacile Calmette–Guérin (M. bovis-BCG, strain 
1173P2 [Pasteur]) and M. bovis (strain ATCC BAA-935 / AF2122/97) were grown in the 
containment level two and three laboratory facilities of The Roslin Institute, University of 
Edinburgh, respectively. Single aliquots containing 1mL of mycobacteria suspended in culture 
media were added to 9mL of Middlebrook 7H9 media (Sigma Aldrich, UK) supplemented with 
Middlebrook ADC growth supplement (Sigma Aldrich, UK) to 10% by volume and 0.5g/500mL 
Tween 80 (Sigma Aldrich, UK).  
Cultures were incubated at 37oC/5% CO2 with agitation in a shaking incubator for 14 days, 
after this time the density was measured daily until an OD600 of 0.6 was reached, indicating 
that the mycobacteria had reached the exponential growth phase. At this time, the 10mL 
culture was added to a further 90mL of Middlebrook 7H9 ADC media and returned to the 
incubator. Again, the cultures were grown 37oC/5% CO2 with agitation for 14 days before daily 
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assessment of the OD value. Once an OD600 of 0.6 had been reached, the mycobacteria were 
aliquoted into sterile 1mL screw-topped Eppendorf tubes and stored at -80 oC until further use.  
Quantification of mycobacteria was conducted throughout by assessing the colony forming 
unit (CFU) count. To achieve this, serial ten-fold dilutions of thawed bacterial stock culture, or 
infected macrophage lysate (Section 11.2.8), were carried out in Middlebrook 7H9 ADC to a 
dilution factor of 1x10-6. Once diluted, 10μL of each dilution was pipetted in duplicate onto 
Middlebrook 7H11 solid agar plates supplemented with Middlebrook OADC mycobacterial 
growth supplement (Sigma Aldrich, UK). Plates were incubated upside down at 37ºC/5% CO2 
for 16 days. Colony numbers were counted at the dilution factor which allowed between 15 
and 50 colonies to be counted to maintain accuracy. The duplicate values were averaged and 
the dilution factor was used to calculate the original CFU/mL in the starting sample.  
11.2.8 Infection of Bone Marrow Derived Macrophages with Mycobacteria  
After 10 days in CSF-1 supplementes culture the resulting BMDM were detached from tissue 
culture plates by removing and discarding the culture media and washing the cell monolayer 
twice with PBS to remove serum remnants; following this, 10mL of non-enzymatic cell 
dissociation solution (Sigma Aldrich, UK) was added to each flask and incubated at 37oC until 
the cells visibly detached from the surface of the plastic as assessed using an inverted light 
microscope. The cell suspension was removed from the plates into 50mL Falcon tubes, 
centrifuged at 600 x g for five minutes and the supernatant was removed and discarded. Cell 
pellets were re-suspended in complete culture media containing r-CSF-1 at concentrations 
with equivalent biological activity to 104U/mL of rh-CSF-1 (as established in Section 11.2.5) 
and cells were diluted to a concentration of 106 cells/mL. A single mL of cell suspension was 
added to each well of a 6-well treated tissue culture plate and incubated at 37oC/5% CO2 for 
16-24 hours to allow the cells to re-adhere to the plastic.  
Aliquots of mycobacterial strains, frozen at -80ºC, were thawed at room temperature and 
diluted in complete culture media to a concentration that would give a defined multiplicity of 
infection (MOI) per mL. Media was removed from cell culture monolayers and replaced with 
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1mL of the mycobacterial suspension. Media was removed from uninfected control wells and 
replaced with 1mL warmed (37oC) complete culture media. 
Plates were centrifuged at 600 x g for five minutes, at room temperature, and then incubated 
at 37ºC/ 5% CO2. At each experimental timepoint, mycobacteria-containing media was 
removed from each well and macrophage monolayers were washed three times with warmed 
sterile PBS (37oC) to remove extra-cellular bacteria. All control wells were treated the same 
way. The PBS was replaced with 1mL per well of sterile cell culture media and plates returned 
to the incubator for the remainder of the infection time-course and samples were taken for 
downstream processing at the appropriate timepoints.  
For cells stimulated with LPS (Section 11.2.10) or infected with mycobacteria (Section 11.2.8), 
cell culture supernatants were harvested at various time points post-stimulation and frozen at 
-80oC before analysis by ELISA (Section 11.2.11) and Griess assay (Section 11.2.12). For 
analysis by reverse-transcription quantitative PCR (RT-qPCR; Section 11.2.13) cells were 
lysed in RNA buffer (RNA ReliaPrep System; Promega, USA) and stored frozen at -80oC until 
further analysis.  
11.2.9 Culture of DH82 Cells  
The cell line, DH82 (CRL-10389; American Type Culture Collection [ATCC], USA), represents 
a macrophage-like immortal cell lineage derived from a spontaneously arising histiocytic 
sarcoma of a 10-year old Labrador in 1988 (Wellman, 1988). Upon receipt of the cell line (on 
dry ice) from ATCC, the vial was defrosted in a water bath pre-warmed to 37oC. The thawed 
cells were transferred to a 15mL Falcon and 10mL of warmed complete culture media was 
added dropwise with agitation. The cells were centrifuged at 600 x g for five minutes and the 
supernatant was removed. Cells were re-suspended in 20mL of complete culture media, 
added to a 75cm2 treated tissue culture flask (NuncTM; Thermo Fisher Scientific, USA) and 
incubated at 37oC/5% CO2. After 24 hours the media was removed (along with any non-
adherent cells) and the cell layer was washed twice with warmed (37oC) sterile PBS; 20mL of 
fresh complete culture media was added and the flask was returned to the incubator. After 
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three days, when the cells reached approximately 80% confluence, the media was removed 
and the cell layer was washed twice with PBS before 10mL 0.25% Trypsin-0.53mM EDTA 
solution (Sigma Aldrich, UK) was added to the flask and incubated at 37oC until the cells visibly 
detached from the plastic. A count of viable cells was performed by mixing 10µL of cell 
suspension with the same volume of 2% sterile filtered Trypan blue and assessed using a 
haemocytometer. The cells were centrifuged at 600 x g for five minutes and the supernatant 
discarded. The cell pellet was then re-suspended in complete culture media to a density of 
1x104 cells/mL and 20mL were added to one or more 75cm2 treated tissue culture flasks 
(NuncTM, Thermo Fisher Scientific, USA) as required and returned to the incubator. Remaining 
cells were cryopreserved to maintain low passage number cells; all experiments were 
performed on cells between passage number two and five. Complete culture media was 
replaced every three days between sub-cultures.   
11.2.10 Stimulation of Bone Marrow Derived Macrophages with 
Lipopolysaccharide 
On day 10 of differentiation in r-CSF-1, BMDM were detached from tissue culture plates 
(Section 11.2.3) by removing and discarding the culture media, washing the cell monolayer 
twice with PBS to remove serum remnants. Following this, 10mL of non-enzymatic cell 
dissociation solution was added to each flask and incubated at 37oC until the cells visibly 
detached from the surface of the plastic as assessed using an inverted light microscope. The 
cell suspension was removed from the plates into 50mL Falcon tubes, centrifuged at 600 x g 
for five minutes and the supernatant was removed and discarded. Cell pellets were re-
suspended in complete culture media containing r-CSF-1 at concentrations with equivalent 
biological activity to 104U/mL of rh-CSF-1 and cells were diluted to a concentration of 
106cells/mL.  
A single mL of cell suspension was added to each well of a 6-well treated tissue culture plate 
and incubated at 37oC/5% CO2 for 16-24 hours to allow the cells to re-adhere to the plastic. 
The cells were treated with LPS from Salmonella enterica serotype Minnesota strain 595 (Re 
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mutant) (Sigma-Aldrich, UK) at a final concentration of 100 ng/ml other than one well in each 
plate where the media was replaced with fresh complete culture media to act as an 
unstimulated control well. Stimulations were run in duplicate for each condition assessed. 
11.2.11 Quantification of Cytokine Secretion by ELISA  
The cytokines TNF-α (DY1507) and IL-6 (DY1609) were quantified by commercial canine 
ELISA purchased from R&D Systems (United States). For each assay, flat bottomed 96-well 
plates (Nunc MaxisorpTM plates; Sigma Aldrich, UK) were coated with the appropriate capture 
antibody diluted in carbonate/bicarbonate buffer or PBS at the concentration instructed and 
incubated overnight at room temperature.  
Wash steps were conducted as follows: plates were washed five times in PBS/ 0.05% Tween-
20, using the Skan Washer 400 plate washer. Coated plates were washed and blocked for 
between one and two hours using 100µL per well of Reagent Buffer (R&D Systems; United 
States). Plates were washed again, and 50μL of supernatants were added to the plate in 
duplicate. Recombinant cytokine was serially diluted 1:2 (in duplicate) to produce a standard 
curve, and the plate was incubated at room temperature for one hour. A wash procedure was 
carried out, and 50μL of the appropriate biotinylated detection antibody was added to each 
well and incubated at room temperature for one hour. Plates were washed and 50μL 
streptavidin-HRP (provided with the ELISA kit, diluted 1:200 in reagent diluent as instructed) 
was added to each well. Plates were incubated for one hour then washed again. Subsequently, 
50μL of TMB substrate solution (1-Step TMB Ultra ELISA Substrate; Thermo Fisher Scientific, 
United States) was added to each well and plates were incubated in the dark until colour 
appeared in the bottom standard. The reaction was stopped by the addition of 25μL 1M H2SO4 
per well. Absorbance was measured at 450nm using the Synergy HT Multi-Mode Microplate 
Reader and Gen 5 software. The results were exported to Microsoft Excel and subsequent 




11.2.12 Quantification of Nitrite by Griess Assay 
Following differentiation, BMDM were stimulated with LPS (as described in Section 11.2.10) 
or were infected with mycobacteria (as described in Section 11.2.8). The concentration of 
nitrite produced was measured in the supernatant at each time point of stimulation or infection 
using the Griess Reagent System (Thermo Fisher Scientific, US). Initially, a seven-point two-
fold serial dilution of nitrite standard diluted in RPMI 1640 culture media was produced ranging 
from 100µM to 1.56µM and 50µL of each concentration was plated in triplicate into a 96-well 
tissue culture plate (Thermo Fisher Scientific, United States). The sulfanilamide and N-1-
napthylethylenediamine dihydrochloride (NED) solutions were left for 15-30 minutes to 
equilibrate to room temperature. During this time 50μL of each experimental sample was 
plated in triplicate in the remainder of the plate. Once equilibrated, 50μL of the sulfanilamide 
solution was added to all experimental samples and wells containing the dilution series for the 
nitrite standard reference curve. The plate was then incubated for between five and ten 
minutes at room temperature, protected from light, before 50μL of the NED solution was added 
to all wells. The plate was again incubated at room temperature for between five and ten 
minutes, protected from light. Once the purple/magenta colour had formed in the wells 
containing the lowest concentration of nitrite standard the absorbance was measured at 
535nm, using the Synergy HT Multi-Mode Microplate Reader and Gen 5 software. 
11.2.13 Quantification of Cytokine Gene Expression by RT-qPCR 
Cells challenged with either LPS or mycobacteria were collected in 500μL RNA buffer (Buffer 
BL+TG; Promega ReliaPrep™ RNA Cell and Tissue Miniprep System) which was stored 
frozen at -80oC until needed. The RNA was extracted by thawing the cell lystate, adding 170μL 
isopropanol to each sample and vortexing each before transferring the solution to a Promega 
ReliaPrep™ Minicolumn. The columns were centrifuged at room temperature at 6,000 x g for 
30 seconds and the flow through was discarded. The RNA was washed sequentially with 
500μL of RNA Wash Buffer 1 and 2 (Promega ReliaPrep™ RNA Cell and Tissue Miniprep 
System) with the columns being centrifuged at 6,000 x g for 60 seconds between each wash. 
The gDNA was removed from the samples by the addition of 30μL of DNase I incubation mix 
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(Promega ReliaPrep™ RNA Cell and Tissue Miniprep System) to each column for 15 minutes 
at room temperature. Each column was washed sequentially with 300μL of Column Wash 
Buffer and twice with 500μL of RNA Wash Buffer 1; columns were centrifuged at 6,000 x g for 
60 seconds at room temperature between washes. The RNA was eluted into 50μL of nuclease-
free water and the quantity of RNA was measured using spectrophotometry (NanodropTM). 
For each sample, 1μg of cDNA was synthesised using the GoScript™ Reverse Transcription 
System Protocol (Promega, USA) according to the manufacturer’s instructions. For each 
sample a reaction was run which did not include the reverse transcriptase enzyme (RT 
negative controls). The RT negative controls were evaluated for gDNA contamination by 
attempting to amplify the constitutively expressed reference gene (i.e. a housekeeping gene) 
HPRT1. For each sample a PCR reaction mixture of 5μL of GoldStar PCR Mix (Eurogentec, 
Belgium) was added 0.25μL of 25 pmol/mL oligonucleotide primer mix, 0.15mL of MgCl2, 1μL 
of sample as template and 3.6μL nuclease-free H2O was prepared. The PCR protocol 
consisted of heating to 95°C for three minutes followed by 25 cycles of heating to 95°C for 30 
seconds, cooling to 60°C for 30 seconds and warming to 72°C for 45 seconds before a final 
step of holding at 72°C for five minutes. The products were analysed by agarose gel 
electrophoresis using a 3% agarose gel and SYBR Safe stain. Only samples free of gDNA 
contamination were used for quantitative PCR (qPCR) analysis.  
The DNA sequences of candidate reference genes and the genes of interest were obtained 
from the NCBI nucleotide database and copied into the input window of the Primer3 website 
(http://primer3.ut.ee/). The product size range was set to between 80 and 150 base pairs. The 
number of primer pairs to be returned was set to ten and the list was rigorously checked in 
order to only select primer pairs that would result in minimal complementarity and therefore 
limit primer dimer formation. Where possible, primer pairs were selected which spanned an 
exon-exon junction and A BLAST search was run to ensure the primer pairs would not anneal 
to any non-target DNA sequences. Two primer pairs were tested per reference gene and 
details of all primers used are detailed in Table 11.2 
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Table 11.2: Canine RT-qPCR primers used in this study. All sequences are provided 5’ to 3’; 
bp: base pairs 
Target 
Gene 
Forward Primer Reverse Primer  Product 
Size 
(bp) 
Reference Genes  
GAPDH (1) GTGAACGGGAAGCTCACTGG TCCGATGCCTGCTTCACTAC 131 
GAPDH (2) GCTGAACGGGAAGCTCACT CGATGCCTGCTTCACTACCT 130 
β-Actin (1) TCCTTCCTGGGCATGGAATC GAGGTCCTTGCGGATGTCAA 87 
β-Actin (2) CTTCCTGGGCATGGAATCCT CCAGGGTACATGGTGGTTCC 129 
HPRT-1 (1) CTTCTGCAGGAGAACCTCCG TCACTAATCACGACGCTGGG 125 
HPRT-1 (2) CTGGCTATCATTGATCAGGTGA AACAAGCTCTGGCCAGTTTTA 112 
RPS-7  (1) CAAGATCGTGAAGCCCAACG ACTTCAATCTCCTTGGCCGC 141 
RPS-7  (2) TGAACTCCGACCTCAAAGCC CCGCCAACTTCAATCTCCTTG 80 
RPL-17 (1) TCTTTCGGGAGGAAATCTCGC ACCTCTCGACTTGCATGATTTTG 98 
RPL-17 (2) GATCACGTTCTTTCGGGAGGA CCTCTCGACTTGCATGATTTTGT 102 
RPL-30 (1) TCTGCATTGTGGGAGCTCTTT CTCCAGCGACTTTTTCGTCTT 125 
RPL-30 (2)  GGAAGAGCTCTGCATTGTGG TCCAGCGACTTTTTCGTCTTCT 130 
Genes of Interest 
MHC-II ACCTTTCTGGCTCCTGTGAC GGACAACTCTGACTCTCAGGC 146 
IL-1β CCTAGGAATGGGGCCTTCATC TGCATGCCAGCTACTACACC 145 
CYP27B1 CTAACCTGCAACCCTCTCCT GGGATTTCTTGCCTCGGCTC 148 
CCL20 GGACATTTGCCATTGGCTCC GGCATAAGGGTCCCAGTGAG 80 
IDO CTGTCCAGCAACTCCAGTCC AGAGACAGGTGAGAGTGTCTGA 91 
NOS2 CTGGCCCTTCTCAATATGGCT CAAGCACAGATGAAGTGGGTG 117 
 
For each gene, a 7-point standard curve of 10-fold dilutions of cDNA was conducted in order 
to calculate the efficiency of the reactions and optimise the primer and cDNA concentrations 
used. All qPCR reactions were performed using Takyon™ ROX SYBR 2X Mastermix 
(Eurogentec, Belgium).  Master mixes were made for each gene transcript as follows; 5.0µL 
2X Takyon mix, 1μL 25pmol mixed forward and reverse primer solution and 1.5µL nuclease-
free H2O.  
A total of 7.5µL of a single master mix was dispensed into each well of a 96 well plate, on ice, 
and 2.5µl of cDNA (diluted to the optimum concentration in nuclease-free H2O) or non-
template control added to appropriate wells. Two reference gene transcripts were evaluated 
contemporaneously to the genes of interest. Each sample to be tested was represented in 
duplicate. Wells were sealed with Ultra Clear qPCR caps and the plate was centrifuged at 400 
x g for two minutes.  The reaction was run on a Stratagene Mx3000P qPCR machine under 
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the following conditions; one cycle of heating to 50°C for two minutes and 95°C for two minutes 
followed by 45 cycles of heating to 95°C for 15 seconds followed by colling to 62°C for 30 
seconds a final single cycle of heating to 95°C for 60 seconds, cooling to 62°C for 30 seconds 
and heating to 95°C for 30 seconds whilst the dissociation curve was recorded. The 
dissociation curve was included in the protocol to ensure that only a single product was 
generated. All RT-qPCR data was analysed using MxPro software and Microsoft Excel.  
Relative quantification of the target transcript compared to the reference transcript was 
calculated using the 2-ΔΔCt method to determine fold-change in gene expression normalised to 












11.3 Results  
11.3.1 Bone marrow cells harvested from dogs differentiate into macrophage-
like cells in response to rh-CSF-1  
Previous studies have shown that rh-CSF-1 readily differentiates murine femoral bone marrow 
cells into mature macrophages and more recently the same has been shown for pigs 
(Kapetanovic et al. 2012; Assouvie et al. 2018). In both of these species, bone marrow cells 
can be cryopreserved and successfully differentiated upon recovery, for pigs this means that 
many cells can be obtained from the same animal and so this reduces the overall number of 
animals required for research purposes.     
In dogs, a number of culture conditions can induce the maturation of circulating monocytes 
into macrophages which are adherent to bacteriological plastic tissue culture dishes (Bueno 
et al. 2005). However, the acquisition of monocytes from dogs ante mortem is ethically difficult 
as it requires an invasive procedure (venepuncture and blood collection) and the number of 
cells obtainable is limited by the size of the dog (and therefore the quantity of blood that it is 
safe to draw). In addition, only a relatively small percentage of canine circulating peripheral 
blood mononuclear cells (PBMC) are monocytes; typically 2-4%, compared, for example, to 
bovine PBMC which are 10-15% monocytes.  
The first aim of this study was to develop a protocol for the efficient removal of bone marrow 
cells from the long bones of dogs, to maintain cell viability following cryopreservation and 
recovery of these cells, and to differentiate bone marrow cells into mature bone marrow 
derived macrophages (BMDM).  
Bone marrow was isolated from three dogs (Table 11.3) which yielded between 1.4x108 and 
1.2x109 cells per animal. Cells were either cryopreserved or plated immediately with the 
addition of 104IU/mL rh-CSF-1 (Figure 11.1) as this concentration has previously been shown 
to be effective for the generation of porcine BMDM and for maturing canine monocytes into 
mature macrophages (Kapetanovic et al. 2012).  
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Table 11.3: Signalment details of the dogs used to obtain bone marrow for the initial BMDM 
culture protocol optimisation.  
Dog Number Breed Age (years) Sex 
Dog 1 Jack Russel Terrier Five Male Neutered 
Dog 2 Staffordshire Bull Terrier Two Male Entire 
Dog 3 Pitbull Terrier One Male Entire 
 
 
Figure 11.1: Bone marrow cells from Dog 1 plated at 106 cells/mL on Day 0 in complete culture 
media supplemented with 104IU/mL rh-CSF-1. Representative image from one dog. 
 
Cells were assessed regularly until the majority had become adherent to the bacteriological 
plate and displayed the approximately round, vacuolated morphology of a mature 
macrophage. For all three dogs, this was found to be greatest after ten days in culture as 






























Figure 11.2: Representative images of BMDM cells from Dog 1 [A], Dog 2 [B] and Dog 3 [C] 
after ten days in complete culture media supplemented with 104IU/mL rh-CSF-1. Images taken 








Following cryopreservation, the viable cell recovery rate was between 63% and 80%. Thawed 
cells differentiated to produce morphologically identical cells to when bone marrow cells were 
plated from fresh (Figre 11.3); therefore future experiments used only cryopreserved cells.  
 
Figure 11.3: Representative image of bone marrow derived macrophage cells from Dog 1. 
The bone marrow cells were initially cryopreserved, thawed and cultured for ten days in 
complete culture media supplemented with 104IU/mL rh-CSF-1. Image taken at x40 
magnification.   
 
11.3.2 Canine bone marrow cells cultured in rh-CSF-1 acquire cell surface molecules 
typical of macrophages within ten days  
Human circulating monocytes are frequently subdivided into classical, intermediate and non-
classical phenotypes based on cell surface CD14 and CD16 expression (reviewed by Ziegler-
Heitbrock and Hofer, 2013) whereas pig monocytes can be grouped by CD16 and CD163 
expression (Ziegler-Heitbrock, 2014). The surface molecule CD172a (SIRPα) is most 
associated with expression on myeloid cells whilst ADGRE-1 (F4/80) is a widely used molecule 
specific to murine macrophages (Bastos et al. 2007; Waddell et al. 2018). The aim of this study 
was to use flow cytometric analysis of these and other cell surface molecules (CSF-1 and the 
CSF-1 receptor [CSF-1r]) to characterise the surface expression profile of canine bone marrow 
cells, as well as to examine and monitor changes in their expression profile during macrophage 
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differentiation in rh-CSF-1. The flow cytometry methodology (including antibodies used) is 
provided in Section 11.2.4.  
Bone marrow from three dogs (Table 11.4) was assessed at four timepoints; Day 0, Day 3, 
Day 6 and Day 10 of differentiation and an example gating strategy as applied to all samples 
is shown in Figure 11.4. The size and granularity of the cells was assessed by comparing the 
side scatter against forward scatter profiles; these cytometry plots from each timepoint for Dog 
4 are shown in Figure 11.5 as a representative example of the changes seen for all animals. 
The percentage of cell surface molecule-positive cells at each time point for all three animals 
tested is shown in Table 11.5 whilst individual plots for the single-colour staining are displayed 
in Figure 11.6. 
Table 11.4: Signalment details of the dogs used to obtain flow cytometry data during the 
differentiation of BMDM cells.  
Dog Number Breed Age (years) Sex 
Dog 3 Pitbull Terrier One Male Entire 
Dog 4 Staffordshire Bull Terrier Three Female Entire 












Table 11.5: The percentage of cells expressing each of the cell surface molecules tested for 
each of the four time points measured. N.B. The anti-CSF-1 receptor antibody tested did not 
label any canine cells at any time point.  
Cell surface 
molecule 
Day 0 Day 3 Day 6 Day 10 
Dog 3 
CSF-1 87.2.0 22.7 53.4 97.0 
ADGRE-1 3.64 8.02 11.2 87.5 
CD172a 59.9 23.1 58.9 97.2 
CD163 11.8 24.2 67.3 94.7 
CD16 47.3 6.88 18.8 56.2 
CD14 58.7 35.6 57.5 95.7 
CD14hi 3.2 6.55 11.5  
CD14/CD172a 54.9 23.0 32.7 98.8 
CD14/CD163 4.6 25.9 52.1 100 
CD14/CD16 28.2 6.6 12.2 50.0 
Dog 4 
CSF-1 59.4 21.2 25.2 96.1 
ADGRE-1 3.1 19.8 24.2 91.8 
CD172a 68.5 58.5 46.3 96.3 
CD163 3.9 17.4 49.8 96.7 
CD16 24.8 4.2 9.89 52.0 
CD14 56.5 20.1 42.4 98.4 
CD14hi 3.8 10.1 22.7  
CD14/CD172a 57.8 22.2 33.5 98.2 
CD14/CD163 3.4 20.1 47.8 93.1 
CD14/CD16 20.2 4.7 11.0 51.2 
Dog 5 
CSF-1 56.3 40.2 80.2 96.6 
ADGRE-1 5.95 43.5 76.9 95.2 
CD172a 52.1 60.7 73.8 99.2 
CD163 63.9 39.4 72.7 98.9 
CD16 27.4 3.7 41.2 61.4 
CD14 47.3 35.8 48.2 98.0 
CD14hi 4.06 15.8 67.6  
CD14/CD172a 60.3 41.4 44.9 97.2 
CD14/CD163 43.2 36.5 48.8 95.3 
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Figure 11.4: Flow cytometry gating strategy. Representative gating strategy (displaying data from Dog 4) for flow cytometry analysis for 
day 0 (A-F), day 3 (G-L), day 6 (M-R) and day 10 (S-X). The forward and side scatter of ungated cells are shown for each day in plots A, G, 
M and S respectively.  Forward scatter height (FSC-H) vs. forward scatter area (FSC-A) plots (B, G, N and T) were used to reduce the 
population to single cells only. Dead cells were excluded by gating only on cells negatively stained with the live-dead marker Zombie VioletTM 
(plots C, H, O and U). The remaing cell populations are shown in plots D, I, P and V with gating applied at 160K SSC-A vs. 140 FSC-A to 
demonstrate the increase in cellular size and granulation over the 10 days of differentiation in r-CSF-1. Plots E, J, Q and W show the gating 
for unstained cells for in the Blue-530-30 channel (FITC [488nm]) and plots F, K, R and X show the same for the Red-670-30 (AlexaFluorTM-
647) channel to show the change in auto-fluorescence over the timecourse. 
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Initially within the total bone marrow cell population there was a large population of mature 
granulocytes (as determined by size (Fsc) and granularity (SSc): oval gate; Figure 11.4). The 
bone marrow cells expressed CSF-1, CD14, CD172a and CD16 at Day 0 (Figure 11.5). Based 
on SSc, the granulocye population expressed CSF-1, CD16 and CD14, and were CD172a 
low. At Day 0 only a small percentage (3-6%) of the total viable bone marrow cells from each 
dog expressed ADGRE-1 and CD163.  
Over the course of differentiation with rhuCSF-1 the large SSc granulocyte population reduced 
between Day 0 and Day 3 (Figure 11.4). This was associated with an initial decline in the total 
percentage of cells expressing CSF-1, CD14, CD172a and CD16 (Figure 11.5). By contrast, 
the putatively monocyte-macrophage population of cells (lower SSc) that expressed ADGRE-
1 and CD163. 
By Day 6 the high SSc granulocyte population observed at day 0 was completely lost and the 
the total percentage of cells expressing CSF-1, CD14, CD172a and CD16 plateaued or slightly 
increased as the maturing monocyte-macrophage cells began to acquire these surface 
proteins. There was a concurrent increase in the percentage of cells expressed ADGRE-1, 
and CD163.  
By Day 10 all cells were adherent, larger (increased FSc), and more granular (increased SSc) 
than any of the cells present at Day 0 (as shown in Figure 11.4) and there is expression of 
CSF-1, CD14, CD172a, ADGRE-1 and CD163 as would be predicted for a pure population of 
mature macrophages (Figure 11.5). For each dog there was a variable proportion of cells 
observed at Day 10 which expressed CD16 (48-62%); suggesting  that in dogs the divisions 
of classical, intermediate and non-classical monocyte subsets may exist, as has been 
demonstrated in human bone marrow though further functional assays are needed to confirm 

































































Figure 11.5: Histogram plots showing the changes in cell surface marker expression of canine 
bone marrow cells after 0 days (A), 3 days (B), 6 days (C) and 10 days (D) in r-CSF-1. Sets of 
plots are shown for each of surface CSF-1 (1), ADGRE-1 (2), CD172a (3), CD163 (4), CD16 
(5) and CD14 (6). Stained cell populations are shown in red and isotype controls are shown in 
blue.  
11.3.3 Both recombinant porcine and recombinant canine CSF-1 can be 
used to derive macrophages from canine bone marrow cells, equivalent to rh-
CSF-1     
Although rh-CSF-1 has been used previously to generate mature macrophages from 
peripherally circulating canine monocytes (Gow et al. 2013), since this finding was published 
a recombinant porcine (rp)-CSF-1 had become commercially available and a recombinant 
canine (rc)-CSF-1 was under development. The aim of this study was to assess the response 
of canine bone marrow cells to rp-CSF-1 and rc-CSF-1 and therefore establish if these growth 
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factors can maintain viable cells and drive macrophage differentiation equivalently or more 
efficiently than rh-CSF-1.  
The biological activity of each r-CSF-1 was assessed by MTT assay. Bone marrow from eight 
dogs was cultured in either rp-CSF-1 (dogs 1-4) or rc-CSF-1 (dogs 5-8) with rh-CSF-1 at 
104IU/mL included for all dogs as a positive control condition. Alongside this cells of the DH82 
cell line, whose growth is CSF-1 independent were included cultured with rp-CSF-1. After ten 
days in culture the MTT assay was performed, the OD570 values were measured and the mean 
of three technical replicates is shown in Table 11.6.  
Table 11.6: Mean OD570 of three technical replicates for each dog after ten days of culturing 
bone marrow in r-CSF-1. Dog 1-4 and DH82 cells were cultured in rp-CSF-1. Dog 5-8 cells 
were cultured in rc-CSF-1. 
Concentration 
of CSF-1 (ng/mL) 
Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Dog 7 Dog 8 DH82 
1000 0.35 0.36 0.01 1.49 0.13 1.64 1.09 2.10 2.55 
500 0.25 0.23 0.01 1.47 0.11 1.23 0.71 0.78 2.54 
250 0.12 0.17 0.01 1.06 0.06 1.01 0.66 0.23 2.53 
125 0.05 0.14 0.01 0.65 0.05 0.79 0.52 0.08 2.48 
62.5 0.05 0.13 0.01 0.55 0.04 0.56 0.48 0.04 2.50 
31.25 0.05 0.08 0.01 0.04 0.011 0.64 0.35 0.02 2.50 
 
104IU/ml rh-CSF-1 0.32 0.34 0.01 1.38 0.08 0.65 0.54 0.18 2.51 
 
 
The OD570 values were plotted for each dog and joined by a curve of best fit (as shown in 
Figure 11.5). The equation of the line allowed the calculation of the concentration of rp-CSF-
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Figure 11.6: MTT assay for BMDM obtained from Dog 4 (■) and DH82 cells (●) cultured in 
varying concentrations of rp-CSF-1. A standard condition 104IU/mL rh-CSF-1 was used as a 
control for each cell type; shown by the red line for DH82 cells and the green line for Dog 4 
BMDM. Dog 4 was one of four dogs used to evaluate the biological efficacy of rp-CSF-1.  
 
Table 11.7: Concentration of recombinant (porcine/canine) CSF-1 (ng/ml) equivalent in 




















(ng/mL) equal to 
104IU/ml rh-CSF-1 
887 905 ∞ 723 487 36 134 226 ∞ 
 
While the MTT assays were used to establish cell viability in each r-CSF-1, the morphology of 
the cells generated was assessed after ten days in culture to ensure that the cells present 
were comparable to those generated by culture with rh-CSF-1. Both tested recombinant 
proteins generated cells with macrophage-like appearance as shown by representative 




Figure 11.7: Representative images of cells in culture after ten days of differentiation in 
complete culture media supplemented with either rc-CSF-1 (Dog 4, left) or rp-CSF-1 (Dog 8, 
right). 
All three recombinant proteins tested induced macrophage differentiation as determined by 
cell morphology and adherence to bacteriological plastic. As might be predicted, the canine 
protein was effective at lower final concentrations than the porcine protein; mean of 221ng/mL 
compared to 838ng/mL respectively. However, there was notable variation between the dogs 
tested. Bone marrow cells from one dog, Dog 3, did not respond at all to the recombinant 
porcine protein despite responding to rh-CSF-1 previously. The concentration of rc-CSF-1 
equivalent to 104IU/mL of rh-CSF-1 ranged from 36-487ng/mL whilst the results for rp-CSF-1 
ranged from 723-905ng/mL. Based on these findings the recombinant proteins were used at 
concentrations of; 104IU/mL rh-CSF-1, 850ng/mL rp-CSF-1 or 250ng/mL rc-CSF-1 to generate 
canine BMDM for further experiments.  
11.3.4 Canine bone marrow dervided macrophages are phagocytic  
A key aspect of macrophage function is their phagocytic capacity. To establish the phagocytic 
ability of the canine BMDM generated herein, differentiated cells from five dogs were assessed 
for their capacity to phagocytose zymosan particles and the resulting images are shown in 






Figure 11.8: Canine BMDM differentiated from Dog 4 in rh-CSF-1 exposed to either PBS 
control (left) or FITC fluorescent Zymozan particles (right) showing uptake of particles (green, 
indicated by white arrows). Cellular filamentous actin was stained with Texas Red phalloidin 
(red) and nuclear material was counterstained with DAPI (blue). Imaged using a Zeiss LSM710 
fluorescent microscope. One representative image of duplicate experiments from three dogs. 
 
11.3.5 Canine BMDM are permissive to Mycobacterium bovis infection and 
demonstrate mycobactericidal activity 
The main objective of developing a methodology for generating canine BMDM herein was to 
establish a model for the study of canine mycobacterial infections, and Mycobacterium (M.) 
bovis infections in particular. Previous studies that have examined the interaction of M. 
tuberculosis with human monocyte-derived macrophages, or M. bovis with bovine 
macrophages (Jensen et al. 2018) have utilised a multiplicity of infection of five (MOI=5). It 
was therefore necessary to establish whether this MOI was suitable for the study of canine 
BMDM-M. bovis interactions and to assess the number of mycobacteria required to achieve 
this in canine BMBM (Nazari et al. 2014; Ruiz et al. 2019). 
The reference strain of M. bovis AF-2122/97 was cultured and quantified whilst BMDM were 
derived from a single dog in rc-CSF-1 (Dog 3). The M. bovis was diluted in complete culture 
media to a range of concentrations/estimated MOI and was then used to challenge 1x106 
BMBM/well in vitro as described in Section 11.2.8. Briefly, at the timepoints 0, 0.5, 1, 2 and 24 
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hours post infection the mycobacteria containing media was removed and cells washed 
thoroughly to allow the remaining macrophages to be lysed and plated to determine the 
number of viable bacteria that had been internalised. The number of CFU of M. bovis in these 
lysates was quantifed by culture and the MOI was retrospecitively calcultated. The results are 
shown in Table 11.8. 
Table 11.8: The multiplicity of infection (MOI) calculated following different durations of 
challenge of canine BMDM with various concentrations of M. bovis AF-2122/97, n=1. 
Concentration 
of M. bovis/mL 
of culture media 
Calculated MOI 
at 0.5 hours post 
challenge 
Calculated MOI 
at 1 hour post 
challenge 
Calculated MOI 
at 2 hours post 
challenge 
Calculated MOI 
at 24 hours post 
challenge 
0 0.00 0.00 0.00 0.00 
1x106 0.97 0.75 0.39 0.33 
2x106 1.95 1.87 0.97 0.43 
5x106 5.03 3.74 1.78 1.57 
1x107 8.82 6.11 3.70 2.86 
These data demonstrate that a MOI=5 was best achieved when cells were challenged with 
five M. bovis per macrophage for 30 minutes before the media was changed. This allowed 
mycobacteria to enter or be phagocytosed by BMDM, but was not long enough for significant 
macrophage mediated killing to occur. The data also demonstrate a notable, rapid decline in 
the recoverable CFU of M. bovis from the BMBM of this animal within a 24 hour period 
indicating potentially potent mycobactericidal activity.  
To confirm this finding, the in vitro challenge was repeated with BMDM derived from six 
additional animals (Dogs 6-11, Table 11.9) and the CFU of M. bovis recovered at each of four 
time points (0, 2, 6 and 24 hours post infection; Figure 11.8). Media containing M. bovis 
containing media was added to canine BMDM and left for 30 minutes before being removed, 
the cells were then washed to remove any extracellular bacilli and complete culture media 
added. The time point ‘0 hours post infection’ was defined as the time that complete culture 





Table 11.9: Signalment details of the dogs from which canine BMDM cells were derived and 
infected with M. bovis.  
Dog Number Breed Age (years) Sex 
Dog 6 Beagle Three Male Entire 
Dog 7 Beagle Three Male Entire 
Dog 8 Beagle Four Male Entire 
Dog 9 Beagle Three Male Entire 
Dog 10 Beagle Four Male Entire 
Dog 11 Beagle Four Male Entire 
 
 
Figure 11.9: Canine BMDM from six dogs were grown for ten days in rh-CSF-1 and exposed 
to M. bovis at a predicted MOI of 5. At 0.5h post-infection cells were washed and media 
replaced. The number of CFU was calculated at the indicated time points post-infection in 
lysates from infected cells. Data represent the mean of duplicate CFU counts. 
This in vitro infection experiment confirmed the initial finding that canine BMDM display 
mycobacericidal activity; within the first six hours post infection there is a ten-fold reduction in 
the recoverable CFU count from approximately 5 mycobacteria/BMDM cell to 0.5 
mycobacteria/BMDM cell. The rate of killing then slows considerably and by 24 hours post 

























Time post infection (hours)
Dog 6 Dog 7 Dog 8 Dog 9 Dog 10 Dog 11
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11.3.6 Canine BMDM and DH82 cells respond to lipopolysaccharide 
stimulation and mycobacterial infection by producing pro-inflammatory 
cytokines but not nitrite  
Based on the key findings of studies in other species, the study presented here examined the 
proinflammatory response of canine BMDM and the DH82 cell line by quantifying the 
proinflammatory cytokines IL-6 and TNF-α in response Salmonella enterica serotype 
Minnesota strain 595 derived LPS, the attenuated M. bovis-BCG and virulent M. bovis. The 
BMDM were derived from three dogs (Dog 6, Dog 7 and Dog 8) and DH82 were routinely 
cultured. Cells were either stimulated with LPS or infected with mycobacteria. Supernatants 
from unstimulated control cells and the challenged cells were taken at 0 hours, 1 hours, 2, 
hour, 4 hours, 7 hours and 24 hours post infection. The supernatants were stored at -80°C 
before subsequent analysis by ELISA for the presence of IL-6 and TNF-α by ELISA and by 
Griess assay to determine the concentration of nitrite present. The cytokine response of the 
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Figure 11.10: The TNFα and IL-6 responses of DH82 cells and canine BMDM to LPS stimulation (A), 
M. bovis-BCG infection (B) or M. bovis infection (C) compared to uninfected/unstimulated BMDM (control 
BMDM) and DH82 cells (control DH82). Data points are the mean of three biological and two technical 






11.3.7 Canine BMDM and DH82 cells show different gene expression profiles 
in response to stimulation with LPS and infection with mycobacteria 
Due to the limitations of available immunological reagents for domestic dogs, futher 
comparison of the canine macrophage response to LPS, M. bovis-BCG and virulent M. bovis 
required the development of a RT-qPCR protocol to examine gene expression rather than to 
detect protein production and secretion. Therefore, it was first necessary to identify genes in 
canine BMDM and the DH82 cell line which retained stable expression levels under all three 
challenge conditions for use as reference genes.  
An initial panel of six genes was selected as shown in Table 11.2. These primer combinabtions 
were assessed by perfroming RT-qPCR on reverse transcriptase positive and negative 
samples. The RNA samples tested were collected from each timepoint and for all three stimuli. 
The primers that amplify hypoxanthine phosphoribosyltransferase 1 (HPRT-1, primer pair 
one), ribosomal protein S7 (RPS7, primer pair one), ribosomal protein L-23 (RPL-23, primer 
pair two) were the only three to give a single RT-qPCR product as determined by melt curve 
analysis (shown in Figure 11.12), and gave a stable expression level as assessed by the cycle 













Figure 11.11: Dissociation curves for the three primer pairs, HPRT-1 [A], RPS-7 [B] and RPL-






Table 11.10: The mean of duplicate Ct values for each candidate reference gene analysed at 

















HPRT-1  DH82 M. bovis 25.35 25.22 24.81 25.33 25.58 25.04 
HPRT-1 DH82 M. bovis 
BCG 
25.15 25.14 25.32 25.18 24.79 24.66 
HPRT-1 DH82 LPS 25.12 25.05 25.21 25.73 25.43 25.28 
 
        
HPRT-1 BMDM M. bovis 24.75 25.14 25.32 25.78 24.79 24.66 
HPRT-1 BMDM M. bovis 
BCG 
25.12 25.05 25.21 25.73 25.43 25.28 
HPRT-1 BMDM LPS 25.13 25.36 24.40 25.57 25.59 25.55 
 
        
RPS7 DH82 M. bovis 26.12 26.2 26.23 25.9 26.16 25.98 
RPS7 DH82 M. bovis 
BCG 
26.18 26.08 26.42 25.97 26.13 25.85 
RPS7 DH82 LPS 26.74 25.96 26.31 25.99 25.89 26.15 
 
        
RPS7 BMDM M. bovis 26.97 25.84 26.40 26.04 25.79 26.16 
RPS7 BMDM M. bovis 
BCG 
27.28 25.72 26.44 26.09 25.66 26.25 
RPS7 BMDM LPS 27.19 25.60 26.48 26.13 25.52 26.33 
 
        
RPL-23 DH82 M. bovis 31.15 31.06 30.83 31.15 30.91 30.40 
RPL-23 DH82 M. bovis 
BCG 
30.83 30.91 30.93 31.18 31.21 31.14 
RPL-23 DH82 LPS 31.21 30.82 31.09 31.15 30.93 30.40 
 
        
RPL-23 BMDM DH82 30.94 30.96 31.29 30.92 30.77 30.86 
RPL-23 BMDM M. bovis 30.97 30.84 31.42 30.92 30.78 30.86 
RPL-23 BMDM LPS 30.95 30.80 31.57 30.85 30.71 30.93 
 
In murine macrophages, nitrite is measurable in the cell supernatant following stimulation with 
LPS due to the upregulation of inducible nitric oxide synthase 2 (NOS2) and the metabolism 
of arginine to produce nitric oxide, an unstable free radical which rapidly forms nitrite in solution 
(Kapetanovic et al. 2012). In porcine BMDM, this process does not occur and neither the nitrite 
product nor NOS2 gene transcript are found following exposure to LPS and instead, pig BMDM 
alternatively upregulate L-tryptophan metabolism via indoleamine 2,3-dioxygenase 1 (IDO1) 
(Kapetanovic et al. 2012). To confirm the lack of nitrite production that suggests both DH82 
cells and primary canine BMDM respond similarly to pig BMDM, the expression of NOS2 and 
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IDO1 were quantified in both cell types following challenge with each of LPS, M. bovis-BCG 
and M. bovis as per Section 11.3.4. The gene expression of major histocompatibility complex 
II (MHC class II), IL-1β, the lymphoattractant chemokine CCL20 (also called MIP3α) and the 
vitamin D3-converting enzyme, Cyp27B1 were also measured by RT-qPCR in the same 
samples, normalised to HPRT-1 and RPS7. The results are given as a fold-change in gene 
expression compared to resting cells (i.e. time 0 hours post infection). Expression changes of 
greater than 2-fold from resting were considered to be biologically significant and are shown 
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Figure 11.12: The fold-change of gene expression after stimulation with LPS or infection with 
M. bovis-BCG or M. bovis for both DH82 and canine BMDM cells. Gene expression was 
compared to resting state for the six genes of interest, normalised to averaged HPRT-1 and 
RPS7 expression. The six bars represent the timecourse analysed; sequentially left to right 
showing 0 hours, 1 hours, 2 hours, 4 hours, 7 hours and 24 hours post infection/stimulation. 
Bars show the mean of three biological (Dog 6, 7 and 8) and two technical replicates for 
BMDM, and two replicate experiments for DH82 cells. Error bars show the standard deviation. 
The dashed line represents a 2-fold change which is considered biologically significant.  
The data presented in Figures 11.9 and 11.11 together demonstrate that canine BMDM display 
archetypal pro-inflammatory responses to all three stimuli examined; LPS, M. bovis-BCG and 
virulent M. bovis. The cytokines IL-6 and TNF-α were both secreted at detectable levels by 
four hours following stimulation. Post-stimulation, canine BMDM also significantly increased 
their expression of both MHC class II and of IL-β. Together these show conclusively that the 
BMDM generated herein are capable of adopting the classically activated phenotype. By 
comparison, the frequently studied DH82 cells also produced TNFα and IL-6 and significantly 
upregulated MHC class II when stimulated but did not show any change in IL-1β mRNA levels. 
There were also other differences between the two cell types in their response to the three 
stimuli examined.  
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In general, the BMDM responded more potently to all stimuli compared to DH82 cells. This 
difference was most clearly seen in response to M. bovis-BCG infection, which had a nearly 
negligible effect on DH82 cells over 24 hours with only small concentrations of IL-6 and TNF-
α secreted and only MHC class II was upregulated across the panel of six genes studied. In 
contrast, BMDM upregulated Cyp27B1, IL-1β, IDO-1, MHC class II and NOS2 gene 
expression as well as secreting significant amounts of both TNF-α (from two hours post 
infection) and IL-6 (from seven hours post infection). In response to M. bovis the concentration 
of TNF-α secreted by DH82 into the supernantant peaked at approximately 400pg/mL at four 
hours post infection before declining, whereas the concentration produced by BMDM 
continued to rise across the 24 hours time course, peaking at approximately 800pg/mL. The 
DH82 cells failed to induce IL-1β gene transcription under any of the conditions studies, which 
is supported by previous studies showing that the protein is not secreted when the cells are 












11.4 Discussion   
The aim of the study presented here was to utilise recombinant CSF-1 to generate canine 
macrophages from bone marrow in order to chararcterise them and then to examine the effect 
of TLR agonism and, critically, to investigate the early response of these cells to mycobacterial 
infection. An additional goal was to compare the response of the generated canine BMDM to 
the selected stimuli with the response of the frequently used DH82 cell line in order to evaluate 
the usefulness of both systems as models for studying canine mycobacterial infections.  
The data presented here demonstrate that the methodology developed herein can be used to 
generate macrophages from canine bone marrow. In keeping with BMDM from humans and 
pigs, the cells were found to be adherent, have typical macrophage morphology, and 
phagocytic capacity; all hallmark features of mature cells of the mononuclear phagocyte 
system. This study is the first to use bone marrow from dogs to generate macrophages where 
previous studies have instead used circulating monocytes. The major advantage of bone 
marrow as a starting source of cells is the ability to obtain many more cells from a single 
animal; allowing multiple experiments to be conducted with cells from a consistent background 
in terms of age, sex and breed that may all influence mature macrophage biology. This 
advantage is further conferred by the methodology shown here to cryopreserve bone marrow 
cells and still derive macrophages on recovery, meaning that significantly fewer animals may 
be needed for studies.  
Established culture protocols for the generation of canine monocyte derived macrophages 
requires seven days to produce mature cells even though the initial cell population is commited 
to the lineage (Heinrich et al. 2017). By comparison, the protocol produced here for BMDM 
takes ten days, only three days longer, suggesting that the use of r-CSF-1 in the method 
described in this study may act to drive bone marrow progenitors to commit to a macrophage 
fate and drives their maturation giving rise to robust differentiation protocol. The use of r-CSF-
1 also adds confidence that the final cell population is comprised purely of macrophages as 
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their survival is maintained in vivo by the action of CSF-1. This study is the first time that the 
surface expression of CSF-1 has been demonstrated on canine macrophages (Hume, 2018).   
Although the protocol almost always resulted in the generation of canine BMDM, individual 
animals varied quite considerably in their responsiveness to r-CSF-1, particualy when different 
r-CSF-1 molecules were directly compared. As this study only included a relatively small 
number of animals it was not possible to identify any individual reason for this variation in 
response; however, it may be a combination of factors such as breed, age and sex of the dog 
that the bone marrow cells were obtained from. Studies with a more homogenous population 
of dogs would be useful to gain better insight into the effect of these factors on the 
differentiation potential of bone marrow cells and their responsiveness to CSF-1 as this may 
also contribute to the susceptibility of an individual to infection and/or disease from 
mycobacterial challenge.  
Previous characterisation of canine monocyte derived macrophages has shown that they 
express the lineage associated surface molecules CD14 and CD163 whilst a subset express 
CD16 (Heinrich et al. 2017). Examination of histiocyte cells lines, such as DH82 cells, has 
additionally shown expression of CD172a (Takada et al. 2018). The data presented here show 
that the canine BMDM produced display the same expression pattern of these cell surface 
molecules; mature cells were consistently (over 95%) positive for CD14, CD163 and CD172a 
whilst just more than half expressed CD16 though this varied slightly from dog to dog. 
Numerous studies have divided blood monocytes from many species into subsets according 
to their expression of the surface markers CD14 and CD16; classical monocytes highly 
express CD14 but do not express CD16 (i.e. they are CD14++CD16−), intermediate cells also 
highly express CD14 but also express CD16 (CD14++CD16+) whilst non-classical monocytes 
express lower levels of CD14 and have high surface CD16 expression (CD14+CD16++) (Mandl 
et al. 2014; Ziegler-Heitbrock et al. 2014). In circulation, the classical phenotype dominates 
against lower numbers of the remaining two subtypes, but only one study has evaluated the 
presence of these subsets in the bone marrow of humans and has shown that the intermediate 
cell phenotype dominates (Mandl et al. 2014). In the present study, CD16 was co-expressed 
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with CD14 on both granuloctyes and monocytes (as defined by their forward and side scatter 
profiles) in undifferentiated bone marrow but this increased during the differentiation process 
so that by Day 10 a significant population of the macrophages were intermediate or non-
classical in phenotype, which is the first time that this has been shown in dogs. In this study it 
was not possible to differentiate CD14+ and CD14++ cells at Day 10 due to all cells being 
beyond the visual field; this was done to keep the cytometer parameters identical at all time 
points but this could be altered in future studies. Similarly, different subsets of human BMDM 
cells have been shown to have different biological functionality such as altered chemokine 
receptor expression profiles (Mandl et al. 2014). Therefore future studies of canine BMDM 
could separate the cells into phenotypic subsets and further explore their individual response 
to stimuli or infection.  
The F4/80 antigen, encoded by the Adgre1 locus, has been widely-used as a monocyte-
macrophage marker in mice, but its value as a macrophage marker in other species is unclear, 
and has even been questioned (Hume, 2018; Waddell et al. 2018). It has been previously 
demonstrated that ADGRE-1 is a myeloid differentiation marker in pigs, absent from 
progenitors in bone marrow, highly-expressed in mature granulocytes, monocytes, and tissue 
macrophages and induced by CSF-1 treatment in vivo (Hume, 2018; Waddell et al. 2018). 
Here, the same expression pattern of ADGRE-1 was demonstrated in canine macrophage 
progenitors in bone marrow and BMDM using the same antibody clone as the porcine study, 
which showed good cross-reactivity to dog. However, the granulocytes within the canine bone 
marrow did not stain positively for ADGRE-1 which was unexpected but was beyond the scope 
of this study to investigate further; future characterisation of the immunophenotype of cells 
within canine bone marrow would determine which cell types could be derived and studied ex 
vivo.  
Similarly to the expression of ADGRE-1, canine BMDM  may be similar to porcine BMDM in 
their pattern of producing TNF-α in response to LPS stimulation but not generating detectable 
nitrite. However, RT-qPCR analysis showed that the canine BMDM and DH82 cells did 
significantly upregulate NOS2 gene expression from four hours post LPS stimulation and so 
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extending the timecourse of this experiment may have revealed production at a later stage 
post stimulation. However, the production of mRNA does not necessarily always correlate with 
the induction of functional enzyme activity as a host of post-transcriptional modifications may 
occur which prevent translation. Alternatively, other reactive nitrogen species may be 
syntesised that are not detected by the Griess assay. The NOS2 enzyme acts to produce nitric 
oxide, an unstable radical that cannot be directly assayed and so nitirite is measured as a 
proxy. Canine BMDM may have redox mechanisms to safely deal with free radicals which 
may, in this case, produce alternative products to nitrite.  
The genes for CCL20, Cyp27B1 and IDO-1 were examined by RT-qPCR analysis as they 
represent different aspects of the host response to tuberculosis infections. The chemokine 
CCL20 attracts lymphocytes and immature dendritic cells to the site of infection and is 
expressed by M. tuberculosis infected human monocyte derived macrophages (Rivero et al. 
2010). The Cyp27B1 enzyme converts vitamin D3 which is a consistent feature of 
granulomatous disease processes, including tuberculosis (Chandra et al. 2004). Tryptophan 
metabolism is governed by IDO-1 and M. tuberculosis infection induces marked upregulation 
of IDO-1 expression in both human and murine macrophages in vitro (Blumenthal et al. 2012). 
In reponse to both mycobacterial infections (M. bovis and M. bovis-BCG) canine BMDM 
significantly (2-fold or greater) increased their expression of CCL20 at four, seven and 24 
hours post infection while IDO-1 and Cyp27B1 mRNA was present at significant levels from 
one hour and then at each subsequent time point of the infection time course examined. These 
data suggest that similar to other species, these genes and the metabolic pathways they 
belong to, are important factors in mycobacterial immunity and that the canine BMDM model 
developed herein is a more biologically appropriate model for the study of canine 
mycobacterial infections than the DH82 cell line.  
Further studies are needed to confirm and expand on the data shown here; further functional 
assessment of the cells such as quantification of phagocytic capacity and their ability to acidify 
phaogomes when stimulated/infected would add the the initial evidence that these cells are in 
fact macrophage. Future experiments could investigate the production of reactive nitrogen 
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species and nitrite by titrating concentrations of LPS and extending the timecourse of the 
challenge study which were logisitically not possible in this study but could be considered for 
future experiments.   
In conclusion; the data presented here demonstrate that canine BMDM can be generated 
using r-CSF-1 supplemented culture media, during culture the resultant cells gain surface 
expression of key macrophage associated proteins. After ten days of differentiation, cells are 
a pure population of adherent cells which are morphologically macrophage-like and are 
phagocytic. Canine BMDM derived in r-CSF-1 comprise both CD16- (classical) and CD16+ 
(intermidate/non-classical) subsets. These BMDM are permissive to mycobacterial infection 
and may represent a more biologically appropriate model for the study of canine tuberculosis 
infections than the commonly used DH82 cell line. These results could be expanded on by 
futher evaluation of the immunophenotypic subsets of canine BMDM and their potentially 
differing functionality as well as comparing different mycobacterial species and strains.  
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Chapter 12: Final Discussion  
 
In the UK, tuberculous mycobacterial infections were historically widely recognised in both 
cats and dogs (Anon, 1892; Anon, 1899). In the early 20th century the incidence of tuberculosis 
(TB) in the human population of the UK was as high as 300 cases per 100,000 of the 
population (Glaziou et al. 2018). Canine TB caused by the human adapted Mycobacterium 
(M.) tuberculosis first received significant attention in the UK in the late 1920s and early 1930s 
when it was shown that companion dogs can act as both spill-over hosts and as a sentinel 
species for human infections (Moore, 1928; Thayer et al. 1930; Adams and Vokwald et al. 
1932; Steinbach and Deskowitz, 1933). Similarly, zoonotic TB (caused by M. bovis infection) 
was commonplace (Glaziou et al. 2018). Until the end of the Georgian era, most of a city's 
milk supply would come from cows living in sheds within city limits, increasing the risk of direct 
spread of TB, either by milk or airborne infection, to city dwellers (Wallace and Crouch, 1933; 
Tobiesen et al. 1934; Galbrieth et al. 1982). During the 1930’s tuberculin testing was 
introduced for cattle in the UK; 40% of all cows were found to be reactors (Glaziou et al. 2018). 
With the introduction of pasteurisation, initially to prolong the shelf-life of milk, came the ability 
to control the major route of transmission of M. bovis disease to humans (Meara, 1976). At the 
same time, forty years of research had focussed on the dog as a model of primary pulmonary 
TB caused by both M. bovis and M. tuberculosis, whilst cases of feline TB due to M. bovis 
were regularly being recorded almost exclusively with alimentary pathology, presumptively 
following the ingestion of contaminated milk (Lemke, 1901; Lewis and Montgomery, 1913; 
Manwaring, 1913; Adams and Volkard, 1932; Howe, 1939a; Howe, 1939b). Interestingly, the 
apparent resistance of dogs to clinical disease and the lack of pathology in cats caused by M. 
tuberculosis had already been noted (Beretta, 1891; McFadyean, 1891).  
With the advent of vaccination, the development of antimicrobial agents, improvements in 
socio-economic conditions and the formation of the National Health Service, between 1940 
and 1990 the incidence of TB in the human population throughout the UK declined by 90% 
and the mortality rate fell by 98% (Glaziou et al. 2018). Throughout the same period, reports 
of companion animal TB in the literature saw a similarly dramatic decline and began to reflect 
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individual and sporadically occurring canine cases whilst reports of feline mycobacteriosis 
became largely limited to incidental findings during post mortem surveys (Dodd, 1952, Cordes 
et al. 1963; Birn et al. 1965).  
Significant recognition of feline TB as a re-emerging clinical entity in the UK entered the 
veterinary literature again in the late 1990’s with a description by Gunn-Moore et al. (1996) of 
19 cases of disease due to “an unusual mycobacterial variant” which retrospectively was likely 
to be M. microti (the vole bacillus). 
This major publication lead on to more in depth investigations into feline mycobacteriosis in 
the UK. Following the development of a feline interferon gamma release assay (IGRA) for cats 
in 2008 and with state funding made available for the gold standard test of specialist 
mycobacterial culture at the Weybridge reference laboratory, it was recognised that these 
infections were much more common than had previously been appreciated (Rhodes et al. 
2008). In 2011, two seminal papers were published by Gunn-Moore et al. (2011a, 2011b) 
describing feline mycobacteriosis in extensive detail. A follow-up study, published in 2013 
(Gunn-Moore et al. 2013), used histopathological submissions to estimate the incidence of 
feline mycobacterial disease and found that it is diagnosed at a rate of 1% of all routine feline 
submissions.  
This is the context into which this thesis is presented; four Chapters (2, 3, 7 and 9) present 
significant new data which build on the currently accessible diagnostic capacity for companion 
animal mycobacterial infections in the UK, evaluating techniques that could be translated into 
clinical settings in both the near future but also points to more advanced methods which could 
form the next generation of diagnostic tests. These Chapters indicate that molecular 
diagnostics using formalin-fixed biopsy tissue is a sensitive method for the identification of TB; 
the test methodology developed and presented in Chapter 2 could readily be translated into a 
commercially available quantitative test and significantly improve the current diagnostic 
capacity for companion animal mycobacterial infections in the UK. Data presented in Chapter 
7 also show the first attempt to develop ante mortem canine tests for TB; the development and 
implementation of the IGRA assay in real time during an outbreak evidenced its utility and it is 
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consequently already being offered to UK clinicians alongside the feline test at Biobest 
Laboratories, Edinburgh (Biobest, 2019).  
Studies presented in this thesis are the first to develop and assess diagnostic serological 
assays for sub-clinical canine TB infections and in Chapter 8, the accuracy of a subset of the 
most promising tests is examined using Bayesian latent class analysis. The findings support 
the implementation of these tests and the possibility of using the comparative ELISA as a 
screening test for working dogs in order to allay fears that hunting hounds may be inadvertently 
contaminating farm land with M. bovis is currently under consideration by the Master of 
Foxhounds Association.  
Two studies, presented in Chapters 3 and 9, explore the inflammatory processes associated 
with TB and other mycobacteria; one in cats and the other in dogs. Whilst the feline study was 
conducted on opportunistically collected blood samples, the canine study evaluated cytokine 
release into cell culture supernatant by cells stimulated with mycobacterial antigens. Despite 
the differences in study methodology, both studies demonstrate a strong cell mediated 
immune response to mycobacteria dominate in both of these species. Whilst these assays are 
currently too expensive to be considered for diagnostic use, the studies demonstrate 
considerable potential for the development of future multiplex cytokine assays which combine 
combinations of these inflammatory molecules into accurate and rapid diagnostic tests; in line 
with those being developed within human medicine, and for detection of TB in cattle (Clifford 
et al. 2019; Coad et al. 2019; Luo et al. 2019) but which are not currently available outside of 
a research context.  
This thesis presents two unprecedented outbreaks of TB in companion animal species 
(Chapters 4 and 5); one canine and the other feline, both caused by the contamination of 
feedstuffs with M. bovis genotype 10:a. The canine outbreak, published in O’Halloran et al. 
2018, was the first time that the transmission of M. bovis between dogs has been documented 
and resulted in nearly 100 dogs being euthanased. The origin of this outbreak was most likely 
to have been a contaminated bovine carcass which was fed inadvertently to the Foxhounds 
housed at the kennel. The findings of the outbreak investigation prompted a government policy 
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review of the feeding of raw products from fallen stock to hounds, permitted under Article 18 
of Commission Regulation (EC) No. 1069/2009.  A condition of this regulation is that fallen 
stock fed are not killed or have not died as a result of the presence or suspected presence of 
a disease communicable to humans or animals. An interpretation of this is that TB reactors, 
normally removed by APHA, and inconclusive reactors, should not be fed. The overall 
likelihood of at least one foxhound becoming infected with M. bovis within the next five years, 
if practices remained unchanged, was considered to be medium. In order to mitigate this risk, 
DEFRA has introduced tighter restrictions on the collection and feeding of fallen stock to 
hounds in registered kennels. As of 10 October 2017, legislation came into effect as a result 
of the findings presented in Chapter 4, to ban the feeding of offal from livestock species to 
dogs from recognised kennels or packs of hounds in England (Anon. 2017). Hunt kennel 
operators are also now required to carry out additional examinations for TB lesions in fallen 
stock originating from high risk premises. Additionally, APHA has developed training materials 
and guidance on the identification of TB in carcases of cattle and other livestock, for collectors 
and kennels feeding fallen stock to hounds.   
The feline outbreak of M. bovis due to contaminated venison being fed raw to cats (Chapter 
4) has highlighted a number of wider problems. It was clear from early in the investigations 
that were undertaken with the owners of cats affected by this outbreak that the public have 
little to no awareness of the microbiological risks presented to them or their pets by feeding 
raw food diets; a finding which is supported by the published literature. This is a deficit which 
urgently requires future work to address to redress the problem. Unlike the canine TB 
outbreak, these cats were affected in geographically disparate areas and countries of the UK 
and this meant that it was more challenging to unite different stakeholders around a unified 
approach to the outbreak, particularly as APHA do not have a statutory responsibility to 
investigate M. bovis infections in pets so initially no culture confirmation was offered pro bono. 
However, the conclusions of the epidemiological investigation were robust as they were 
evidenced by a number of culture isolates of M. bovis being whole genome sequenced, 
proving that they were genetically identical. As noted in the investigation, the withdrawal of UK 
Government funding to enable the culture high-risk companion animal samples in recent years 
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has led to owners showing a reluctance to choose this option. Negotiations are ongoing within 
the APHA as a result of the data presented within this thesis to potentially reinstate at least a 
portion of such funding to aid in the case of future outbreak situations. Owners who opted not 
to pay for culture testing were instead using tests viewed as un-validated by APHA and so 
future work is needed to increase the confidence in the accuracy of diagnostic tests for 
companion animal mycobacterial infections aside from culture.  
As well as the devastating impact of both of these unparalleled outbreaks on the animals 
affected, significant attendant risks to public health also emerged which were investigated 
contemporaneously (Chapters 4 and 6). Jointly, these public health investigations identified 
five people with latent TB infections (LTBI); almost equal to the six cases of M. bovis 
transmitted from cats to humans in the last 150 years (Public Health England, 2014). Due to 
the latent state of these infections it is not possible to definitively prove that they were zoonotic 
in origin, but the risk is considered “plausible” and “real” (O’Halloran et al. 2018). The nature 
of these investigations are by their nature complex and publications included in this thesis sets 
out a robust formal methodology for the approach (Phipps et al. 2019). The protocol was 
developed during the canine outbreak and was then successfully utilised when the feline cases 
emerged. This highlights the importance of understanding the nature of the pathogen causing 
the disease to establish zoonotic risk and inform appropriate action.  
Both of the outbreaks referred to above were caused by the same genotype of M. bovis, 
namely 10:a, and in both instances a number of cats and dogs were affected by severe and 
fulminant clinical disease which resulted in death or euthanasia on welfare grounds. This is 
clearly at odds with the conventional dogma in which TB is viewed as a chronic disease with 
an insidious onset before more severe clinical signs develop. Interestingly, in both instances 
pathological findings occurred which cannot be fully explained by our current knowledge of TB 
dynamics and kinetics in these species, such as the severe, necrotising renal lesions seen in 
a number of kennel dogs at post mortem examination. Chapter 11 of this thesis begins to 
characterise a novel in vitro method for the reliable generation of canine bone marrow derived 
macrophages using recombinant CSF-1. It is hoped that this work will now allow for the 
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characterisation of host-pathogen interactions between strains or subtypes M. bovis which 
have now been successfully isolated from animals affected by these outbreaks and canine 
bone marrow derived macrophages and the macrophage-like DH82 cell line. 
Finally, Chapter 10 formally examines our current knowledge of canine TB and brings the 
published literature for this species in line with that which is currently the case for feline 
mycobacteriosis.  
To conclude, this thesis has presented data which significantly add to our current knowledge 
with respect to the clinical aspects of TB in both cats and dogs in the UK. In the future, studies 
should focus on further understanding of the host-pathogen interaction. This will enable the 
development of additional diagnostic tests, or potentially vaccines that will enable the control 
of TB in companion animals 
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(?̅? + 𝟐𝑺𝑫) 
Positive 
control  
(?̅? − 𝟐𝑺𝑫) 
PPDA  
(?̅? − 𝟐𝑺𝑫) 
PPDB  
(?̅? − 𝟐𝑺𝑫) 
ESAT-
6/CFP-10  
(?̅? − 𝟐𝑺𝑫) 
Significant 
Responses 
1 0.05 3.41 -0.09 0.1 0 B only 
2 0.09 2.11 0.03 0.05 0.29 EC only 
3 0.12 0.65 0.17 0.13 0.13 Fail 
4 0.01 3.99 0.06 0.36 0.36 B>A +E 
5 0.03 4.11 0.48 1.62 0.96 B>A +E 
6 0.09 2.59 0.23 0.69 0 B>A 
7 0.01 3.73 0.05 0.3 0.77 B>A +E 
8 0.2 3.05 -0.07 0.05 0.03 Negative 
9 0.03 4.06 0.15 0.61 1.18 B>A +E 
10 0.03 2.69 0.03 0.07 0 Negative 
11 0.11 0.25 0.07 0.09 0.07 Fail 
12 0.09 2.87 0.02 0 0 Negative 
13 0.06 3.88 0.2 0.52 0.63 B>A +E 
14 0.07 2.27 0.06 0.16 0 B only 
15 0.08 2.27 0.05 0.06 0.08 Negative 
16 0.04 0.2 0.01 0 0.05 Fail 
17 0.3 3.51 0.45 0.3 0.5 A>B + E 
18 0.18 2.8 0.13 0.13 0.23 B>A +E 
19 0.01 4.25 0.17 0.44 2.24 B>A +E 
20 0.03 4.05 0.06 0.03 0 Negative 
21 0.09 2.11 0.03 0.05 0.29 EC only 
22 0.13 1.79 0.1 0.1 0.1 Negative 
23 0.32 2.8 0 0.1 0.09 Fail 
24 0.07 3.16 0.08 0.14 0 B>A 
25 0.08 3.34 0.06 0.21 0.03 B only 
26 0.08 3.94 0.05 0.45 0.06 B only 
27 0.1 2.84 0.5 1.5 0.8 B>A +E 
28 0.16 3.35 0.03 0.04 0.07 Negative 
29 0.04 3.65 1.4 1.68 1.89 B>A +E 
30 0.14 3.5 0.36 0.71 2.56 B>A +E 
31 0.05 2.76 0.08 0.14 0.24 B+E 
32 0.15 2.18 0 0.12 0 Negative 
33 0.3 3.02 0.12 0.04 0 Negative 
34 0.25 3.03 0.01 0.04 0 Negative 
35 0.12 3.29 0.05 0.81 0.71 B+E 
457 
 
36 0.08 1.99 0.01 0 0 Negative 
37 0.02 3.05 0 0.25 0.21 B+E 
38 0.07 3.33 0.06 0.07 0 Negative 
39 0.18 2.8 0.13 0.13 0.23 B>A +E 
40 0.07 2.48 0.01 0.03 0.08 EC only 
41 0.25 1.34 0.03 0 0.18 Negative 
42 0.12 4 0 0.01 0.01 Negative 
43 0.04 0.71 0.04 0 0.03 Fail 
44 0.08 0.26 0.05 0 0 Fail 
45 0.05 4.62 0 0.51 0.21 B+E 
46 0.09 2.18 0.06 0.08 0.14 EC only 
65 0.06 4.51 0.07 0.04 -0.02 Negative 
66 0.01 4.17 0.02 0.01 0.40 EC only 
67 0.16 4.32 0.03 -0.18 0.08 Negative 
68 0.26 4.47 0.00 0.04 -0.01 Negative 
69 0.05 0.79 0.01 -0.20 0.46 EC only 
70 0.06 2.00 0.03 -0.05 -0.03 Negative 
71 0.08 2.22 0.06 0.02 0.02 Negative 
72 0.02 4.60 0.01 -0.03 -0.01 Negative 
73 
     
Fail 
74 0.13 0.65 0.01 0.04 0.00 Negative 
75 -0.01 2.01 -0.01 0.00 -0.01 Negative 
76 0.00 2.27 -0.01 -0.01 -0.01 Negative 
77 0.01 4.51 0.00 0.08 0.00 Negative 
78 
     
Fail 
79 0.01 2.44 -0.02 -0.03 -0.02 Negative 
80 0.02 4.42 0.01 -0.01 -0.01 Negative 
81 0.00 2.52 0.00 0.02 -0.01 Negative 
82 0.82 3.91 0.18 0.29 0.07 Negative 
83 0.00 3.34 0.00 0.00 -0.25 Negative 
84 0.02 4.61 0.01 0.02 0.01 Negative 
85 0.06 3.91 0.01 0.10 -0.01 B only 
86 0.01 4.10 0.44 1.25 0.26 B>A +E 
87 0.01 4.28 0.19 1.05 0.13 B>A +E 
88 0.02 4.23 0.01 0.12 0.02 B only 
89 0.03 4.24 0.03 0.18 0.00 B only 
90 0.02 4.10 0.12 1.32 1.70 B>A +E 
91 
     
Fail 
92 1.19 3.43 0.20 1.18 1.05 Fail 
93 0.03 3.16 0.07 0.29 0.10 B>A +E 
94 -0.01 0.86 -0.01 -0.01 -0.01 Negative 
95 0.97 3.55 0.00 -0.01 0.00 Negative 
96 0.02 3.66 0.03 0.04 0.02 Negative 
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97 0.01 4.73 0.10 0.11 0.00 B>A 
98 0.01 4.30 0.01 0.95 0.01 B only 
99 0.66 3.98 0.01 0.01 0.01 Negative 
100 0.02 4.16 0.02 0.22 0.02 B only 
101 0.02 4.15 -0.34 0.02 0.00 Negative 
102 -0.06 4.42 -0.07 -0.08 -0.17 Negative 
103 0.01 4.19 0.01 -0.13 0.02 Negative 
104 0.08 2.73 -0.05 -0.04 -0.05 Negative 
105 -0.06 4.44 -0.06 -0.08 -0.07 Negative 
106 0.08 4.49 0.14 -0.03 -0.04 A only 
107 0.00 4.42 -0.02 -0.05 -0.06 Negative 
108 0.09 4.64 -0.01 -0.02 -0.04 Negative 
109 0.11 4.51 0.03 -0.03 -0.03 Negative 
110 0.04 4.39 0.01 0.01 -0.01 Negative 
P1 0.15 1.11 0.09 0.09 0.05 Negative 
P2 0.20 2.35 0.08 0.10 0.12 Negative 
P3 0.39 3.48 0.16 0.13 0.13 Negative 
111 0.26 0.62 0.08 0.31 0.17 Positive 
112 0.49 2.05 0.09 0.09 0.07 Negative 
113 0.14 0.86 0.10 0.09 0.08 Negative 
114 0.34 1.79 0.08 0.11 0.06 Negative 
115 0.12 1.85 0.14 0.17 0.11 Positive 
116 0.19 2.98 0.13 0.13 0.10 Negative 
117 0.14 3.37 0.09 0.12 0.11 Negative 
118 0.14 2.97 0.08 0.20 0.15 Positive 
119 0.11 3.13 0.11 1.18 0.48 Positive 
120 0.18 2.59 0.16 0.71 0.49 Positive 
121 0.16 1.17 0.07 0.13 0.06 Negative 
122 0.26 4.07 0.11 0.27 0.31 Positive 
123 0.17 4.01 0.11 0.19 0.25 Positive 
124 0.20 4.00 0.14 0.05 0.14 Negative 
125 0.17 3.43 0.14 0.25 0.14 Positive 
126 0.26 4.13 0.13 0.16 0.14 Negative 
127 0.21 4.42 0.39 1.44 0.41 Positive 
128 0.16 3.91 0.20 0.94 1.59 Positive 
129 0.16 3.80 0.14 0.28 0.18 Positive 
130 0.14 3.68 0.40 0.42 0.21 Positive 
131 0.19 4.14 0.22 1.37 0.57 Positive 
132 0.20 3.62 0.20 0.10 0.05 Negative 
133 0.13 3.19 0.31 1.51 0.33 Positive 
134 0.13 2.84 0.09 0.09 0.10 Negative 
135 0.13 1.95 0.25 0.16 0.10 Positive 
136 0.15 2.56 0.00 0.16 0.11 Positive 
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137 0.24 3.15 0.19 0.16 0.15 Negative 
138 0.13 2.54 0.11 0.18 0.13 Positive 
139 0.32 2.87 0.12 0.09 0.09 Negative 
140 0.32 3.38 0.18 0.17 0.37 Positive 
141 0.15 2.41 0.13 0.14 0.09 Negative 
142 0.15 2.30 -0.16 0.20 0.37 Positive 
143 0.30 3.38 0.19 -0.05 -0.07 Negative 
144 0.23 2.98 0.14 0.15 0.12 Negative 
145 0.15 3.16 0.17 0.10 0.11 Positive 
146 0.12 0.08 0.09 0.07 0.10 Fail 
147 0.16 1.74 0.05 0.15 0.12 Negative 
148 0.31 1.43 0.12 0.18 0.15 Negative 
149 0.17 2.10 0.19 0.27 0.14 Positive 
150 0.50 2.45 0.14 0.12 0.14 Negative 
151 0.24 3.04 0.19 0.17 0.12 Negative 
152 0.16 0.91 0.09 0.12 0.08 Negative 
153 0.15 0.57 0.10 0.12 0.09 Negative 
154 0.20 1.50 0.06 0.10 0.10 Negative 
155 0.14 0.25 0.10 0.08 0.10 Negative 
156 0.10 1.07 0.28 0.63 0.13 Positive 
157 0.24 4.48 0.13 0.16 0.15 Negative 
158 0.66 3.45 0.25 0.70 0.22 Positive 
159 0.15 2.61 0.17 0.89 0.22 Positive 
160 0.15 2.59 0.34 0.56 0.08 Positive 
161 0.37 1.80 0.16 0.19 0.12 Negative 
162 0.27 4.50 1.00 2.79 1.58 Positive 
163 0.19 1.83 0.18 0.52 0.12 Positive 
164 0.39 2.62 0.42 1.06 0.02 Positive 
165 0.34 3.60 0.24 0.19 0.21 Negative 
166 0.35 4.04 0.22 0.78 0.20 Positive 
167 0.60 3.41 0.16 0.16 0.23 Negative 
168 0.25 3.91 0.67 1.15 0.26 Positive 
169 0.25 1.47 0.27 0.21 0.17 Positive 
170 0.27 2.80 0.20 0.74 0.45 Positive 
171 0.28 3.15 0.20 0.25 0.08 Negative 
172 0.43 0.82 0.09 0.11 0.17 Negative 
173 0.44 2.65 0.22 0.31 0.15 Negative 
174 0.27 3.56 0.45 0.96 0.53 Positive 
175 0.50 3.05 0.15 0.10 0.04 Negative 
176 0.22 2.61 0.20 0.28 0.12 Positive 
177 0.27 2.89 0.15 0.18 0.18 Negative 
178 0.31 2.82 0.28 0.70 0.33 Positive 
179 0.44 1.48 0.02 0.12 0.16 Negative 
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180 0.14 0.23 0.08 0.06 0.06 Negative 
181 0.08 2.17 0.10 0.13 0.08 Positive 
182 0.09 2.74 0.19 0.88 0.14 Positive 
183 0.10 3.48 0.11 0.08 0.06 Positive 
184 0.22 2.50 0.05 -0.08 0.04 Negative 
185 0.27 2.65 0.08 0.12 0.11 Negative 
186 0.17 3.49 0.81 0.73 0.25 Positive 
187 0.11 2.35 0.10 0.10 0.08 Negative 
188 0.09 2.60 -0.03 0.09 0.07 Negative 
189 0.07 2.54 0.07 0.09 0.07 Positive 
190 0.10 2.66 0.05 0.07 -0.01 Negative 
Y1 0.19 3.20 0.12 0.09 0.09 Negative 
Y2 0.13 3.95 0.07 0.09 0.10 Negative 
Y3 0.37 2.13 0.12 0.14 0.13 Negative 
 
 
Appendix 1.2: Serology results for the 164 hounds tested 
 











1 Negative 8.01 Negative 0 
2 Negative 1.31 Negative 0 
3 Negative 2.04 Negative 0 
4 Negative 0 Negative 0 
5 Negative 3.51 Negative 0 
6 Visible positive 127 Negative 0 
7 Negative 0 Negative 0 
8 Negative 2.43 Negative 0 
9 Negative 0 Negative 0 
10 Negative 1.22 Negative 0.9 
11 Negative 0 Negative 0 
12 Negative 0 Visible positive 88.75 
13 Negative 0 Negative 0 
14 Negative 0 Negative 0 
15 Intermediate 73.62 Negative 0 
16 Negative 0 Negative 0 
17 Negative 0 Negative 0 
18 Negative 0 Negative 0 
19 Negative 0 Negative 0 
20 Negative 0 Negative 0 
21 Negative 0 Negative 0 
22 Negative 0 Negative 0 
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23 Negative 1.54 Negative 0 
24 Negative 15.56 Negative 0.65 
25 Negative 0 Intermediate 18.54 
26 Negative 0 Negative 0 
27 Visible positive 389.21 Negative 0 
28 Negative 0 Negative 0 
29 Negative 0.89 Negative 0 
30 Visible positive 297.47 Negative 3.46 
31 Negative 5.79 Negative 0 
32 Negative 8.59 Negative 0 
33 Negative 0 Negative 0 
34 Negative 6.79 Negative 0 
35 Negative 0 Negative 0 
36 Negative 9.42 Negative 0 
37 Negative 0 Negative 0 
38 Negative 0 Negative 0 
39 Negative 0 Negative 0 
40 Visible positive 146.04 Negative 0 
41 Negative 0.7 Negative 0 
42 Negative 1.23 Negative 0 
43 Negative 1.59 Negative 0 
44 Negative 11.31 Negative 0 
45 Negative 0 Negative 0 
46 Negativeative 12.71 Negativeative 0.93 
47 Negativeative 0 Negativeative 0 
48 Negativeative 0 Negativeative 0 
49 Negativeative 17.72 Negativeative 0 
50 Negativeative 0.6 Negativeative 0 
51 Negativeative 0 Negativeative 3.69 
52 Negativeative 0 Negativeative 0 
53 Visible positive 124.43 Negativeative 0 
54 Negativeative 0 Negativeative 0 
55 Negativeative 16.33 Negativeative 0 
56 Negativeative 0 Negativeative 0 
57 Negativeative 17 Negativeative 0 
58 Negativeative 0 Negativeative 0 
59 Negativeative 0 Negativeative 0 
60 Negativeative 11.73 Negativeative 0 
61 Negativeative 0 Negativeative 0 
62 Negativeative 21.97 Negativeative 0 
63 Negativeative 0 Intermediate 34.66 
64 Negativeative 6.61 Negativeative 0 
65 Negativeative 9.07 Negativeative 0 
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66 Negativeative 5.04 Negativeative 0 
67 Negativeative 0.98 Negativeative 0 
68 Negativeative 5.33 Negativeative 0 
69 Negativeative 10.51 Negativeative 0 
70 Intermediate 58.72 Negativeative 2.32 
71 Negativeative 12.14 Negativeative 0 
72 Negativeative 7.78 Negativeative 0 
73 Negativeative 6.86 Negativeative 0 
74 Negativeative 0.71 Negativeative 0 
75 Negativeative 0 Negativeative 3.9 
76 Negativeative 2.05 Negativeative 0 
77 Negativeative 1.16 Negativeative 0 
78 Negativeative 9.58 Negativeative 0 
79 Negativeative 1.93 Negativeative 0 
80 Negativeative 0.9 Negativeative 0 
81 Negativeative 0 Negativeative 0 
82 Negativeative 0.23 Negativeative 0 
83 Negativeative 10.54 Visible positive 113.65 
84 Negativeative 13.82 Negativeative 0 
85 Negativeative 20.39 Negativeative 0 
86 Negativeative 6.13 Negativeative 0 
87 Negativeative 21.99 Negativeative 0 
88 Negativeative 0 Negativeative 0 
89 Negativeative 0 Negativeative 0 
90 Negativeative 3.22 Negativeative 0 
91 Negativeative 14.56 Negativeative 0 
92 Negativeative 0 Negativeative 0 
93 Negativeative 0 Negativeative 0 
94 Negativeative 0 Negativeative 0 
95 Negativeative 4.63 Negativeative 4.07 
96 Negativeative 2.15 Intermediate 10.64 
97 Negativeative 6.28 Negativeative 0 
98 Negativeative 0 Negativeative 0 
99 Negativeative 2.68 Negativeative 0 
100 Negativeative 0 Negativeative 0 
101 Negativeative 20.84 Negativeative 0 
102 Negativeative 0 Negativeative 0 
103 Negativeative 17.41 Negativeative 0 
104 Negativeative 0 Negativeative 0 
105 Negativeative 2.16 Intermediate 8.94 
106 Negativeative 0 Negativeative 0 
107 Visible positive 4169.89 Negativeative 0 
108 Negativeative 0 Negativeative 0 
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109 Negativeative 0 Negativeative 0 
110 Negativeative 1.66 Negativeative 0 
111 Negativeative 0 Intermediate 14.36 
112 Negativeative 0 Negativeative 0 
113 Negativeative 0 Negativeative 0 
114 Negativeative 0 Negativeative 0 
115 Negativeative 6.45 Negativeative 0 
116 Negativeative 20.97 Negativeative 0 
117 Negativeative 8.53 Negativeative 0 
118 Negativeative 6.43 Negativeative 0 
119 Visible positive 905.4 Negativeative 0 
120 Negativeative 0 Negativeative 0 
121 Negativeative 0 Negativeative 0 
122 Negativeative 0 Negativeative 0 
123 Negativeative 0 Intermediate 13.78 
124 Negativeative 0 Negativeative 0 
125 Negativeative 0 Negativeative 2.83 
126 Negativeative 0 Intermediate 27.02 
127 Negativeative 0 Negativeative 0 
128 Negativeative 2.29 Negativeative 0 
129 Negativeative 0 Negativeative 1.53 
130 Negativeative 0 Negativeative 0 
131 Negativeative 0 Negativeative 0 
132 Negativeative 14.72 Negativeative 0 
133 Negativeative 0.83 Negativeative 0 
134 Negativeative 0 Negativeative 0 
135 Negativeative 0 Negativeative 0 
136 Negativeative 0 Negativeative 0 
137 Negativeative 6.53 Negativeative 0 
138 Negativeative 12.78 Negativeative 0 
139 Negativeative 4.67 Negativeative 4.39 
140 Negativeative 6.93 Negativeative 0 
141 Negativeative 7.88 Negativeative 0 
142 Negativeative 0 Negativeative 0 
143 Negativeative 0 Negativeative 0 
144 Negativeative 0 Negativeative 0 
145 Negativeative 9.27 Negativeative 0 
146 Negativeative 0 Negativeative 0 
147 Negativeative 0 Negativeative 0 
148 Negativeative 0 Negativeative 0 
149 Negativeative 0 Negativeative 0 
150 Negativeative 0 Negativeative 0 
151 Negativeative 0 Negativeative 0 
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152 Negativeative 0 Negativeative 0 
153 Negativeative 0 Negativeative 0 
154 Negativeative 0 Negativeative 0 
155 Negativeative 0 Negativeative 0 
156 Negativeative 0 Negativeative 0 
157 Visible positive 115.53 Negativeative 0 
158 Negativeative 0 Negativeative 0 
159 Visible positive 286.51 Negativeative 2.85 
160 Negativeative 0 Negativeative 0 
161 Negativeative 8.89 Negativeative 0 
162 Negativeative 0 Negativeative 0 
163 Negativeative 0.82 Negativeative 0 
164 Negativeative 0 Negativeative 0 
165 Negativeative 0 Negativeative 0 
166 Negativeative 0 Negativeative 0 
167 Negativeative 0 Negativeative 0 
168 Negativeative 0 Negativeative 0 
169 Negativeative 0 Negativeative 0 
170 Negativeative 0 Negativeative 0 
 
Appendix 2: WinBUGS syntax of Model One 
Model{ 
X[1:16] ~ dmulti(p[1:16], n) 






p[4] <- pi*SeIGRA*SeCompPPD*SeDPP*SeIdexx + (1-pi)*(1-SpIGRA)*(1-SpCompPPD)*(1-
SpDPP)*(1-SpIdexx)  
p[5] <- pi*(1-SeIGRA)*SeCompPPD*SeDPP*(1-SeIdexx) + (1-pi)*SpIGRA*(1-
SpCompPPD)*(1-SpDPP)*SpIdexx 
p[6] <- pi*(1-SeIGRA)*(1-SeCompPPD)*(1-SeDPP)*SeIdexx + (1-
pi)*SpIGRA*SpCompPPD*SpDPP*(1-SpIdexx)  
p[7] <- pi*(1-SeIGRA)*SeCompPPD*(1-SeDPP)*(1-SeIdexx) + (1-pi)*SpIGRA*(1-
SpCompPPD)*SpDPP*SpIdexx 
p[8] <- pi*(1-SeIGRA)*(1-SeCompPPD)*SeDPP*(1-SeIdexx) + (1-
pi)*SpIGRA*SpCompPPD*(1-SpDPP)*SpIdexx 
p[9] <- pi*SeIGRA*SeCompPPD*SeDPP*(1-SeIdexx) + (1-pi)*(1-SpIGRA)*(1-
SpCompPPD)*(1-SpDPP)*SpIdexx 
p[10] <- pi*(1-SeIGRA)*(1-SeCompPPD)*SeDPP*SeIdexx + (1-
pi)*SpIGRA*SpCompPPD*(1-SpDPP)*(1-SpIdexx)  




p[12] <- pi*SeIGRA*(1-SeCompPPD)*(1-SeDPP)*SeIdexx + (1-pi)*(1-
SpIGRA)*SpCompPPD*SpDPP*(1-SpIdexx) 
p[13] <- pi*(1-SeIGRA)*SeCompPPD*SeDPP*SeIdexx + (1-pi)*SpIGRA*(1-
SpCompPPD)*(1-SpDPP)*(1-SpIdexx)  
p[14] <- pi*SeIGRA*SeCompPPD*(1-SeDPP)*SeIdexx + (1-pi)*(1-SpIGRA)*(1-
SpCompPPD)*SpDPP*(1-SpIdexx)  
p[15] <- pi*(1-SeIGRA)*SeCompPPD*(1-SeDPP)*SeIdexx + (1-pi)*SpIGRA*(1-
SpCompPPD)*SpDPP*(1-SpIdexx)  
p[16] <- pi*SeIGRA*(1-SeCompPPD)*SeDPP*SeIdexx + (1-pi)*(1-
SpIGRA)*SpCompPPD*(1-SpDPP)*(1-SpIdexx) 
pi ~ dbeta(1.0,1.0) 
SeIGRA ~ dbeta (1.0,1.0)  
SpIGRA ~ dbeta (1.0,1.0)  
SeCompPPD ~ dbeta (1.0,1.0)  
SpCompPPD ~ dbeta (1.0,1.0)  
SeDPP ~ dbeta (1.0,1.0)  
SpDPP ~ dbeta (1.0,1.0)  
SeIdexx ~ dbeta (1.0,1.0)  
SpIdexx ~ dbeta (1.0,1.0) 
ppvIGRA <- pi*SeIGRA/(pi*SeIGRA+(1-pi)*(1-SpIGRA))  
ppvCompPPD <- pi*SeCompPPD/(pi*SeCompPPD+(1-pi)*(1-SpCompPPD))  
ppvDPP <- pi*SeDPP/(pi*SeDPP+(1-pi)*(1-SpDPP))  
ppvIdexx <- pi*SeIdexx/(pi*SeIdexx+(1-pi)*(1-SpIdexx))  
npvIGRA <- SpIGRA*(1-pi)/(SpIGRA*(1-pi)+pi*(1-SeIGRA)) 
npvCompPPD <- SpCompPPD*(1-pi)/(SpCompPPD*(1-pi)+pi*(1-SeCompPPD)) 
npvDPP <- SpDPP*(1-pi)/(SpDPP*(1-pi)+pi*(1-SeDPP)) 
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